UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 26, 2015

 

 

CAREVIEW COMMUNICATIONS, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-54090 95-4659068

(State or other jurisdiction of incorporation)

 

(Commission File Number) (IRS Employer Identification No.)

   

405 State Highway 121, Suite B-240, Lewisville, TX 75067

(Address of principal executive offices and Zip Code)

 

(972) 943-6050

(Registrant’s telephone number, including area code)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

 
 

 

TABLE OF CONTENTS

    Page
Item 1.01 Entry into a Material Definitive Agreement 3
     
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 5
     
Item 3.02 Unregistered Sale of Equity Securities 5
     
Item 8.01 Other Events 5
     
Item 9.01 (d) Exhibits 6

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

On June 26, 2015, CareView Communications, Inc. (the “Company”) and certain of its subsidiaries entered into a Credit Agreement (the “Credit Agreement”) with PDL BioPharma, Inc., as administrative agent and lender (the “Lender”). Under the Credit Agreement, the Lender made available to the Company up to $40 million in two tranches of $20 million each.

In the event that a specified milestone relating to the placement of the Company’s products (the “Tranche One Milestone”) occurs on or before October 31, 2015, the Lender will fund the Company $20 million (“Tranche One”). In the event that additional specified milestones relating to the placement of the Company’s products and revenue occur on or before June 30, 2017, the Lender will fund the Company an additional $20 million (“Tranche Two” and, together with Tranche One, the “Loans”). Outstanding borrowings under Tranche One bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under Tranche Two bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment under each of Tranche One and Tranche Two will commence on the ninth interest payment date. The Company may elect to pay a portion of the interest due in the form of additional Loans during the first eight interest payment dates. Each tranche will mature on the fifth anniversary of the date borrowed. The Company may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

The obligations under the Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.

The Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the parties, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the parties, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets.

The Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

The Company had no relationship with the Lender, material or otherwise, prior to entering into the Credit Agreement.

Contemporaneously with the execution of the Credit Agreement on June 26, 2015, the Company issued to the Lender a warrant to purchase 4,444,445 shares of the Company’s common stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “Warrant”). The warrant expires on June 26, 2025.

In addition, contemporaneously with the execution of the Credit Agreement on June 26, 2015:

·       the Company and the Lender executed a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of common stock issuable upon exercise of the Warrant (the “PDL RRA”);

 

 
 

 

·       the Company, the Lender, CareView Communications, Inc., a Texas corporation and a subsidiary of the Company (“CareView TX”) and CareView Operations, LLC, a Texas limited liability company and a subsidiary of the Company (“CareView LLC”) executed a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) pursuant to which certain of the Company’s subsidiaries guaranteed the Company’s performance of its obligations under the Credit Agreement and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing the Company’s performance of the same;

 

·       CareView TX executed (i) a Patent Security Agreement (the “Patent Security Agreement”) and (ii) a Trademark Security Agreement (the “Trademark Security Agreement”) pursuant to which CareView TX granted the Lender a security interest in CareView TX’s tangible and intangible assets securing the Company’s performance of its obligations under the Credit Agreement;

 

·       the Company, the Lender, HealthCor Partners Fund, LP (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, LP (“HealthCor Hybrid” and, together with HealthCor Partners, the “HealthCor Funds”) and the Second Lien Claimholders (as defined therein) executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”) pursuant to which the Company granted first-priority liens on its and CareView TX’s pledged assets to the Lender and second-priority liens on such pledged assets to the HealthCor Funds and the Second Lien Claimholders (as defined therein);

 

·       the Company, the HealthCor Funds and the other investors named therein executed a Seventh Amendment to Note and Warrant Purchase Agreement dated April 21, 2011, as amended (the “Note and Warrant Purchase Agreement”), pursuant to which the Note and Warrant Purchase Agreement was amended to permit the Company to enter into and the perform its obligations under the Credit Agreement (the “Seventh Amendment to NWPA”);

 

·       the Company and the HealthCor Funds executed an Amendment to Registration Rights Agreement dated April 21, 2011 (the “HC RRA”) pursuant to which the HC RRA was amended to make its priority of registration consistent with the PDL RRA (the “Amendment to HC RRA”); and

 
 

 

·       the Company entered into the following allonges with respect to its Senior Secured Convertible Notes issued pursuant to the Note and Warrant Purchase Agreement: Allonge No. 1 to the Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Hybrid, Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Hybrid, Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Hybrid, and Allonge No. 1 to Senior Secured Convertible Notes (issued February 17, 2015) by and among the Company, HealthCor Partners and certain investors named therein (collectively, the “Allonges”). The Allonges amended (i) the Senior Secured Convertible Notes (issued April 21, 2011) to extend, in the event that Tranche Two is funded, the maturity date for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022 and (ii) the Senior Secured Convertible Notes (issued January 31, 2012) to set the maturity date at April 20, 2021 and, in the event that Tranche Two is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022. The Allonges also made certain other amendments to each of the Senior Secured Convertible Notes issued under the Note and Warrant Purchase Agreement, including to subordinate the notes to the Loans and to increase certain event of default acceleration and payment thresholds.

The foregoing descriptions of the Credit Agreement, the Warrant, the PDL RRA, the Guarantee and Collateral Agreement, the Patent Security Agreement, the Trademark Security Agreement, the Subordination and Intercreditor Agreement, the Seventh Amendment to NWPA, the Amendment to HC RRA and the Allonges, are qualified, in their entirety, by reference to each agreement, copies of which are attached as exhibits to this Current Report on Form 8-K and are incorporated by reference into this Item 1.01.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K that relates to the creation of a direct financial obligation of the Company is incorporated by reference into this Item 2.03.

Item 3.02 Unregistered Sale of Equity Securities.

As described above in Item 1.01, on June 26, 2015 the Company issued to the Lender a warrant to purchase 4,444,445 shares of the Company’s common stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “Warrant”). The Warrant was issued in reliance upon the exemption from registration provided by Regulation D under the Securities Act of 1933, as amended.

The foregoing description of the Warrant is qualified, in its entirety, by reference to the Warrant, a copy of which is attached as an exhibit to this Current Report on Form 8-K and is incorporated by reference into this Item 3.02.

Item 8.01 Other Events.

On June 29, 2015, the Company issued a press release announcing the execution of the Credit Agreement and the issuance of the Warrant. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 8.01 and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

 
 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exh. No. Date Document
10.01 06/26/15 Credit Agreement between the Company, CareView TX and the Lender
     
10.02 06/26/15 Subordination and Intercreditor Agreement between the Company, the Lender, the HealthCor Funds and the Second Lien Claimholders
     
10.03 06/26/15 Patent Security Agreement of CareView TX
     
10.04 06/26/15 Trademark Security Agreement of CareView TX
     
10.05 06/26/15 Guarantee and Collateral Agreement between the Company, CareView TX, CareView LLC and the Lender
     
10.06 06/26/15 Registration Rights Agreement between the Company and the Lender
     
10.07 06/26/15 Warrant to purchase 4,444,445 shares of the Company’s common stock issued to the Lender
     
10.08 06/26/15 Seventh Amendment to Note and Warrant Purchase Agreement between the Company,  the HealthCor Funds and the Investors named therein
     
10.09 06/26/15 Amendment to Registration Rights Agreement between the Company and the HealthCor Funds
     
10.10 06/26/15 Allonge No. 1 to the Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Partners
     
10.11 06/26/15 Allonge No. 1 to Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Hybrid
     
10.12 06/26/15 Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Partners
     
10.13 06/26/15 Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Hybrid
     

 

 
 

 

 

10.14 06/26/15 Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Partners
     
10.15 06/26/15 Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Hybrid
     
10.16 06/26/15 Allonge No. 1 to Senior Secured Convertible Notes (issued February 17, 2015) by and among the Company, HealthCor Partners and certain investors named therein
     
99.1 06/29/15 Press Release announcing execution of the Credit Agreement and issuance of the Warrant

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 29, 2015 CAREVIEW COMMUNICATIONS, INC.
   
  By:  /s/ Steven G. Johnson
    Steven G. Johnson
Chief Executive Officer

 

 

 

 

 

 

 

 

Careview Communications, Inc. 8-K  

 

Exhibit 10.01  

 

EXECUTION VERSION

 

 

CREDIT AGREEMENT

 

dated as of June 26, 2015

 

among

 

CAREVIEW COMMUNICATIONS, INC.,

a Nevada corporation,

 

as Holdings,

 

CAREVIEW COMMUNICATIONS, INC.,

a Texas corporation,

 

as the Borrower,

 

PDL BIOPHARMA, INC.,

 

as the Lender,

 

and

 

PDL BIOPHARMA, INC.,

 

as the Agent

 

 

 
 

 

TABLE OF CONTENTS  

             
              Page
             
Section 1.   Definitions; Interpretation   1
    1.1 Definitions   1
    1.2 Interpretation   15
         
Section 2.   Credit Facilities   16
    2.1 Loans   16
      2.1.1 Loans   16
      2.1.2 General   17
    2.2 Loan Accounting   17
      2.2.1 Recordkeeping   17
      2.2.2 Notes   17
    2.3 Interest   17
      2.3.1 Interest Rate   17
      2.3.2 Interest Payments   19
      2.3.3 Computation of Interest   19
    2.4 Amortization; Prepayment   19
      2.4.1 Amortization   19
      2.4.2 Voluntary Prepayment; Termination   20
    2.5 Payment Upon Maturity   20
    2.6 Making of Payments   20
    2.7 Application of Payments and Proceeds   21
    2.8 Payment Dates   21
    2.9 Set-off   21
    2.10 Currency Matters   21
    2.11 Protective Advances   21
    2.12 Fees; Equity Issuance   22
      2.12.1 Closing Fee   22
      2.12.2 Equity Issuance   22
         
Section 3.   Yield Protection   22
    3.1 Taxes   22
    3.2 Increased Cost   24
    3.3 Mitigation of Circumstances   25
    3.4 Conclusiveness of Statements; Survival   25
         
Section 4.   Conditions Precedent   26
    4.1 Closing Date   26
      4.1.1 Delivery of Loan Documents   26
      4.1.2 Representations and Warranties   28
      4.1.3 No Default   28
      4.1.4 No Material Adverse Change   28
    4.2 Tranche One Loan   28
      4.2.1 Delivery of Borrowing Request   28
      4.2.2 Tranche One Milestone   28
      4.2.3 Delivery of Tranche One Milestone Notice   28
      4.2.4 Payment of Closing Fee and Fees and Expenses   28
      4.2.5 Notes   28

 

ii
 

 

TABLE OF CONTENTS

             
              Page
             
      4.2.6 Officer’s Certificate   29
      4.2.7 Representations and Warranties   29
      4.2.8 No Default   29
      4.2.9 No Material Adverse Change   29
    4.3 Tranche Two Loan   29
      4.3.1 Delivery of Borrowing Request   29
      4.3.2 Tranche Two Milestone   29
      4.3.3 Delivery of Tranche Two Milestone Notice   29
      4.3.4 Payment of Fees and Expenses   29
      4.3.5 Officer’s Certificate   30
      4.3.6 Representations and Warranties   30
      4.3.7 No Default   30
      4.3.8 No Material Adverse Change   30
      4.3.9 Note   30
         
Section 5.   Representations and Warranties   30
    5.1 Organization   30
    5.2 Authorization; No Conflict   31
    5.3 Validity; Binding Nature   31
    5.4 Financial Condition   31
    5.5 No Material Adverse Change   31
    5.6 Litigation   32
    5.7 Ownership of Properties; Liens; Real Property   32
    5.8 Capitalization; Subsidiaries   32
    5.9 Pension Plans   33
    5.10 Compliance with Law; Investment Company Act; Other Regulated Entities   33
    5.11 Margin Stock   34
    5.12 Taxes   34
    5.13 Solvency   34
    5.14 Environmental Matters   35
    5.15 Insurance   35
    5.16 Information   35
    5.17 Intellectual Property   36
    5.18 Labor Matters   39
    5.19 No Default   39
    5.20 Foreign Assets Control Regulations and Anti-Money Laundering   40
      5.20.1 OFAC   40
      5.20.2 PATRIOT Act   40
    5.21 Non-Competes   40
         
Section 6.   Affirmative Covenants   40
    6.1 Information   40
      6.1.1 Annual Report   40
      6.1.2 Quarterly Reports   41
      6.1.3 Monthly Reports   41
      6.1.4 Compliance Certificate   41

 

iii
 

 

TABLE OF CONTENTS 

             
              Page
             
      6.1.5 Notice of Default; Litigation; ERISA Matters   42
      6.1.6 Budgets   42
      6.1.7 Other Information   42
    6.2 Books; Records; Inspections   43
    6.3 Maintenance of Property; Insurance   43
    6.4 Compliance with Laws and Contractual Obligations; Payment of Taxes and Liabilities   44
    6.5 Maintenance of Existence   45
    6.6 Environmental Matters   45
    6.7 Further Assurances   45
    6.8 Conference Calls   47
    6.9 Tranche One Milestone Notice   47
    6.10 Tranche Two Milestone Notice   47
    6.11 Post-Closing Obligations   47
         
Section 7.   Negative Covenants   48
    7.1 Debt   48
    7.2 Liens   49
    7.3 Restricted Payments   50
    7.4 Mergers; Consolidations; Asset Sales   52
    7.5 Modification of Organizational Documents; HealthCor Debt Documents   53
    7.6 Use of Proceeds   53
    7.7 Transactions with Affiliates   53
    7.8 Inconsistent Agreements   54
    7.9 Business Activities   54
    7.10 Investments   54
    7.11 Fiscal Year   55
    7.12 Deposit Accounts and Securities Accounts   55
    7.13 Sale-Leasebacks   56
    7.14 Hazardous Substances   56
    7.15 ERISA Liability   56
    7.16 Liquidity   56
    7.17 Permitted Activities of Holdings   56
         
Section 8.   Events of Default; Remedies   57
    8.1 Events of Default   57
      8.1.1 Non-Payment of Credit Agreement   57
      8.1.2 No Default Under Other Debt; Material Contracts   57
      8.1.3 Bankruptcy; Insolvency   57
      8.1.4 Non-Compliance with Loan Documents   58
      8.1.5 Representations; Warranties   58
      8.1.6 Judgments   58
      8.1.7 Invalidity of Collateral Documents   59
      8.1.8 Invalidity of Subordination Provisions   59
      8.1.9 Change of Control   59
    8.2 Remedies   59

 

iv
 

 

TABLE OF CONTENTS  

           
            Page
         
Section 9.   The Agent   60
    9.1 Appointment; Authorization   60
    9.2 Delegation of Duties   60
    9.3 Limited Liability   60
    9.4 Successor Agent   60
    9.5 Collateral Matters   61
    9.6 Collateral Agent   61
         
Section 10.   Miscellaneous   61
    10.1 Waiver; Amendments   61
    10.2 Notices   62
    10.3 Costs; Expenses   62
    10.4 Indemnification by the Borrower   62
    10.5 Marshaling; Payments Set Aside   63
    10.6 Nonliability of the Lender   63
    10.7 Confidentiality   64
    10.8 Captions   64
    10.9 Nature of Remedies   64
    10.10 Counterparts   64
    10.11 Severability   64
    10.12 Entire Agreement   65
    10.13 Successors; Assigns   65
    10.14 Governing Law   65
    10.15 Forum Selection; Consent to Jurisdiction; Service of Process   66
    10.16 Waiver of Jury Trial   66
             
    SCHEDULES    
           
    Schedule 1.1(a) Subsidiary Guarantors    
    Schedule 10.2 Addresses for Notices    
           
    EXHIBITS    
           
    Exhibit A Form of Note    
    Exhibit B Form of Compliance Certificate    

 

v
 

 

CREDIT AGREEMENT

 

This Credit Agreement dated as of June 26, 2015 (as amended, restated, supplemented or otherwise modified from time to time, this “ Agreement ”), is made among CareView Communications, Inc., a Nevada corporation (“ Holdings ”), CareView Communications, Inc., a Texas corporation and a wholly-owned subsidiary of Holdings (the “ Borrower ”), PDL BioPharma, Inc., a Delaware corporation, as the lender (the “ Lender ”), and PDL BioPharma, Inc., a Delaware corporation, not individually, but as the Agent (as defined below).

 

The Borrower has agreed to enter into this Agreement with the Lender and the Agent evidencing its agreement to incur the Loans, and in connection therewith, to make the representations and warranties, covenants and undertakings as hereinafter set forth.

 

Section 1. Definitions; Interpretation .

 

1.1             Definitions . When used herein the following terms shall have the following meanings:

 

Accounts ” means “accounts” as defined in the UCC, and also means a right to payment of a monetary obligation, whether or not earned by performance, (a) for property that has been or is to be sold, leased, licensed, assigned or otherwise disposed of, or (b) for services rendered or to be rendered.

 

Acquisition ” means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of all or substantially all of any business or division of a Person, (b) the acquisition of in excess of 50% of the Capital Stock of any Person, or otherwise causing any Person to become a Subsidiary, (c) a merger, consolidation, amalgamation or any other combination with another Person (other than a combination between two Persons that prior to the merger, consolidation, amalgamation or combination were already Loan Parties) and (d) the acquisition from any Person of a brand, line of business, division, branch or product line, or of marketing rights, patent rights or other Intellectual Property rights with respect to a product line, operating division, product or potential product or other unit of operation.

 

Affiliate ” of any Person means (a) any other Person which, directly or indirectly, controls or is controlled by or is under common control with such Person and (b) any officer or director of such Person. A Person shall be deemed to be “controlled by” any other Person if such Person possesses, directly or indirectly, power to vote 10% or more of the securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Unless expressly stated otherwise herein, neither the Agent nor the Lender shall be deemed an Affiliate of any Loan Party.

 

Agent ” means PDL BioPharma, Inc. in its capacity as administrative agent for the Lender hereunder and any successor thereto in such capacity.

 

1
 

 

Agreement ” has the meaning set forth in the Preamble .

 

Applicable Law ” means all applicable provisions of all (i) constitutions, treaties, statutes, laws, rules, regulations and ordinances of any Governmental Authority, (ii) authorizations, consents, approvals, permits or licenses issued by, or a registration or filing with, any Governmental Authority and (iii) orders, decisions, judgments, awards and decrees of any Governmental Authority (including common law and principles of public policy).

 

Billable CareView System Unit ” means, as of any date of determination, each room control platform or nurse station monitor (each, a “ Unit ”) for which each of the following clauses (i) to (iii) is true: (i) such Unit is mounted (where applicable) and operational, (ii) required personnel have been trained in the use of such Unit and (iii) the Borrower is receiving revenue as of such date in respect of such Unit.

 

Borrower ” has the meaning set forth in the Preamble .

 

Borrowing Request ” means an irrevocable written notice of borrowing delivered by the Borrower to the Agent and appropriately specifying (a) the aggregate principal amount of the Loans to be incurred, (b) the date of such borrowing (which shall be a Business Day), (c) the account details and wiring instructions for the Borrower and (d) that the applicable conditions set forth in Section 4 of this Agreement have been satisfied.

 

Business Day ” means any day on which commercial banks are open for commercial banking business in New York, New York.

 

Capital Lease ” means, with respect to any Person, any lease of (or other agreement conveying the right to use) any real or personal property by such Person that, in conformity with GAAP, is accounted for as a capital lease on the balance sheet of such Person.

 

Capital Stock ” means all shares of capital stock (whether denominated as common stock or preferred stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in, or Stock Equivalents (regardless of how designated) of, a Person (other than an individual), whether voting or non-voting.

 

CareView Hillcrest JV ” means CareView-Hillcrest, LLC, a Wisconsin limited liability company and a variable interest entity in which Holdings owns 50% of the Capital Stock.

 

CareView System ” means the suite of video monitoring guest services and related applications of Holdings and its Subsidiaries provided and installed in healthcare facilities and designed to enhance patient care and safety.

 

CareView Saline JV ” means CareView-Saline, LLC, a Wisconsin limited liability company and a variable interest entity in which Holdings owns 50% of the Capital Stock.

 

2
 

 

Cash Equivalent Investment ” means, at any time, (a) any evidence of Debt, maturing not more than one year after such time, issued or guaranteed by the United States government or any agency thereof, (b) commercial paper, or corporate demand notes, in each case rated at least A-l by Standard & Poor’s Ratings Group or P-l by Moody’s Investors Service, Inc., (c) any certificate of deposit (or time deposit represented by a certificate of deposit) or banker’s acceptance maturing not more than one year after such time, or any overnight Federal Funds transaction that is issued or sold by a commercial banking institution that is a member of the Federal Reserve System and has a combined capital and surplus and undivided profits of not less than $500,000,000, (d) any repurchase agreement entered into with any commercial banking institution of the nature referred to in clause (c) above which (i) is secured by a fully perfected security interest in any obligation of the type described in any of clauses (a) through (c) above and (ii) has a market value at the time such repurchase agreement is entered into of not less than 100% of the repurchase obligation of such commercial banking institution thereunder, (e) money market accounts or mutual funds which invest predominantly in assets satisfying the foregoing requirements and (f) other short term liquid investments approved in writing by the Agent.

 

CFC ” means a Person that is a “controlled foreign corporation” as defined in Section 957 of the IRC.

 

Change of Control ” means an event or series of events by which:

 

(a)            any “person” or “group” (within the meaning of the Exchange Act and the rules of the SEC thereunder) (other than the Permitted Holders), shall own, directly or indirectly, beneficially or of record, shares representing more than 35% of the aggregate ordinary voting power represented by the issued and outstanding Capital Stock of Holdings;

 

(b)            the Permitted Holders shall own, directly or indirectly, beneficially or of record, shares representing more than 50% of the aggregate ordinary voting power represented by the issued and outstanding Capital Stock of Holdings;

 

(c)            Holdings shall cease to directly own, beneficially and of record, 100% of the issued and outstanding Capital Stock of the Borrower; or

 

(d)            all or substantially all of the assets of Holdings or the Borrower are disposed of in any one or more related transactions.

 

Closing Date ” means the date on which the conditions set forth in Section 4.1 have been satisfied or waived by the Agent in its sole discretion.

 

Closing Fee ” means the closing fee due from the Borrower to the Lender in an aggregate amount equal to 1.0% of the aggregate principal amount of the Commitments, which closing fee is fully earned as of the Closing Date and shall be due and payable on or before the earliest of (i) the Tranche One Funding Date, (ii) December 31, 2015, irrespective of whether the Tranche One Funding Date has occurred as of such date, and (iii) the termination of this Credit Agreement by the Borrower and the payment of all outstanding Obligations hereunder pursuant to Section 2.4.2 .

 

Collateral ” has the meaning set forth in the Guarantee and Collateral Agreement.

 

Collateral Access Agreement ” means an agreement in form and substance satisfactory to the Agent in its reasonable discretion pursuant to which a mortgagee or lessor of real property on which Collateral is stored or otherwise located, or a warehouseman, processor or other bailee of inventory or other property owned by any Loan Party, acknowledges the Liens of the Agent and waives (or, if approved by the Agent, subordinates) any Liens held by such Person on such property, and, in the case of any such agreement with a mortgagee or lessor, permits the Agent reasonable access to and use of such real property during the continuance of an Event of Default to assemble, complete and sell any Collateral stored or otherwise located thereon.

 

3
 

 

Collateral Documents ” means, collectively, the Guarantee and Collateral Agreement (including as may be supplemented by the joinder of any Subsidiary or any other Person who intends to guarantee the Obligations) and each other agreement or instrument pursuant to or in connection with which any Loan Party grants a security interest in any Collateral to the Agent for the benefit of the Lender or pursuant to which any such security interest in Collateral is perfected, each as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms hereof and thereof.

 

Commitments ” means the Tranche One Commitment and the Tranche Two Commitment.

 

Compliance Certificate ” means a certificate substantially in the form of Exhibit B and otherwise satisfactory to the Agent in all respects.

 

Connection Income Taxes ” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

 

Consolidated EBITDA ” means, for any period, Consolidated Net Income for such period plus (a) without duplication and to the extent deducted in determining such Consolidated Net Income, the sum of (i) consolidated interest expense paid or accrued for such period, (ii) consolidated income tax expense for such period, (iii) all amounts attributable to depreciation and amortization for such period and (iv) non-cash expense associated with granting stock options, warrants or other similar securities, and minus (b) without duplication to the extent included in determining such Consolidated Net Income, any extraordinary, unusual or non-recurring gains and all non-cash items of income for such period, all determined on a consolidated basis in accordance with GAAP.

 

Consolidated Net Income ” means, for any period, the net income or loss of Holdings and its consolidated Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP; provided that there shall be excluded the income of any Person that is not a Loan Party except to the extent of the amount of cash dividends or similar cash distributions actually paid by such Person to a Loan Party.

 

Contingent Obligation ” means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to or otherwise to invest in a debtor, to provide security for the obligations of a debtor or otherwise to assure a creditor against loss) any indebtedness, obligation or other liability of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Stock of any other Person. The amount of any Person’s obligation in respect of any Contingent Obligation shall (subject to any limitation set forth therein) be deemed to be the principal amount of the indebtedness, obligation or other liability supported thereby or the amount of the dividends or distributions guaranteed, as applicable.

 

4
 

 

Control Agreement ” means a tri-party deposit account, securities account or commodities account Control Agreement by and among the applicable Loan Party, the Agent and the depository, securities intermediary or commodities intermediary, each in form and substance reasonably satisfactory to the Agent and in any event providing to the Agent “control” of such deposit account, securities or commodities account within the meaning of Articles 8 and 9 of the UCC.

 

Controlled Investment Affiliate ” means, as to any Person, any other Person that (a) is an Affiliate of such Person and (b) is organized by such Person (or any Person controlling such Person) primarily for the purposes of making equity investments in Holdings or other portfolio companies.

 

Copyrights ” means all rights, title and interests (and all related IP Ancillary Rights) arising under any Applicable Law in copyrights and all mask work, database and design rights, whether or not registered or published, all registrations and recordations thereof and all applications in connection therewith.

 

Debt ” of any Person means, without duplication, (a) all indebtedness of such Person for borrowed money, (b) all indebtedness of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person as lessee under Capital Leases which have been or should be recorded as liabilities on a balance sheet of such Person in accordance with GAAP, (d) all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business), (e) all indebtedness secured by a Lien on the property of such Person, whether or not such indebtedness shall have been assumed by such Person (with the amount thereof being measured as the fair market value of such property), (f) all obligations, contingent or otherwise, with respect to letters of credit (whether or not drawn), banker’s acceptances and surety bonds issued for the account of such Person, (g) all Hedging Obligations of such Person, (h) all Contingent Obligations of such Person for obligations of any other Person constituting Debt (under another clause of this definition) of such Person, (i) earn-out, purchase price adjustment and similar obligations, (j) all obligations of such Person in respect of Disqualified Capital Stock issued by such Person, (k) all obligations of such Person under any synthetic lease transaction, where such obligations are considered borrowed money indebtedness for tax purposes but the transaction is classified as an operating lease in accordance with GAAP and (l) all indebtedness of the types listed in clauses (a) through (k) of any partnership of which such Person is a general partner.

 

Default ” means any event that, if it continues uncured, will, with the lapse of time or the giving of notice or both, constitute an Event of Default.

 

Default Rate ” has the meaning set forth in Section 2.3.1(c) .

 

Disclosure Letter ” means the letter dated as of the date of this Agreement delivered by the Loan Parties to the Agent and the Lender in connection with the execution and delivery of this Agreement; provided that the Disclosure Letter may be updated or supplemented a reasonable time prior to the Tranche Two Funding Date in a manner reasonably acceptable to the Agent and the Lender.

 

5
 

 

Disposition ” has the meaning set forth in Section 7.4(b) .

 

Disqualified Capital Stock ” means any Capital Stock which, by its terms (or by the terms of any security into which it is convertible or for which it is exchangeable), or upon the happening of any event, (a) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable or is redeemable at the option of the holder thereof, in whole or in part, on or prior to the date ninety-one (91) days after the latest Maturity Date then in effect, (b) is convertible into or exchangeable (unless at the sole option of the issuer thereof) for (i) debt securities or (ii) any Capital Stock referred to in clause (a) above, in each case at any time on or prior to the date ninety-one (91) days after the latest Maturity Date then in effect, or (c) contains any repurchase obligation which may come into effect prior to the date ninety-one (91) days after the latest Maturity Date then in effect; provided that any Capital Stock that would not constitute Disqualified Capital Stock but for provisions thereof giving holders thereof (or the holders of any security into or for which such Capital Stock is convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem or repurchase such Capital Stock upon the occurrence of a change in control occurring prior to the date ninety-one (91) days after the latest Maturity Date then in effect, shall not constitute Disqualified Capital Stock if such Capital Stock provides that the issuer thereof will not redeem or repurchase any such Capital Stock pursuant to such provisions prior to the repayment in full of the Obligations.

 

Dollar ” and “ $ ” mean lawful currency of the United States of America.

 

Environmental Claims ” means all claims, however asserted, by any governmental, regulatory or judicial authority or other Person alleging potential liability or responsibility under or for violation of any Environmental Law, or for release or injury to the environment or any Person or property or natural resources.

 

Environmental Laws ” means all present or future federal, state, provincial or local laws, statutes, common law duties, rules, regulations, ordinances and codes, including all amendments, together with all administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case relating to any matter arising out of or relating to health and safety, or pollution or protection of the environment, natural resources or the workplace, including any of the foregoing relating to the presence, use, production, recycling, reclamation, generation, handling, transport, treatment, storage, disposal, distribution, discharge, release, emission, control, cleanup or investigation or management of any Hazardous Substance.

 

ERISA ” means the Employee Retirement Income Security Act of 1974, as amended.

 

Event of Default ” means any of the events described in Section 8.1 .

 

Exchange Act ” means the United States Securities Exchange Act of 1934, as amended.

 

6
 

 

Excluded Taxes ” means any of the following Taxes required to be withheld or deducted from a payment to the Lender: (a) Taxes imposed on or measured by the Lender’s net income, franchise Taxes in lieu of Taxes on net income, and branch profits Taxes, in each case (i) imposed by the jurisdiction under which the Lender is organized or has its principal office or (ii) that are Other Connection Taxes, (b) U. S. federal withholding taxes pursuant to a law in effect at the time such Lender first becomes a party to this Agreement, except to the extent that, pursuant to Section 3.1(a) , amounts with respect to such Taxes were payable to such Lender’s assignor immediately before such Lender became a party hereto, and (c) any U. S. federal withholding taxes imposed pursuant to FATCA.

 

FATCA ” means Sections 1471 through 1474 of the IRC, as of the date of this Agreement (or any amended or successor provision that is substantively comparable and not materially more burdensome to comply with), and any current or future regulations issued thereunder or official interpretations thereof.

 

Fiscal Quarter ” means a fiscal quarter of a Fiscal Year.

 

Fiscal Year ” means the fiscal year of Holdings and the consolidated Subsidiaries, which period shall be the 12-month period ending on December 31 of each year.

 

FRB ” means the Board of Governors of the Federal Reserve System or any successor thereto.

 

GAAP ” means generally accepted accounting principles as in effect in the United States of America.

 

Governmental Authority ” means any nation or government, any state, province, municipality or other political subdivision thereof, any central bank (or similar monetary or regulatory authority) thereof, any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank), and any corporation or other entity owned or controlled, through stock or capital ownership or otherwise, by any of the foregoing.

 

Guarantee and Collateral Agreement ” means the Guarantee and Collateral Agreement dated as of the Closing Date, executed by Holdings, the Borrower, the Subsidiary Guarantors and each other person that becomes party to such Guarantee and Collateral Agreement in favor of the Agent, and governed by the laws of the State of New York, as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms hereof and thereof.

 

Hazardous Substances ” means any waste, chemical, substance, or material listed, defined, classified, or regulated as a hazardous waste, hazardous substance, pollutant, contaminant, toxic substance, or hazardous, dangerous or radioactive material, chemical or waste or any waste, chemical, substance or material otherwise regulated by any Environmental Law, including, without limitation, any petroleum or any derivative, waste, or byproduct thereof, radon, asbestos, and polychlorinated biphenyls, and any other substance, the storage, manufacture, disposal, treatment, generation, use, transportation, remediation, release into or concentration in the environment of which is prohibited, controlled, regulated or licensed by any governmental authority under any Environmental Law.

 

7
 

 

Healthcare Laws ” means all federal and state laws applicable to the business of the Borrower or any other Loan Party, regulating the manufacturing, labeling, promotion and provision of and payment for healthcare products and services, including HIPAA, Section 1128B(b) of the Social Security Act, as amended, 42 U.S.C. Section 1320a-7b (Criminal Penalties Involving Medicare or State Health Care Programs), commonly referred to as the “ Federal Anti-Kickback Statute ,” Section 1877 of the Social Security Act, as amended, 42 U.S.C. Section 1395nn (Limitation on Certain Physician Referrals), commonly referred to as “ Stark Statute ,” U.S. Federal Food, Drug, and Cosmetic Act, as amended from time to time (21 U.S.C. Section 301 et seq.), all applicable Good Manufacturing Practice requirements addressed in the FDA’s Quality System Regulation (21 C.F.R. Part 820), the Medical Devices Regulations, 21 C.F.R. Part 812, and Parts 50, 54, and 56, all applicable labeling requirements address in FDA’s Device Labeling Regulation (21 C.F.R. Part 801), and all rules, regulations and guidance promulgated thereunder, including the Medicare Regulations and the Medicaid Regulations.

 

HealthCor Debt Documents ” means (i) the HealthCor Note and Warrant Purchase Agreement, (ii) all notes evidencing the Debt of Holdings issued thereunder, and (iii) all other documents and instruments executed and delivered in connection with the Debt of Holdings issued thereunder, in each case in effect as of the Closing Date or as amended, restated, supplemented or otherwise modified in accordance with the terms of the Intercreditor Agreement and the terms hereof.

 

HealthCor Debt Documents Amendments ” means (i) the Seventh Amendment dated as of June 26, 2015 to the HealthCor Note and Warrant Purchase Agreement,   by and among Holdings, HealthCor Partners Fund, L.P.  and HealthCor Hybrid Offshore Master Fund, L.P., (ii) the Amendment dated as of June 26, 2015 to the Registration Rights Agreement relating to the HealthCor Note and Warrant Purchase Agreement, (iii) Allonge No. 1 to the Senior Secured Convertible Notes (issued February 17, 2015) payable to each of the investors named therein, (iv) Allonge No. 1 to the Senior Secured Convertible Note (issued January 16, 2014) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P., (v) Allonge No. 1 to the Senior Secured Convertible Note (issued January 16, 2014) payable to the order of HealthCor Partners Fund, L.P., (vi) Allonge No. 1 to the Senior Secured Convertible Note (issued January 31, 2012) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P., (vii) Allonge No. 1 to the Senior Secured Convertible Note (issued January 31, 2012) payable to the order of HealthCor Partners Fund, L.P., (viii) Allonge No. 1 to the Senior Secured Convertible Note (issued April 21, 2011) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. and (ix) Allonge No. 1 to Senior Secured Convertible Note (issued April 21, 2011) payable to the order of HealthCor Partners Fund, L.P.

 

HealthCor Note and Warrant Purchase Agreement ” means the Note and Warrant Purchase Agreement dated as of April 21, 2011, among Holdings, HealthCor Partners Fund, L.P., HealthCor Hybrid Offshore Master Fund, L.P., and the other investors party thereto, as amended pursuant to the First Amendment dated December 30, 2011, the Second Amendment dated January 31, 2012, the Third Amendment dated August 20, 2013, the Fourth Amendment dated January 16, 2014, the Fifth Amendment dated December 15, 2014, and the Sixth Amendment dated March 31, 2015, and as further amended, restated, supplemented or otherwise modified pursuant to (i) the Seventh Amendment dated as of June 26, 2015 by and among Holdings, HealthCor Partners Fund, L.P. and HealthCor Hybrid Offshore Master Fund, L.P. and (ii) the terms of the Intercreditor Agreement.

 

8
 

 

HealthCor Obligations ” means all obligations of the Loan Parties, including accrued interest, outstanding pursuant to the HealthCor Debt Documents.

 

Hedging Obligation ” means, with respect to any Person, any liability of such Person under any interest rate, currency or commodity swap agreement, cap agreement or collar agreement, and any other agreement or arrangement designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity prices. The amount of any Person’s obligation in respect of any Hedging Obligation shall be deemed to be the incremental obligation that would be reflected in the financial statements of such Person in accordance with GAAP.

 

Indemnified Liabilities ” has the meaning set forth in Section 10.4 .

 

Indemnified Taxes ” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a) , Other Taxes.

 

Intellectual Property ” means all rights, title and interests in intellectual property arising under any Applicable Law and all IP Ancillary Rights relating thereto, including all Copyrights, Patents, Trademarks, Internet Domain Names, Trade Secrets, industrial designs, integrated circuit topographies, and rights under IP Licenses.

 

Intelliview License Agreement ” has the meaning set forth in Section 5.17(f) .

 

Intelliview License Assignment ” has the meaning set forth in Section 5.17(f) .

 

Intercreditor Agreement ” means the subordination and intercreditor agreement dated as of the Closing Date among Holdings, the Borrower, the Subsidiary Guarantors, the Lender, the Agent and the secured parties party to the HealthCor Debt Documents, in form and substance satisfactory to the Agent.

 

Interest Payment Date ” means the last Business Day of each March, June, September and December.

 

Internet Domain Name ” means all right, title and interest (and all related IP Ancillary Rights) arising under any Applicable Law in Internet domain names.

 

Investment ” means, with respect to any Person, (a) the purchase or other acquisition of any debt or equity security of any other Person, (b) the making of any loan, advance or capital contribution to any other Person, (c) becoming obligated with respect to a Contingent Obligation in respect of obligations of any other Person or (d) the making of an Acquisition.

 

9
 

 

IP Ancillary Rights ” means, with respect to an item of Intellectual Property all foreign counterparts to, and all divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions of, such Intellectual Property and all income, royalties, proceeds and liabilities at any time due or payable or asserted under or with respect to any of the foregoing or otherwise with respect to such Intellectual Property, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other IP Ancillary Right.

 

IP License ” means all contractual obligations (and all related IP Ancillary Rights), whether written or oral, granting any right, title and interest in any Intellectual Property.

 

IRC ” means the Internal Revenue Code of 1986, as amended.

 

IRS ” has the meaning set forth in Section 3.1(d) .

 

Legal Costs ” means, with respect to any Person, (a) all fees and charges of any counsel, accountants, auditors, appraisers, consultants and other professionals to such Person and (b) all court costs and similar legal expenses.

 

Lender ” has the meaning set forth in the Preamble .

 

Lender Party ” has the meaning set forth in Section 10.4 .

 

Lien ” means, with respect to any Person, any interest granted by such Person in any real or personal property, asset or other right owned or being purchased or acquired by such Person which secures payment or performance of any obligation and shall include any mortgage, lien, encumbrance, charge or other security interest of any kind, whether arising by contract, as a matter of law, by judicial process or otherwise.

 

Liquidity ” means, at any time, the aggregate amount of cash held by the Loan Parties at such time (in deposit accounts located in the United States that are subject to Control Agreements in form and substance reasonably satisfactory to the Agent) that are not (A) subject to any Liens (other than Liens under the Collateral Documents and the HealthCor Debt Documents and customary setoff rights with respect to deposit accounts or other funds maintained with depository institutions that are created by law or by applicable account agreements in favor of such depositary institutions or securities intermediaries), (B) required to be maintained or kept segregated from the general assets of Holdings, the Borrower or any other Subsidiary for the purpose of securing or providing a source of payment for Debt or other obligations that are or from time to time may be owed to one or more creditors of Holdings, the Borrower or any other Subsidiary (other than to secure the Obligations or the HealthCor Obligations) or (C) held by any Subsidiary that is subject to restrictions on its ability to pay dividends or distributions.

 

Loan Documents ” means this Agreement, the Notes, the Collateral Documents, the Perfection Certificate delivered by the Loan Parties on or prior to the Closing Date (as supplemented pursuant to the terms of the Guarantee and Collateral Agreement), the Disclosure Letter, the Intercreditor Agreement and all other documents, certificates, instruments and agreements delivered in connection with the foregoing, all as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms hereof and thereof.

 

10
 

 

Loan Party ” means Holdings, the Borrower, each Subsidiary Guarantor and each other person that guarantees the Obligations pursuant to the Guarantee and Collateral Agreement.

 

Loans ” means the Tranche One Loan and the Tranche Two Loan.

 

Margin Stock ” means any “margin stock” as defined in Regulation T, U or X of the FRB.

 

Material Adverse Effect ” means (a) a material adverse change in, or a material adverse effect upon, the operations, assets, business, properties or condition (financial or otherwise) of the Loan Parties and their Subsidiaries taken as a whole, (b) a material impairment of the ability of any Loan Party to perform in any material respect any of its Obligations under any Loan Document to which it is a party or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against any Loan Party of any Loan Document to which it is a party. For the avoidance of doubt, a decrease (or volatile fluctuations) in the share price of the Capital Stock of Holdings shall not be deemed, in and of itself, a Material Adverse Effect (it being understood that the underlying facts or circumstances giving rise or contributing to such decrease or volatile fluctuations may be taken into account in determining whether there has been, or could reasonably be expected to have or result in, a Material Adverse Effect).

 

Maturity Date ” means (i) with respect to the Tranche One Loan, the Tranche One Maturity Date, and (ii) with respect to the Tranche Two Loan, the Tranche Two Maturity Date.

 

Note ” means a promissory note in substantially the form of Exhibit A or otherwise in form and substance acceptable to the Lender and the Agent, as the same may be replaced, substituted, amended, restated or otherwise modified from time to time.

 

Obligations ” means all liabilities, indebtedness and obligations (including interest accrued at the rate provided in the applicable Loan Document after the commencement of a bankruptcy proceeding whether or not a claim for such interest is allowed) of any Loan Party under this Agreement or otherwise with respect to any Loan or Protective Advance, or any Loan Party under any other Loan Document or any Collateral Document, including the Closing Fee, in each case howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, or due or to become due. The parties agree that the Closing Fee is fully earned as of the Closing Date and shall be due and payable in accordance with Section 2.12.1 or otherwise upon any acceleration of the Obligations in accordance with the Agreement.

 

OFAC ” has the meaning set forth in Section 5.20.1.

 

Other Connection Taxes ” means, with respect to the Lender, Taxes imposed as a result of a present or former connection between the Lender and the jurisdiction imposing such Tax (other than any such connection arising from the Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction with respect to, or enforced or sold or assigned an interest in, any Loan or Loan Document).

 

Other Taxes ” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document.

 

11
 

 

Paid in Full ” or “ Payment in Full ” means, with respect to any Obligations, the payment in full in cash and performance of all such Obligations, other than contingent indemnification obligations as to which no unsatisfied claim has been asserted.

 

Patents ” means all (i) all patents and certificates of invention, or similar property rights, and applications for any of the foregoing, of the United States, any other country or any political subdivision thereof, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom, (vii) all proceeds of the foregoing, including, without limitation, licenses, royalties, and income, and (viii) without duplication, all IP Ancillary Rights in respect of the foregoing.

 

Perfection Certificate ” means the Perfection Certificate dated as of the date hereof delivered by the Loan Parties to the Agent and the Lender in connection with the execution and delivery of this Agreement, as amended, supplemented or otherwise modified from time to time.

 

Permitted Holders ” means HealthCor Management, LP; HealthCor Associates, LLC; HealthCor Hybrid Offshore Master Fund, LP; HealthCor Hybrid Offshore GP, LLC; HealthCor Group, LLC; HealthCor Partners Management, L.P.; HealthCor Partners Management GP, LLC; HealthCor Partners Fund, LP; HealthCor Partners, LP; HealthCor Partners GP, LLC and their respective Controlled Investment Affiliates.

 

Permitted Lien ” means any Lien expressly permitted by Section 7.2 .

 

Permitted Refinancing ” means any replacement, renewal, refinancing or extension of any existing Debt (the “ Original Debt ”), in any such case, permitted by this Agreement (a) that does not exceed the aggregate principal amount (plus accrued interest and any applicable premium and associated fees and expenses) of the Original Debt, (b) that does not have a weighted average life to maturity at the time of such replacement, renewal, refinancing or extension that is less than the weighted average life to maturity of the Original Debt, (c) that does not rank at the time of such replacement, renewal, refinancing or extension senior to the Original Debt, (d) that is not secured by any Lien on any asset other than the assets that secured the Original Debt (or would have been required to secure the Original Debt pursuant to the terms thereof); (e) with respect to which the primary obligor in respect of, and the Persons (if any) that guarantee, such Debt (resulting from such replacement, renewal, refinancing or extension) are the primary obligor in respect of, and the Persons (if any) that guaranteed, respectively, the Original Debt, and (f) that does not contain terms (including, without limitation, terms relating to security, amortization, interest rate, premiums, fees, covenants, subordination, event of default and remedies) that are materially less favorable to any Loan Party (as determined by such Loan Party in the exercise of its reasonable business judgment), or otherwise adverse to the interests of the Agent and the Lender, than those applicable to the Original Debt.

 

Person ” means any natural person, corporation, partnership, trust, limited liability company, association, Governmental Authority or unit, or any other entity, whether acting in an individual, fiduciary or other capacity.

 

12
 

 

PIK Interest ” has the meaning set forth in Section 2.3.1(a) .

 

Product ” means and includes the CareView System and all component products and services therein, any and all future iterations of any of the foregoing and any other products developed by any Loan Party.

 

Protective Advance ” has the meaning set forth in Section 2.11 .

 

Registered Intellectual Property ” has the meaning set forth in Section 5.17(a) .

 

Registration Rights Agreement ” means the Registration Rights Agreement dated as of June 26, 2015 by and between Holdings and the Lender.

 

Restricted Payment ” has the meaning set forth in Section 7.3 .

 

SEC ” means the United States Securities and Exchange Commission.

 

Stock Equivalents ” means all securities convertible into or exchangeable for Capital Stock or any other Stock Equivalent, and all warrants, options or other rights to purchase, subscribe for or otherwise acquire any Capital Stock or any other Stock Equivalent, whether or not presently convertible, exchangeable or exercisable. For the avoidance of doubt, “Stock Equivalent” shall not include debt instruments that are convertible into Capital Stock or Stock Equivalents.

 

Subsidiary ” means, with respect to any Person, a corporation, partnership, limited liability company or other entity of which such Person owns, directly or indirectly, such number of outstanding shares of voting Capital Stock as to have more than 50% of the ordinary voting power for the election of directors or other managers of such corporation, partnership, limited liability company or other entity. Unless the context otherwise requires, each reference to Subsidiaries herein shall be a reference to Subsidiaries of Holdings. For the avoidance of doubt, neither the CareView Hillcrest JV or the CareView Saline JV shall be deemed “Subsidiaries” for purposes of this Agreement and the other Loan Documents unless and until it is a Wholly-Owned Subsidiary.

 

Subsidiary Guarantor ” means each Subsidiary listed on Schedule 1.1(a) as a guarantor and each other Subsidiary that is or becomes a party to the Guarantee and Collateral Agreement in accordance with the terms thereof.

 

Tax Returns ” has the meaning set forth in Section 5.12 .

 

Taxes ” has the meaning set forth in Section 3.1(a) .

 

Trade Secrets ” means all right, title and interest (and all related IP Ancillary Rights) arising under any Applicable Law in or relating to trade secrets.

 

Trademark ” means all rights, title and interests (and all related IP Ancillary Rights) arising under any Applicable Law in trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers and, in each case, all goodwill associated therewith, all registrations and recordations thereof and all applications in connection therewith.

 

13
 

 

Tranche One Commitment ” means, as to the Lender, the Lender’s commitment to provide the Tranche One Loan in the aggregate principal amount of $20,000,000 pursuant to Section 2.1.1(a) .

 

Tranche One Funding Date ” means the date on which the conditions set forth in Section 4.2 have been satisfied or waived by the Agent in its sole discretion and the Tranche One Loan is funded, which date shall occur no later than November 25, 2015.

 

Tranche One Interest-Only Period ” means the period beginning on the Tranche One Funding Date and continuing through and including the eighth (8th) Interest Payment Date after the Tranche One Funding Date.

 

Tranche One Loan ” means the term loan from the Lender pursuant to Section 2.1.1(a) , together with any PIK Interest accrued thereon and added to the aggregate principal balance thereof in accordance with Section 2.3.1(a) .

 

Tranche One Loan Request Date ” has the meaning set forth in Section 2.1.1(a) .

 

Tranche One Maturity Date ” means the date that is the fifth (5th) anniversary of the Tranche One Funding Date.

 

Tranche One Milestone ” has the meaning set forth in Section 4.2.2 .

 

Tranche One Milestone Notice ” means written notice from the Borrower to the Agent that the Tranche One Milestone has occurred, accompanied by a certificate of Holdings signed by the chief financial officer and/or chief accounting officer of Holdings certifying as to the occurrence of the Tranche One Milestone.

 

Tranche Two Commitment ” means, as to the Lender, the Lender’s commitment to provide the Tranche Two Loan in the aggregate principal amount of $20,000,000 pursuant to Section 2.1.1(b) .

 

Tranche Two Funding Date ” means the date on which the conditions set forth in Section 4.3 have been satisfied or waived by the Agent in its sole discretion and the Tranche Two Loan is funded, which date shall occur no later than July 26, 2017.

 

Tranche Two Interest-Only Period ” means the period beginning on the Tranche Two Funding Date and continuing through and including the eighth (8th) Interest Payment Date after the Tranche Two Funding Date.

 

Tranche Two Loan ” means the term loan from the Lender pursuant to Section 2.1.1(b) , together with any PIK Interest accrued thereon and added to the aggregate principal balance thereof in accordance with Section 2.3.1(b) .

 

Tranche Two Loan Request Date ” has the meaning set forth in Section 2.1.1(b) .

 

14
 

 

Tranche Two Maturity Date ” means the date that is the fifth (5th) anniversary of the Tranche Two Funding Date.

 

Tranche Two Milestone ” has the meaning set forth in Section 4.3.2 .

 

Tranche Two Milestone Notice ” means written notice from the Borrower to the Agent that the Tranche Two Milestone has occurred, accompanied by a certificate of Holdings signed by the chief financial officer and/or chief accounting officer of Holdings certifying as to the occurrence of the Tranche Two Milestone.

 

UCC ” means the Uniform Commercial Code as in effect in from time to time in the State of New York.

 

Warrants ” means a number of common stock purchase warrants sufficient to entitle the holder thereof to purchase 4,444,445 shares of common stock of Holdings.

 

Wholly-Owned Subsidiary ” means, as to any Subsidiary, all of the Capital Stock of which (except directors’ qualifying shares) are at the time directly or indirectly owned by Holdings and/or another Wholly-Owned Subsidiary of Holdings.

 

1.2             Interpretation . In the case of this Agreement and each other Loan Document, (a) the meanings of defined terms are equally applicable to the singular and plural forms of the defined terms; (b) Annex, Exhibit, Schedule and Section references in each Loan Document are to the particular Annex, Exhibit, Schedule and Section of such Loan Document unless otherwise specified; (c) the term “including” is not limiting and means “including but not limited to”; (d) in the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”; the words “to” and “until” each mean “to but excluding”, and the word “through” means “to and including”; (e) unless otherwise expressly provided in such Loan Document, (i) references to agreements and other contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto, but only to the extent such amendments and other modifications are not prohibited by the terms of any Loan Document, and (ii) references to any statute or regulation shall be construed as including all statutory and regulatory provisions amending, replacing, supplementing or interpreting such statute or regulation; (f) this Agreement and the other Loan Documents may use several different limitations, tests or measurements to regulate the same or similar matters, all of which are cumulative and each of which shall be performed in accordance with its terms; and (g) this Agreement and the other Loan Documents are the result of negotiations among and have been reviewed by counsel to Holdings, the Borrower, the Lender, the Agent, and the other parties hereto and thereto and are the products of all parties; accordingly, this Agreement and the other Loan Documents, in each case, shall not be construed against the Agent or the Lender merely because of the Agent’s or the Lender’s involvement in their preparation. Any reference in any Loan Document to a Permitted Lien is not intended to subordinate or postpone, and shall not be interpreted as subordinating or postponing, or as any agreement to subordinate or postpone, any Lien created by any of the Loan Documents to any Permitted Lien. If at any time any change in GAAP (including the adoption of IFRS) would affect the computation of any financial measure, covenant or requirement set forth in any Loan Document, and either the Borrower or the Lender shall so request, the Agent, the Lender and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP; provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP as in effect prior to such change therein and (ii) the Borrower shall provide to the Agent and the Lender financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between the calculations of such ratio or requirement made before and after giving effect to such change in GAAP. Without limiting the foregoing, leases shall continue to be classified and accounted for on a basis consistent with that reflected in the current financial statements of Holdings for all purposes of this Agreement, notwithstanding any change in GAAP relating thereto, unless the parties hereto enter into a mutually acceptable amendment addressing such changes, as provided for above.

 

15
 

 

Section 2. Credit Facilities .

 

2.1            Loans .

 

2.1.1          Loans . Subject to the terms and conditions set forth in this Agreement, the Lender agrees to lend to the Borrower funds in an aggregate principal amount not to exceed the aggregate Commitments as follows:

 

   (a)            on the Tranche One Funding Date, subject to satisfaction of the Tranche One Milestone, the entire amount of its Tranche One Commitment, after which the Tranche One Commitment shall terminate in full; provided that the Tranche One Funding Date shall occur no later than November 25, 2015; provided , further , that if (i) the Tranche One Milestone has occurred and (ii) the Borrower has failed to deliver the Borrowing Request for the Tranche One Loan in accordance with Section 4.2.1 no later than five Business Days after the date that the Tranche One Milestone Notice was or should have been delivered pursuant to Section 6.9 (such fifth Business Day, the “ Tranche One Loan Request Date ”), then the Borrower shall automatically be deemed to have requested a borrowing of the entire amount of the Tranche One Commitment on the tenth Business Day after the Tranche One Loan Request Date and, subject to the satisfaction of the conditions set forth in Section 4.2 , such loan will be funded.

 

  (b)            on the Tranche Two Funding Date, subject to satisfaction of the Tranche Two Milestone, the entire amount of its Tranche Two Commitment, after which the Tranche Two Commitment shall terminate in full; provided that the Tranche Two Funding Date shall occur no later than July 26, 2017; provided , further , that if (i) the Tranche Two Milestone has occurred and (ii) the Borrower has failed to deliver the Borrowing Request for the Tranche Two Loan in accordance with Section 4.3.1 no later than five Business Days after the date that the Tranche Two Milestone Notice was or should have been delivered pursuant to Section 6.10 (such fifth Business Day, the “ Tranche Two Loan Request Date ”), then the Borrower shall automatically be deemed to have requested a borrowing of the entire amount of the Tranche Two Commitment on the tenth Business Day after the Tranche Two Loan Request Date and, subject to the satisfaction of the conditions set forth in Section 4.3 , such loan will be funded.

 

16
 

 

2.1.2          General . No portion of the Loans may be re-borrowed once repaid. $15,000,000 of the proceeds of each of the Tranche One Loan and (if funded) the Tranche Two Loan shall be used to pay for capital expenditures in connection with the manufacture and placement of CareView Systems, and the remaining proceeds of each of the Tranche One Loan and the Tranche Two Loan may be used for general corporate purposes, in each case, in compliance with the Loan Documents and Applicable Law.

 

2.2            Loan Accounting .

 

2.2.1          Recordkeeping . The Agent, on behalf of the Lender, shall record in its records the date and amount of the Loans made by the Lender, accrued interest and each repayment of principal or interest thereon. The aggregate unpaid principal amount so recorded shall, absent manifest error, be presumptive evidence of the principal amount of the Loans owing and unpaid. The failure to so record any such amount or any error in so recording any such amount shall not, however, limit or otherwise affect the Obligations of the Borrower hereunder or under any Note to repay the principal amount of the Loans hereunder, together with all interest accruing thereon.

 

2.2.2          Notes . At the request of the Lender, the Loans shall be evidenced by one or more Notes, with appropriate insertions, payable to the order of the Lender in a face principal amount equal to the Loans and payable in such amounts and on such dates as are set forth herein.

 

2.3            Interest .

 

2.3.1          Interest Rate .

 

   (a)            The Borrower promises to pay interest on the unpaid principal amount of the Tranche One Loan for the period commencing on the Tranche One Funding Date until such Tranche One Loan is Paid in Full, at a rate payable in cash per annum equal to 13.5%. During the Tranche One Interest-Only Period, the Borrower may elect to pay up to 1.0% per annum of interest on the Tranche One Loan, for each Interest Payment Date occurring during the Tranche One Interest-Only Period, as interest paid-in-kind (“ PIK Interest ”) and such PIK Interest shall be added to the aggregate principal balance of the Tranche One Loan in arrears on such Interest Payment Date. The Borrower shall deliver to the Agent, at least three (3) Business Days prior to the applicable Interest Payment Date, a written notice setting forth (i) its election to pay an amount of interest in the form of PIK Interest, (ii) whether interest on the Tranche One Loan shall take the form of PIK Interest and (iii) the amount of interest that shall constitute PIK Interest on the applicable Interest Payment Date. Any such election shall be deemed to remain in effect until superseded by a subsequent notice delivered as set forth in the preceding sentence or until the Tranche One Interest-Only Period has expired.

 

17
 

 

(b)            The Borrower promises to pay interest on the unpaid principal amount of the Tranche Two Loan for the period commencing on the Tranche Two Funding Date, until such Tranche Two Loan is Paid in Full, at a rate payable in cash per annum equal to 13.0%. During the Tranche Two Interest-Only Period, the Borrower may elect to pay up to 1.0% per annum of interest on the Tranche Two Loan, for each Interest Payment Date occurring during the Tranche Two Interest-Only Period, as PIK Interest and such PIK Interest shall be added to the aggregate principal balance of the Tranche Two Loan in arrears on such Interest Payment Date. The Borrower shall deliver to the Agent, at least three (3) Business Days prior to the applicable Interest Payment Date, a written notice setting forth (i) its election to pay an amount of interest in the form of PIK Interest, (ii) whether interest on the Tranche Two Loan shall take the form of PIK Interest and (iii) the amount of interest that shall constitute PIK Interest on the applicable Interest Payment Date. Any such election shall be deemed to remain in effect until superseded by a subsequent notice delivered as set forth in the preceding sentence or until the Tranche Two Interest-Only Period has expired. Any such written notice of any election or modification of an election to pay PIK Interest in respect of the Tranche Two Loan may be combined with any written notice of any election or modification of an election to pay PIK Interest in respect of the Tranche One Loan described in Section 2.3.1(a) above.

 

(c)            The foregoing notwithstanding, (i) at any time an Event of Default has occurred and is continuing, the interest rate then applicable to the Loans shall automatically be increased, without demand or notice of any kind from the Lender (including declaration or notice of an Event of Default), by five percent (5.00%) per annum (any such increased rate, the “ Default Rate ”) and (ii) any such increase may thereafter be waived or rescinded by the Lender in its sole discretion by written notice to the Borrower. In the event that the Obligations in respect of the Tranche One Loan are not Paid in Full as of the Tranche One Maturity Date or any existing Obligations are not Paid in Full as of the Tranche Two Maturity Date, or in the event that the Obligations shall be declared or shall become due and payable pursuant to Section 8.2 , the Obligations shall bear interest subsequent thereto at the Default Rate and such interest shall be payable in cash on demand. In no event shall interest or other amounts payable by the Borrower to the Lender hereunder exceed the maximum rate permitted under Applicable Law, and if any such provision of this Agreement is in contravention of any such law, (x) any amounts paid hereunder shall be deemed to be and shall be applied against the principal amount of the Obligations to the extent necessary such that the amounts paid hereunder do not exceed the maximum rate under Applicable Law and (y) such provision shall otherwise be deemed modified as necessary to limit such amounts paid to the maximum rate permitted under Applicable Law.

 

18
 

 

2.3.2           Interest Payments .

 

  (a)            Interest accrued on the Tranche One Loan during the period from the Tranche One Funding Date until the Tranche One Maturity Date shall accrue and be payable in cash (subject to Section 2.3.1(a) ) quarterly on each Interest Payment Date, in arrears ( provided , however , that PIK Interest, if any, shall accrue and be added to the aggregate principal balance of the Tranche One Loan in arrears on such Interest Payment Date), and, to the extent not paid in advance, upon a prepayment of the Tranche One Loan in accordance with Section 2.4 and on the Tranche One Maturity Date, in each such case, in cash. After the Tranche One Maturity Date and at any time an Event of Default exists, all accrued interest on the Tranche One Loan shall be payable in cash on demand at the rates specified in Section 2.3.1 .

 

  (b)            Interest accrued on the Tranche Two Loan during the period from the Tranche Two Funding Date until the Tranche Two Maturity Date shall accrue and be payable in cash (subject to Section 2.3.1(b) ) quarterly on each Interest Payment Date, in arrears ( provided , however , that PIK Interest, if any, shall accrue and be added to the aggregate principal balance of the Tranche Two Loan in arrears on such Interest Payment Date), and, to the extent not paid in advance, upon a prepayment of the Tranche Two Loan in accordance with Section 2.4 and on the Tranche Two Maturity Date, in each such case, in cash. After the Tranche Two Maturity Date and at any time an Event of Default exists, all accrued interest on the Tranche Two Loan shall be payable in cash on demand at the rates specified in Section 2.3.1 .

 

2.3.3           Computation of Interest . Interest on the Loans shall be computed on the basis of a 360-day year comprised of twelve 30-day months. For partial months, interest shall be calculated on the number of days actually elapsed in a 30-day month.

 

2.4           Amortization; Prepayment .

 

2.4.1           Amortization .

 

  (a)            Commencing on the first Interest Payment Date following the Tranche One Interest-Only Period, the Borrower shall repay the Tranche One Loan to the Agent, for the account of the Lender, on each Interest Payment Date following the Tranche One Interest-Only Period, an amortization payment in aggregate principal amount equal to the quotient of (i) the aggregate principal amount of the Tranche One Loan outstanding on the first Interest Payment Date following the Tranche One Interest-Only Period, divided by (ii) the number of Interest Payment Dates remaining from and including such first Interest Payment Date following the Tranche One Interest-Only Period through and including the Tranche One Maturity Date (which amortization payment shall be reduced as a result of the application of prepayments in accordance with Section 2.7 ), provided that solely for purposes of calculating the number of Interest Payment Dates for this clause (a)(ii) , Interest Payment Dates shall be deemed to include the Tranche One Maturity Date.

 

19
 

 

   (b)            Commencing on the first Interest Payment Date following the Tranche Two Interest-Only Period, the Borrower shall repay the Tranche Two Loan to the Agent, for the account of the Lender, on each Interest Payment Date following the Tranche Two Interest-Only Period, an amortization payment in aggregate principal amount equal to the quotient of (i) the aggregate principal amount of the Tranche Two Loan outstanding on the first Interest Payment Date following the Tranche Two Interest-Only Period, divided by (ii) the number of Interest Payment Dates remaining from and including such first Interest Payment Date following the Tranche Two Interest-Only Period through and including the Tranche Two Maturity Date (which amortization payments shall be reduced as a result of the application of prepayments in accordance with Section 2.7 ), provided that for purposes of calculating the number of Interest Payment Dates for this clause (b)(ii) , Interest Payment Dates shall be deemed to include the Tranche Two Maturity Date.

 

  (c)            The amount of each amortization payment specified in Section 2.4.1(a) and (b) as determined by the Agent shall be binding on the Borrower absent manifest error.

 

2.4.2          Voluntary Prepayment; Termination . The Borrower may, on at least three (3) Business Days’ written notice to the Agent, not later than 12:00 p.m. New York City time on such day, prepay any of the Tranche One Loan or the Tranche Two Loan in whole or in part without premium or penalty (together with accrued and unpaid interest to the date of prepayment on such prepaid amount); provided , however , that each partial prepayment that is not of the entire outstanding amount of any Loan shall be in an aggregate amount that is an integral multiple of $1,000,000. The Borrower may also, on at least three (3) Business Days’ written notice to the Agent, not later than 12:00 p.m. New York City time on such day, terminate this Agreement and Borrower’s liabilities hereunder without premium or penalty by paying to the Lender the full amount of all outstanding Obligations (other than inchoate indemnification obligations).

 

2.5            Payment Upon Maturity . The Tranche One Loan, any accrued but unpaid interest thereon and, if the Tranche Two Loan has not been funded hereunder, any other Obligations then outstanding, shall be Paid in Full on the Tranche One Maturity Date. The Tranche Two Loan, and any other Obligations then outstanding, shall be Paid in Full on the Tranche Two Maturity Date.

 

2.6            Making of Payments . All payments on the Loans in accordance with this Agreement, including all payments of fees and expenses, shall be made by the Borrower to the Agent without setoff, recoupment or counterclaim and in immediately available funds, in United States Dollars, by wire transfer to the account of the Agent specified by the Agent, in any case, not later than 1:00 p.m. New York City time on the date due, and funds received after that hour shall be deemed to have been received by the Agent on the following Business Day. The Agent shall promptly remit to the Lender all payments received in collected funds by the Agent for the account of such Lender.

 

20
 

 

2.7             Application of Payments and Proceeds . Each voluntary prepayment of the outstanding Tranche One Loan or the Tranche Two Loan pursuant to Section 2.4.2 shall be applied to reduce the subsequent scheduled amortization payments of such Loan to be made pursuant to Section 2.4.1 as the Borrower may elect in its sole discretion.

 

2.8             Payment Dates . If any payment of principal of or interest on a Loan, or of any fees, falls due on a day which is not a Business Day, then such due date shall be extended to the immediately following Business Day and, in the case of principal, additional interest shall accrue and be payable for the period of any such extension.

 

2.9             Set-off . The Borrower agrees that the Agent, the Lender and their respective Affiliates have all rights of set-off, counterclaim and bankers’ lien provided by Applicable Law, and in addition thereto, the Borrower agrees that at any time an Event of Default has occurred and is continuing, the Agent and the Lender may apply to the payment of any Obligations of the Borrower hereunder, whether or not then due, any and all balances, credits, deposits, accounts or moneys of the Borrower then or thereafter maintained with the Agent or such Lender.

 

2.10           Currency Matters . All amounts payable under this Agreement and the other Loan Documents to the Agent and/or the Lender shall be payable in Dollars.

 

2.11           Protective Advances . Whether or not an Event of Default or a Default shall have occurred and be continuing, the Agent is authorized by the Borrower and the Lender, from time to time in the Agent’s sole discretion (but the Agent shall have absolutely no obligation to), to make disbursements or advances to the Borrower or any other Loan Party in amounts which the Agent, in its sole discretion, deems necessary or desirable (i) to preserve or protect the Collateral, or any portion thereof, (ii) to enhance the likelihood of, or maximize the amount of, repayment of the Loans and other Obligations, or (iii) to pay any other amount chargeable to or required to be paid by the Borrower or any other Loan Party pursuant to the terms of this Agreement and the other Loan Documents, including, without limitation, payments of principal, interest, fees and reimbursable expenses (any of such disbursements or advances are in this Section 2.12 referred to as “ Protective Advances ”). Unless otherwise agreed by the Lender in its sole discretion, Protective Advances shall bear interest at a rate payable in cash per annum equal to 13.5% plus the Default Rate. Each Protective Advance shall be secured by the Liens in favor of the Agent in and to the Collateral and shall constitute Obligations hereunder. The Protective Advances shall constitute Obligations hereunder which are subject to the rights of the Agent, the Lender and their respective Affiliates in accordance with Section 2.9 . The Borrower shall pay the unpaid principal amount and all unpaid and accrued interest of each Protective Advance on the earliest of (i) the Tranche One Maturity Date, (ii) the Tranche Two Maturity Date and (iii) the date on which demand for payment is made by the Agent. The Agent shall promptly notify the Lender and the Borrower in writing of each such Protective Advance, which notice shall include a description of the amount and the purpose of such Protective Advance. Any other terms with respect to the extension of any Protective Advance may be set forth in a separate agreement satisfactory to each of the Agent and the Lender in its sole discretion.

 

21
 

 

2.12          Fees; Equity Issuance.

 

2.12.1        Closing Fee . As consideration for the agreements of the Lender hereunder, the Borrower agrees to pay to the Lender, for its own account, the Closing Fee on or prior to the earliest of (i) the Tranche One Funding Date, (ii) December 31, 2015, irrespective of whether the Tranche One Funding Date has occurred as of such date, and (iii) the termination of this Credit Agreement by the Borrower and the payment of all outstanding Obligations hereunder pursuant to Section 2.4.2 .

 

2.12.2        Equity Issuance  As consideration for the agreements of the Lender hereunder, the Borrower agrees to issue and deliver to the Lender, for its own account, on or prior or the Closing Date, the Warrants and the Registration Rights Agreement. The Lender and the Borrower agree that the aggregate fair market value (as of the date hereof) of the Warrants is equal to $1,257,778.

 

Section 3. Yield Protection .

 

3.1            Taxes .

 

  (a)            All payments of principal and interest on the Loans and all other amounts payable under any Loan Document shall be made free and clear of and without deduction or withholding for any present or future income, excise, stamp, documentary, property or franchise taxes or other taxes, fees, imposts, duties, levies, deductions, withholdings (including backup withholding) or other charges of any nature whatsoever imposed by any taxing authority, including any interest, additions to tax or penalties applicable thereto (“ Taxes ”), except as required by Applicable Law. If any withholding or deduction from any payment to be made by the Borrower hereunder is required in respect of any Taxes pursuant to any Applicable Law (as determined in the good faith reasonable discretion of the Borrower or the Agent), then the Borrower shall: (i) timely pay directly to the relevant taxing authority the full amount required to be so withheld or deducted; (ii) within thirty (30) days after the date of any such payment of Taxes, forward to the Agent an official receipt or other documentation satisfactory to the Agent evidencing such payment to such relevant taxing authority; and (iii) in the case of Indemnified Taxes, pay to the Agent for the account of the Lender such additional amount or amounts as is necessary to ensure that the net amount actually received by the Lender will equal the full amount the Lender would have received had no such withholding or deduction (including withholdings and deductions applicable to any additional sums payable under this Section 3.1 ) been required.

 

  (b)            The Borrower shall timely pay to the relevant Governmental Authority in accordance with Applicable Law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.

 

22
 

 

(c)            The Loan Parties shall jointly and severally reimburse and indemnify, within 30 days after receipt of demand therefor (with copy to the Agent), the Agent and the Lender for all Indemnified Taxes and Other Taxes (including any Indemnified Taxes and Other Taxes imposed by any jurisdiction on amounts payable under this Section 3.1 ) paid by the Agent or the Lender, or required to be withheld or deducted from a payment to the Agent or the Lender, and any liabilities arising therefrom or with respect thereto (including any penalty, interest or expense), whether or not such Taxes were correctly or legally asserted. A certificate of the Agent or the Lender (or of the Agent on behalf of the Lender) claiming any compensation under this clause (c) , setting forth the amounts to be paid thereunder and delivered to the Borrower with a copy to the Agent, shall be conclusive, binding and final for all purposes, absent manifest error.

 

(d)            On or prior to the date it becomes a party to this Agreement, and from time to time thereafter as required by law or reasonably requested in writing by the Borrower, the Lender (including for this purpose any assignee of the Lender that becomes a party to this Agreement) shall (but only so long as the Lender remains lawfully able to do so) provide the Borrower with such documents and forms as prescribed by the Internal Revenue Service (“ IRS ”) in order to certify that payments to the Lender are exempt from or entitled to a reduced rate of U.S. federal withholding tax on payments pursuant to this Agreement or any other Loan Document. Without limiting the generality of the foregoing, any Lender that is the beneficial owner of payments made under this Agreement will (but only so long as the Lender remains lawfully able to do so) provide: (i) in the case of a beneficial owner that is U.S. person within the meaning of Section 7701 of the IRC, IRS Form W-9 certifying that such beneficial owner is exempt from U.S. Federal backup withholding tax, (ii) in the case of a beneficial owner claiming the benefits of the exemption for portfolio interest under Section 881(c) of the IRC, both (A) IRS Form W-8BEN and (B) a certificate to the effect that such beneficial owner is not (1) a “bank” within the meaning of Section 881(c)(3)(A) of the IRC, (2) a “10 percent shareholder” of Holdings within the meaning of Section 881(c)(3)(B) of the IRC, or (3) a “controlled foreign corporation” described in Section 881(c)(3)(C) of the IRC, (iii) in the case of a beneficial owner that is not a U.S. person within the meaning of Section 7701 of the IRC claiming the benefits of an income tax treaty to which the United States is a party, IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest,” “business profits” or “other income” article of such tax treaty; and (iv) in the case of a beneficial owner for whom payments under this Agreement constitute income that is effectively connected with such beneficial owner’s conduct of a trade or business in the United States, IRS Form W-8ECI. Any Lender that is not the beneficial owner of payments made under this Agreement, such as an entity treated as a partnership for U.S. federal income tax purposes, will (but only so long as the Lender remains lawfully able to do so) provide (x) an IRS Form W-8IMY on behalf of itself and (y) on behalf of each such beneficial owner, the forms set forth in clauses (i) through (iv) of the preceding sentence that would be required of such beneficial owner if such beneficial owner were a Lender. If a payment made to the Lender under this Agreement would be subject to U.S. federal withholding tax imposed by FATCA if the Lender were to fail to comply with the applicable reporting requirements of FATCA, the Lender shall (but only so long as the Lender remains lawfully able to do so) deliver to the Borrower, at the time or times prescribed by law or reasonably requested in writing by the Borrower, such documentation prescribed by applicable law or reasonably requested in writing by the Borrower as may be necessary for the Borrower to comply with its obligations under FATCA, to determine that the Lender has complied with its obligations under FATCA, or to determine the amount to deduct and withhold from such payment. Solely for purposes of the preceding sentence, FATCA shall include any amendments made to FATCA after the date of this Agreement.

 

23
 

 

(e)            If the Lender determines, in its sole discretion exercised in good faith, that it has received a refund of any Indemnified Taxes or Other Taxes as to which it has been indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this Section, the Lender shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrower under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by the Lender, and without interest (other than any interest paid by the relevant taxing authority with respect to such refund), provided that the Borrower, upon the request of the Lender, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant taxing authority) to the Lender in the event the Lender is required to repay such refund to such taxing authority. Notwithstanding anything to the contrary in this clause (e) , in no event will the Lender be required to pay any amount to the Borrower pursuant to this clause (e) the payment of which would place the Lender in a less favorable net after-Tax position than the Lender would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This clause (e) shall not be construed to require the Lender to make available its tax returns (or any other information relating to its taxes that it deems confidential) to the Borrower or any other Person.

 

(f)            The provisions of this Section 3.1 shall survive the termination of this Agreement and repayment of all Obligations.

 

3.2             Increased Cost .

 

(a)            If, after the Closing Date, the adoption or taking effect of, or any change in, any Applicable Law, rule, regulation or treaty, or any change in the interpretation or administration of any Applicable Law, rule, regulation or treaty by any Governmental Authority, central bank or comparable agency charged with the interpretation or administration thereof, or compliance by the Lender with any request, rule, guideline or directive (whether or not having the force of law) of any such authority, central bank or comparable agency: (i) shall impose, modify or deem applicable any reserve (including any reserve imposed by the FRB), special deposit or similar requirement against assets of, deposits with or for the account of, or credit extended by the Lender; (ii) shall subject the Lender or the Agent to any Taxes (other than Taxes described in clauses (b) and (c) of the definition of Excluded Taxes, Taxes indemnified pursuant to Section 3.1 and Connection Income Taxes); or (iii) shall impose on the Lender any other condition affecting its Loan, its Note or its obligation to make the Loan; and the result of anything described in clauses (i) through (iii) above is to increase the cost to (or to impose a cost on) such Lender of making or maintaining its Loan, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or under its Note with respect thereto, then, upon demand by such Lender (which demand shall be accompanied by a statement setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail, a copy of which shall be furnished to the Agent), the Borrower shall pay directly to the Lender such additional amount as will compensate the Lender for such increased cost or such reduction.

 

24
 

 

(b)            If the Lender shall reasonably determine that any change in, or the adoption or phase-in of, any Applicable Law, rule or regulation regarding capital adequacy, or any change in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation or administration thereof, or the compliance by the Lender or any Person controlling the Lender with any request or directive regarding capital adequacy (whether or not having the force of law) of any such authority, central bank or comparable agency, has or would have the effect of reducing the rate of return on the Lender’s or such controlling Person’s capital as a consequence of such Lender’s Commitments hereunder to a level below that which the Lender or such controlling Person could have achieved but for such change, adoption, phase-in or compliance (taking into consideration the Lender’s or such controlling Person’s policies with respect to capital adequacy) by an amount deemed by the Lender or such controlling Person to be material, then from time to time, upon demand by the Lender (which demand shall be accompanied by a statement setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail, a copy of which shall be furnished to the Agent), the Borrower shall pay to the Lender such additional amount as will compensate the Lender or such controlling Person for such reduction.

 

(c)            Notwithstanding anything herein to the contrary, (i) all requests, rules, guidelines, requirements and directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or by United States or foreign regulatory authorities, in each case pursuant to Basel III, and (ii) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, requirements and directives thereunder or issued in connection therewith or in implementation thereof, shall in each case be deemed to be a change in Applicable Law, regardless of the date enacted, adopted, issued or implemented. Notwithstanding anything to the contrary in this Section 3.2 , the Borrower shall not be required to compensate the Lender for any amounts in this Section 3.2 (excluding Taxes described in Section 3.2(a)(ii) ) incurred more than 180 days prior to the date that the Lender delivers the statement making the demand for such payment.

 

3.3             Mitigation of Circumstances . The Lender will use commercially reasonable efforts available to it (and not, in such Lender’s sole judgment, otherwise disadvantageous to such Lender) to mitigate or avoid, any obligation by the Borrower to pay any amount pursuant to Section 3.1 or 3.2 ; provided , that this Section 3.3 shall not apply to, or operate to prevent, any assignment of the Loan and the rights and obligations of the Lender pursuant to Section 10.13 . The Borrower hereby agrees to pay all reasonable costs and expenses incurred by the Lender in connection with this Section 3.3 .

 

3.4             Conclusiveness of Statements; Survival . Determinations and statements of the Lender pursuant to Sections 3.1 or 3.2 shall be conclusive absent demonstrable error provided that the Lender or the Agent provides the Borrower with written notification of such determinations and statements. The Lender may use reasonable averaging and attribution methods in determining compensation under Sections 3.1 or 3.2 and the provisions of such Sections shall survive repayment of the Loan, cancellation of the Notes and termination of this Agreement.

 

25
 

 

Section 4. Conditions Precedent.

 

4.1            Closing Date . The occurrence of the Closing Date and the effectiveness of this Agreement is subject to the following conditions precedent, each of which shall be satisfactory in all respects to the Agent and the Lender:

 

4.1.1          Delivery of Loan Documents . The Borrower shall have delivered the following documents in form and substance satisfactory to the Agent (and, as applicable, duly executed by all Persons named as parties thereto and dated the Closing Date or an earlier date satisfactory to the Agent):

 

  (a)             Agreement . This Agreement.

 

  (b)             Collateral Documents . The Guarantee and Collateral Agreement and all other Collateral Documents, and all instruments, documents, certificates and agreements executed or delivered pursuant thereto (including Intellectual Property assignments and pledged equity and limited liability company interests in the Subsidiaries, if any, with undated irrevocable transfer powers executed in blank), in each case, executed and delivered by each Loan Party and each other Person named as a party thereto.

 

  (c)             Intercreditor Agreement . The Intercreditor Agreement.

 

  (d)             HealthCor Debt Documents Amendments . Each of the HealthCor Debt Documents Amendments.

 

  (e)             Financing Statements . Properly completed Uniform Commercial Code financing statements and other filings and documents required by law or the Loan Documents to provide the Agent with perfected first priority Liens (subject only to Permitted Liens) in the Collateral.

 

  (f)             Warrants . The Warrants and the Registration Rights Agreement.

 

  (g)             Lien Searches . Copies of Uniform Commercial Code search reports listing all effective financing statements or equivalent filings filed against any Loan Party, with copies of such financing statements and filings; and copies of Patent, Trademark, Copyright and Internet Domain Name search reports conducted by the Borrower listing all effective collateral assignments in respect of such Intellectual Property filed with respect to any Loan Party, with copies of such collateral assignment documentation.

 

26
 

 

(h)             Authorization Documents . For each Loan Party, such Person’s (i) charter (or similar formation document), certified as of a recent date by the appropriate Governmental Authority (as applicable) in its jurisdiction of incorporation (or formation), (ii) limited liability company agreement, partnership agreement and bylaws (and similar governing document) (as applicable), (iii) resolutions of its board of directors (or similar governing body) approving and authorizing such Person’s execution, delivery and performance of the Loan Documents to which it is party and the transactions contemplated thereby, (vi) signature and incumbency certificates of its officers authorized to execute the Loan Documents, in each case with respect to clauses (i) through (iv) , all certified by its secretary or an assistant secretary (or similar officer) as being in full force and effect without modification and (v) good standing certificates in its jurisdiction of incorporation (or formation) and in each other jurisdiction requested by the Agent or the Lender, in each case, dated as of a recent date.

 

(i)             Opinions of Counsel . Opinions, addressed to the Agent and the Lender and dated as of the Closing Date, from each of (i) Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to Holdings and the Borrower, and (ii) local counsel to the Loan Parties in each jurisdiction in which any Loan Party is organized and the laws of which are not covered by the opinion letter referred to in clause (i) above, in each case in form and substance satisfactory to the Agent.

 

(j)             Insurance .  Certificates or other evidence of insurance in effect as required by Section 6.3(b) .

 

(k)             Control Agreements . A Control Agreement for each deposit account and securities account maintained by any Loan Party (other than zero balance, payroll and similar accounts) in form and substance reasonably satisfactory to the Agent.

 

(l)             Payment of Fees and Expenses . The Borrower shall have paid, on or prior to the Closing Date, subject to Section 10.3 , without duplication, all costs and expenses (including, to the extent invoiced, payment or reimbursement of all Legal Costs) incurred by the Agent and the Lender in connection with the preparation, execution and delivery of this Agreement, the other Loan Documents and the transactions contemplated hereby and thereby which are required to be paid by the Borrower, provided that such costs and expenses incurred by the Agent and the Lender and reimbursable by the Borrower pursuant to this paragraph (l) shall not exceed $150,000.

 

(m)            Officer’s Certificate . A certificate, dated the Closing Date and signed by the chief executive officer or the chief financial officer of each of Holdings and the Borrower, confirming compliance with the conditions set forth in Section 4.1.2 , 4.1.3 , and 4.1.4 .

 

(n)             Other Documents . Such other certificates, documents and agreements that may be listed on the closing checklist provided by the Agent to the Borrower or as the Agent or the Lender may request.

 

27
 

 

4.1.2           Representations and Warranties . Each representation and warranty by each Loan Party contained herein or in any other Loan Document to which such Loan Party is a party, shall be true and correct in all material respects (without duplication of any materiality qualifier contained therein) as of the Closing Date (or as of a specific earlier date if such representation or warranty expressly relates to an earlier date).

 

4.1.3           No Default . No Default or Event of Default shall have occurred and be continuing.

 

4.1.4           No Material Adverse Change . Since December 31, 2014, no event or occurrence shall have occurred that has resulted or could reasonably be expected to result in a Material Adverse Effect.

 

4.2           Tranche One Loan . The obligation of the Lender to make the Tranche One Loan is subject to the following conditions precedent, each of which shall be satisfactory in all respects to the Agent and the Lender:

 

4.2.1           Delivery of Borrowing Request . On or prior to the Tranche One Loan Request Date, the Borrower shall have delivered to Agent a Borrowing Request requesting that the entire amount of the Tranche One Commitment be funded on a date that is no less than five Business Days and no more than ten Business Days from the date of such Borrowing Request (or shall be deemed to have delivered such a Borrowing Request pursuant to Section 2.1.1(a) ).

 

4.2.2           Tranche One Milestone . On or prior to October 31, 2015, the Borrower shall have placed in service a minimum of 9,000 Billable CareView System Units (the “ Tranche One Milestone ”). For the avoidance of doubt, if the Tranche One Milestone shall not have occurred on or prior to October 31, 2015, the condition set forth in this Section 4.2.2 shall not be satisfied.

 

4.2.3           Delivery of Tranche One Milestone Notice . The Borrower shall have delivered to Agent the Tranche One Milestone Notice in accordance with Section 6.9 .

 

4.2.4           Payment of Closing Fee and Fees and Expenses . The Borrower shall have paid, on or prior to the Tranche One Funding Date, (i) the Closing Fee, (ii) all fees and expenses owing and payable to the Agent and the Lender as of such date and (iii) subject to Section 10.3 , without duplication, all costs and expenses incurred by the Agent and the Lender in connection with the funding of the Tranche One Loan which are required to be paid by the Borrower, and shall provide evidence acceptable to the Agent of the foregoing.

 

4.2.5           Notes . A Note in respect of the Tranche One Loan.

 

28
 

 

4.2.6           Officer’s Certificate . A certificate, dated the Tranche One Funding Date and signed by the chief executive officer or the chief financial officer of each of Holdings and the Borrower, confirming compliance with the conditions set forth in Section 4.2.7 , 4.2.8 , and 4.2.9 .

 

4.2.7           Representations and Warranties . Each representation and warranty by each Loan Party contained herein or in any other Loan Document to which such Loan Party is a party, shall be true and correct in all material respects (without duplication of any materiality qualifier contained therein) as of the Tranche One Funding Date (or as of a specific earlier date if such representation or warranty expressly relates to an earlier date).

 

4.2.8           No Default . No Default or Event of Default shall have occurred and be continuing.

 

4.2.9           No Material Adverse Change . Since December 31, 2014, no event or occurrence shall have occurred that has resulted or could reasonably be expected to result in a Material Adverse Effect.

 

4.3             Tranche Two Loan . The obligation of the Lender to make the Tranche Two Loan is subject to the following conditions precedent, each of which shall be satisfactory in all respects to the Agent and the Lender:

 

4.3.1           Delivery of Borrowing Request . On or prior to the Tranche Two Loan Request Date, the Borrower shall have delivered to Agent a Borrowing Request requesting that the entire amount of the Tranche Two Commitment be funded on a date that is no less than five Business Days and no more than ten Business Days from the date of such Borrowing Request (or shall be deemed to have delivered such a Borrowing Request pursuant to Section 2.1.1(b) ).

 

4.3.2           Tranche Two Milestone . On or prior to June 30, 2017, (a) the Borrower shall have placed in service a minimum of 27,750 Billable CareView System Units and (b) the Consolidated EBITDA of Holdings, computed on an annualized basis for the three-calendar month period immediately preceding the Tranche Two Funding Date, shall not be less than $7,000,000 (the foregoing conditions, collectively, the “ Tranche Two Milestone ”). For the avoidance of doubt, if the Tranche Two Milestone shall have not occurred on or prior to June 30, 2017, the condition set forth in this Section 4.3.2 shall not be satisfied.

 

4.3.3           Delivery of Tranche Two Milestone Notice . The Borrower shall have delivered to Agent the Tranche Two Milestone Notice in accordance with Section 6.10 .

 

4.3.4           Payment of Fees and Expenses . The Borrower shall have paid, on or prior to the Tranche Two Funding Date, (i) all fees and expenses owing and payable to the Agent and the Lender as of such date and (ii) subject to Section 10.3 , without duplication, all costs and expenses incurred by the Agent and the Lender in connection with the funding of the Tranche Two Loan which are required to be paid by the Borrower, and shall provide evidence acceptable to the Agent of the foregoing.

 

29
 

 

4.3.5           Officer’s Certificate . A certificate, dated the Tranche Two Funding Date and signed by the chief executive officer or the chief financial officer of each of Holdings and the Borrower, confirming compliance with the conditions set forth in Section 4.3.6 , 4.3.7 , and 4.3.8 .

 

4.3.6           Representations and Warranties . Each representation and warranty by each Loan Party contained herein or in any other Loan Document to which such Loan Party is a party, shall be true and correct in all material respects (without duplication of any materiality qualifier contained therein) as of the Tranche Two Funding Date (or as of a specific earlier date if such representation or warranty expressly relates to an earlier date).

 

4.3.7           No Default . No Default or Event of Default shall have occurred and be continuing.

 

4.3.8           No Material Adverse Change . Since December 31, 2014, no event or occurrence shall have occurred that has resulted or could reasonably be expected to result in a Material Adverse Effect.

 

4.3.9           Note . The Borrower shall have delivered a Note in respect of the Tranche Two Loan in form and substance satisfactory to the Agent, duly executed by the Borrower.

 

Section 5.               Representations and Warranties . To induce the Agent and the Lender to enter into this Agreement and to induce the Lender to advance the Loans hereunder, each of Holdings and the Borrower represents and warrants to the Agent and the Lender that each of the following are, and after giving effect to the borrowing of the Loans, will be, true, correct and complete:

 

5.1             Organization . Holdings is a corporation validly existing and in good standing under the laws of the State of Nevada; the Borrower is a corporation validly existing and in good standing under the laws of the State of Texas; each other Loan Party and each of its Subsidiaries is duly organized, validly existing and in good standing (as applicable) under the laws of the jurisdiction of its incorporation or organization, has all power and authority and all material governmental approvals required for the ownership and operation of its properties and the conduct of its business as now conducted and as proposed to be conducted and is qualified to do business, and is in good standing (as applicable), in every jurisdiction where, because of the nature of its activities or properties, such qualification is required, except for such jurisdictions where the failure to so qualify could not reasonably be expected to have a Material Adverse Effect.

 

30
 

 

5.2             Authorization; No Conflict . Each Loan Party is duly authorized to execute and deliver each Loan Document to which it is a party, the Borrower is duly authorized to borrow monies hereunder, the granting of the security interests pursuant to the Collateral Documents is within the corporate purposes of the Borrower and each other Loan Party party thereto, and the Borrower and each other Loan Party is duly authorized to perform its Obligations under each Loan Document to which it is a party. The execution, delivery and performance by Holdings and the Borrower of this Agreement and by Holdings, the Borrower and each Loan Party of each Loan Document to which it is a party, and the borrowings by the Borrower hereunder, do not and will not (a) require any consent or approval of, or registration or filing with or any other action by, any Governmental Authority (other than (i) any consent or approval which has been obtained and is in full force and effect and (ii) recordings and filings in connection with the Liens granted to the Agent under the Collateral Documents), (b) conflict with (i) any provision of material Applicable Law, (ii) the charter, by-laws, limited liability company agreement, partnership agreement or other organizational documents of any Loan Party or (iii) any material agreement, indenture, instrument or other document, or any judgment, order or decree, which is binding upon any Loan Party or any of their respective properties or (c) require, or result in, the creation or imposition of any Lien on any asset of the Borrower or any other Loan Party (other than Liens in favor of the Agent created pursuant to the Collateral Documents).

 

5.3             Validity; Binding Nature . Each of this Agreement and each other Loan Document to which Holdings, the Borrower or any other Loan Party is a party is the legal, valid and binding obligation of such Person, enforceable against such Person in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting the enforceability of creditors’ rights generally and to general principles of equity.

 

5.4             Financial Condition . The unaudited consolidated financial statements of Holdings and its Subsidiaries (presented on a consolidated basis) as at March 31, 2015, and the audited consolidated financial statements of Holdings and its Subsidiaries (presented on a consolidated basis) as at December 31, 2014, have been prepared in accordance with GAAP, subject to, in the case of unaudited financial statements, the absence of footnotes and year-end adjustments, and present fairly the consolidated financial condition of such Persons as at such dates and the results of their operations and cash flows for the periods then ended. As of the Closing Date, the Borrower and its Subsidiaries have no material liabilities other than as set forth on the foregoing financial statements other than trade payables incurred in the ordinary course of business.

 

5.5             No Material Adverse Change . Since December 31, 2014, there has been no event or occurrence that has resulted or could reasonably be expected to result in a Material Adverse Effect.

 

31
 

 

5.6             Litigation . No litigation (including derivative actions), arbitration proceeding or governmental investigation or proceeding is pending or, to any Loan Party’s knowledge, threatened in writing, against any Loan Party or any of its Subsidiaries or any of their respective properties which (i) purport to affect or pertain to this Agreement, any other Loan Document or any of the transactions contemplated hereby or (ii) that could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. No injunction, writ, temporary restraining order or any order of any nature has been issued by any court or other Governmental Authority purporting to enjoin or restrain the execution, delivery or performance of this Agreement, any other Loan Document, or directing that the transactions provided for herein not be consummated as herein provided. Except as set forth in Section 5.6 of the Disclosure Letter, neither any Loan Party nor any of its Subsidiaries is the subject of an audit or, to the knowledge of the Loan Parties, any review or investigation by any Governmental Authority (excluding the IRS and other taxing authorities) concerning the violation or possible violation of any requirement of Applicable Law.

 

5.7             Ownership of Properties; Liens; Real Property . There are no Liens on the Collateral other than those granted in favor of the Agent to secure the Obligations and other Permitted Liens. Each Loan Party and each of its Subsidiaries owns good and, in the case of owned real property, marketable title to all of its properties and assets, real and personal, tangible and intangible, of any nature whatsoever (including Patents, Trademarks, trade names, service marks and Copyrights), free and clear of all Liens, charges and claims (including infringement claims with respect to Intellectual Property) other than Permitted Liens. Section 5.7 of the Disclosure Letter lists all of the real property owned, leased, subleased or otherwise owned or occupied by any Loan Party as of the Closing Date.

 

5.8             Capitalization; Subsidiaries .

 

(a)             Equity Interests . Section 5.8(a) of the Disclosure Letter sets forth, as of the Closing Date, the name and jurisdiction of incorporation or organization of, and the percentage of each class of Capital Stock owned by Holdings, the Borrower or any other Subsidiary in, (i) each Subsidiary and (ii) each joint venture in which Holdings, the Borrower or any other Subsidiary owns any Capital Stock. All Capital Stock in each Subsidiary owned by Holdings, the Borrower or any other Subsidiary are duly and validly issued and, in the case of each Subsidiary that is a corporation, are fully paid and non-assessable, and are owned by the Borrower, directly or indirectly through Wholly-Owned Subsidiaries. Each Loan Party is the record and beneficial owner of, and has good title to, the Capital Stock pledged by it to the Agent under the Collateral Documents, free of any and all Liens, rights or claims of other Persons, other than Liens created under the Collateral Documents and other Permitted Liens. Each Loan Party is the record and beneficial owner of, and has good title to, the Capital Stock pledged by it to the Agent under the Collateral Documents, free of any and all Liens, rights or claims of other persons, except the security interest created by the Collateral Documents, and there are no outstanding warrants, options or other rights to purchase, or shareholder, voting trust or similar agreements outstanding with respect to, or property that is convertible into, or that requires the issuance or sale of, any such pledged Capital Stock.

 

32
 

 

(b)             No Consent of Third Parties Required . Except as set forth in Section 5.8(b) of the Disclosure Letter, no consent of any Person, including any other general or limited partner, any other member of a limited liability company, any other shareholder or any other trust beneficiary, is necessary or reasonably desirable (from the perspective of a secured party) in connection with the creation, perfection or first priority status of the security interest of the Agent in any Capital Stock pledged to the Agent for the benefit of the Lender under the Collateral Documents or the exercise by the Agent of the voting or other rights provided for in the Collateral Documents or the exercise of rights and remedies in respect thereof.

 

5.9             Pension Plans . No Loan Parties have any liability under ERISA and no Loan Party sponsors any “pension plan” or has any liability subject to Title IV of ERISA.

 

5.10           Compliance with Law; Investment Company Act; Other Regulated Entities .

 

(a)            Each Loan Party and each of its Subsidiaries possesses all, and is not in default under any, necessary authorizations, permits, licenses, certifications and approvals from all Governmental Authorities in order to conduct their respective businesses as presently conducted, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect. All business and operations of each Loan Party and each of its Subsidiaries complies with all Applicable Law, except where the failure to so comply would not reasonably be expected to result in a Material Adverse Effect. No Loan Party or any of its Subsidiaries is operating any aspect of its business under any agreement, settlement, judgment, decree, injunction, order or other arrangement with any Governmental Authority. None of any Loan Party, any Person controlling any Loan Party, or any Subsidiary of any Loan Party, is subject to regulation under any Federal or state statute, rule or regulation limiting its ability to incur Debt, pledge its assets or perform its Obligations under the Loan Documents.

 

(b)            No Loan Party or any of its Subsidiaries is an “investment company” or a company “controlled” by an “investment company” or a “subsidiary” of an “investment company”, within the meaning of the Investment Company Act of 1940.

 

(c)            As of the Closing Date, no Loan Party is aware of any current or former employee that is a “whistleblower” as defined in Section 240.21F-2 of the Exchange Act.

 

(d)            Without limiting the generality of the foregoing, except where noncompliance, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect:

 

  (i)            any financial relationships of any Loan Party or any Subsidiary with any Person (i) comply with all applicable Healthcare Laws including, without limitation, the Federal Anti-Kickback Statute, the Stark Statute and applicable state anti-kickback and self-referral laws; (ii) reflect fair market value, have commercially reasonable terms, and were negotiated at arm’s length; and (iii) do not obligate such Person to purchase, use, recommend, or arrange for the use of any Products or services of the Borrower, any Loan Party, or any Subsidiary; and

 

33
 

 

(ii)            each Loan Party and each of its Subsidiaries have implemented policies and procedures to monitor, collect, and report, and will report, any payments or transfers of value to certain healthcare providers and teaching hospitals, in accordance with industry standards and the Affordable Care Act of 2010 and its implementing regulations and state disclosure and transparency laws.

 

5.11             Margin Stock . No Loan Party or any of its Subsidiaries is engaged or will engage, principally or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying Margin Stock. No portion of the Obligations is secured directly or indirectly by Margin Stock.

 

5.12             Taxes . Each Loan Party and each of its Subsidiaries has filed all federal, state, local and foreign income, sales, goods and services, harmonized sales and franchise and all other material tax returns, reports and statements (collectively, the “Tax Returns”) with the appropriate Governmental Authorities in all jurisdictions in which such Tax Returns are or were required to be filed. All such Tax Returns are true, correct and complete in all material respects. All Taxes reflected therein and all material Taxes otherwise due and payable have been paid prior to the date on which any liability may be added thereto for non-payment thereof, except for those contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves are maintained on the books of the appropriate Loan Party, as applicable. No Tax Return is under audit or examination by any Governmental Authority and no written notice of such an audit or examination or any written assertion of any claim for Taxes has been given or made by any Governmental Authority. Proper and accurate amounts have been withheld by each Loan Party and each of its Subsidiaries, as applicable, from their respective employees for all periods in compliance with the tax, social security and unemployment withholding provisions of Applicable Law and such withholdings have been timely paid to the respective Governmental Authorities in accordance with Applicable Law. No Loan Party has been a member of an affiliated, combined or unitary group other than the group of which a Loan Party is the common parent or has liability for Taxes of any other person by contract, as a successor or transferor or otherwise by operation of law.

 

5.13             Solvency . Both immediately before and after giving effect to (a) the Loan or Loans made on or prior to the date this representation and warranty is made or remade, (b) the disbursement of proceeds of such Loan or Loans, and (c) the payment and accrual of all transaction costs in connection with the foregoing, with respect to the Loan Parties, on a consolidated basis, (i) the fair value of the assets of the Loan Parties, on a consolidated basis, is greater than the amount of the liabilities (including disputed, contingent and unliquidated liabilities) of the Loan Parties, on a consolidated basis, as such value is established and such liabilities evaluated, (ii) the present fair saleable value of the assets of the Loan Parties, on a consolidated basis, is not less than the amount that will be required to pay the probable liability on the debts of the Loan Parties, on a consolidated basis, as they become absolute and matured, (iii) the Loan Parties, on a consolidated basis, are able to realize upon their assets and pay their debts and other liabilities (including disputed, contingent and unliquidated liabilities) as they mature in the normal course of business, (iv) none of the Loan Parties intends to, and does not believe that it will, incur debts or liabilities beyond its ability to pay as such debts and liabilities mature, and (v) none of the Loan Parties is engaged in business or a transaction, or is about to engage in business or a transaction, for which its property would constitute unreasonably small capital.

 

34
 

 

5.14             Environmental Matters . The on-going operations of each Loan Party and each of its Subsidiaries comply in all respects with all Environmental Laws, except such non-compliance which could not (if enforced in accordance with Applicable Law) reasonably be expected to result in a Material Adverse Effect. Each Loan Party and each of its Subsidiaries have obtained, and maintained in good standing, all licenses, permits, authorizations and registrations required under any Environmental Law and necessary for their respective ordinary course operations, and each Loan Party and each of its Subsidiaries are in compliance with all material terms and conditions thereof, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect. No Loan Party or any of its Subsidiaries or any of their respective properties or operations is subject to any outstanding written order from or agreement with any federal, state or local Governmental Authority, nor subject to any judicial or docketed administrative proceeding, nor subject to any indemnification agreement  respecting any Environmental Law, Environmental Claim or Hazardous Substance, that would reasonably be expected to have a Material Adverse Effect.

 

5.15             Insurance . Each Loan Party and its properties are insured with financially sound and reputable insurance companies which are not Affiliates of Holdings, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where such Loan Party operates. A true and complete listing of such insurance of the Loan Parties as of the Closing Date, including issuers and coverages, is set forth in Section 5.15 of the Disclosure Letter.

 

5.16             Information . All information heretofore or contemporaneously herewith furnished in writing by the Borrower or any other Loan Party to the Agent or the Lender for purposes of or in connection with this Agreement and the transactions contemplated hereby is, and all written information hereafter furnished by or on behalf of the Borrower or any Loan Party to the Agent or the Lender pursuant hereto or in connection herewith will be, taken as a whole, true and accurate in every material respect on the date as of which such information is dated or certified, and none of such information is or will be incomplete, taken as a whole, by omitting to state any material fact necessary to make such information not misleading in light of the circumstances under which it was made (it being recognized by the Agent and the Lender that any projections and forecasts provided by Holdings or the Borrower are based on good faith estimates and assumptions believed by Holdings or the Borrower to be reasonable as of the date of the applicable projections or assumptions and that actual results during the period or periods covered by any such projections and forecasts may differ from projected or forecasted results and such differences may be material).

 

35
 

 

5.17             Intellectual Property .

 

(a)             Schedule 5.17(a) of the Disclosure Letter sets forth a true and complete list of all Patents (including patent applications, but excluding expired patent applications), registered Trademarks, applications for registration of Trademarks, registered Copyrights and applications for registration of Copyrights owned by or exclusively licensed to any Loan Party or any of its Subsidiaries (collectively, the “ Registered Intellectual Property ”). A Loan Party or a Subsidiary thereof exclusively owns, free and clear of all Liens, all right, title and interest in and to, all Registered Intellectual Property that is indicated on Schedule 5.17(a) of the Disclosure Letter as owned by such Loan Party or Subsidiary. All of the Registered Intellectual Property is subsisting and, to Borrower’s knowledge, all of the Registered Intellectual Property (excluding any applications included therein) is valid and enforceable. To Borrower’s knowledge, there are no facts (including any material prior art not disclosed to the applicable granting authority in connection with any issued Patents included in the Registered Intellectual Property) that would invalidate or render unenforceable any issued Patents included in the Registered Intellectual Property. Without limiting the generality of the foregoing, no prior art exists that would invalidate any of U.S. Patent Nos. 7,612,666, 7,477,285 or 9,041,810.

 

(b)            No Loan Party or any Subsidiary has received any written notice that the use or exploitation by such any Loan Party or Subsidiary of any Intellectual Property owned by or licensed to such Loan Party or Subsidiary, or the use, manufacture, sale or distribution of the Product, infringes or misappropriates the Intellectual Property of any third party and, to Borrower’s knowledge, there is no reasonable basis for any such claim. To Borrower’s knowledge, there is no reasonable basis for any claim that the making, having made, use, offer for sale, import or sale of the Product by Borrower or its agents (or use of the Product in accordance with its intended use) infringes or misappropriates the Intellectual Property of any third party. Except as listed on Schedule 5.17(b) of the Disclosure Letter, there are no written claims (including interferences, oppositions or cancellation actions) against any Loan Party or any Subsidiary thereof that are presently pending or, to the knowledge of Borrower, threatened, contesting the validity, ownership or enforceability of any of the Registered Intellectual Property and, to the knowledge of Borrower, no third party is infringing or misappropriating any of the Registered Intellectual Property (excluding patent applications). The Registered Intellectual Property is not subject to any outstanding order, injunction, judgment, decree or arbitration award restricting the use thereof. In the last twelve (12) months, no Loan Party or any Subsidiary thereof has taken any action (or failed to take any action) that has resulted in the loss, lapse, abandonment, invalidity or unenforceability of any of the Registered Intellectual Property or any other Intellectual Property owned by any Loan Party or Subsidiary thereof.

 

36
 

 

 

 

(c)            Except as set forth on Schedule 5.17(c) of the Disclosure Letter, (i) no Loan Party or any Subsidiary has granted any licenses under Registered Intellectual Property or any other material Intellectual Property owned by any Loan Party or any Subsidiary thereof to third parties; and (ii) no Loan Party or any Subsidiary thereof is party to any contract with any Person that limits or restricts the use of the Registered Intellectual Property or any other material Intellectual Property owned by any Loan Party or any Subsidiary thereof that requires any payments for such use.

 

(d)            No Loan Party or any of its Subsidiaries has filed any disclaimer or made or permitted any other voluntary reduction in the scope of any Patent included in the Registered Intellectual Property. None of the Patents included in Registered Intellectual Property has been or is currently involved in any interference, re-examination, opposition, derivation or other post-grant proceedings and no such proceedings are, to the knowledge of Borrower, threatened.

 

(e)            At least one valid and enforceable claim of an issued and subsisting patent included in the Registered Intellectual Property covers the Product, including any anticipated Product. Without limiting the generality of the foregoing, at least one valid and enforceable claim of each of U.S. Patent No. 7,612,666, U.S. Patent No. 7,477,285 and U.S. Patent No. 9,041,810 covers the Product as sold commercially as of the Closing Date.

 

(f)            Borrower has provided to Lender true, correct and complete copies of the Intelliview License Agreement and the Intelliview License Assignment. Borrower has a valid and enforceable exclusive license under the “Licensor IP” (as defined in the Intelliview License Agreement) in accordance with the terms of the Intelliview License Agreement. The Intelliview License Agreement is in full force and effect and is the legal, valid and binding obligation of Intelliview Technologies, Inc., enforceable against Intelliview Technologies, Inc. in accordance with its terms, subject, as to the enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar Applicable Law affecting creditors’ rights generally and general equitable principles. The execution and delivery of, and performance of obligations under, the Intelliview License Agreement were and are within the powers of Intelliview Technologies, Inc. The Intelliview License Agreement was duly authorized by all necessary action on the part of, and validly executed and delivered by, Intelliview Technologies, Inc. The Intelliview License Assignment was duly authorized by all necessary action on the part of, and validly executed and delivered by, Mann Equity, LLC. Borrower is not in breach or violation of or in default under the Intelliview License Agreement. Borrower has received no written notice from Intelliview Technologies, Inc. or any other Person to the effect that the Intelliview License Agreement is not an enforceable obligation of Intelliview Technologies, Inc. Borrower will be able to secure the full cooperation and assistance of and from Intelliview Technologies, Inc. and Wael Badawy as may be necessary for Borrower to effectively enforce U.S. Patent No. 7,612,666 against infringers within the medical field and to effectively defend challenges to the validity and enforceability of U.S. Patent No. 7,612,666. For the purposes hereof, (i) the term “ Intelliview License Agreement ” means the License Agreement effective as of September 1, 2011 between Intelliview Technologies, Inc., and Borrower (as assignee of Mann Equity, LLC) and (ii) the term “ Intelliview License Assignment ” means the Instrument of Assignment and Assumption made as of September 1, 2011 between Mann Equity, LLC and Borrower.

 

37
 

 

(g)            To Borrower’s knowledge, each Loan Party and each of its Subsidiaries owns, or is licensed or otherwise has the right to use, all Intellectual Property necessary to conduct its business as currently conducted. The conduct and operations of the businesses of each Loan Party and each of its Subsidiaries do not and, to Borrower’s knowledge, the anticipated Products of the Loan Parties and its Subsidiaries, upon their commercial release, will not, infringe upon, misappropriate, dilute or violate any Intellectual Property owned by any other Person. No Loan Party or any of its Subsidiaries has received any written notice or claim that (i) asserts any right, title or interest with respect to, or (ii) contests any right, title or interest of any Loan Party or any of its Subsidiaries in, any Intellectual Property, any anticipated Products and applications derived or expected to be derived therefrom, or the development and commercialization of any Products derived or expected to be derived therefrom. To Borrower’s knowledge, the Intellectual Property owned by the Loan Parties and their Subsidiaries is sufficient, and conveys adequate rights, title and interests, for the Borrower, the other Loan Parties and their Subsidiaries to develop and commercialize their anticipated Products and Intellectual Property applications.

 

(h)            Each Loan Party and each of its Subsidiaries (either itself or through licensees) has (i) used each Trademark owned by it on each and every trademark class of goods in the ordinary course of business in order to maintain such Trademark in full force free from any claim of abandonment for non-use in any class of goods for which registration was obtained, (ii) maintained in the ordinary course of business the quality of products and services offered under such Trademark and taken all necessary steps to ensure that all licensed users of such Trademark maintain as in the past such quality, (iii) used such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Law, (iv) not adopted or used any mark which is confusingly similar to or a colorable imitation of such Trademark that the Agent, for the benefit of the Lender, has not obtained a perfected security interest in and (v) not (and has not permitted any licensee or sublicensee thereof to have) done any act or knowingly omitted to do any act whereby such Trademark may become invalidated or impaired in any way.

 

(i)             Each Loan Party and each of its Subsidiaries (either itself or through licensees) has not done any act, or omitted to do any act, whereby any of its Patents may become forfeited, abandoned or dedicated to the public.

 

(j)             Each Loan Party and each of its Subsidiaries (either itself or through licensees) has not acted or omitted to act whereby any portion of its Copyrights may become invalidated or otherwise impaired. Such Loan Party or such Subsidiary has not (either itself or through licensees) done any act whereby any portion of its Copyrights may fall into the public domain as a result of any such act.

 

(k)            Each Loan Party (either itself or through licensees) has used proper statutory notice in connection with the use of each of its Patents, Trademarks and Copyrights included in the Intellectual Property of such Loan Party.

 

(l)             Each Loan Party and each of its Subsidiaries has taken all reasonable and necessary steps, including, without limitation, in any proceeding before the Patent and Trademark Office, the Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the relevant registration) and to maintain each registration of its Intellectual Property, including, without limitation, the payment of required fees and taxes, the filing of responses to office actions issued by the Patent and Trademark Office and the Copyright Office, the filing of applications for renewal or extension, the filing of affidavits of use and affidavits of incontestability, the filing of divisional, continuation, continuation-in-part, reissue, and renewal applications or extensions, the payment of maintenance fees, and the participation in interference, reexamination, opposition, cancellation, infringement and misappropriation proceedings.

 

38
 

 

(m)           No Loan Party or any of its Subsidiaries (either itself or through licensees) (i) has abandoned any of its Intellectual Property or (ii) has abandoned any right to file an application for letters patent, trademark, or copyright, in each case except where such abandonment could not reasonably be expected to have a Material Adverse Effect.

 

(n)            Each Loan Party and each of its Subsidiaries has done all things that are necessary and proper within such Loan Party’s or such Subsidiary’s power and control to keep each license of Intellectual Property held by such Loan Party or such Subsidiary as licensee or licensor in full force and effect.

 

(o)            Each Loan Party and each of its Subsidiaries has maintained all of its rights to its Internet Domain Names in full force and effect, except that each Loan Party and each of its Subsidiaries may elect not to renew any Internet Domain Name the failure of which could not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.

 

5.18             Labor Matters . No Loan Party or any of its Subsidiaries is subject to any labor or collective bargaining agreement. There are no existing or threatened strikes, lockouts or other labor disputes involving any Loan Party or any of its Subsidiaries that individually or in the aggregate could reasonably be expected to have a Material Adverse Effect. Hours worked by and payment made to employees of the Borrower, the other Loan Parties and any Subsidiary are not in violation of the Fair Labor Standards Act or any other Applicable Law, rule or regulation dealing with such matters, except for any such violations which would not reasonably be expected to have a Material Adverse Effect.

 

5.19             No Default . No Loan Party or any of its Subsidiaries is in default under or with respect to any contractual obligation which, individually or together with all such defaults, could reasonably be expected to have a Material Adverse Effect.

 

39
 

 

5.20            Foreign Assets Control Regulations and Anti-Money Laundering .

 

  5.20.1             OFAC . Each Loan Party and each of its Subsidiaries is and will remain in compliance in all material respects with all U.S. economic sanctions laws, executive orders and implementing regulations as promulgated by the U.S. Treasury Department’s Office of Foreign Assets Control (“ OFAC ”) and all applicable anti-money laundering and counter-terrorism financing provisions of the Bank Secrecy Act of 1970 and all regulations issued pursuant to any of the foregoing. No Loan Party and no Subsidiary (i) is a Person designated by the U.S. government on the list of the Specially Designated Nationals and Blocked Persons (the “ SDN List ”) with which a U.S. Person cannot deal with or otherwise engage in business transactions, (ii) is a Person who is otherwise the target of U.S. economic sanctions laws such that a U.S. Person cannot deal or otherwise engage in business transactions with such Person or (iii) is controlled by (including without limitation by virtue of such person being a director or owning voting shares or interests), or acts, directly or indirectly, for or on behalf of, any person or entity on the SDN List, a terrorist list maintained by a U.S. Government Authority or a foreign government that is the target of U.S. economic sanctions prohibitions such that the entry into, or performance under, this Agreement or any other Loan Document would be prohibited under U.S. law.

 

  5.20.2             PATRIOT Act . The Loan Parties and each of their Affiliates are in compliance in all material respects with (a) the Trading with the Enemy Act, and each of the foreign assets control regulations of the United States Treasury Department (31 C.F.R., Subtitle B Chapter V, as amended) and any other enabling legislation or executive order relating thereto and (b) the PATRIOT Act. No part of the proceeds of any Loan will be used directly or indirectly for any payments to any government official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977.

 

5.21           Non-Competes . None of the Loan Parties nor any of their executive officers is subject to a non-compete agreement that prohibits or would materially interfere with the development, commercialization or marketing of any Product.

 

Section 6.               Affirmative Covenants . Until all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted) are Paid in Full, each of Holdings and the Borrower agrees that, unless at any time the Lender shall otherwise expressly consent in writing, it will:

 

6.1            Information . Furnish to the Agent and the Lender:

 

6.1.1             Annual Report . As soon as available and in any event within 90 days (or such earlier date on which Borrower is required to file a Form 10-K under the Exchange Act) after the end of each Fiscal Year, beginning with the Fiscal Year ending December 31, 2015, (i) the consolidated balance sheet of Holdings as of the end of such Fiscal Year and related consolidated statements of income, cash flows and stockholders’ equity for such Fiscal Year, in comparative form with such financial statements as of the end of, and for, the preceding Fiscal Year, and notes thereto, all prepared in accordance with GAAP and accompanied by an opinion of BDO USA, LLP or other independent public accountants of recognized national standing (which opinion shall not be qualified as to scope or contain any explanatory paragraph expressing substantial doubt about the ability of Holdings to continue as a going concern), stating that such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Holdings as of the dates and for the periods specified in accordance with GAAP, and (ii) a narrative report and management’s discussion and analysis of the financial condition and results of operations of Holdings for such Fiscal Year, as compared to amounts for the previous Fiscal Year (it being understood that the information required by clauses (i) and (ii) may be furnished in the form of a Form 10-K filed with the SEC via the EDGAR System).

 

40
 

 

6.1.2             Quarterly Reports . As soon as available and in any event within 45 days (or such earlier date on which Holdings is required to file a Form 10-Q under the Exchange Act) after the end of each of the first three Fiscal Quarters of each Fiscal Year, beginning with the Fiscal Quarter ending June 30, 2015, (i) the consolidated balance sheet of Holdings as of the end of such Fiscal Quarter and related consolidated statements of income and cash flows for such Fiscal Quarter and for the then elapsed portion of the Fiscal Year, in comparative form with the consolidated statements of income and cash flows for the comparable periods in the previous Fiscal Year, and notes thereto, all prepared in accordance with GAAP and accompanied by a certificate of the chief financial officer of Holdings stating that such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Holdings as of the date and for the periods specified in accordance with GAAP consistently applied, and on a basis consistent with audited financial statements referred to in Section 6.1.1 , subject to normal year-end audit adjustments, and (ii) a narrative report and management’s discussion and analysis, of the financial condition and results of operations for such Fiscal Quarter and the then elapsed portion of the Fiscal Year, as compared to the comparable periods in the previous Fiscal Year (it being understood that the information required by this Section 6.1.2 may be furnished in the form of a Form 10-Q filed with the SEC via the EDGAR System).

 

6.1.3             Monthly Reports . Commencing with respect to the first calendar month after the Closing Date, promptly when available and in any event within 30 days of the end of such calendar month and each subsequent calendar month (including any calendar month ending December 31), a consolidated balance sheet of Holdings and its Subsidiaries as of the end of such calendar month, together with consolidated statements of income and cash flows for such period prepared on a basis consistent with GAAP, together with a comparison with the budget for such period of the current Fiscal Year, all certified by the chief financial officer of Holdings.

 

6.1.4             Compliance Certificate . Contemporaneously with the furnishing of the financial statements required pursuant to Sections 6.1.1 and 6.1.2 , a duly completed Compliance Certificate signed by the chief financial officer of Holdings to the effect that such officer has not become aware of any Event of Default or Default that has occurred and is continuing or, if there is any such Event of Default or Default, describing it and the steps, if any, being taken to cure it, and providing such other information as required thereby.

 

41
 

 

6.1.5          Notice of Default; Litigation; ERISA Matters . Promptly upon becoming aware of any of the following, written notice describing the same and the steps being taken by the Borrower or the applicable Loan Party affected thereby with respect thereto:

 

  (a)            the occurrence of an Event of Default or a Default;

 

  (b)            any litigation, arbitration or governmental investigation or proceeding not previously disclosed by Holdings or the Borrower to the Lender which has been instituted or, to the knowledge of Holdings or the Borrower, is threatened in writing against any Loan Party or any of its Subsidiaries which could reasonably be expected to have a Material Adverse Effect;

 

  (c)            any cancellation or material change in coverage in any insurance maintained by Holdings, the Borrower or any other Loan Party; or

 

  (d)            any other event (including (i) any violation of any Environmental Law or the assertion of any Environmental Claim, (ii) any violation or noncompliance with any Applicable Law or (iii) any breach or non-performance of, or any default under, any contractual obligation of any Loan Party or any of its Subsidiaries), in all cases which could reasonably be expected to have a Material Adverse Effect.

 

6.1.6          Budgets . As soon as practicable, and in any event not later than 90 days after the commencement of each Fiscal Year, a budget of Holdings and its Subsidiaries for such Fiscal Year (including quarterly operating and cash flow budgets) prepared in a manner satisfactory to the Agent, accompanied by a certificate of the chief financial officer of Holdings to the effect that (a) such budget was prepared by Holdings in good faith, (b) Holdings has a reasonable basis for the assumptions contained in such budget and (c) such budget has been prepared in accordance with such assumptions.

 

6.1.7          Other Information . Promptly from time to time, such other information concerning Holdings and any of its Subsidiaries as the Lender or the Agent may reasonably request.

 

42
 

 

6.2             Books; Records; Inspections .

 

(a)            Keep, and cause each Loan Party and each of its Subsidiaries to keep, its books and records in accordance with sound business practices sufficient to allow the preparation of financial statements in accordance with GAAP.

 

(b)            Permit, and cause each other Loan Party to permit, at reasonable times during business hours and with reasonable prior notice, the Agent, the Lender, or any representative of the foregoing to: (i) inspect (at the sole expense of the Borrower) the properties and operations of Holdings, the Borrower or any such Loan Party; (ii) visit any or all of its offices, to discuss its financial matters with its directors or officers and its independent auditors, if any (and Holdings and the Borrower hereby authorize such independent auditors, if any, to discuss such financial matters with the Lender or the Agent or any representative thereof), (iii) examine (and, at the expense of the Borrower, photocopy extracts from) any of its books or other records; and (iv)(A) inspect (at the sole expense of the Borrower) the Collateral and other tangible assets of Holdings, the Borrower or any such Loan Party, (B) perform appraisals of the equipment of Holdings, the Borrower or any such Loan Party, and (C) inspect, audit, check and make copies of and extracts from the books, records, computer data, computer programs, journals, orders, receipts, correspondence and other data relating to any Collateral, for purposes of or otherwise in connection with conducting a review, audit or appraisal of such books and records. If an Event of Default has occurred and is continuing, the Agent, the Lender, or any representative of the foregoing may take any of the actions specified in clauses (i) through (iv) of this Section 6.2(b) without notice to the Borrower. Notwithstanding the foregoing, except during the continuance of an Event of Default, all visits and inspections by the Agent, the Lender, or any representative thereof pursuant to this Section 6.2(b) in excess of one time during a calendar year shall not be at the Loan Parties’ expense, but shall be at the sole expense of the Agent or Lender.

 

6.3             Maintenance of Property; Insurance .

 

(a)            Keep, and cause each other Loan Party and each of its Subsidiaries to keep, all property useful and necessary in the business of Holdings, the Borrower, such other Loan Party or such Subsidiary in good working order and condition, ordinary wear and tear excepted, and maintain, and cause each other Loan Party to maintain, its Intellectual Property in accordance with the provisions of the Collateral Documents.

 

(b)            Maintain, and cause each other Loan Party and each of its Subsidiaries to maintain, with responsible insurance companies, such insurance coverage as shall be required by Applicable Laws, and such other insurance, to such extent and against such hazards and liabilities, as is customarily maintained by companies similarly situated; provided that in any event, such insurance shall insure against all risks and liabilities of the type insured against as of the Closing Date and shall have insured amounts no less than, and deductibles no higher than, those amounts provided for as of the Closing Date. Upon request of the Agent or the Lender and to the extent not previously delivered to the Agent or Lender, the Borrower shall furnish to the Agent or such Lender a certificate setting forth in reasonable detail the nature and extent of all insurance maintained by the Borrower and each other Loan Party; provided , however , that except during the continuance of an Event of Default, such certificate shall not be requested more than once during a calendar year. Holdings and the Borrower shall cause each issuer of an insurance policy to provide the Agent with an endorsement (i) showing the Agent as a lenders’ loss payee with respect to each policy of property or casualty insurance and naming the Agent as an additional insured with respect to each policy of liability insurance, (ii) providing that 30 days’ notice will be given to the Agent prior to any cancellation of such policy and (iii) reasonably acceptable in all other respects to the Agent.

 

43
 

 

(c)            Unless the Borrower provides the Agent with evidence of the continuing insurance coverage required by this Agreement, the Agent may purchase insurance (to the extent of such insurance coverage as shall be required by clause (b) above) at the Borrower’s expense to protect the Agent’s and the Lender’s interests in the Collateral. This insurance may, but need not, protect the Borrower’s and each other Loan Party’s interests. The coverage that the Agent purchases may, but need not, pay any claim that is made against the Borrower or any other Loan Party in connection with the Collateral. The Borrower may later cancel any insurance purchased by the Agent, but only after providing the Agent with evidence that the Borrower has obtained the insurance coverage required by this Agreement. If the Agent purchases insurance for the Collateral, as set forth above, the Borrower will be responsible for the costs of that insurance, including interest and any other charges that may be imposed with the placement of the insurance, until the effective date of the cancellation or expiration of the insurance. The costs of such insurance may be added to the principal amount of either Loan owing hereunder as determined by the Agent in its sole discretion.

 

(d)            To, and to cause each Loan Party and each of its Subsidiaries to: (i) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to its business; (ii) promptly advise the Agent in writing of material infringement of which it is aware by a third party of its Intellectual Property; and (iii) not allow any Intellectual Property material to its business to be abandoned, forfeited or dedicated to the public without the Agent’s prior written consent.

 

6.4             Compliance with Laws and Contractual Obligations; Payment of Taxes and Liabilities . (a) Comply, and cause each other Loan Party and each of its Subsidiaries to comply, with all Applicable Laws   and all indentures, agreements and other instruments binding upon it or its property, except where failure to comply could not reasonably be expected to have a Material Adverse Effect; (b) without limiting clause (a) above, ensure, and cause each other Loan Party and each of its Subsidiaries to ensure, that no Person who owns a controlling interest in or otherwise controls a Loan Party or one of its Subsidiaries is or shall be (i) listed on the Specially Designated Nationals and Blocked Person List maintained by OFAC, the United States Department of the Treasury, and/or any other similar lists maintained by OFAC pursuant to any authorizing statute, executive order or regulation or (ii) a Person designated under Section 1(b), (c) or (d) of Executive Order 13224, any related enabling legislation or any other similar executive orders; (c) without limiting clause (a) above, comply and cause each other Loan Party and each of its Subsidiaries to comply, with all applicable Bank Secrecy Act and anti-money laundering laws and regulations; and (d) timely prepare and file all Tax Returns required to be filed by Applicable Law and pay, and cause each other Loan Party and each of its Subsidiaries to pay, prior to delinquency, all Taxes against it or any of its property, as well as claims of any kind which, if unpaid, could become a Lien on any of its property; provided that the foregoing shall not require the Borrower, any other Loan Party or any of their Subsidiaries to pay any such Tax or charge so long as it shall promptly contest the validity thereof in good faith by appropriate proceedings and shall set aside on its books adequate reserves with respect thereto in accordance with GAAP.

 

44
 

 

6.5             Maintenance of Existence . Maintain and preserve, and (subject to Section 7.4 ) cause each other Loan Party and each of its Subsidiaries to maintain and preserve, (a) its existence and good standing (as applicable) in the jurisdiction of its organization and (b) its qualification to do business and good standing (as applicable) in each jurisdiction where the nature of its business makes such qualification necessary, except, in each case, as not prohibited hereunder and as would not reasonably be expected to have Material Adverse Effect.

 

6.6             Environmental Matters . If any release or disposal of Hazardous Substances shall occur or shall have occurred on or from any real property of any Loan Party or any of its Subsidiaries, cause, or direct the applicable Loan Party or Subsidiary to cause, the prompt containment and removal of such Hazardous Substances and the remediation of such real property as is necessary to comply with all Environmental Laws except as would not reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, Holdings and the Borrower shall, and shall cause each other Loan Party and Subsidiary to, comply with each Applicable Law and judicial or administrative order requiring the performance at any real property by any Loan Party or any of its Subsidiaries of activities in response to the release or threatened release of a Hazardous Substance. If any violation of any Environmental Law shall occur or shall have occurred at any real property or any other assets of any Loan Party or any of its Subsidiaries or otherwise in connection with their operations, cause, or direct the applicable Loan Party or Subsidiary to cause, the prompt correction of such violation.

 

6.7             Further Assurances .

 

(a)             Further Assurances . Promptly upon request by the Agent, take, and cause each other Loan Party and each of its Subsidiaries to take, such additional actions as the Agent may reasonably require from time to time in order (i) to subject to the Liens created by any of the Collateral Documents any of the properties, rights or interests, whether now owned or hereafter acquired, covered or intended to be covered by any of the Collateral Documents, (ii) to perfect and maintain the validity, effectiveness and priority of any of the Collateral Documents and the Liens intended to be created thereby, and (iii) to assure, convey, grant, assign, transfer, preserve, protect and confirm to the Agent and the Lender the rights granted or now or hereafter intended to be granted to the Agent and the Lender under any Loan Document.

 

45
 

 

(b)             Additional Subsidiaries . Without limiting the generality of the foregoing and except as otherwise approved in writing by the Lender, cause, and cause each of the Loan Parties to cause, each of their Subsidiaries (including any such Subsidiary formed or acquired after the Closing Date) other than CFCs to the extent a guaranty of the Obligation by such CFCs could reasonably be expected to result in a material adverse tax consequence for Holdings or the Borrower under Section 956 of the IRC, to guaranty the Obligations and cause each such Subsidiary to grant to the Agent, for the benefit of the Agent and the Lender, a security interest in, subject to the limitations set forth herein or set forth in the Guarantee and Collateral Agreement, all of such Subsidiary’s property to secure such guaranty, in each case pursuant to the execution and delivery of a joinder to the Guarantee and Collateral Agreement and such other documents as may be reasonably requested, each in form and substance reasonably satisfactory to the Agent. Furthermore and except as otherwise approved in writing by the Lender, Holdings and the Borrower shall, and shall cause each of its Subsidiaries (including, any such Subsidiary formed or acquired after the Closing Date) to, pledge (i) all of the Capital Stock of each of its Subsidiaries that are not CFCs and (ii)(A) all of the nonvoting Capital Stock of each of its Subsidiaries that are CFCs, and (B) 65% of the voting Capital Stock of each of its Subsidiaries that are CFCs if the pledge of a greater percentage of such voting Capital Stock could reasonably be expected to result in a material adverse tax consequence for Holdings or the Borrower under Section 956 of the IRC (and 100% of such voting Capital Stock if no such material adverse tax consequence could reasonably be expected), to the Agent, for the benefit of the Lender, to secure the Obligations, in each case pursuant to documents in form and substance reasonably satisfactory to the Agent. In connection with each pledge of Capital Stock that is certificated, as promptly as practicable, Holdings, the Borrower and each other Loan Party shall deliver, or cause to be delivered, to the Agent, irrevocable proxies and stock powers and/or assignments, as applicable, duly executed in blank, in each case pursuant to documents in form and substance satisfactory to the Agent.

 

(c)             Collateral Access Agreements . The Borrower and each other Loan Party shall be under an ongoing obligation to obtain a Collateral Access Agreement from the lessor of each leased property and bailee in possession of any Collateral with a book value in excess of $100,000 with respect to each location in the United States where any Collateral is stored or located (other than hospital or acute care sites on which CareView Systems are installed), which Collateral Access Agreement shall be in form and substance reasonably satisfactory to the Agent.

 

(d)             Intellectual Property . Without limiting the requirements of the Collateral Documents, in the event that any Loan Party shall acquire, develop, or otherwise obtain, register or seek to register any Patent, Copyright, Trademark, or other Intellectual Property with any United States Governmental Authority, or obtain, register or seek to register any application for, or license in respect of, any of the foregoing, Holdings and the Borrower shall notify the Agent, in the case of an application to register a Copyright, within five (5) Business Days thereof, and in the case of any other application seeking to register or apply for Intellectual Property, on a quarterly basis concurrently with the delivery of the reports required under Section 6.1.2 , and shall promptly thereafter execute and deliver to the Agent, for the benefit of the Lender, such Intellectual Property security agreements, other Collateral Documents or other documents as the Agent may request in order to secure and perfect the security interest in respect of such Intellectual Property (it being understood that this sentence only applies to registered Intellectual Property).

 

46
 

 

(e)             Registered Intellectual Property . Holdings and Borrower shall (i) take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to preserve and maintain the Registered Intellectual Property (including Borrower’s rights as an exclusive licensee under the Intelliview License Agreement), including payment of applicable maintenance fees or annuities, and (ii) prosecute any corrections, substitutions, reissues, reviews and reexaminations of Patents included in the Registered Intellectual Property.

 

6.8             Conference Calls . After delivery of the financial statements pursuant to Sections 6.1.1 and 6.1.2 , at the request of the Agent, cause the chief financial officer of Holdings to participate in conference calls with the Agent and the Lender to discuss, among other things, the financial condition of the Loan Parties and any financial or earnings reports.

 

6.9             Tranche One Milestone Notice . As promptly as practicable and in any event within three (3) Business Days after the satisfaction of the Tranche One Milestone, Holdings and the Borrower shall deliver to Agent the Tranche One Milestone Notice.

 

6.10           Tranche Two Milestone Notice . As promptly as practicable and in any event within three (3) Business Days after the satisfaction of the Tranche Two Milestone, Holdings and the Borrower shall deliver to Agent the Tranche Two Milestone Notice.

 

6.11           Post-Closing Obligations .

 

(a)             Insurance . Within 15 days after the Closing Date, Holdings shall deliver endorsements naming the Agent as lenders’ loss payee and/or additional insured, as applicable, in form and substance reasonably acceptable to the Agent for the insurance policies required by Section 6.3(b) .

 

(b)             Collateral Access Agreement . Holdings shall use commercially reasonable efforts to deliver within 30 days of the request by the Agent therefor a Collateral Access Agreement from the lessor of each leased property and bailee in possession of any Collateral with a book value in excess of $100,000 with respect to each location in the United States where any Collateral is stored or located (other than hospital or acute care sites on which CareView Systems are installed), which Collateral Access Agreement shall be in form and substance reasonably satisfactory to the Agent as required by Section 6.7(c) . The Agent hereby requests the delivery of a Collateral Access Agreement for the premises leased by the Borrower and located at 405 State Highway 121, Suite B-240, Lewisville, TX 75067.

 

47
 

 

Section 7.               Negative Covenants . Until the Obligations are Paid in Full, each of Holdings and the Borrower agrees that, unless at any time the Agent, on behalf of the Lender, shall otherwise expressly consent in writing (such consent to be withheld in the Lender’s sole discretion), it will:

 

7.1             Debt . Not, and not suffer or permit any Loan Party or any other Subsidiary, to, create, incur, assume or suffer to exist any Debt, except:

 

(a)            Obligations under this Agreement and the other Loan Documents;

 

(b)            Debt in respect of Capital Leases and purchase money Debt, in each case incurred in the ordinary course of business for the purpose of financing all or any part of the cost of acquiring, repair, construction or improvement of fixed or capital assets; provided that the aggregate principal amount of all such Debt at any time outstanding shall not exceed $1,000,000;

 

(c)            (i) Debt of the Borrower to any Loan Party that is a Wholly-Owned Subsidiary or Debt of any Loan Party that is a Wholly-Owned Subsidiary to the Borrower or another Loan Party that is a Wholly-Owned Subsidiary; provided that all such Debt in this clause (i) shall be evidenced by a global intercompany demand note in form and substance satisfactory to the Agent and pledged and delivered to the Agent pursuant to the applicable Collateral Document as additional collateral security for the Obligations, and the obligations under such demand note shall be subordinated to the Obligations hereunder in a manner satisfactory to the Agent; (ii) Debt of a Loan Party to a non-Loan Party permitted by Section 7.10(a)(ii) ; and (iii) Debt of any Wholly-Owned Subsidiary that is not a Loan Party to another Wholly-Owned Subsidiary that is not a Loan Party;

 

(d)            Debt existing as of the Closing Date and described in Section 7.1 of the Disclosure Letter (other than the HealthCor Obligations), and any Permitted Refinancing thereof;

 

(e)            Contingent Obligations arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions permitted under Section 7.4 ;

 

(f)            HealthCor Obligations in an aggregate principal amount not to exceed the aggregate principal amount of the HealthCor Notes outstanding as of the Closing Date, plus accrued interest thereon that is paid-in-kind and added to the principal balance thereof in accordance with the terms of the HealthCor Debt Documents, and any Permitted Refinancing thereof so long as concurrently with the closing of any such Permitted Refinancing the lenders or investors (or any agent with the power to enter into a binding obligation on behalf of such lenders or investors) in respect of such Permitted Refinancing enter into an intercreditor agreement satisfactory in form and substance to the Agent;

 

(g)            Debt incurred in connection with the financing of insurance premiums in the ordinary course of business;

 

(h)            Debt arising from the honoring by a bank or other financial institution of a check, draft or similar instrument drawn against insufficient funds in the ordinary course of business, provided that such Debt is extinguished within two (2) Business Days of notice to Holdings, the Borrower or the relevant Subsidiary of its incurrence;

 

48
 

 

(i)            guaranties by the Borrower of the Debt of any Loan Party that is a Wholly-Owned Subsidiary or guaranties by any Subsidiary of the Debt of the Borrower in each case so long as such Debt is otherwise permitted under Section 7.1(a) or (b) ;

 

(j)            reimbursement obligations under corporate credit cards not to exceed $750,000 in the aggregate at any time; and

 

(k)            other unsecured Debt in an amount not to exceed $250,000 in the aggregate at any time outstanding.

 

7.2             Liens . Not, and not suffer or permit any Loan Party or any other Subsidiary to, create or permit to exist any Lien on any of its real or personal properties, assets or rights of whatsoever nature (whether now owned or hereafter acquired), except :

 

(a)            Liens arising under the Loan Documents;

 

(b)            Liens for Taxes or other governmental charges not at the time delinquent or thereafter payable without penalty, or being diligently contested in good faith by appropriate proceedings and for which it maintains adequate reserves in accordance with GAAP and the execution or other enforcement of which is effectively stayed;

 

(c)            (i) Liens of carriers, warehousemen, mechanics, customs brokers, landlords and materialmen and other similar Liens imposed by law and (ii) Liens consisting of pledges or deposits incurred in connection with worker’s compensation, unemployment compensation and other types of social security (excluding Liens arising under ERISA) or in connection with surety bonds, bids, performance bonds and similar obligations for sums not overdue or being diligently contested in good faith by appropriate proceedings and not involving any deposits or advances or borrowed money or the deferred purchase price of property or services and, in each case, for which it maintains adequate reserves in accordance with GAAP;

 

(d)            Liens existing as of the Closing Date and described in Section 7.2 of the Disclosure Letter (other than Liens securing the HealthCor Obligations);

 

(e)            Liens securing Debt permitted by Section 7.1(b) ; provided , however, that any such Lien (i) attaches only to the property being leased or financed and any accessions thereto and proceeds thereof and (ii) attaches to such property within 30 days of the acquisition thereof and attaches solely to the property so acquired and any accessions thereto and proceeds thereof;

 

(f)            Liens securing the HealthCor Obligations permitted by Section 7.1(f) , provided that such Liens are subject to the terms of the Intercreditor Agreement, and Liens securing any Permitted Refinancing of the HealthCor Obligations so long as such Permitted Refinancing is incurred in compliance with Section 7.1(f) ;

 

49
 

 

(g)            attachments, appeal bonds, judgments and other similar Liens in connection with judgments the existence of which do not constitute an Event of Default;

 

(h)            easements, encroachments, rights of way, leases, subleases, restrictions, minor defects or irregularities in title and other similar Liens not interfering in any material respect with the ordinary conduct of the business of Holdings, the Borrower or any Subsidiary;

 

(i)            any interest or title of a lessor or sublessor under any lease (other than a Capital Lease) or of a licensor or sublicensor under any license, in each case permitted by this Agreement;

 

(j)            leases, licenses, subleases or sublicenses granted to third parties in the ordinary course of business which do not interfere in any material respect with, or materially detract from the value of, the business of Holdings and its Subsidiaries, taken as a whole, as determined by the Borrower in its good faith business judgment;

 

(k)            Liens arising from precautionary uniform commercial code financing statements filed under any lease (other than a Capital Lease) permitted by this Agreement;

 

(l)            bankers’ liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection with deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses;

 

(m)            Liens consisting of pledged cash securing Debt permitted by Section 7.1(j) ; and

 

(n)            the replacement, extension or renewal of any Lien permitted by clause (d) above upon or in the same property subject thereto arising out of the Permitted Refinancing of the Debt secured thereby.

 

7.3             Restricted Payments . Not, and not suffer or permit any Loan Party or any other Subsidiary to, (i) declare or make any dividend payment or other distribution of assets, properties, cash, rights, obligations or securities on account of any Capital Stock or Stock Equivalent, (ii) purchase, redeem or otherwise acquire for value any Capital Stock now or hereafter outstanding (including the Capital Stock that comprises any Investment in a joint venture in which a Subsidiary is a stockholder or partner) or (iii) make any payment or prepayment of principal of, premium, if any, interest, fees, redemption, exchange, purchase, retirement, defeasance, sinking fund or similar payment with respect to, Debt that is subordinated by its terms to the payment of the Obligations (the items described in clauses (i) , (ii) and (iii) above are referred to as “ Restricted Payments ”), except:

 

(a)            any Subsidiary may declare and pay dividends to, repay intercompany debt owed to, and make internal profit-sharing payments to, (i) the Borrower, (ii) any other Loan Party that is a Wholly-Owned Subsidiary or (iii) so long as such Subsidiary is not a Loan Party, any other Subsidiary that is not a Loan Party;

 

50
 

 

(b)            any Loan Party may purchase, redeem or acquire for value any Capital Stock or Stock Equivalents issued by any Loan Party that is a Wholly-Owned Subsidiary;

 

(c)            each Loan Party may declare and make dividend payments or other distributions payable solely in the common stock or other common equity interests of such Loan Party;

 

(d)            Holdings may make cash payments in lieu of the issuance of fractional shares upon conversion or in connection with the exercise of warrants or similar securities;

 

(e)            Holdings may make repurchases of Capital Stock from any present or former employee, director, officer or consultant (or the assigns, estate, heirs or current or former spouses thereof) upon the death, disability or termination of employment of such employee, director, officer or consultant, pursuant to a stock repurchase program approved by the Board of Directors of Holdings, provided that such repurchases do not exceed $1,000,000 in the aggregate during the term of this Agreement;

 

(f)            the Borrower may make Restricted Payments to Holdings to the extent necessary to permit Holdings to pay general administrative costs and expenses (which may include out-of-pocket legal, accounting and filing costs, other reasonable and customary corporate overhead expenses incurred in the ordinary course of business and customary transaction-based fees and expenses of third-party investment bankers and advisers for services rendered to Holdings relating to Holdings and its Subsidiaries), so long as Holdings applies the amount of any such Restricted Payment for such purpose within 90 days of receipt;

 

(g)            the Borrower may make Restricted Payments to Holdings to the extent necessary to permit Holdings to discharge the consolidated, combined or similar tax liabilities of Holdings and its Subsidiaries or other fees necessary to maintain the legal existence of Holdings, in each case so long as Holdings applies the amount of any such Restricted Payment for such purpose;

 

(h)            payments in respect of the HealthCor Obligations permitted by the terms of the Intercreditor Agreement, and any dividend by the Borrower to Holdings in order to permit Holdings to make such payments; and

 

(i)             the conversion of the HealthCor Debt Obligations into, or the exchange of the HealthCor Debt Obligations for, Capital Stock of Holdings other than Disqualified Capital Stock, together with cash in lieu of fractional shares of such Capital Stock in an amount not to exceed $50,000.

 

51
 

 

For the avoidance of doubt, Investments permitted by Section 7.10 shall not constitute Restricted Payments.

 

7.4             Mergers; Consolidations; Asset Sales .

 

(a)            Not, and not suffer or permit any Loan Party or any other Subsidiary to, be a party to any merger, consolidation or amalgamation, except for any such merger or consolidation (i) of any Subsidiary into (A) the Borrower (so long as the Borrower survives such merger), (B) any Loan Party that is a Wholly-Owned Subsidiary (so long as such Loan Party that is a Wholly-Owned Subsidiary survives such merger), or (C) so long as such Subsidiary is not a Loan Party, any Wholly-Owned Subsidiary that is not a Loan Party, or (ii) in which the Obligations shall be Paid in Full prior to or concurrently with the consummation of such transaction.

 

(b)            Not, and not suffer or permit any Loan Party or any other Subsidiary to, sell, transfer, dispose of, convey, lease or license any of its assets (including Intellectual Property) or the Capital Stock of any Loan Party or any other Subsidiary, or sell or assign with or without recourse any receivables (any such transaction, a “Disposition”), except:

 

(i)            Dispositions of inventory, worn-out or surplus equipment, all in the ordinary course of business;

 

(ii)           the abandonment or other Disposition of Intellectual Property that is no longer useful or material to the conduct of the business of any Loan Party as determined by such Loan Party in its reasonable business judgment;

 

(iii)          Dispositions of cash and Cash Equivalent Investments;

 

(iv)          non-exclusive licenses, sublicenses, leases or subleases (including any non-exclusive license or sublicense of Intellectual Property) granted to third parties in the ordinary course of business not interfering with the business of the Loan Parties in any material respect, as determined by the Borrower in its reasonable business judgement;

 

(v)           the granting of Liens permitted under Section 7.2 , Restricted Payments permitted by Section 7.3 , transactions permitted by Section 7.4(a) and Investments permitted by Section 7.10 ;

 

(vi)          Dispositions as a result of any casualty or other insured damage to, or any taking under power of eminent domain or by condemnation or similar proceeding of, any property or asset of any Loan Party; provided that the proceeds thereof are promptly applied to replace such assets;

 

(vii)         other Dispositions not to exceed $100,000 per year;

 

52
 

 

(viii)        Dispositions among the Loan Parties; and

 

(ix)           Dispositions in which the Obligations shall be Paid in Full prior to or concurrently with the consummation of such transaction.

 

7.5             Modification of Organizational Documents; HealthCor Debt Documents . Not (a) waive, amend or modify, and not suffer or permit any waiver, amendment or modification of, any term of the charter, limited liability company agreement, partnership agreement, articles of incorporation, by-laws or other organizational documents of Holdings, the Borrower or any other Loan Party or any Subsidiary, in each case except for those amendments and modifications that do not materially adversely affect the interests of the Agent or the Lender under the Loan Documents or in the Collateral (it being understood and agreed that any adverse impact on the effectiveness or validity of any Collateral Document or the Liens granted to the Agent thereunder shall each be deemed to materially adversely affect such interests of the Agent and the Lender) or (b) amend, or permit to be amended, the terms of the limited liability company operating agreement of CareView Operations, L.L.C., a Texas limited liability company and a Wholly-Owned Subsidiary of Borrower, to provide that the limited liability company interests of such issuer shall be treated as securities governed by Chapter 8 of the Uniform Commercial Code as in effect from time to time in the State of Texas.

 

Notwithstanding the foregoing, each Loan Party may change its name, provided that such Loan Party (i) gives at least ten (10) days’ prior written notice to the Agent and (ii) concurrently with the effectiveness of such name change, delivers to the Agent for filing properly completed Uniform Commercial Code financing statements reflecting the new name and any other filings and documents required by law or the Loan Documents to provide the Agent with a continuing, perfected first priority Liens (subject only to Permitted Liens) in the Collateral owned by such Loan Party. Holdings and the Borrower shall not, and shall not permit any Loan Party or any other Subsidiary to, amend, modify or otherwise change the terms of the HealthCor Debt Documents in a manner prohibited by the terms of the Intercreditor Agreement.

 

7.6             Use of Proceeds . Not use the proceeds of the Loan for any purposes other than solely as expressly provided in Section 2.1.2 .

 

7.7             Transactions with Affiliates . Not, and not suffer or permit any Loan Party or any other Subsidiary to, enter into any transaction or arrangement with any Affiliate of the Borrower, of any such Loan Party or of any such Subsidiary, except:

 

(a)            Restricted Payments permitted by Section 7.3 , intercompany loans among Loan Parties permitted by Section 7.1(c) , transactions permitted by Section 7.4(a) and Investments permitted by Section 7.10(a) and (b) ;

 

53
 

 

(b)            transactions that are consummated on arm’s-length terms, approved by the Board of Directors of Holdings;

 

(c)            payment of compensation and benefits (including customary indemnities) to officers, directors and employees of the Loan Parties or a Subsidiary for actual services rendered to the Loan Parties or such Subsidiary in the ordinary course of business; and

 

(d)            Investments permitted pursuant to Section 7.10(h) and (i) .

 

7.8             Inconsistent Agreements . Not, and not suffer or permit any other Loan Party or any other Subsidiary to, enter into any agreement containing any provision which would (i) prohibit the Borrower or any other Loan Party from granting to the Agent and the Lender a Lien on any of its assets that constitute Collateral or prohibit any other Subsidiary from granting to the Agent and the Lender a Lien on any of its assets or (ii) other than pursuant to the Loan Documents, create or permit to exist or become effective any encumbrance or restriction on the ability of any other Subsidiary to (x) pay dividends or make other distributions to the Borrower or any Wholly-Owned Subsidiary, or pay any Debt owed to the Borrower or any Wholly-Owned Subsidiary, (y) make loans or advances to the Borrower or any Wholly-Owned Subsidiary or (z) transfer any of its assets or properties to the Borrower or any Wholly-Owned Subsidiary, except, in each case above: (a) negative pledges and restrictions on Liens in favor of any holder of Debt under agreements permitted under Section 7.1(b) , (d) , and (j) but solely to the extent any negative pledge or limitation on Liens relates to the property that is the subject of such Debt or applicable agreement or the cash securing such obligations and the proceeds and products thereof, (b) customary restrictions on leases, subleases, licenses or asset sale agreements otherwise permitted hereby so long as such restrictions relate to the assets subject thereto, (c) customary provisions restricting assignment of any agreement entered into in the ordinary course of business, (d) prohibitions and limitations that exist pursuant to Applicable Law and (e) the prohibitions and limitations set forth in the HealthCor Debt Documents as in existence on the Closing Date or as may be amended pursuant to the terms hereof and of the Intercreditor Agreement.

 

7.9             Business Activities . Not, and not suffer or permit any Loan Party to, engage in any line of business other than the businesses described in Holdings’ Form 10-K filed with the SEC via the EDGAR System on March 31, 2015 engaged in on the Closing Date and businesses reasonably related thereto.

 

7.10           Investments . Not, and not suffer or permit any Loan Party or any other Subsidiary to, make or permit to exist, any Investment in any other Person, except the following:

 

(a)            Investments (i) between or among the Borrower and the Loan Parties that are Wholly-Owned Subsidiaries; (ii) by Subsidiaries that are not Loan Parties in Loan Parties; provided that such Investments permitted by this clause (ii) shall be limited to unsecured Debt subordinated in right of payment to the payment in full of the Obligations pursuant to the terms of a subordination agreement acceptable to Agent; (iii) by Subsidiaries that are not Loan Parties in Subsidiaries that are not Loan Parties; and (iv) by Holdings in the Borrower

 

54
 

 

(b)            Investments constituting Debt permitted by Section 7.1(c) ;

 

(c)            Contingent Obligations constituting Debt permitted by Section 7.1 ;

 

(d)            Cash and Cash Equivalent Investments;

 

(e)            Investments existing as of the Closing Date and set forth in Section 7.10 of the Disclosure Letter;

 

(f)            extensions of trade credit in the ordinary course of business;

 

(g)            notes payable, or stock or other securities issued by an account debtor pursuant to settlement in the ordinary course of business of such account debtor’s accounts receivable owing to Holdings or its Subsidiaries;

 

(h)            Investments consisting of non-cash loans to employees, officers, directors or consultants for the purpose of purchasing Capital Stock of Holdings so long as the proceeds of such loans are used entirely to pay the purchase price of such Capital Stock;

 

(i)             Investments consisting of loans or advances to employees, officers and directors of a Loan Party for reasonable travel and entertainment expenses and reasonable relocation costs and expenses and other ordinary business purposes; provided , however , that the aggregate outstanding principal amount of all loans permitted pursuant to this clause (i) shall not exceed $250,000 at any time; and

 

(j)             other Investments in an aggregate amount not to exceed $250,000 at any time outstanding.

 

7.11           Fiscal Year . Not, and not suffer or permit any other Loan Party to, change its Fiscal Year without the prior written consent of the Agent.

 

7.12           Deposit Accounts and Securities Accounts . Not, and not suffer or permit any Loan Party to, maintain or establish any deposit account or securities account other than the deposit accounts and securities accounts set forth in Section 7.12 of the Disclosure Letter without prior written notice to the Agent and unless the Agent, the Borrower or such other applicable Loan Party and the bank or securities intermediary at which such deposit account or securities account, as applicable, is to be opened or maintained enter into a Control Agreement regarding such deposit account or securities account, as applicable, on terms reasonably satisfactory to the Agent.

 

55
 

 

7.13             Sale-Leasebacks . Not, and not suffer or permit any Loan Party or any other Subsidiary to, engage in a sale leaseback, synthetic lease or similar transaction involving any of its assets.

 

7.14             Hazardous Substances . Not, and not suffer or permit any other Loan Party or any of its Subsidiaries to, cause or suffer to exist any release of any Hazardous Substances at, to or from any real property owned, leased, subleased or otherwise operated or occupied by any Loan Party or any of its Subsidiaries that would violate any Environmental Law, form the basis for any Environmental Claims or otherwise adversely affect the value or marketability of any real property (whether or not owned by any Loan Party), other than such violations, Environmental Claims and effects that would not, in the aggregate, be reasonably be expected to have a Material Adverse Effect. Notwithstanding the foregoing, under no circumstances will any Loan Party cause or suffer to exist any disposal of any Hazardous Substances at, on, under or in any real property owned, leased, subleased, or otherwise operated or occupied by any Loan Party.

 

7.15             ERISA Liability . Not suffer or permit any liability under ERISA and the sponsorship of any “pension plan” or any liability subject to Title IV of ERISA.

 

7.16             Liquidity . Not suffer or permit Liquidity to be less than $3,250,000 at any time.

 

7.17             Permitted Activities of Holdings . Holdings shall not engage in any business, operations or activity, or hold any property, other than (i) holding Capital Stock of the Borrower, CareView Operations, L.L.C., a Texas limited liability company, CareView Hillcrest JV, and CareView Saline JV, (ii) issuing, selling and converting its own Capital Stock, (iii) paying taxes (and participating in tax, accounting and other administrative matters as a member of a consolidated group), (iv) holding directors’ and shareholders’ meetings, preparing corporate and similar records and other activities required to maintain its separate corporate or other legal structure, (v) preparing reports to, and preparing and making notices to and filings with, the SEC, other Governmental Authorities and its stockholders, (vi) receiving, and holding proceeds of, Restricted Payments from the Borrower, and making Restricted Payments, each to the extent permitted by Section 7.3 , (vii) the performance of its obligations with respect to the Loan Documents and the HealthCor Debt Documents, (viii) providing indemnification to its officers and directors, (ix) the making of Investments in the Borrower, (x) opening deposit accounts and security accounts permitted by Section 7.12 ; (xi) ownership of Intellectual Property and (xii) any activities incidental or related to the businesses, operations or activities described in clauses (i) through (xi) ; provided , that in no event shall Holdings create or acquire any Subsidiary (other than Borrower) that is not also a Subsidiary of Borrower.

 

56
 

 

Section 8. Events of Default; Remedies .

 

8.1            Events of Default . Each of the following shall constitute an Event of Default under this Agreement:

 

8.1.1         Non-Payment of Credit Agreement . (a) Any default in the payment when due of the principal of any Loan, or (b) any default not cured within three (3) Business Days in the payment when due of any interest, fee, or other amount payable hereunder, including any payment in respect of any amount due under any other Loan Document, shall occur.

 

8.1.2         No Default Under Other Debt; Material Contracts .

 

(a)            Any default shall occur under the terms applicable to any Debt (other than the Obligations and the HealthCor Obligations) of any Loan Party or any of its Subsidiaries having an aggregate principal amount (for all such Debt so affected and including undrawn committed or available amounts and amounts owing to all creditors under any combined or syndicated credit arrangement) exceeding $500,000 and such default shall result in the acceleration of the maturity of such Debt or permit the holder or holders thereof, or any trustee or agent for such holder or holders, to cause such Debt to become due and payable (or require the Borrower, any other Loan Party or any of their Subsidiaries to purchase or redeem such Debt or post cash collateral in respect thereof) prior to its scheduled maturity.

 

(b)            Any “Event of Default” (as defined in any of the HealthCor Debt Documents) by any Loan Party shall occur in respect of the HealthCor Obligations.

 

(c)            Any breach or non-performance of, or any default under, any material agreement, indenture, instrument or other document of any Loan Party or any of its Subsidiaries shall have occurred.

 

8.1.3         Bankruptcy; Insolvency . (i) Any Loan Party or any of its Subsidiaries becomes insolvent or generally fails to pay, or admits in writing its inability or refusal to pay, debts as they become due; (ii) any Loan Party or any of its Subsidiaries commences any case, proceeding or other action (x) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (y) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets; or (iii) there shall be commenced against any Loan Party or any of its Subsidiaries any case, proceeding or other action of a nature referred to in clause (ii) above that (x) results in the entry of an order for relief or any such adjudication or appointment or (y) remains undismissed or undischarged for a period of 60 days; (iv) there shall be commenced against any Loan Party or any of its Subsidiaries any case, proceeding or other action seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of its assets that results in the entry of an order for any such relief that shall not have been vacated, discharged, or stayed or bonded pending appeal within 60 days from the entry thereof; (v) any Loan Party shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clause (ii) , (iii) or (iv) above; or (vi) any Loan Party or any of its Subsidiaries shall make a general assignment for the benefit of its creditors.

 

57
 

 

8.1.4         Non-Compliance with Loan Documents . (a) Failure by Holdings or the Borrower to comply with or to perform any covenant set forth in Sections 6.1 , 6.5 , 6.8 , 6.9 , 6.10 and 7 ; or (b) failure by any Loan Party to comply with or to perform any other provision of this Agreement or any other Loan Document applicable to it (and not constituting an Event of Default under any other provision of this Section 8 ), and continuance of such failure described in this clause (b) for 30 days.

 

8.1.5         Representations; Warranties . Any representation or warranty made by or in respect of any Loan Party herein or any other Loan Document is breached or is false or misleading in any material respect (without duplication of any materiality qualifier contained therein), or any schedule, certificate, financial statement, report, notice or other writing furnished by or on behalf of any Loan Party to the Agent or the Lender in connection herewith is false or misleading in any material respect on the date as of which the facts therein set forth are stated or certified.

 

8.1.6         Judgments .

 

(a)            Final judgment or judgments for the payment of money aggregating in excess of $500,000 shall be rendered against any Loan Party or any of its Subsidiaries and shall not have been paid, discharged or vacated or had execution thereof stayed pending appeal within 30 days after entry or filing of such judgments, or shall not have been discharged within 30 days after the expiration of such stay; provided , however , that any judgment which is covered by insurance or an indemnity from a credit-worthy party shall not be included in calculating the $500,000 amount set forth above so long as Holdings provides the Agent a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to the Agent) to the effect that such judgment is covered by insurance or an indemnity and that Holdings will receive the proceeds of such insurance or indemnity within 30 days of the issuance of such judgment; or

 

(b)            One or more non-monetary judgments, orders or decrees shall be rendered against any one or more of the Loan Parties or any of their respective Subsidiaries which has had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, and there shall be any period of thirty (30) consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect.

 

58
 

 

8.1.7          Invalidity of Collateral Documents . Any Collateral Document shall cease to be in full force and effect; or any Loan Party shall contest in any manner the validity, binding nature or enforceability of any Collateral Document.

 

8.1.8          Invalidity of Subordination Provisions . Any subordination provision in any document or instrument governing Debt that is intended to be subordinated to the Obligations or any subordination provision in any subordination agreement that relates to any such Debt, or any subordination provision in any guaranty by any Loan Party of any such Debt, shall cease to be in full force and effect, or any Person (including the holder of any applicable Debt) shall contest in any manner the validity, binding nature or enforceability of any such provision.

 

8.1.9          Change of Control . (a) A Change of Control shall occur, or (b) a “Change of Control” or other similar event shall occur, as defined in, or under, any indenture, agreement, instrument or other documentation evidencing or otherwise relating to any Debt in excess of $500,000.

 

8.2            Remedies . If any Event of Default described in Section 8.1.3 shall occur, the Loans and all other Obligations shall become immediately due and payable and all outstanding Commitments shall terminate, all without presentment, demand, protest or notice of any kind; and, if any other Event of Default shall occur and be continuing, the Agent may, and upon the written request of the Lender shall, declare all or any part of the Loans and other Obligations to be due and payable and/or all or any part of the Commitments then outstanding to be terminated, whereupon the Loans and other Obligations shall become immediately due and payable (in whole or in part, as applicable), and such Commitments shall immediately terminate (in whole or in part, as applicable), all without presentment, demand, protest or notice of any kind. Any cash collateral delivered hereunder shall be applied by the Agent to any remaining Obligations and any excess remaining after the Obligations shall have been Paid in Full shall be delivered to the Borrower or as a court of competent jurisdiction may elect. Upon the declaration of the Obligations to be, or the Obligations becoming, due and payable pursuant to this Section 8.2 such Obligations shall bear interest at the Default Rate as provided in Section 2.3.1 .

 

59
 

 

Section 9. The Agent .

 

9.1             Appointment; Authorization . Lender hereby irrevocably appoints, designates and authorizes the Agent to take such action on its behalf under the provisions of this Agreement and each other Loan Document and to exercise such powers and perform such duties as are expressly delegated to it by the terms of this Agreement or any other Loan Document, together with such powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary contained elsewhere in this Agreement or in any other Loan Document, the Agent shall not have any duty or responsibility except those expressly set forth herein, nor shall the Agent have or be deemed to have any fiduciary relationship with the Lender, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against the Agent.

 

9.2             Delegation of Duties . The Agent may execute any of its duties under this Agreement or any other Loan Document by or through agents, employees or attorneys in fact and shall be entitled to advice of counsel concerning all matters pertaining to such duties. The Agent shall not be responsible for the negligence or misconduct of any agent or attorney in fact that it selects with reasonable care.

 

9.3             Limited Liability . None of the Agent or any of its directors, officers, employees or agents shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby (except to the extent resulting from its own gross negligence or willful misconduct as determined in a final non-appealable judgment by a court of competent jurisdiction), or (b) be responsible in any manner to the Lender for any recital, statement, representation or warranty made by any Loan Party or Affiliate of any Loan Party, or any officer thereof, contained in this Agreement or in any other Loan Document, or in any certificate, report, statement or other document referred to or provided for in, or received by the Agent under or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document (or the creation, perfection or priority of any Lien or security interest therein), or for any failure of any Loan Party or any other party to any Loan Document to perform its Obligations hereunder or thereunder. The Agent shall not be under any obligation to the Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of any Loan Party or Affiliate of any Loan Party.

 

9.4             Successor Agent . The Agent may resign as the Agent at any time upon 10 days’ prior notice to the Lender and the Borrower. If the Agent resigns under this Agreement, the Lender shall, with (so long as no Event of Default has occurred and is continuing) the consent of the Borrower (which shall not be unreasonably withheld or delayed), appoint a successor agent for the Lender. If no successor agent is appointed prior to the effective date of the resignation of the Agent, the Agent may appoint, on behalf of the Lender after consulting with the Lender and (so long as no Event of Default has occurred and is continuing) the Borrower, a successor agent. Upon the acceptance of its appointment as successor agent hereunder, such successor agent shall succeed to all the rights, powers and duties of the retiring Agent and the term “the Agent” shall mean such successor agent, and the retiring Agent’s appointment, powers and duties as the Agent shall be terminated. After the Agent’s resignation hereunder as the Agent, the provisions of this Section 9 and Sections 10.4 and 10.5 shall continue to inure to its benefit as to any actions taken or omitted to be taken by it while it was the Agent under this Agreement. If no successor agent has accepted appointment as the Agent by the date which is 30 days following a retiring the Agent’s notice of resignation, the retiring Agent’s resignation shall nevertheless thereupon become effective and the Lender shall perform all of the duties of the Agent hereunder until such time as the Lender shall appoint a successor agent as provided for above.

 

60
 

 

9.5             Collateral Matters . Lender irrevocably authorizes the Agent, at its option and in its discretion, to release any Lien granted to or held by the Agent under any Collateral Document (i) when all Obligations have been Paid in Full; (ii) constituting property sold or to be sold or disposed of as part of or in connection with any sale or other disposition permitted hereunder (it being agreed and understood that the Agent may conclusively rely without further inquiry on a certificate of an officer of Holdings or the Borrower as to the sale or other disposition of property being made in compliance with this Agreement); or (iii) subject to Section 10.1 , if approved, authorized or ratified in writing by the Lender. The Agent shall have the right, in accordance with the Collateral Documents, to sell, lease or otherwise dispose of any Collateral for cash, credit or any combination thereof, and the Agent may purchase any Collateral at public or, if permitted by law, private sale and, in lieu of actual payment of the purchase price, may credit bid and setoff the amount of such price against the Obligations.

 

9.6             Collateral Agent . Lender hereby appoints PDL BioPharma, Inc. as its collateral agent under the Guarantee and Collateral Agreement and agrees that in so acting PDL BioPharma, Inc. will have all the rights, protections, exculpations, indemnities and other benefits provided to PDL BioPharma, Inc. under Section 9 hereof, and authorizes and directs PDL BioPharma, Inc. to take or refrain from taking any and all action that it deems necessary or advisable in fulfilling its role as Collateral Agent under the Guarantee and Collateral Agreement.

 

Section 10. Miscellaneous .

 

10.1           Waiver; Amendments . No delay on the part of the Agent or the Lender in the exercise of any right, power or remedy shall operate as a waiver thereof, nor shall any single or partial exercise by any of them of any right, power or remedy preclude other or further exercise thereof, or the exercise of any other right, power or remedy. No amendment, modification or waiver of, or consent with respect to, any provision of this Agreement, the Notes or any of the other Loan Documents (or any subordination and intercreditor agreement or other subordination provisions relating to any other Debt) shall in any event be effective unless the same shall be in writing and approved by the Agent and the Lender, and then any such amendment, modification, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. No provision of Section 9 or other provision of this Agreement affecting the Agent in its capacity as such shall be amended, modified or waived without the consent of the Agent.

 

61
 

 

10.2             Notices . All notices hereunder shall be in writing (including facsimile transmission) and shall be sent to the applicable party at its address shown on Schedule 10.2 or at such other address as such party may, by written notice received by the other parties, have designated as its address for such purpose. Notices sent by facsimile or other electronic transmission shall be deemed to have been given when sent; notices sent to the Loan Parties by mail shall be deemed to have been given three (3) Business Days after the date when sent by registered or certified mail, postage prepaid; and notices sent by hand delivery or overnight courier service shall be deemed to have been given when received.

 

10.3             Costs; Expenses . The Borrower agrees to pay within five (5) Business Days of receipt of a reasonably detailed invoice (a) all reasonable out-of-pocket and documented costs and expenses of the Agent and the Lender (including Legal Costs) in connection with the administration (including perfection and protection of Collateral subsequent to the Closing Date) of this Agreement, the other Loan Documents and all other documents provided for herein or delivered or to be delivered hereunder or in connection herewith (including any proposed or actual amendment, supplement or waiver to any Loan Document), and (b) all out-of-pocket costs and expenses (including Legal Costs) incurred by the Agent and the Lender in connection with the collection of the Obligations and enforcement of this Agreement, the other Loan Documents or any such other documents. All Obligations provided for in this Section 10.3 shall survive repayment of the Loan, cancellation of the Notes and termination of this Agreement.

 

10.4             Indemnification by the Borrower . In consideration of the execution and delivery of this Agreement by the Agent and the Lender and the agreement to extend the Commitments provided hereunder, the Borrower hereby agrees to indemnify, exonerate and hold the Agent, the Lender and each of the officers, directors, employees, Affiliates, controlling persons, advisors and agents of the Agent and the Lender (each, a “ Lender Party ”) free and harmless from and against any and all actions, causes of action, suits, losses, liabilities (including, without limitation, strict liabilities), obligations, damages, penalties, judgments, fines, disbursements, expenses and costs, including Legal Costs (collectively, the “ Indemnified Liabilities ”), incurred by the Lender Parties or asserted against the Lender Party by any Person (including in connection with any action, suit or proceeding brought by any Loan Party or any Lender Party) as a result of, or arising out of, or relating to the execution, delivery, performance, administration or enforcement of this Agreement or any other Loan Document, the use of proceeds of the Loans, or the violation of, noncompliance with or liability under, any Environmental Law applicable to the operations of any Loan Party, except to the extent any such Indemnified Liabilities result from the applicable Lender Party’s own gross negligence, willful misconduct or material breach of any Loan Document, in each case as determined by a court of competent jurisdiction in a final, non-appealable determination. If and to the extent that the foregoing undertaking may be unenforceable for any reason, the Borrower hereby agrees to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under Applicable Law. All Obligations provided for in this Section 10.4 shall survive repayment of the Loan, cancellation of the Notes, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral Documents and termination of this Agreement.

 

62
 

 

10.5             Marshaling; Payments Set Aside . Neither the Agent nor the Lender shall be under any obligation to marshal any assets in favor of any Loan Party or any other Person or against or in payment of any or all of the Obligations. To the extent that the Borrower or any other Loan Party makes a payment or payments to the Agent or the Lender, or the Agent or the Lender enforces its Liens or exercises its rights of set-off, and such payment or payments or the proceeds of such enforcement or set-off or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Agent or the Lender in its discretion) to be repaid to a trustee, receiver or any other party in connection with any bankruptcy, insolvency or similar proceeding, or otherwise, then (a) to the extent of such recovery, the obligation hereunder or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or set-off had not occurred and (b) the Lender severally agrees to pay to the Agent upon demand its ratable share of the total amount so recovered from or repaid by the Agent to the extent paid to such Lender.

 

10.6             Nonliability of the Lender . The relationship between the Borrower on the one hand and the Lender and the Agent on the other hand shall be solely that of borrower and lender. Neither the Agent nor the Lender shall have any fiduciary responsibility to the Borrower or any other Loan Party. Neither the Agent nor the Lender undertakes any responsibility to the Borrower or any other Loan Party to review or inform (including payment of all outstanding principal) the Borrower or any other Loan Party of any matter in connection with any phase of the Borrower’s or any other Loan Party’s business or operations. Execution of this Agreement by Holdings and the Borrower constitutes a full, complete and irrevocable release of any and all claims which Holdings or the Borrower may have at law or in equity in respect of all prior discussions and understandings, oral or written, relating to the subject matter of this Agreement and the other Loan Documents. None of Holdings, the Borrower, the Agent or the Lender shall have any liability with respect to, and Holdings, the Borrower, the Agent and the Lender each hereby waives, releases and agrees not to sue for, any special, indirect, punitive or consequential damages or liabilities.

 

63
 

 

10.7             Confidentiality . The Agent and the Lender agree to maintain as confidential all information provided to them and designated as confidential by any Loan Party, except that the Agent and the Lender may disclose such information (a) to Persons employed or engaged by the Agent or the Lender or any of their Affiliates (including collateral managers of the Lender) in evaluating, approving, structuring or administering the Loan and the Commitments; (b) to any assignee or participant or potential assignee or participant that has agreed to comply with the covenant contained in this Section 10.7 (and any such assignee or participant or potential assignee or participant may disclose such information to Persons employed or engaged by them as described in clause (a) above); (c) as required or requested by any federal or state regulatory authority or examiner, or as reasonably believed by the Agent or the Lender to be compelled by any court decree, subpoena or legal or administrative order or process; (d) as, on the advice of the Agent’s or the Lender’s counsel, is required by law; (e) in connection with the exercise of any right or remedy under the Loan Documents or in connection with any litigation to which the Agent or the Lender is a party; (f) to any nationally recognized rating agency or investor of the Lender that requires access to information about the Lender’s investment portfolio in connection with ratings issued or investment decisions with respect to the Lender; (g) that ceases to be confidential through no fault of the Agent or the Lender (or their Affiliates or Persons employed by them); or (h) to a Person that is an investor or prospective investor in the Agent or any of its Affiliates; provided , that, with respect to clauses (a) , (b) and (h) , the Agent or the Lender may disclose such information to the extent that such Person or assignee, as applicable, agrees to be bound by provisions substantially similar to the provisions of this Section 10.7 .

 

10.8             Captions . Captions used in this Agreement are for convenience only and shall not affect the construction of this Agreement.

 

10.9             Nature of Remedies . All Obligations of the Loan Parties and rights of the Agent and the Lender expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of the Agent or the Lender, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

10.10           Counterparts . This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Agreement. Receipt by facsimile or electronic transmission (including PDF) of any executed signature page to this Agreement or any other Loan Document shall constitute effective delivery of such signature page.

 

10.11           Severability . The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.

 

64
 

 

10.12             Entire Agreement . This Agreement, together with the other Loan Documents, embodies the entire agreement and understanding among the parties hereto and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written, relating to the subject matter hereof and thereof and any prior arrangements made with respect to the payment by Holdings or the Borrower of (or any indemnification for) any fees, costs or expenses payable to or incurred (or to be incurred) by or on behalf of the Agent or the Lender

 

10.13             Successors; Assigns . This Agreement shall be binding upon the Borrower, each other Loan Party party hereto, the Lender and the Agent and their respective successors and assigns, and shall inure to the benefit of the Borrower, each other Loan Party party hereto, the Lender and the Agent and the successors and assigns of the Lender and the Agent. No other Person shall be a direct or indirect legal beneficiary of, or have any direct or indirect cause of action or claim in connection with, this Agreement or any of the other Loan Documents. The Borrower and each other Loan Party party hereto may not assign or transfer any of its rights or Obligations under this Agreement without the prior written consent of the Agent and the Lender. The Lender may sell, transfer, or assign any or all of its rights and obligations hereunder to any Person acceptable to the Lender pursuant to assignment documentation reasonably acceptable to Lender and such assignee; provided , however , that so long as no Event of Default has occurred and is continuing, the Lender shall not assign or transfer any of its rights and obligations hereunder to any Person which is a direct competitor of Holdings or the Borrower (as reasonably determined by Agent) without Holdings’ prior written consent. Such assignee shall be deemed automatically to have become a party hereto and, to the extent that rights and obligations hereunder have been assigned to such assignee pursuant to such assignment documentation, shall have the rights and obligations of a Lender hereunder. The Agent (acting solely for this purpose as the agent of the Borrower) shall maintain a register for the recordation of the names and addresses of the Lender and its assignees and participants, and the amounts of principal and interest owing to any of them hereunder from time to time (the “ Register ”). The entries in the Register shall be conclusive absent manifest error, and Holdings, the Borrower, the Agent and the Lender and its assignees and participants shall treat each person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement and all references to the Lender in this Agreement shall include any such assignee of the Lender.

 

10.14             Governing Law . THIS AGREEMENT AND EACH NOTE SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

 

65
 

 

10.15             Forum Selection; Consent to Jurisdiction; Service of Process . ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH LOAN PARTY HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH LOAN PARTY FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK. EACH LOAN PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. Each Loan Party hereby appoints CT Corporation as such Loan Party’s agent where notices and demands to or upon such Loan Party in respect of this Agreement or any other Loan Document may be served (without prejudice to the right of the Agent or the Lender to serve process in any other manner permitted by law). If for any reason such process agent is unable to serve as such, such Loan Party will within 30 days appoint a substitute process agent located in the State of New York and give notice of such appointment to the Agent.

 

10.16             Waiver of Jury Trial . EACH LOAN PARTY, THE AGENT AND THE LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT, ANY NOTE, ANY OTHER LOAN DOCUMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY LENDING RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

 

[ Signature pages follow ]

 

66
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their duly authorized officers as of the date first set forth above.

 

  CAREVIEW COMMUNICATIONS, INC. ,
  a Nevada corporation,
  as Holdings
   
   By:   /s/ Steven Johnson
     Name: Steven Johnson
 Title: President

 

  CAREVIEW COMMUNICATIONS, INC. ,
  a Texas corporation,
  as Borrower
   
   By:  /s/ Steven Johnson
     Name: Steven Johnson
 Title: President

 

[ Signature Page to CareView Communications, Inc. Credit Agreement

 
 

  PDL BIOPHARMA, INC. ,
  a Delaware corporation,
  as the Agent and the Lender
   
   By: /s/ John P. McLaughlin
    Name: John P. McLaughlin
Title: President and Chief Executive Officer

[ Signature Page to CareView Communications, Inc. Credit Agreement ]

 

 
 

 

SCHEDULE 1.1(a)

 

Subsidiary Guarantors

 

1.           CareView Operations, L.L.C., a Texas limited liability company 

 

Schedule 1.1(a)

 

 
 

 

SCHEDULE 10.2

 

Addresses for Notices

 

LOAN PARTIES:

 

  CareView Communications, Inc., a Nevada corporation, as Holdings,
  CareView Communications, Inc., a Texas corporation, as the Borrower, and
  CareView Operations, L.L.C., as a Subsidiary Guarantor

 

405 State Highway 121 Bypass 

Suite B-240 

Lewisville, Texas 75067 

Attention: Matthew Jackson, Esq., General Counsel 

Telephone: (972) 943-6050 

Facsimile: (972) 403-7659

 

with a copy (which shall not constitute notice) to :

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

One Financial Center 

Boston, MA 02111 

Attention: Meryl Epstein, Esq.

Telephone: (617) 348-1635 

Facsimile: (617) 542-2241 

E-mail: MJEpstein@mintz.com

 

LENDER AND AGENT:

 

PDL BioPharma, Inc., as the Lender and the Agent

 

932 Southwood Boulevard 

Incline Village, NV 89451 

Attention: General Counsel 

Telephone: (775) 832-8500 

Facsimile: (775) 832-8501

 

with a copy (which shall not constitute notice) to :

 

Andrew Cheng, Esq. 

Gibson Dunn & Crutcher LLP 

333 South Grand Avenue, Los Angeles, CA 90071-3197 

Telephone: (213) 229-7684 

Facsimile: (213) 229-6684 

Email: ACheng@gibsondunn.com

 

Schedule 10.2

 

 
 

 

EXHIBIT B

 

EXHIBIT A

 

Form of Note

 

FORM OF] 

[TRANCHE ONE][TRANCHE TWO] TERM NOTE

     
$[20,000,000.00]    New York, New York
[DATE]    

 

FOR VALUE RECEIVED, the undersigned, CAREVIEW COMMUNICATIONS, INC., a Texas corporation (the “ Borrower ”), hereby unconditionally promises to pay to PDL BIOPHARMA, INC., a Delaware corporation (the “ Lender ”), or its registered assigns at the address specified in the Credit Agreement (as hereinafter defined; each capitalized term used and not otherwise defined herein having the meaning assigned to it in the Credit Agreement) in lawful money of the United States and in immediately available funds, the unpaid amount of the Obligations relating to the [ Tranche One Loan ][ Tranche Two Loan ] outstanding under the Credit Agreement. Amounts evidenced hereby shall be paid in the amounts and on the dates specified in Section 2 of the Credit Agreement. Any principal amount of this Note prepaid or repaid may not be reborrowed. The outstanding principal balance of this Note together with all accrued and unpaid interest thereon shall be due and payable on the [ Tranche One Maturity Date ][ Tranche Two Maturity Date ].

 

The holder of this Note is authorized (but not required) to endorse on the schedules annexed hereto and made a part hereof or on a continuation thereof which shall be attached hereto and made a part hereof the date, the type and amount of the Obligations relating to the [ Tranche One Loan ][ Tranche Two Loan ] and the date, type and amount of each payment or prepayment in respect thereof. Each such endorsement shall constitute prima facie evidence of the accuracy of the information endorsed. The failure of such holder to make any such endorsement or any error in any such endorsement shall not affect the Obligations.

 

This Note (a) is one of the Notes referred to in the Credit Agreement dated as of June [•], 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrower, CareView Communications, Inc., a Nevada corporation and the direct parent of the Borrower (“ Holdings ”), the Lender, as lender and as agent, and any other entities from time to time party thereto and (b) is subject to the provisions of the Credit Agreement. This Note is secured and guaranteed as provided in the Loan Documents. Reference is hereby made to the Loan Documents for a description of the properties and assets in which a security interest has been granted, the nature and extent of the security and the guarantees, the terms and conditions upon which the security interests and each guarantee were granted and the rights of the holder of this Note in respect thereof. Borrower acknowledges and agrees that Lender, as agent, may exercise all rights provided in the Loan Documents with respect to this Note.

 

Schedule 10.2

 

 
 

 

Upon the occurrence and during the continuance of any one or more of the Events of Default, all Obligations under the Credit Agreement as evidenced by this Note shall become, or may be declared to be, immediately due and payable, all as provided in the Credit Agreement.

 

All parties now and hereafter liable with respect to this Note, whether as maker, principal, surety, guarantor, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.

 

NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN OR IN THE CREDIT AGREEMENT, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE CREDIT AGREEMENT.

 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE LAWS OF ANY OTHER JURISDICTION THAT MIGHT BE APPLIED BECAUSE OF THE CONFLICTS OF LAWS PRINCIPLES OF THE STATE OF NEW YORK (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

 

  CAREVIEW COMMUNICATIONS, INC. ,
  a Texas corporation
   
   By:
    Name:
Title:

 

3
 

 

 

EXHIBIT B

 

Form of Compliance Certificate

 

[FORM OF]  

COMPLIANCE CERTIFICATE

 

Date: __________________, 20_____

 

This Compliance Certificate (this “ Certificate ”) is given by CAREVIEW COMMUNICATIONS, INC., a Nevada corporation (“ Holdings ”) on behalf of itself and CAREVIEW COMMUNICATIONS, INC., a Texas corporation (“ Borrower ”), pursuant to that certain Credit Agreement dated as of June [•], 2015 (as may be amended, restated, supplemented or otherwise modified as of the date hereof, the “ Credit Agreement ”; each capitalized term used and not otherwise defined herein having the meaning assigned to it in the Credit Agreement), by and among Holdings, Borrower and PDL BIOPHARMA, INC., as lender (“ Lender ”) and as agent (“ Agent ”).

 

Pursuant to Section 6.1.4 of the Credit Agreement, the undersigned hereby certifies that he or she is the duly appointed, qualified, and acting Chief Financial Officer of Holdings, and in such capacity as an officer and not in an individual capacity, certifies on behalf of Holdings and the Borrower to the Agent as of the date hereof as follows:

 

1.          The financial statements delivered contemporaneously with this Certificate fairly present, in all material respects, in accordance with GAAP consistently applied, the consolidated financial condition, results of operations and cash flows of Holdings and its Subsidiaries as of the dates and for the periods specified by such financial statements (subject, in the case of interim financial statements, to normal year-end audit adjustments);

 

2.          The undersigned officer has reviewed the terms of the Credit Agreement and made, or caused to be made under such officer’s supervision, a review in reasonable detail of the transactions and condition (financial or otherwise) of Holdings and its Subsidiaries during the accounting period covered by such financial statements; and

 

3.          Such review has not disclosed the existence during or at the end of such accounting period, and such officer has no knowledge of the existence as of the date hereof, of any condition or event that constitutes a Default or an Event of Default[, except as set forth on Schedule 1 hereto 1 , which includes a description of the nature and period of existence of such Default or Event of Default and what action Holdings and the Borrower have taken, are undertaking or propose to take with respect thereto].

 

[Signature page follows]

 

 

  1   [ Schedule 1 should be prepared and attached if a Default or Event of Default has occurred.]

 

4
 

 

EXHIBIT B

 

IN WITNESS WHEREOF, Holdings has caused this Certificate to be executed as of the date first above written.

 

  CAREVIEW COMMUNICATIONS, INC. ,
  a Nevada corporation
   
   By:
    Name:
Title:

 

Exhibit B

 

 

 

 

Careview Communications, Inc. 8-K

 

Exhibit 10.2

 

EXECUTION VERSION

 

SUBORDINATION AND INTERCREDITOR AGREEMENT

 

dated as of June 26, 2015

 

between

 

PDL BIOPHARMA, INC.,

as agent for the First Lien Claimholders

 

and

 

EACH OF THE NOTE INVESTORS SIGNATORY TO THAT CERTAIN NOTE AND
WARRANT PURCHASE AGREEMENT DEFINED HEREIN,

as the initial Second Lien Claimholders,

 

and

 

each other Second Lien Claimholder who becomes a party hereto

pursuant to the terms hereof

 

 
 

 

         
        Page
         
    TABLE OF CONTENTS    
         
        Page
         
SECTION 1.   DEFINITIONS   2
1.1   Defined Terms   2
1.2   Terms Generally   6
SECTION 2.   LIEN PRIORITIES   7
2.1   Relative Priorities   7
2.2   Prohibition on Contesting Liens   7
2.3   No New Liens   7
2.4   Payment Subordination   8
SECTION 3.   ENFORCEMENT   9
3.1   Exercise of Remedies   9
SECTION 4.   PAYMENTS   12
4.1   Application of Proceeds   12
4.2   Payments in Violation of Agreement   12
SECTION 5.   OTHER AGREEMENTS   13
5.1   Releases   13
5.2   Insurance   14
5.3   Amendments to First Lien Loan Documents and Second Lien Loan Documents   14
5.4   When Discharge of First Lien Obligations Deemed to Not Have Occurred   16
5.5   Purchase Right   17
SECTION 6.   INSOLVENCY OR LIQUIDATION PROCEEDINGS   17
6.1   Finance Issues   17
6.2   Relief from the Automatic Stay   18
6.3   Adequate Protection   18
6.4   No Waiver   19
6.5   Avoidance Issues   19
6.6   Certain Voting Rights   19
6.7   No X-Clause; Reorganization Securities   19
6.8   Post-Petition Interest   20
6.9   Waiver   20
6.10   Separate Grants of Security and Separate Classification   20
6.11   PDL as Bailee for Perfection   21
6.12   Proofs of Claim   22
SECTION 7.   RELIANCE; WAIVERS; ETC.   22
7.1   Reliance   22
7.2   No Warranties or Liability   22

 

i
 

 

         
        Page
         
7.3   No Waiver of Lien Priorities   23
7.4   Obligations Unconditional   24
SECTION 8.   MISCELLANEOUS   25
8.1   Conflicts   25
8.2   Effectiveness; Continuing Nature of this Agreement; Severability   25
8.3   Amendments; Waivers   26
8.4   Information Concerning Financial Condition of the Borrower and the Grantors and their Subsidiaries   26
8.5   Subrogation   27
8.6   Application of Payments   27
8.7   Governing Law   27
8.8   Waiver of Right to Trial by Jury   27
8.9   Notices   28
8.10   Further Assurances   28
8.11   Binding on Successors and Assigns   28
8.12   Specific Performance   28
8.13   Headings   28
8.14   Counterparts   28
8.15   Authorization   29
8.16   No Third Party Beneficiaries   29
8.17   Provisions Solely to Define Relative Rights   29
8.18   Additional Second Lien Claimholders   29
     
ANNEXES    
     
Annex I   Notices
     
Annex II   Form of Joinder Agreement
     
Annex III   Note Investors

 

ii
 

 

SUBORDINATION AND INTERCREDITOR AGREEMENT

 

This SUBORDINATION AND INTERCREDITOR AGREEMENT (this “ Agreement ”), is dated as of June 26, 2015, and entered into by and between PDL BIOPHARMA, INC., a Delaware corporation, in its capacity as agent for the First Lien Claimholders (as defined below) (including its successors and assigns from time to time, “ PDL ”), and EACH OF THE NOTE INVESTORS SIGNATORY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT (AS DEFINED HEREIN) as the initial Second Lien Claimholders (as defined below) and each other Second Lien Claimholder that becomes a party hereto pursuant to Section 8.18.

 

R E C I T A L S

 

WHEREAS, CAREVIEW COMMUNICATIONS, INC., a Texas corporation (the “ Borrower ”), CAREVIEW COMMUNICATIONS, INC., a Nevada corporation (“ Holdings ”), the First Lien Lender and PDL have entered into that certain Credit Agreement dated as of June 26, 2015 (as amended, amended and restated, supplemented, modified, replaced or Refinanced from time to time, the “ Credit Agreement ”);

 

WHEREAS, Holdings and the Note Investors have entered into that certain Note and Warrant Purchase Agreement dated as of April 21, 2011 (as amended as of the date hereof, and as further amended, amended and restated, supplemented, modified, replaced or Refinanced from time to time in accordance with the terms hereof, the “ Note Purchase Agreement ”), pursuant to which certain subordinated secured promissory notes have been issued to Holdings (the “ Subordinated Notes ”);

 

WHEREAS, the obligations of the Borrower under the Credit Agreement are secured by first-priority Liens on substantially all of the assets of the Grantors pursuant to the terms of the Guarantee and Collateral Agreement dated as of June 26, 2015 (the “ First Lien Security Agreement ”) by the Grantors in favor of PDL;

 

WHEREAS, the obligations of Holdings under the Second Lien Note Documents are secured by second-priority Liens on substantially all of the assets of the Grantors pursuant to the Amended and Restated Pledge and Security Agreement dated as of February 17, 2015 by and among the Grantors (as amended in accordance with the terms hereof, the “ Second Lien Security Agreement ”); and

 

WHEREAS, (i) PDL, on behalf of the First Lien Claimholders, (ii) each of the Note Investors, as the initial Second Lien Claimholders, and (iii) each other Second Lien Claimholder who becomes a party hereto, have agreed to the relative priority of the respective Liens of the First Lien Claimholders and the Second Lien Claimholders on the assets of the Borrower, Holdings and the other Grantors and certain other rights, priorities and interests as set forth in this Agreement.

 

 
 

 

AGREEMENT

 

In consideration of the foregoing, the mutual covenants and obligations herein set forth and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

SECTION 1.          Definitions .

 

1.1           Defined Terms .  As used in the Agreement, the following terms shall have the following meanings:

 

363 Sale ” has the meaning assigned to that term in Section 6.1 .

 

Acceleration Notice ” has the meaning assigned to that term in Section 5.5 .

 

Affiliate ” means, as to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such Person or is a director or officer of such Person.  For purposes of this definition, the term “control” (including the terms “controlling,” “controlled by” and “under common control with”) of a Person means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting interests, by contract or otherwise.

 

Bankruptcy Code ” means Title 11 of the United States Code entitled “Bankruptcy,” as now and hereafter in effect, or any successor statute.

 

Borrower ” has the meaning assigned to that term in the Recitals to this Agreement.

 

Business Day ” means a day of the year on which banks are not required or authorized by law to close in New York City.

 

Collateral ” means all of the assets and property of the Borrower, whether real, personal or mixed constituting both First Lien Collateral and Second Lien Collateral.

 

Credit Agreement ” has the meaning assigned to that term in the Recitals to this Agreement.

 

Credit Agreement Default Interest ” means the increased interest accruing on the Loans under the Credit Agreement as a result of the imposition of the Default Rate in accordance with Section 2.3.1(c) of the Credit Agreement as in effect on the date hereof.

 

Debtor Relief Laws ” means the Bankruptcy Code, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

 

DIP Financing ” has the meaning assigned to that term in Section 6.1 .

 

2
 

 

Discharge of First Lien Obligations ” means, except to the extent otherwise expressly provided in Section 5.4 :

 

(a)           payment in full in cash of the principal of and interest (including interest accruing on or after the commencement of any Insolvency or Liquidation Proceeding, whether or not such interest would be allowed in such Insolvency or Liquidation Proceeding, and including any Protective Advance) constituting First Lien Obligations;

 

(b)           payment in full in cash of all other First Lien Obligations that are due and payable or otherwise accrued and owing at or prior to the time such principal and interest are paid; and

 

(c)           termination or expiration of all commitments, if any, to extend credit that would constitute First Lien Obligations.

 

Disposition ” has the meaning assigned to that term in Section 5.1(b) .

 

First Lien Cap Amount ” has the meaning assigned to that term in Section 5.3(a) .

 

First Lien Claimholders ” means, at any relevant time, the holders of First Lien Obligations at that time, including the First Lien Lender, PDL and any other secured parties under the First Lien Loan Documents.

 

First Lien Collateral ” means any and all Collateral and otherwise all “Collateral” as defined in the Credit Agreement with respect to which a Lien is granted as security for the First Lien Obligations.

 

First Lien Collateral Documents ” means the Collateral Documents (as defined in the Credit Agreement) and any other agreement, document or instrument pursuant to which a Lien is granted securing any First Lien Obligations or under which rights or remedies with respect to such Liens are governed.

 

First Lien Lender ” means the “Lender” under and as defined in the First Lien Loan Documents.

 

First Lien Loan Documents ” means the Credit Agreement and the First Lien Collateral Documents, and each of the other agreements, documents and instruments providing for or evidencing any other First Lien Obligation, and any other document or instrument executed or delivered at any time in connection with any First Lien Obligations, including any intercreditor or joinder agreement among holders of First Lien Obligations to the extent such are effective at the relevant time, as each may be amended, amended and restated, supplemented, modified, renewed or extended from time to time in accordance with the provisions of this Agreement.

 

First Lien Obligations ” means all Obligations outstanding under, and as defined in, the Credit Agreement and the other First Lien Loan Documents.  Without limiting the generality of the foregoing, “First Lien Obligations” shall include Credit Agreement Default Interest and all interest accrued or accruing (or that would, absent commencement of an Insolvency or Liquidation Proceeding, accrue) after commencement of an Insolvency or Liquidation Proceeding in accordance with the rate specified in the relevant First Lien Loan Document, whether or not the claim for such interest is allowed as a claim in such Insolvency or Liquidation Proceeding.

 

3
 

 

First Lien Recovery ” has the meaning assigned to that term in Section 6.5 .

 

First Lien Security Agreement ” has the meaning assigned to that term in the Recitals to this Agreement.

 

Grantors ” means the Borrower, Holdings and any Person that is or becomes a party to the First Lien Security Agreement or the Second Lien Security Agreement, as applicable, that guarantees, or that otherwise provides credit support for, the Obligations of the Borrower or Holdings under the First Lien Loan Documents or the Second Lien Loan Documents, as applicable.

 

Insolvency or Liquidation Proceeding ” means:

 

(a)           any voluntary or involuntary case or proceeding under the Bankruptcy Code with respect to the Borrower, Holdings or any Grantor;

 

(b)           any other voluntary or involuntary insolvency, reorganization or bankruptcy case or proceeding, or any receivership, liquidation, reorganization or other similar case or proceeding, with respect to the Borrower, Holdings or any Grantor or with respect to a material portion of its assets;

 

(c)           any liquidation, dissolution, reorganization or winding up of the Borrower, Holdings or any Grantor, whether voluntary or involuntary and whether or not involving insolvency or bankruptcy; or

 

(d)           any assignment for the benefit of creditors or any other marshaling of assets and liabilities of the Borrower, Holdings or any Grantor.

 

Joinder Agreement ” means each agreement, in the form of Annex II hereto, executed and delivered by each Additional Second Lien Claimholder that shall become a party hereunder.

 

Lien ” means any lien, security interest or other charge or encumbrance of any kind, or any other type of preferential arrangement, including, without limitation, the lien or retained security title of a conditional vendor and any easement, right of way or other encumbrance on title to real property.

 

New Agent ” has the meaning assigned to that term in Section 5.4 .

 

Note Investors ” means the Investors holding the Subordinated Notes outstanding on the date hereof, as set forth on Annex III hereto.

 

Note Purchase Agreement ” has the meaning assigned to that term in the Recitals to this Agreement.

 

4
 

 

Obligations ” means all obligations of every nature of the Borrower, Holdings or any Grantor from time to time owed to the First Lien Claimholders, the Second Lien Claimholders or any of them or their respective Affiliates, in each case under the First Lien Loan Documents or the Second Lien Loan Documents, as applicable, whether for principal, interest, fees, expenses, indemnification or otherwise and all guarantees of any of the foregoing.

 

Payment Blockage Notice ” means a written notice to Second Lien Agent from PDL or any First Lien Lender (a) of the occurrence and continuance of an Event of Default under the Credit Agreement, or (b) that a scheduled payment of interest under the Subordinated Notes will cause an Event of Default.

 

PDL ” has the meaning assigned to that term in the Preamble to this Agreement.

 

Person ” means an individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.

 

Pledged Collateral ” has the meaning assigned to that term in Section 6.11 .

 

Protective Advance ” means the “Protective Advances” made by PDL pursuant to Section 2.11 of the Credit Agreement as in effect on the date hereof.

 

Purchase Notice ” has the meaning assigned to that term in Section 5.5 .

 

Refinance ” means, in respect of the First Lien Obligations or the Second Lien Obligations, to refinance, extend, renew, defease, amend, modify, supplement, restructure, replace, refund or repay, or to issue other indebtedness in exchange or replacement for, such First Lien Obligations or Second Lien Obligations, as applicable, in whole or in part.  “Refinanced” and “Refinancing” shall have correlative meanings.

 

Required Second Lien Claimholders ” means Second Lien Claimholders holding greater than 50% of the aggregate principal amount of the Subordinated Notes.

 

Second Lien Agent ” means HealthCor Partners Fund, L.P., a Cayman Islands limited partnership.

 

Second Lien Claimholders ” means, at any relevant time, the Second Lien Agent, the Note Investors and each other holder of Second Lien Obligations.

 

Second Lien Collateral ” means any and all Collateral and otherwise all “Collateral” as defined in the Second Lien Security Agreement with respect to which a Lien is granted as security for the Second Lien Obligations.

 

Second Lien Collateral Documents ” means the Second Lien Security Agreement, the Amended and Restated Intellectual Property Security Agreement dated as of February 17, 2015 by and among the Second Lien Agent and the Grantors, and any other agreement, document or instrument pursuant to which a Lien is granted securing any Second Lien Obligations or under which rights or remedies with respect to such Liens are governed.

 

5
 

 

Second Lien Loan Documents ” means the Note Purchase Agreement, the Subordinated Notes, the Second Lien Collateral Documents and each of the other agreements, documents and instruments providing for or evidencing any other Second Lien Obligation, and any other document or instrument executed or delivered at any time in connection with any Second Lien Obligations, including any intercreditor or joinder agreement among holders of Second Lien Obligations to the extent such are effective at the relevant time, as each may be amended, restated, supplemented, modified, renewed or extended from time to time in accordance with the provisions of this Agreement.

 

Second Lien Obligations ” means all Obligations outstanding under the Note Purchase Agreement and the other Second Lien Loan Documents as defined in the Second Lien Security Agreement.

 

Second Lien Recovery ” has the meaning assigned to that term in Section 6.5 .

 

Second Lien Security Agreement ” has the meaning assigned to that term in the Recitals to this Agreement.

 

UCC ” means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.

 

1.2           Terms Generally .  The definitions of terms in this Agreement shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.”  The word “will” shall be construed to have the same meaning and effect as the word “shall.”  Unless the context requires otherwise:

 

(a)            any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, amended and restated, supplemented, modified, renewed or extended, but only if such amendment, amendment and restatement, supplement, modification, renewal or extension comply with the terms hereof;

 

(b)            any reference herein to any Person shall be construed to include such Person’s permitted successors and assigns;

 

(c)            the words “herein,” “hereof” and “hereunder” and words of similar import shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof;

 

(d)            all references herein to Sections shall be construed to refer to Sections of this Agreement; and

 

(e)            the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.

 

6
 

 

SECTION 2.          Lien Priorities .

 

2.1           Relative Priorities .  Notwithstanding the date, time, method, manner or order of grant, attachment or perfection of any Liens securing the Second Lien Obligations granted on the Collateral or of any Liens securing the First Lien Obligations granted on the Collateral, and notwithstanding any provision of the UCC or any other applicable law or the Second Lien Loan Documents or any defect or deficiencies in or failure to perfect the Liens securing the First Lien Obligations or any other circumstance whatsoever, each Second Lien Claimholder agrees that:

 

(a)            any Lien on the Collateral securing any First Lien Obligations now or hereafter held by or on behalf of PDL, any First Lien Claimholders or any agent or trustee therefor, regardless of how acquired, whether by grant, possession, statute, operation of law, subrogation or otherwise, shall be senior in all respects and prior to any Lien on the Collateral securing any Second Lien Obligations; and

 

(b)            any Lien on the Collateral securing any Second Lien Obligations now or hereafter held by any Second Lien Claimholders or any agent or trustee therefor, regardless of how acquired, whether by grant, possession, statute, operation of law, subrogation or otherwise, shall be junior and subordinate in all respects to all Liens on the Collateral securing any First Lien Obligations.  All Liens on the Collateral securing any First Lien Obligations shall be and remain senior in all respects and prior to all Liens on the Collateral securing any Second Lien Obligations for all purposes, whether or not such Liens securing any First Lien Obligations are subordinated to any Lien securing any other obligation of the Borrower, any Grantor or any other Person.

 

2.2           Prohibition on Contesting Liens .  Each Second Lien Claimholder agrees, and PDL agrees for itself and on behalf of each First Lien Claimholder, that it will not (and hereby waives any right to) contest or support any other Person in contesting, in any proceeding (including any Insolvency or Liquidation Proceeding), the perfection, priority, validity or enforceability of a Lien held by or on behalf of any of the First Lien Claimholders in the First Lien Collateral or by or on behalf of any of the Second Lien Claimholders in the Second Lien Collateral, as the case may be, or the provisions of this Agreement; provided that nothing in this Agreement shall be construed to prevent or impair the rights of PDL or any First Lien Claimholder to enforce this Agreement, including the provisions of this Agreement relating to the priority of the Liens securing the First Lien Obligations as provided in Sections 2.1 and 3.1 , or the rights of any Second Lien Claimholder to enforce this Agreement.

 

2.3           No New Liens .  So long as the Discharge of First Lien Obligations has not occurred, the parties hereto agree that, after the date hereof, no Second Lien Claimholder shall acquire or hold any Lien on any assets of a Grantor (and no Grantor shall grant such Lien) securing any Second Lien Obligations that are not also subject to a first priority lien in respect of the First Lien Obligations under the First Lien Loan Documents.  If any Second Lien Claimholder shall (nonetheless and in breach hereof) acquire or hold any Lien on any assets of a Grantor that is not also subject to a first priority lien in respect of the First Lien Obligations under the First Lien Loan Documents, then such Second Lien Claimholder shall, without the need for any further consent of any party and notwithstanding anything to the contrary in any other document, be deemed to also hold and have held such Lien for the benefit of PDL as security for the First Lien Obligations (subject to the lien priority and other terms hereof) and shall use its best efforts to promptly notify PDL in writing of such Lien and in any event take such actions as may be requested by PDL to assign or release such Lien to PDL (and/or its designee) as security for the First Lien Obligations.  To the extent that this Section 2.3 is not complied with for any reason, without limiting any other rights and remedies available to PDL or the First Lien Claimholders, each Second Lien Claimholder agrees that any amounts received by or distributed to it pursuant to or as a result of Liens granted in contravention of this Section 2.3 shall be subject to Section 4.2 .

 

7
 

 

2.4           Payment Subordination.

 

(a)            Each Grantor covenants and agrees, and each Second Lien Claimholder likewise covenants and agrees, notwithstanding anything to the contrary contained in any of the Second Lien Loan Documents, that the payment of any and all of the Second Lien Obligations shall be subordinate and subject in right and time of payment, to the extent and in the manner hereinafter set forth, to the Discharge of First Lien Obligations.  Each First Lien Claimholder shall be deemed to have extended the First Lien Obligations in reliance upon the provisions contained in this Agreement.  Except as otherwise permitted under Section 2.4(b) below, until the date of the Discharge of First Lien Obligations, no Grantor shall make and no Second Lien Claimholder shall accept any distribution, whether in cash, securities or other property, on account of any Second Lien Obligation.

 

(b)            Notwithstanding Section 2.4(a) , but subject to Section 2.4(c) , the Second Lien Claimholders may receive and retain the following distributions in respect of the Second Lien Obligations: (i) payment of interest in kind that is capitalized and added to the outstanding principal amount of the Subordinated Notes in accordance with the terms thereof as in effect as of the date hereof, (ii) the conversion of the Subordinated Notes into Capital Stock of Holdings other than Disqualified Capital Stock (each such term used in this clause (b)(ii) but not defined herein as defined in the Credit Agreement) and the payment of cash in lieu of fractional shares permitted by Section 7.3(f) of the Credit Agreement, (iii) so long as the Second Lien Agent has not received a Payment Blockage Notice, (A) quarterly payments of interest accrued on the Subordinated Notes in cash in accordance with the terms of the Second Lien Loan Documents in effect as of the date hereof and (B) reimbursement for actual, reasonable out-of-pocket legal fees and expenses incurred by Second Lien Agent in connection with the preparation and amendment of the Second Lien Loan Documents and this Agreement, and (iv) adequate protection payments permitted by Section 6.3(b) .

 

(c)            Unless and until the Discharge of the First Lien Obligations has occurred, in any Insolvency or Liquidation Proceeding, (i) no direct or indirect payment or distribution of any kind or any character, whether in cash, property or securities shall be accepted by any Second Lien Claimholder from any Grantor on account of the Second Lien Obligations, and (ii) PDL, on behalf of the First Lien Claimholders, shall be entitled to receive directly, for application to the payment of the First Lien Obligations any payment or distribution of any kind or character, whether in cash, property or securities made by any Grantor on account of the Second Lien Obligations.

 

8
 

 

SECTION 3.          Enforcement .

 

3.1           Exercise of Remedies .

 

(a)            Until the Discharge of First Lien Obligations has occurred, whether or not any Insolvency or Liquidation Proceeding has been commenced by or against any Grantor, each Second Lien Claimholder:

 

(1)            (i) except for payments permitted by Section 2.4(b) , will not take from or for the account of any Grantor, by set-off or in any other manner, the whole or any part of any moneys which may now or hereafter be owing by any such Grantor with respect to the Second Lien Obligations; (ii) will not sue for payment of, or to initiate or participate with others in any suit, action or proceeding against any Grantor to (x) enforce payment of or to collect the whole or any part of the Second Lien Obligations (which shall include, for the avoidance of doubt, any demand or collection of payment at maturity), or (y) commence judicial enforcement of any of the rights and remedies under the Second Lien Loan Documents or applicable law with respect to the Second Lien Obligations; and (iii) will not exercise any put option or cause any Grantor to honor any redemption or mandatory prepayment obligation under any Second Lien Loan Document;

 

(2)            will not exercise or seek to exercise any remedies with respect to any Collateral or institute any action or proceeding with respect to such remedies (including any action of foreclosure);

 

(3)            will not contest, protest, object to, or take any action to hinder or delay (including taking action to commence an involuntary Insolvency or Liquidation Proceeding) any foreclosure proceeding or action brought by PDL or any First Lien Claimholder or any other exercise by PDL or any First Lien Claimholder of any rights and remedies relating to the Collateral under the First Lien Loan Documents or otherwise; and

 

(4)            except as may be permitted in Section 3.1(c) , will not object to the forbearance by PDL or the First Lien Claimholders from bringing or pursuing any foreclosure proceeding or action or any other exercise of any rights or remedies relating to the Collateral;

 

provided, that, in the case of clause (3) above, the Liens granted to secure the Second Lien Obligations of the Second Lien Claimholders shall attach to any remaining proceeds resulting from actions taken by PDL or any First Lien Claimholder in accordance with this Agreement after application of such proceeds to effect a Discharge of First Lien Obligations.

 

9
 

 

(b)          Until the Discharge of First Lien Obligations has occurred, whether or not any Insolvency or Liquidation Proceeding has been commenced by or against the Borrower or any Grantor, PDL and the First Lien Claimholders shall have the right to enforce rights, exercise remedies (including set-off and the right to credit bid their debt) and make determinations regarding the release, Disposition, or restrictions with respect to the Collateral without any consultation with or the consent of any Second Lien Claimholder; provided, that the Lien securing the Second Lien Obligations shall remain on the remaining proceeds of such Collateral released or disposed of subject to the relative priorities described in Section 2 after application of such proceeds to the extent necessary to effect a Discharge of First Lien Obligations.  In exercising rights and remedies with respect to the Collateral, PDL and the First Lien Claimholders may enforce the provisions of the First Lien Loan Documents and exercise remedies thereunder, all in such order and in such manner as they may determine in the exercise of their sole discretion.  Such exercise and enforcement shall include the rights of any agent appointed by them to sell or otherwise dispose of Collateral upon foreclosure, to incur expenses in connection with such sale or disposition and to exercise all the rights and remedies of a secured creditor under the UCC and of a secured creditor under the Debtor Relief Laws of any applicable jurisdiction.  Upon Discharge of First Lien Obligations, PDL shall deliver to the Second Lien Agent any remaining proceeds of Collateral held by PDL.

 

(c)         Notwithstanding the foregoing, any Second Lien Claimholder may:

 

(1)            file a claim or statement of interest with respect to the Second Lien Obligations after the commencement of any Insolvency or Liquidation Proceeding by or against any Grantor;

 

(2)            take any action (not adverse to the first priority status of the Liens on the Collateral securing the First Lien Obligations or the rights of PDL or the First Lien Claimholders to exercise remedies in respect thereof) in order to create, perfect, preserve or protect its Lien on the Collateral;

 

(3)            file any necessary responsive or defensive pleadings in opposition to any motion, claim, adversary proceeding or other pleading made by any person objecting to or otherwise seeking the disallowance of the claims of the Second Lien Claimholders or the Lien securing the Second Lien Obligations;

 

(4)            join (but not exercise any control over) a judicial foreclosure or Lien enforcement proceeding with respect to the Collateral initiated by PDL or any other First Lien Claimholder, to the extent that such action could not reasonably be expected to interfere with any such enforcement action, but no Second Lien Claimholder may receive any proceeds thereof unless expressly permitted herein;

 

(5)            receive from the Borrower and retain any dividends, distributions or other payments made by the Borrower to its stockholders to the extent the same are permitted by or consented to under the Credit Agreement, none of which rights shall be deemed to be subordinated hereunder;

 

(6)            accelerate the Second Lien Obligations as a result of an event of default under the Second Lien Loan Documents so long as the Second Lien Claimholders comply with all other terms and conditions of this Agreement;

 

10
 

 

(7)            receive reimbursement for actual, reasonable out-of-pocket legal fees and expenses incurred by Second Lien Agent in connection with the preparation and amendment of the Second Lien Loan Documents and this Agreement;

 

(8)            file any pleadings, objections, motions or agreements which assert rights or interests available to unsecured creditors of the Grantors arising under either any Insolvency or Liquidation Proceeding or applicable non-bankruptcy law, in each case not inconsistent with the terms of this Agreement; and

 

(9)            vote on any plan of reorganization, file any proof of claim, make other filings and make any arguments and motions that are, in each case, in accordance with the terms of this Agreement, with respect to the Second Lien Obligations and the Collateral.

 

Each Second Lien Claimholder agrees that it will not take or receive any Collateral or any proceeds of Collateral in connection with the exercise of any right or remedy (including set-off) with respect to any Collateral in its capacity as a creditor in violation of this Agreement.  Without limiting the generality of the foregoing, unless and until the Discharge of First Lien Obligations has occurred, except as expressly provided in Section 6.3(b) and this Section 3.1(c) , the sole right of the Second Lien Claimholders with respect to the Second Lien Collateral is to hold a Lien on the Second Lien Collateral pursuant to the Second Lien Collateral Documents for the period and to the extent granted therein and to receive a share of the proceeds thereof, if any, after the Discharge of First Lien Obligations has occurred.

 

(d)            Subject to Section 3.1(c) and Section 6.3(b) :

 

(1)            each Second Lien Claimholder agrees that such Second Lien Claimholder will not take any action that would hinder any exercise of remedies under the First Lien Loan Documents (including taking action to commence an involuntary Insolvency or Liquidation Proceeding) or is otherwise prohibited hereunder, including any sale, lease, exchange, transfer or other Disposition of the Collateral, whether by foreclosure or otherwise;

 

(2)            each Second Lien Claimholder hereby waives any and all rights such Second Lien Claimholder may have as a junior lien creditor or otherwise to object to the manner in which PDL or the First Lien Claimholders seek to enforce or collect the First Lien Obligations or the Liens securing the First Lien Obligations granted in any of the First Lien Collateral undertaken in accordance with this Agreement, regardless of whether any action or failure to act by or on behalf of PDL or First Lien Claimholders is adverse to the interest of the Second Lien Claimholders; and

 

(3)            each Second Lien Claimholder acknowledges and agrees that no covenant, agreement or restriction contained in the Second Lien Collateral Documents or any other Second Lien Loan Document (other than this Agreement) shall be deemed to restrict in any way the rights and remedies of PDL or the First Lien Claimholders with respect to the Collateral as set forth in this Agreement and the First Lien Loan Documents.

 

11
 

 

(e)            Subject to the terms and conditions of this Agreement, the Second Lien Agent and the Second Lien Claimholders may exercise rights and remedies as unsecured creditors against the Company or any other Grantor that has guaranteed or granted Liens to secure the Second Lien Obligations in accordance with the terms of the Second Lien Loan Documents and applicable law; provided that in the event that any Second Lien Claimholder becomes a judgment Lien creditor in respect of the Second Lien Collateral as a result of its enforcement of its rights as an unsecured creditor with respect to the Second Lien Obligations, such judgment Lien shall be subject to the terms of this Agreement for all purposes (including in relation to the First Lien Obligations) as the other Liens securing the Second Lien Obligations are subject to this Agreement.

 

(f)            Nothing in this Agreement impairs or otherwise adversely affects any rights or remedies PDL or the First Lien Claimholders may have with respect to the First Lien Collateral.

 

(g)            PDL shall inform the Second Lien Claimholders of any exercise of remedies by PDL in respect of any Collateral.  The Second Lien Claimholders shall inform PDL of any exercise of remedies by such Second Lien Claimholders in respect of any Collateral (notwithstanding that any such exercise of remedies shall be prohibited by the terms of this Agreement).

 

SECTION 4.       Payments .

 

4.1           Application of Proceeds .  So long as the Discharge of First Lien Obligations has not occurred, whether or not any Insolvency or Liquidation Proceeding has been commenced by or against the Borrower or any Grantor, any Collateral or proceeds thereof received in connection with the sale or other disposition of, or collection on, such Collateral upon the exercise of remedies by PDL or the First Lien Claimholders shall be applied by PDL to the First Lien Obligations in such order as specified in the relevant First Lien Loan Documents.  Upon the Discharge of First Lien Obligations, PDL shall deliver to the Second Lien Claimholders any Collateral and the proceeds of such Collateral held by it in the same form as received, with any necessary endorsements or as a court of competent jurisdiction may otherwise direct, to be applied by the Second Lien Claimholders to the Second Lien Obligations in such order as specified in the Second Lien Collateral Documents.

 

4.2           Payments in Violation of Agreement .  So long as the Discharge of First Lien Obligations has not occurred, whether or not any Insolvency or Liquidation Proceeding has been commenced by or against the Borrower or any Grantor, any payment received by any Second Lien Claimholders in respect of the Second Lien Obligations in contravention of this Agreement shall be segregated and held in trust and forthwith paid over to PDL for the benefit of the First Lien Claimholders in the same form as received, with any necessary endorsements or as a court of competent jurisdiction may otherwise direct.  PDL is hereby authorized to make any such endorsements as agent for any Second Lien Claimholders.  This authorization is coupled with an interest and is irrevocable until the Discharge of the First Lien Obligations.

 

12
 

 

SECTION 5.       Other Agreements .

 

5.1           Releases .

 

(a)            If, in connection with the exercise of PDL’s remedies in respect of the Collateral provided for by the First Lien Loan Documents, PDL releases for itself or on behalf of any of the First Lien Claimholders any of its Liens on any part of the Collateral or releases any Grantor from its guaranty of the First Lien Obligations in connection with the sale of the stock or substantially all the assets of the Borrower or any Grantor, then the Liens, if any, of the Second Lien Claimholders on such Collateral and the obligations of such Grantor included in the Second Lien Obligations shall be automatically, unconditionally and simultaneously released; provided that the net proceeds from the sale of such Collateral as a result of the exercise of such remedies are applied to pay Obligations under the Credit Agreement as provided therein.  The Second Lien Claimholders shall promptly execute and deliver to PDL or the Borrower or the applicable Grantor such termination statements, releases and other documents as PDL, the Borrower or such Grantor may reasonably request to effectively confirm such release.

 

(b)            If in connection with any sale, lease, exchange, transfer or other disposition of any Collateral (collectively, a “ Disposition ”) permitted under the terms of both the First Lien Loan Documents and the Second Lien Loan Documents (other than in connection with the exercise of PDL’s remedies in respect of the Collateral provided for by the First Lien Loan Documents), PDL releases for itself or on behalf of any of the First Lien Claimholders any of its Liens on any part of the Collateral or releases any Grantor from its guaranty of the First Lien Obligations in connection with the sale of the stock, or substantially all the assets, of the Borrower or the applicable Grantor other than (A) in connection with the Discharge of First Lien Obligations and (B) after the occurrence and during the continuance of any Event of Default under the Note Purchase Agreement, then the Liens, if any, of the Second Lien Claimholders on such Collateral and the obligations of such Grantor under its guaranty of the Second Lien Obligations shall be automatically, unconditionally and simultaneously released; provided that the net proceeds from any Disposition are applied to repay Obligations under the Credit Agreement to the extent required thereby.  The Second Lien Claimholders shall promptly execute and deliver to PDL, the Borrower or the applicable Grantor such termination statements, releases and other documents as PDL, the Borrower or the applicable Grantor may reasonably request to effectively confirm such release.

 

(c)            Until the Discharge of First Lien Obligations occurs, each Second Lien Claimholder hereby irrevocably constitutes and appoints PDL and any officer or agent of PDL, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Second Lien Claimholder or such holder or in the PDL’s own name, from time to time in PDL’s discretion, for the purpose of carrying out the terms of this Section 5.1 , to take any and all appropriate action and to execute any and all documents and instruments that may be necessary to accomplish the purposes of this Section 5.1 , including any endorsements or other instruments of transfer or release.

 

13
 

 

(d)            Until the Discharge of First Lien Obligations occurs, to the extent that PDL or the First Lien Claimholders (i) have released any Lien on Collateral or any Grantor from its obligations under its guaranty and any such Liens or guaranty are later reinstated or (ii) obtain any new Liens or additional guaranties from any Grantor in respect of assets that constitute Collateral, then the Second Lien Claimholders shall be granted a Lien on any such assets, or an additional guaranty, as the case may be, in each case subject to the subordination provisions of this Agreement (for the avoidance of doubt, whether payment  or lien subordination).

 

5.2            Insurance .  Unless and until the Discharge of First Lien Obligations has occurred, subject to the terms of, and the rights of the Grantors under, the First Lien Loan Documents, PDL and the First Lien Claimholders shall have the sole and exclusive right to adjust settlement for any insurance policy covering the Collateral in the event of any loss thereunder and to approve any award granted in any condemnation or similar proceeding (or any deed in lieu of condemnation) affecting the Collateral.  Unless and until the Discharge of First Lien Obligations has occurred, and subject to the rights of the Grantors under the First Lien Loan Documents, all proceeds of any such policy and any such award (or any payments with respect to a deed in lieu of condemnation) if in respect of the Collateral and to the extent required by the First Lien Loan Documents shall be paid to PDL for the benefit of the First Lien Claimholders pursuant to the terms of the First Lien Loan Documents and after the Discharge of the First Lien Obligations, to the Second Lien Claimholders to the extent required under the Second Lien Collateral Documents.  To the extent no Second Lien Obligations are outstanding, all proceeds of any such policy and any such award (or any payments with respect to a deed in lieu of condemnation) if in respect of the Collateral shall be paid to such other Person as may be entitled thereto or as a court of competent jurisdiction may otherwise direct.  Until the Discharge of First Lien Obligations has occurred, if any Second Lien Claimholders shall at any time receive any proceeds of any such insurance policy or any such award or payment in contravention of this Agreement, it shall segregate and hold in trust and forthwith pay such proceeds over to PDL in accordance with the terms of Section 4.2 .

 

5.3            Amendments to First Lien Loan Documents and Second Lien Loan Documents .

 

(a)            The First Lien Loan Documents may be amended, supplemented or otherwise modified in accordance with their terms and the Credit Agreement may be Refinanced, in each case, without notice to or the consent of the Second Lien Claimholders, all without affecting the lien subordination or other provisions of this Agreement; provided, however that the holders of such Refinancing debt bind themselves in a writing addressed to the Second Lien Agent and the Second Lien Claimholders to the terms of this Agreement and any such amendment, supplement, modification or Refinancing shall not, without the consent of the Second Lien Agent: (i) increase the then outstanding principal amount of the “Loans” under the Credit Agreement to an aggregate amount that is greater than Forty-Four Million Dollars ($44,000,000), excluding the capitalization of accrued interest and Protective Advances (the maximum principal amount described herein is referred to herein as the “ First Lien Cap Amount ”); (ii) extend the Tranche One Maturity Date or the Tranche Two Maturity Date beyond the dates set forth in the Credit Agreement as in effect on the date hereof; or (iii) increase the interest rate applicable to the First Lien Obligations by more than two percent (2%) over the interest rate set forth in the Credit Agreement as in effect on the date hereof, excluding increases as a result of the imposition of the “Default Rate” as defined in Section 2.3.1(c) of the Credit Agreement as in effect on the date hereof.

 

14
 

 

(b)            No Second Lien Loan Document may be Refinanced, amended, supplemented or otherwise modified without the prior written consent of PDL, except as required by Section 5.3(c) below and except with respect to the following changes (which do not require the prior written consent of PDL):

 

(1)            amendments or modifications (including waivers) of representations, warranties, conditions precedent, covenants, prepayment obligations, defaults, or events of default to make them less restrictive as to any Grantor;

 

(2)            amendments or modifications (including waivers) extending any date upon which a scheduled or required payment of principal, interest or other amount is due in respect of the Second Lien Obligations; and

 

(3)            amendments or modifications reducing the interest rate, fees and other amounts payable by any Grantor under the Second Lien Loan Documents;

 

provided that no such Refinancing, amendment, supplement or modification may alter or otherwise adversely affect or diminish in any way the rights, remedies and priorities afforded the First Lien Claimholders under this Agreement.

 

(c)            The Borrower agrees that the Subordinated Notes shall be amended to include the following language (or language to similar effect approved by PDL):

 

“Notwithstanding anything herein to the contrary, the rights and remedies granted to the Holder pursuant to this Note, the lien and security interest granted to the Agent securing this Note and the exercise of any right or remedy by the Holder or Agent relating to this Note are subject to the provisions of the Subordination and Intercreditor Agreement dated as of June 26, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “ Intercreditor Agreement ”), among PDL BIOPHARMA, INC. and EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, and certain other persons party or that may become party thereto from time to time.  In the event of any conflict between the terms of the Intercreditor Agreement and this Note, the Purchase Agreement and the other Transaction Documents (as defined in the Purchase Agreement), the terms of the Intercreditor Agreement shall govern and control.”

 

15
 

 

(d)            In the event PDL or the First Lien Claimholders and the Borrower (or the Borrower and the applicable Grantor) enter into any amendment, waiver or consent in respect of any of the First Lien Loan Documents for the purpose of adding to, or deleting from, or waiving or consenting to any departures from any provisions of, any First Lien Loan Document or changing in any manner the rights of PDL, such First Lien Claimholders, the Borrower or any such Grantor, then such amendment, waiver or consent shall apply automatically to any comparable provision of any Second Lien Loan Document without the consent of the Second Lien Claimholders and without any action by any Grantor; provided that:

 

(1)           no such amendment, waiver or consent shall have the effect of:

 

(A)            removing or releasing assets subject to the Lien of the Second Lien Collateral Documents, except to the extent that a release of such Lien is permitted or required by Section 5.1 of this Agreement and provided that there is a corresponding release of the Liens securing the First Lien Obligations;

 

(B)            imposing duties on any Second Lien Claimholder without its consent; or

 

(C)            permitting other Liens on the Second Lien Collateral not permitted under the terms of the Second Lien Loan Documents or Section 6 ; and

 

(2)            notice of such amendment, waiver or consent shall have been given to the Second Lien Agent within ten (10) Business Days after the effective date of such amendment, waiver or consent.

 

5.4           When Discharge of First Lien Obligations Deemed to Not Have Occurred .  If concurrently with the Discharge of First Lien Obligations, the Borrower or any Grantor thereafter enters into any Refinancing of any First Lien Loan Document evidencing a First Lien Obligation, which Refinancing is permitted by the Second Lien Loan Documents, then such Discharge of First Lien Obligations shall automatically be deemed not to have occurred for all purposes of this Agreement, and, from and after the date on which the New First Lien Debt Notice (as defined below) is delivered to the Second Lien Agent in accordance with the next sentence, the obligations under such Refinancing of the First Lien Loan Document shall automatically be treated as First Lien Obligations for all purposes of this Agreement, including for purposes of the Lien priorities and rights in respect of Collateral set forth herein.  Upon receipt of a notice (the “ New First Lien Debt Notice ”) stating that the Borrower or any Grantor has entered into a new First Lien Loan Document (which notice shall include the identity of the new first lien agent, such agent, the “ New Agent ”), the Second Lien Agent and any other Second Lien Claimholders shall promptly enter into such documents and agreements (including amendments or supplements to this Agreement) as the Borrower, any Grantor or such New Agent shall reasonably request in order to provide to the New Agent the rights contemplated hereby, in each case consistent in all material respects with the terms of this Agreement.  The New Agent shall agree in a writing addressed to the Second Lien Agent to be bound by the terms of this Agreement. If the new First Lien Obligations under the new First Lien Documents are secured by assets of the Grantors constituting Collateral that do not also secure the Second Lien Obligations, then the Second Lien Obligations shall be secured at such time by a second priority Lien on such assets to the same extent provided in the Second Lien Collateral Documents and this Agreement.

 

16
 

 

5.5           Purchase Right .  Without prejudice to the enforcement of the First Lien Claimholders remedies, PDL agrees to give the Second Lien Agent written notice (an “ Acceleration Notice ”) within five (5) Business Days after PDL accelerates the First Lien Obligations.  Upon receipt of an Acceleration Notice, the Second Lien Claimholders or, at the election of the Second Lien Agent, an assignee designated by the Second Lien Agent shall have the option to purchase the aggregate amount of outstanding First Lien Obligations (including unfunded commitments under the Credit Agreement) at a purchase price equal to the principal of, and all accrued and unpaid interest (including any Credit Agreement Default Interest), fees and expenses in respect of, all First Lien Obligations outstanding at the time of purchase, and without warranty or representation or recourse.  If the Second Lien Claimholders or an assignee designated by the Second Lien Agent desire to exercise such option, the Second Lien Agent shall deliver written notice (a “ Purchase Notice ”) to PDL within ten (10) Business Days of the receipt of the Acceleration Notice, which Purchase Notice once delivered shall be irrevocable, and the parties shall close such purchase within twenty (20) days of the delivery of such Purchase Notice.  If the Second Lien Agent delivers a Purchase Notice, the purchase of the First Lien Obligations shall be consummated pursuant to documentation mutually acceptable to each of PDL and the Second Lien Agent or its assignee; provided that the First Lien Obligations so purchased shall not include any rights of the First Lien Claimholders with respect to indemnification or other obligations of the Grantors under the First Lien Documents that are expressly stated to survive the termination of the First Lien Documents.  If the Second Lien Agent fails to deliver a Purchase Notice with the timeframe set forth above, or otherwise deliver written notice to PDL that neither the Second Lien Claimholders nor an assignee of the Second Lien Agent desire to purchase the First Lien Obligations, the First Lien Claimholders shall have no further obligations pursuant to this Section 5.5.  Notwithstanding anything to the contrary set forth in this Section 5.5, nothing herein shall be deemed to limit the rights of PDL and the First Lien Claimholders to commence or to continue to pursue enforcement actions against the Collateral during any period prior to or after the delivery or receipt of any Acceleration Notice or Purchase Notice.

 

SECTION 6.       Insolvency Or Liquidation Proceedings .

 

6.1           Finance Issues .  Until the Discharge of First Lien Obligations has occurred, if any Grantor shall be subject to any Insolvency or Liquidation Proceeding and PDL shall desire to permit the use of “Cash Collateral” (as such term is defined in Section 363(a) of the Bankruptcy Code) on which PDL or any other creditor has a Lien or to permit such Grantor to obtain financing, whether from the First Lien Claimholders or any other Person, under Section 364 of the Bankruptcy Code or any similar Debtor Relief Law (“ DIP Financing ”) or to sell Collateral under Section 363 of the Bankruptcy Code or any similar Debtor Relief Law (“ 363 Sale ”), then each Second Lien Claimholder agrees that it will raise no objection to such Cash Collateral use, DIP Financing or 363 Sale (it being understood, for the avoidance of doubt, that Section 5.3(a) hereof shall not apply to any such DIP Financing).  To the extent the Liens securing the First Lien Obligations are subordinated to or pari passu with a DIP Financing permitted by PDL, the Second Lien Claimholders will subordinate their Liens in any Collateral (x) to the Liens securing such DIP Financing (and all Obligations relating thereto) (y) will not object to and will subordinate their Liens in the Collateral to any “carve-out” for professional fees and expenses and United States Trustee fees agreed to by the First Lien Claimholders (provided that such fees and expenses are reasonably appropriate for a Chapter 11 case involving a debtor of similar size and scope as the Company), and (z) will not request adequate protection or any other relief in connection therewith (except as expressly agreed by PDL or to the extent permitted by Section 6.3 ).

 

17
 

 

6.2           Relief from the Automatic Stay .  Until the Discharge of First Lien Obligations has occurred, each Second Lien Claimholder agrees that none of them shall seek (or support any other Person seeking) relief from the automatic stay or any other stay in any Insolvency or Liquidation Proceeding in respect of the Collateral without the prior written consent of PDL, except if PDL or the First Lien Claimholders have obtained relief from the automatic stay with respect to all or a portion of the Collateral, then the Second Lien Claimholders may seek relief from the automatic stay with respect to such Collateral in order to preserve their rights therein.

 

6.3           Adequate Protection .

 

(a)            Each Second Lien Claimholder agrees that none of them shall contest (or support any other Person contesting):

 

(1)            any request by PDL or the First Lien Claimholders, acting either directly or indirectly through the Borrower, for adequate protection; or

 

(2)            any objection by PDL or the First Lien Claimholders, acting either directly or indirectly through the Borrower, to any motion, relief, action or proceeding based on PDL or the First Lien Claimholders claiming a lack of adequate protection.

 

(b)            Notwithstanding the foregoing provisions in this Section 6.3 , in any Insolvency or Liquidation Proceeding:

 

(1)            if the First Lien Claimholders (or any subset thereof) are granted adequate protection in the form of additional collateral in connection with any Collateral or Cash Collateral use or DIP Financing or 363 Sale, then the Second Lien Claimholders may seek or request adequate protection in the form of a Lien on such additional collateral, which Lien will be subordinated to the Liens securing the First Lien Obligations and such Cash Collateral use or DIP Financing (and all Obligations relating thereto) on the same basis as the other Liens securing the Second Lien Obligations are so subordinated to the First Lien Obligations under this Agreement; and

 

(2)            in the event any Second Lien Claimholder seeks or requests adequate protection in respect of the Second Lien Obligations and such adequate protection is granted in the form of additional collateral, then each Second Lien Claimholder agrees that (x) PDL shall also be granted a senior Lien on such additional collateral as security for the First Lien Obligations and for any Cash Collateral use or DIP Financing provided by the First Lien Claimholders, and (y) that any Lien on such additional collateral securing the Second Lien Obligations shall be subordinated to the Lien on such collateral securing the First Lien Obligations and any such DIP Financing provided by the First Lien Claimholders (and all Obligations relating thereto) and to any other Liens granted to the First Lien Claimholders as adequate protection on the same basis as the other Liens securing the Second Lien Obligations are so subordinated to such First Lien Obligations under this Agreement.  Except as otherwise expressly set forth in Section 6.1 or in connection with the exercise of remedies with respect to any Collateral, nothing herein shall limit the rights of the Second Lien Claimholders to seek adequate protection with respect to their rights in the Collateral in any Insolvency or Liquidation Proceeding (including adequate protection in the form of a cash payment, periodic cash payments or otherwise).

 

18
 

 

6.4           No Waiver .  Nothing contained herein shall prohibit or in any way limit PDL or any First Lien Claimholder from objecting in any Insolvency or Liquidation Proceeding or otherwise to any action taken by any of the Second Lien Claimholders, other than as provided in Sections 6.1 through 6.3 hereof, including the seeking by any Second Lien Claimholder of adequate protection or the asserting by any Second Lien Claimholders of any of its rights and remedies under the Second Lien Loan Documents or otherwise.

 

6.5           Avoidance Issues .  If any First Lien Claimholder is required in any Insolvency or Liquidation Proceeding or otherwise to turn over or otherwise pay to the estate of a Grantor any amount paid in respect of the First Lien Obligations (a “ First Lien Recovery ”), then such First Lien Claimholders shall be entitled to a reinstatement of the First Lien Obligations with respect to all such recovered amounts.  If this Agreement shall have been terminated prior to such First Lien Recovery, this Agreement shall be reinstated in full force and effect, and such prior termination shall not diminish, release, discharge, impair or otherwise affect the obligations of the parties hereto from such date of reinstatement.  If any Second Lien Claimholder is required in any Insolvency or Liquidation Proceeding or otherwise to turn over or otherwise pay to the estate of a Grantor any amount paid in respect of the Second Lien Obligations (a “ Second Lien Recovery ”), then such Second Lien Claimholders shall be entitled to a reinstatement of the Second Lien Obligations with respect to all such recovered amounts.  If this Agreement shall have been terminated prior to such Second Lien Recovery, this Agreement shall be reinstated in full force and effect, and such prior termination shall not diminish, release, discharge, impair or otherwise affect the obligations of the parties hereto from such date of reinstatement.

 

6.6           Certain Voting Rights .  No Second Lien Claimholder shall directly or indirectly propose, support or vote in favor of any a plan of reorganization or similar dispositive restructuring plan in connection with an Insolvency or Liquidation Proceeding that is inconsistent with the terms and conditions of this Agreement.

 

6.7           No X-Clause; Reorganization Securities .  This Agreement does not contain an “X-clause” as an exception to the provisions of Section 2.4 or the payment turnover of set forth in Section 4.2 , and any securities or debt instruments received by the Second Lien Claimholders prior to the Discharge of the First Lien Obligations shall be subject to the terms of this Agreement, including Sections 2.4 and 4.2 . Notwithstanding the previous sentence, if, for any reason, in any Insolvency or Liquidation Proceeding, debt obligations of the reorganized debtor secured by Liens upon any property of the reorganized debtor are distributed pursuant to a plan of reorganization or similar dispositive restructuring plan, both on account of the First Lien Obligations and on account of the Second Lien Obligations, then, to the extent the debt obligations distributed on account of the First Lien Obligations and on account of the Second Lien Obligations are secured by Liens upon the same property, the provisions of this Agreement will survive the distribution of such debt obligations pursuant to such plan and will apply with like effect to the Liens securing such debt obligations.

 

19
 

 

6.8            Post-Petition Interest .

 

(a)            No Second Lien Claimholder shall oppose or seek to challenge any claim by PDL or any First Lien Claimholder for allowance in any Insolvency or Liquidation Proceeding of First Lien Obligations consisting of post-petition interest, fees or expenses to the extent of the value of any First Lien Claimholder’s Lien without regard to the existence of the Lien of the Second Lien Claimholders on any Collateral.

 

(b)            Neither PDL nor any other First Lien Claimholder shall oppose or seek to challenge any claim by any Second Lien Claimholder for allowance in any Insolvency or Liquidation Proceeding of Second Lien Obligations consisting of post-petition interest, fees or expenses to the extent of the value of the Lien of the Second Lien Claimholders on the Collateral (after taking into account the First Lien Collateral).

 

6.9            Waiver .  Each Second Lien Claimholder hereby waives any claim it may hereafter have against any First Lien Claimholder arising out of the election of any First Lien Claimholder of the application of Section 1111(b)(2) of the Bankruptcy Code, out of any cash collateral or financing arrangement or out of any grant of a security interest in connection with the Collateral in any Insolvency or Liquidation Proceeding.

 

6.10          Separate Grants of Security and Separate Classification .  Each Second Lien Claimholder acknowledges and agrees and PDL acknowledges and agrees for itself and on behalf of the First Lien Claimholders that:

 

(a)            the grants of Liens pursuant to the First Lien Collateral Documents and the Second Lien Collateral Documents constitute two separate and distinct grants of Liens; and

 

(b)            because of, among other things, their differing rights in the Collateral, the Second Lien Obligations are fundamentally different from the First Lien Obligations and must be separately classified in any plan of reorganization proposed or adopted in an Insolvency or Liquidation Proceeding.

 

To further effectuate the intent of the parties as provided in the immediately preceding sentence, if it is held that the claims of the First Lien Claimholders and the Second Lien Claimholders in respect of any Collateral constitute only one secured claim (rather than separate classes of senior and junior secured claims), then each of the parties hereto hereby acknowledges and agrees that, subject to Sections 2.1 and 4.1 , all distributions shall be made as if there were separate classes of senior and junior secured claims against the Borrower and the Grantors in respect of such Collateral (with the effect being that, to the extent that the aggregate value of the Collateral is sufficient (for this purpose ignoring all claims held by the Second Lien Claimholders), the First Lien Claimholders shall be entitled to receive, in addition to amounts otherwise distributed to them in respect of principal, pre-petition interest and other claims, all amounts owing in respect of post-petition interest, including any additional interest payable pursuant to the Credit Agreement, arising from or related to a default, that is disallowed as a claim in any Insolvency or Liquidation Proceeding, before any distribution is made in respect of the claims held by the Second Lien Claimholders with respect to the Collateral, with each Second Lien Claimholder hereby acknowledging and agreeing to turn over to PDL for itself and on behalf of the First Lien Claimholders amounts otherwise received or receivable by them to the extent necessary to effectuate the intent of this sentence (with respect to the payment of post-petition interest), even if such turnover has the effect of reducing the claim or recovery of the Second Lien Claimholders).

 

20
 

 

6.11          PDL as Bailee for Perfection.

 

(a)            If PDL has any Collateral in its possession or control (such Collateral being the “ Pledged Collateral ”), then, subject to Section 2.1 and this Section 6.11 , PDL will possess or control the Pledged Collateral as bailee and/or agent for perfection for the benefit of the Second Lien Agent as secured party, so as to satisfy the requirements of Sections 8-106(d)(3), 8-301(a)(2) and 9-313(c) of the UCC.  In this Section 6.11 , “control” has the meaning given that term in sections 8-106 and 9-104 of the UCC.

 

(b)            PDL will have no obligation to any First Lien Claimholder or Second Lien Claimholder to ensure that any Pledged Collateral is genuine or owned by any of the Grantors or to preserve rights or benefits of any Person except as expressly set forth in this Section 6.11 .  The duties or responsibilities of PDL under this Section 6.11 will be limited solely to possessing or controlling the Pledged Collateral as bailee and/or agent for perfection in accordance with this Section 6.11 and delivering the Pledged Collateral upon a Discharge of First Lien Obligations as provided in subsection (d) below.

 

(c)            Each Second Lien Claimholder hereby waives and releases PDL from all claims and liabilities arising out of PDL’s role under this Section 6.11 other than as a result of PDL’s gross negligence or willful misconduct. The First Lien Collateral Agent acting pursuant to this Section 6.11 shall not have by reason of this Agreement or any other document a fiduciary relationship in respect of the Second Lien Agent or any Second Lien Claimholder.

 

(d)            Upon the Discharge of First Lien Obligations, PDL will deliver or transfer control of any Pledged Collateral in its possession or control, together with any necessary endorsements (which endorsements will be without recourse and without any representation or warranty), (x) first , to the Second Lien Agent if any Second Lien Obligations remain outstanding, and (y) second , to the Borrower, and will take any other action reasonably requested by the Second Lien Agent (at the expense of the Borrower or, upon default by the Borrower in payment or reimbursement thereof, the Second Lien Agent) in connection with the Second Lien Agent obtaining a first-priority security interest in the Pledged Collateral.  In furtherance of the foregoing, to the extent PDL is party to any deposit account control agreement, securities account control agreement, or collateral access agreement with any financial institution, securities intermediary or landlord or bailee which agreement provides for PDL to have “control” over any Pledged Collateral, after the Discharge of First Lien Obligations PDL agrees to use reasonable efforts to assign its rights under such agreement to the Second Lien Agent; provided that, to the extent any such financial institution, securities intermediary or landlord or bailee refuses to consent to such assignment or elects to terminate such agreement as a result of the Discharge of First Lien Obligations, PDL shall have no duty or obligation to the Second Lien Agent, other than the obligation to deliver the Pledged Collateral to the Second Lien Agent.

 

21
 

 

6.12         Proofs of Claim .  If a proper proof of claim has not been filed by the Second Lien Claimholders or the Second Lien Agent on behalf of the Second Lien Claimholders with respect to the Second Lien Obligations or any of the Second Lien Collateral in the form required in such Insolvency or Liquidation Proceeding at least ten (10) days prior to the expiration of the time for filing thereof, PDL shall have the right (but not the duty) to file an appropriate claim for and on behalf of the Second Lien Claimholders with respect to any of the Second Lien Obligations or any of the Second Lien Collateral.  In furtherance of the foregoing, the Second Lien Agent hereby appoints PDL as its attorney-in-fact, with full authority in the place and stead of the Second Lien Agent and full power of substitution and in the name of the Second Lien Claimholders or otherwise, to execute and deliver any document or instrument that PDL is required or permitted to deliver pursuant to this Section 6.12 , such appointment being coupled with an interest and irrevocable.

 

SECTION 7.           Reliance; Waivers; Etc.

 

7.1           Reliance .  Other than any reliance on the terms of this Agreement, PDL acknowledges on behalf of itself and the First Lien Claimholders that it and the First Lien Claimholders have, independently and without reliance on any Second Lien Claimholder, and based on documents and information deemed by them appropriate, made their own credit analysis and decision to enter into such First Lien Loan Documents and be bound by the terms of this Agreement and they will continue to make their own credit decision in taking or not taking any action under the First Lien Loan Documents or this Agreement.  Each Second Lien Claimholder acknowledges that it and the Second Lien Claimholders have, independently and without reliance on PDL or any First Lien Claimholder, and based on documents and information deemed by them appropriate, made their own credit analysis and decision to enter into each of the Second Lien Loan Documents and be bound by the terms of this Agreement and they will continue to make their own credit decision in taking or not taking any action under the Second Lien Loan Documents or this Agreement.

 

7.2           No Warranties or Liability .  PDL acknowledges and agrees on behalf of itself and the First Lien Claimholders that the Second Lien Claimholders have made no express or implied representation or warranty, including with respect to the execution, validity, legality, completeness, collectability or enforceability of any of the Second Lien Loan Documents, the ownership of any Collateral or the perfection or priority of any Liens thereon.  Except as otherwise provided herein, the Second Lien Claimholders will be entitled to manage and supervise their respective loans and extensions of credit under the Second Lien Loan Documents in accordance with law and as they may otherwise, in their sole discretion, deem appropriate.  Except as otherwise provided herein, each Second Lien Claimholder acknowledges and agrees that PDL and the First Lien Claimholders have made no express or implied representation or warranty, including with respect to the execution, validity, legality, completeness, collectability or enforceability of any of the First Lien Loan Documents, the ownership of any Collateral or the perfection or priority of any Liens thereon.  Except as otherwise provided herein, the First Lien Claimholders will be entitled to manage and supervise their respective loans and extensions of credit under their respective First Lien Loan Documents in accordance with law and as they may otherwise, in their sole discretion, deem appropriate.  The Second Lien Claimholders shall have no duty to PDL or any of the First Lien Claimholders, and PDL and the First Lien Claimholders shall have no duty to the Second Lien Claimholders, to act or refrain from acting in a manner that allows or results in the occurrence or continuance of an event of default or default under any agreements with the Borrower or any Grantor (including the First Lien Loan Documents and the Second Lien Loan Documents), regardless of any knowledge thereof that they may have or be charged with.

 

22
 

 

7.3           No Waiver of Lien Priorities .

 

(a)            No right of the First Lien Claimholders, PDL or any of them to enforce any provision of this Agreement or any First Lien Loan Document shall at any time in any way be prejudiced or impaired by any act or failure to act on the part of the Borrower or any Grantor or by any act or failure to act by any First Lien Claimholder or PDL, or by any noncompliance by any Person with the terms, provisions and covenants of this Agreement, any of the First Lien Loan Documents or any of the Second Lien Loan Documents, regardless of any knowledge thereof that PDL or the First Lien Claimholders or any of them may have or be otherwise charged with.

 

(b)            Without in any way limiting the generality of the foregoing paragraph (but subject to the rights of the Borrower under the First Lien Loan Documents and subject to the provisions of this Agreement, including Section 5.3(a) ), the First Lien Claimholders, PDL and any of them may, at any time and from time to time in accordance with the First Lien Loan Documents and/or applicable law, without the consent of or notice to any Second Lien Claimholders, without incurring any liabilities to any Second Lien Claimholders and without impairing or releasing the Lien priorities and other benefits provided in this Agreement (even if any right of subrogation or other right or remedy of any Second Lien Claimholders is affected, impaired or extinguished thereby) do any one or more of the following:

 

(1)            change the manner, place or terms of payment, change or extend the time of payment of or amend, renew, exchange, increase or alter the terms of any of the First Lien Obligations or any Lien on any First Lien Collateral or guaranty thereof or any liability of the Borrower or any Grantor, or any liability incurred directly or indirectly in respect thereof (including any increase in or extension of the First Lien Obligations, without any restriction as to the tenor or terms of any such increase or extension) or otherwise amend, renew, exchange, extend, modify or supplement in any manner any Liens held by PDL or any of the First Lien Claimholders, the First Lien Obligations or any of the First Lien Loan Documents;

 

(2)             sell, exchange, release, surrender, realize upon, enforce or otherwise deal with in any manner and in any order any part of the First Lien Collateral or any liability of the Borrower or any Grantor to the First Lien Claimholders or PDL or any liability incurred directly or indirectly in respect thereof;

 

23
 

 

(3)            settle or compromise any First Lien Obligation or any other liability of the Borrower or any Grantor or any security therefor or any liability incurred directly or indirectly in respect thereof and apply any sums by whomsoever paid and however realized to any liability (including the First Lien Obligations) in any manner or order; and

 

(4)            exercise or delay in or refrain from exercising any right or remedy against the Borrower, any Grantor or any other Person, elect any remedy and otherwise deal freely with the Borrower or any Grantor or any First Lien Collateral and any security and any guarantor or any liability of the Borrower or any Grantor to the First Lien Claimholders or any liability incurred directly or indirectly in respect thereof.

 

(c)           Except as otherwise provided herein, each Second Lien Claimholder agrees that the First Lien Claimholders and PDL shall have no liability to any Second Lien Claimholders, and each Second Lien Claimholder hereby waives any claim against any First Lien Claimholder or PDL arising out of any and all actions that the First Lien Claimholders or PDL may take or permit or omit to take with respect to:

 

(1)            the First Lien Loan Documents (other than this Agreement);

 

(2)            the collection of the First Lien Obligations in accordance with applicable law and the First Lien Loan Documents; or

 

(3)             the foreclosur e upon, or sale, liquidation or other disposition of, any First Lien Collateral in accordance with applicable law and the First Lien Loan Documents.

 

Each Second Lien Claimholder agrees that the First Lien Claimholders and PDL have no duty to them in respect of the maintenance or preservation of the First Lien Collateral, the First Lien Obligations or otherwise.

 

(d)           Until the Discharge of First Lien Obligations, each Second Lien Claimholder agrees not to assert and hereby waives, to the fullest extent permitted by law, any right to demand, request, plead or otherwise assert or otherwise claim the benefit of any marshaling, appraisal, valuation or other similar right that may otherwise be available under applicable law with respect to any Collateral or any other similar rights a junior secured creditor may have under applicable law.

 

7.4           Obligations Unconditional .  All rights, interests, agreements and obligations of PDL and the First Lien Claimholders and the Second Lien Claimholders, respectively, hereunder shall remain in full force and effect irrespective of:

 

(a)            any lack of validity or enforceability of any First Lien Loan Documents or any Second Lien Loan Documents;

 

24
 

 

(b)            except as otherwise expressly set forth in this Agreement, any change in the time, manner or place of payment of or in any other terms of all or any of the First Lien Obligations or Second Lien Obligations or any amendment or waiver or other modification, including any increase in the amount thereof, whether by course of conduct or otherwise, of the terms of any First Lien Loan Document or any Second Lien Loan Document;

 

(c)            except as otherwise expressly set forth in this Agreement, any change in any security interest in any Collateral or any other collateral or any amendment, waiver or other modification, whether in writing or by course of conduct or otherwise, of all or any of the First Lien Obligations or Second Lien Obligations or any guaranty thereof;

 

(d)            the commencement of any Insolvency or Liquidation Proceeding in respect of any Grantor; or

 

(e)            any other circumstances that otherwise might constitute a defense available to or a discharge of the Borrower or any Grantor in respect of PDL, the First Lien Obligations, any First Lien Claimholder, the Second Lien Obligations or any Second Lien Claimholder in respect of this Agreement.

 

SECTION 8.       Miscellaneous .

 

8.1           Conflicts .  In the event of any conflict between the provisions of this Agreement and the provisions of the First Lien Loan Documents or the Second Lien Loan Documents, the provisions of this Agreement shall govern and control.

 

8.2           Effectiveness; Continuing Nature of this Agreement; Severability .  This Agreement shall become effective when executed and delivered by the parties hereto.  This is a continuing agreement of lien subordination and the First Lien Claimholders may continue, at any time and without notice to any Second Lien Claimholder, to extend credit and other financial accommodations and lend monies to or for the benefit of the Borrower constituting First Lien Obligations in reliance hereon.  Each Second Lien Claimholder hereby waives any right it may have under applicable law to revoke this Agreement or any of the provisions of this Agreement.  The terms of this Agreement shall survive and shall continue in full force and effect in any Insolvency or Liquidation Proceeding.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall not invalidate the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  All references to any Grantor shall include such Grantor as debtor and debtor-in-possession and any receiver or trustee for such Grantor (as the case may be) in any Insolvency or Liquidation Proceeding.  This Agreement shall terminate and be of no further force and effect:

 

(a)            with respect to PDL, the First Lien Claimholders and the First Lien Obligations, on the date of the Discharge of First Lien Obligations, subject to the rights of the First Lien Claimholders under Section 6.5 ; and

 

25
 

 

(b)            with respect to the Second Lien Claimholders and the Second Lien Obligations, upon the later of (1) the date upon which the obligations under the Note Purchase Agreement terminate if there are no other Second Lien Obligations outstanding on such date and (2) if there are other Second Lien Obligations outstanding on such date, the date upon which such Second Lien Obligations terminate.

 

8.3           Amendments; Waivers .  No amendment, modification or waiver of any of the provisions of this Agreement by any Second Lien Claimholder or PDL shall be deemed to be made unless the same shall be in writing signed on behalf of PDL, the Required Second Lien Claimholders or its or their authorized agent, and each waiver, if any, shall be a waiver only with respect to the specific instance involved and shall in no way impair the rights of the parties making such waiver or the obligations of the other parties hereto in any other respect or at any other time.  Notwithstanding the foregoing, no Grantor shall have any right to consent to or approve any amendment, modification or waiver of any provision of this Agreement except to the extent its rights are directly affected.

 

8.4           Information Concerning Financial Condition of the Borrower and the Grantors and their Subsidiaries .  PDL and the First Lien Claimholders, on the one hand, and the Second Lien Claimholders, on the other hand, shall each be responsible for keeping themselves informed of (a) the financial condition of the Borrower and the Grantors and their respective subsidiaries and all endorsers and/or guarantors of the First Lien Obligations or the Second Lien Obligations and (b) all other circumstances bearing upon the risk of nonpayment of the First Lien Obligations or the Second Lien Obligations.  The First Lien Claimholders on the one hand and the Second Lien Claimholders on the other shall have no duty to advise the other of information known to it or them regarding such condition or any such circumstances or otherwise.  In the event any of the First Lien Claimholders, in its or their sole discretion, undertakes at any time or from time to time to provide any such information to any Second Lien Claimholder, or any of the Second Lien Claimholders, in its or their sole discretion, undertakes at any time or from time to time to provide any such information to any First Lien Claimholder, it or they shall be under no obligation:

 

(a)            to make, and the First Lien Claimholders or the Second Lien Claimholders, as the case may be, shall not make, any express or implied representation or warranty, including with respect to the accuracy, completeness, truthfulness or validity of any such information so provided;

 

(b)            to provide any additional information or to provide any such information on any subsequent occasion;

 

(c)            to undertake any investigation; or

 

(d)            to disclose any information that pursuant to accepted or reasonable commercial finance practices such party wishes to maintain confidential or is otherwise required to maintain confidential.

 

26
 

 

8.5           Subrogation .  With respect to the value of any payments or distributions in cash, property or other assets that any of the Second Lien Claimholders pays over to PDL or the First Lien Claimholders under the terms of this Agreement, the Second Lien Claimholders shall be subrogated to the rights of PDL and the First Lien Claimholders; provided , that each Second Lien Claimholder agrees not to assert or enforce all such rights of subrogation it may acquire as a result of any payment hereunder until the Discharge of First Lien Obligations has occurred.  The Borrower acknowledges and agrees that the value of any payments or distributions in cash, property or other assets received by the Second Lien Claimholders that are paid over to PDL or the First Lien Claimholders pursuant to this Agreement shall not reduce any of the Second Lien Obligations.

 

8.6           Application of Payments .  All payments received by PDL or the First Lien Claimholders may be applied, reversed and reapplied, in whole or in part, to such part of the First Lien Obligations provided for in the First Lien Loan Documents.  Each Second Lien Claimholder assents to any extension or postponement of the time of payment of the First Lien Obligations or any part thereof and to any other indulgence with respect thereto, to any substitution, exchange or release of any security that may at any time secure any part of the First Lien Obligations and to the addition or release of any other Person primarily or secondarily liable therefor.

 

8.7           Governing Law.

 

(a)            THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

 

(b)            EACH PARTY HERETO HEREBY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK AND OF THE SUPREME COURT OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY (INCLUDING ITS APPELLATE DIVISION), AND OF ANY OTHER APPELLATE COURT IN THE STATE OF NEW YORK, FOR THE PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.  EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

8.8           Waiver of Right to Trial by Jury .

 

EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER ANY LOAN DOCUMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO ANY LOAN DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

27
 

 

8.9             Notices .  All notices to the Second Lien Claimholders and the First Lien Claimholders permitted or required under this Agreement shall also be sent to PDL.  Unless otherwise specifically provided herein, any notice hereunder shall be in writing and may be personally served, electronically mailed or sent by facsimile or United States mail or courier service and shall be deemed to have been given when delivered in person or by courier service and signed for against receipt thereof upon receipt of facsimile or electronic mail or three Business Days after depositing it in the United States mail with postage prepaid and properly addressed.  For the purposes hereof, the addresses of the parties hereto shall be as set forth on Annex I hereto or, as to each party, at such other address as may be designated by such party in a written notice to all of the other parties.

 

8.10           Further Assurances .  PDL agrees on behalf of itself and the First Lien Claimholders, each Second Lien Claimholder agrees and each Grantor agrees that it shall take such further action and shall execute and deliver such additional documents and instruments as PDL or the majority of the Second Lien Claimholders may reasonably request to effectuate the terms of and the Lien priorities contemplated by this Agreement.

 

8.11           Binding on Successors and Assigns .  This Agreement shall be binding upon PDL, the First Lien Claimholders, the Second Lien Claimholders, the Grantors and their respective successors and assigns.

 

8.12           Specific Performance .  Each of PDL, any First Lien Claimholder and any Second Lien Claimholder may demand specific performance of this Agreement.  PDL hereby irrevocably waives on behalf of itself and the First Lien Claimholders, and each Second Lien Claimholder irrevocably waives, any defense based on the adequacy of a remedy at law and any other defense that might be asserted to bar the remedy of specific performance in any action that may be brought by PDL or the First Lien Claimholders or the Second Lien Claimholders, as the case may be.

 

8.13           Headings .  Section headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect.

 

8.14           Counterparts .  This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  Delivery by facsimile or other electronic means of an executed counterpart of a signature page to this Agreement shall be effective as delivery of an original executed counterpart of this Agreement.

 

28
 

 

8.15           Authorization .  By its signature, each Person executing this Agreement on behalf of a party hereto represents and warrants to the other parties hereto that it is duly authorized to execute this Agreement.

 

8.16           No Third Party Beneficiaries .  This Agreement and the rights and benefits hereof shall inure to the benefit of each of the parties hereto and its respective successors and assigns and shall inure to the benefit of each of the First Lien Claimholders and the Second Lien Claimholders.  Nothing in this Agreement shall impair, as between the Borrower and PDL and the First Lien Claimholders, or as between the Borrower and the Second Lien Claimholders, the obligations of the Borrower to pay principal, interest, fees and other amounts as provided in the First Lien Loan Documents and the Second Lien Loan Documents, respectively.

 

8.17           Provisions Solely to Define Relative Rights .  The provisions of this Agreement are and are intended solely for the purpose of defining the relative rights of PDL and the First Lien Claimholders on the one hand and the Second Lien Claimholders on the other hand.  None of the Borrower, the Grantors or any creditor thereof shall have any rights hereunder, and none of the Borrower or any Grantor may rely on the terms hereof.  Nothing in this Agreement is intended to or shall impair the obligations of the Borrower, which are absolute and unconditional, to pay the First Lien Obligations and the Second Lien Obligations as and when the same shall become due and payable in accordance with their terms.

 

8.18           Additional Second Lien Claimholders .  Each holder of Second Lien Obligations shall become a Second Lien Claimholder for all purposes of this Agreement and such holder of Second Lien Obligations, upon execution and delivery by such holder of Second Lien Obligations of a Joinder Agreement, shall thereafter for all purposes be a party hereto and have the same rights, benefits and obligations as a Second Lien Claimholder, as applicable, party hereto.

 

[Signature Pages Follow]

 

29
 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

     
  First Lien Claimholder:
     
  PDL BIOPHARMA, INC.
     
  By: /s/ John P. McLaughlin
    Name: John P. McLaughlin
    Title: President and CEO

 

Signature Page to Subordination and Intercreditor Agreement 

 

 
 

  

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

     
  Second Lien Claimholders:
     
  HEALTHCOR PARTNERS FUND, L.P.
     
  By: HealthCor Partners Management L.P., as Manager
     
  By: HealthCor Partners Management, G.P., LLC, as General Partner
     
     
     
  By: /s/ J. C. Lightcap
     
  Name: Jeffrey Lightcap
     
  Title: Senior Managing Director
     
     
     
  HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.
     
  By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
     
  By: /s/ Joseph P. Healey
     
  Name: Joseph P. Healey
     
  Title: Co-CEO

 

Signature Page to Subordination and Intercreditor Agreement 

 

 
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

   
  Second Lien Claimholders:
   
  /s/ Allen Wheeler
  Allen Wheeler
   
  /s/ Steven Johnson
  Steven Johnson
   
  /s/ James R. Higgins
  Dr. James R. Higgins

 

Signature Page to Subordination and Intercreditor Agreement 

 

 
 

  

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

     
  Second Lien Claimholders:
   
  Raymond James & Assoc. Inc, not in its corporate capacity but solely as Custodian of the Individual Retirement Account of Sandra K McRee. Further, all representations, warranties and covenants (including indemnities) set forth herein are being made by Sandra K. McRee, not Raymond James & Assoc. Inc.
     
  By: /s/ Robert Blain
     
  Name: Robert Blain
     
  Title: Custodian
     
  /s/ Sandra K. McRee
  Sandra K. McRee
  Beneficial Owner

 

Signature Page to Subordination and Intercreditor Agreement 

 

 
 

 

            IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

   
  Second Lien Claimholders:
   
  /s/ Stephen Berkley
  Stephen Berkley
   
  /s/ Alexandra Berkley
  Alexandra Berkley
   
  /s/ Steven B. Epstein
  Steven B. Epstein
   
  /s/ Deborah L. Epstein
  Deborah L. Epstein
   
  /s/ Jason Epstein
  Jason Peter Epstein
   
  /s/ Gregory Harris Epstein
  Gregory Harris Epstein
   
  /s/ David Epstein
  David Epstein

 

Signature Page to Subordination and Intercreditor Agreement

 

 
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above.  

     
  Second Lien Claimholders:
     
  /s/ Juliann Martin
  Juliann Martin
     
  /s/ Jason Thompson
  Jason Thompson
     
  Thompson Family Investments, LLC
     
  By: /s/ Jason Thompson
  Name: Jason Thompson
  Title: Manager

 

Signature Page to Subordination and Intercreditor Agreement

 

 
 

  

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

     
  Second Lien Claimholders:
     
  /s/ Irwin Lieber
  Irwin Leiber
     
  /s/ Joseph P. Healey
  Joseph P. Healey
     
  /s/ Arthur B. Cohen
  Arthur B. Cohen
     
  SJ2, LLC
     
  By: /s/ Michael Mashaal
  Name: Michael Mashaal
  Title: Authorized Signatory
     
  The Joseph P. Healey 2011 Family Trust
     
  By: /s/ Joseph Dowling
  Name: Joseph Dowling
  Title: Trustee

 

Signature Page to Subordination and Intercreditor Agreement

 

 
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Subordination and Intercreditor Agreement as of the date first written above. 

     
  Second Lien Claimholders:
   
  Morgan Stanley Smith Barney LLC, not in its corporate capacity but solely as Custodian of the Individual Retirement Account of Jeffrey C. Lightcap
   
  By: /s/ Gregory L. Williams
 

Name: Gregory L. Williams 

Title: NTI Associate 

     
  /s/ J. C. Lightcap
  Jeffrey C. Lightcap
Beneficial Owner
   
  Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Brian R. Lightcap
   
  By: /s/ Ira L. Schwartz
 

Name: Ira L. Schwartz 

Title: Trustee 

   
  Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Megan M. Lightcap
   
  By: /s/ Ira L. Schwartz
 

Name: Ira L. Schwartz 

Title: Trustee 

   
  Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Bradford C. Lightcap
  By: /s/ Ira L. Schwartz
 

Name: Ira L. Schwartz 

Title: Trustee 

 

Signature Page to Subordination and Intercreditor Agreement

 

 
 

 

Acknowledgment

 

The undersigned hereby acknowledges that it has received a copy of the foregoing Subordination and Intercreditor Agreement and agrees to recognize all rights granted to the First Lien Claimholders and the Second Lien Claimholders thereunder and agrees that it will not do any act or perform any obligation which is not in accordance with the agreements set forth in such Subordination and Intercreditor Agreement. The undersigned further acknowledges and agrees that it is not an intended beneficiary or third party beneficiary under the Subordination and Intercreditor Agreement, as amended, amended and restated, supplemented or otherwise modified hereafter. 

     
Acknowledged and agreed as of the date first set forth above:
 
CAREVIEW COMMUNICATIONS, INC., a Texas corporation
     
By: /s/ Steven Johnson  
  Name: Steven Johnson  
  Title:  President and CEO  
     
CAREVIEW COMMUNICATIONS, INC., a Nevada corporation
     
By: /s/ Steven Johnson  
  Name: Steven Johnson  
  Title: President and CEO  
     
CAREVIEW OPERATIONS, LLC, a Texas limited liability company
     
By: /s/ Steven Johnson  
  Name: Steven Johnson  
  Title: President and CEO  

 

Signature Page to Subordination and Intercreditor Agreement

 

 
 

 

Annex I to Subordination and Intercreditor Agreement

 

Notices

 

First Lien:

 

PDL BIOPHARMA,INC.
932 Southwood Boulevard
Incline Village, NV 89451
Attention: General Counsel
Telephone: (775) 832-8500
Facsimile: (775) 832-8501

  

Second Lien:

 

c/o HealthCor Partners
Carnegie Hall Towers
152 West 57th Street
New York, NY 10019
Attention: Jeffrey C. Lightcap, Senior Managing Director
Telephone: (212) 622-7800
Facsimile: (212) 622-7742

 

with a copy to:

 

Locke Lord LLP
2800 Financial Plaza
Providence, RI 02903
Attention: Eugene W. McDermott, Jr.
Telephone: (401) 276-6471
Facsimile: (888) 325-9069 

 

Borrower:

 

CareView Communications, Inc.
405 State Highway 121 Bypass
Suite B-240
Lewisville, Texas 75067
Attention: Matthew Jackson, Esq., General Counsel
Telephone: (972) 943-6050
Facsimile: (972) 403-7659

 

A-I- 1
 

  

with a copy to:

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
Attention: Meryl Epstein, Esq.
Telephone: (617) 348-1635
Facsimile: (617) 542-2241

 

A-I- 2
 

 

Annex II to Subordination and Intercreditor Agreement

 

Form of Joinder Agreement

 

JOINDER AGREEMENT, dated as of ____________, 20__, made by ______________________, a _______________ (the “ Additional Second Lien Claimholder ”), in connection with that certain Subordination and Intercreditor Agreement dated as of June 26, 2015 (the “ Intercreditor Agreement ”), by and among PDL BIOPHARMA, INC., a Delaware corporation, in its capacity as agent for the First Lien Claimholders (as defined therein) (including its successors and assigns from time to time, “ PDL ”), EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011 and each other Second Lien Claimholder party thereto. All capitalized terms not defined herein shall have the meaning ascribed to them in the Intercreditor Agreement. 

 

W I T N E S S E T H:

 

WHEREAS, the Intercreditor Agreement requires the Additional Second Lien Claimholder to become a party to the Intercreditor Agreement; and

 

WHEREAS, the Additional Second Lien Claimholder has agreed to execute and deliver this Joinder Agreement in order to become a party to the Intercreditor Agreement.

 

NOW, THEREFORE, IT IS AGREED:

 

1.           Additional Grantor . By executing and delivering this Joinder Agreement, the Additional Second Lien Claimholder, as provided in Section 8.18 of the Intercreditor Agreement, hereby becomes a party to the Intercreditor Agreement as a Second Lien Claimholder thereunder with the same force and effect as if originally named therein as a Second Lien Claimholder and, without limiting the generality of the foregoing, hereby expressly assumes all obligations and liabilities of a Second Lien Claimholder thereunder.

 

2.           Counterparts . This Joinder Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery by facsimile or other electronic means of an executed counterpart of a signature page to this Joinder Agreement shall be effective as delivery of an original executed counterpart of this Joinder Agreement.

 

3.           GOVERNING LAW . THIS JOINDER AGREEMENT SHALL BE GOVERNED BY, THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

 

A-II- 1
 

 

Annex III to Subordination and Intercreditor Agreement

 

Note Investors

 

1. Senior Secured Convertible Notes (issued February 17, 2015 ) payable to each of the following:

 

a. Allen Wheeler

 

b. Steven Johnson

 

c. Sandra McRee

 

d. James R. Higgins MD

 

e. Steven B. Epstein and Deborah L. Epstein

 

f. Stephen Berkley and Alexandra Berkley

 

g. Jason Peter Epstein

 

h. Gregory Harris Epstein

 

i. David Epstein

 

j. Juliann Martin

 

k. Jason Thompson

 

l. Thompson Family Investments, LLC

 

m. Irwin Leiber

 

n. SJ2, LLC

 

o. MSSB C/F Jeffrey C. Lightcap

 

p. Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Bradford C. Lightcap

 

q. Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Brian R. Lightcap

 

r. Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Megan M. Lightcap

 

s. Joseph P. Healey

 

A-III- 1
 

 

t. The Joseph P. Healey 2011 Family Trust

 

u. Arthur B. Cohen

 

v. HealthCor Partners Fund, L.P.

 

2. Senior Secured Convertible Note (issued January 16, 2014 ) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P.

 

3. Senior Secured Convertible Note (issued January 16, 2014 ) payable to the order of HealthCor Partners Fund, L.P.

 

4. Senior Secured Convertible Note (issued January 31, 2012 ) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P.

 

5. Senior Secured Convertible Note (issued January 31, 2012 ) payable to the order of HealthCor Partners Fund, L.P.

 

6. Senior Secured Convertible Note (issued April 21, 2011 ) payable to the order of HealthCor Hybrid Offshore Master Fund, L.P.

 

7. Senior Secured Convertible Note (issued April 21, 2011 ) payable to the order of HealthCor Partners Fund, L.P.

 

A-III- 2

 

 Careview Communications, Inc. 8-K

Exhibit10.03

 

EXECUTION VERSION

 

 

 

PATENT SECURITY AGREEMENT

 

WHEREAS, CAREVIEW COMMUNICATIONS, INC., a Texas corporation (herein referred to as “Grantor”), having an address at 405 State Highway 121 Bypass, Suite B-240, Lewisville, Texas 75067, owns the letters patent and/or applications for letters patent of the United States of America more particularly described on Schedule 1-A annexed hereto as part hereof (the “Patents”);

 

WHEREAS, the Grantor has entered into a Guarantee and Collateral Agreement, dated as of June 26, 2015 (said Guarantee and Collateral Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”; capitalized terms used but not otherwise defined herein having the meaning assigned to them in the Guarantee and Collateral Agreement) in favor of the Agent, for itself and the Lender party to the Credit Agreement (the “Secured Creditors”); and

 

WHEREAS, pursuant to the Guarantee and Collateral Agreement, the Grantor has granted to the Secured Creditors a security interest in all right, title and interest of Grantor in and to the Patents, together with all registrations and recordings thereof, including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, all whether now or hereafter owned or licensable by Grantor, and all reissues, divisions, continuations, continuations-in-part, term restorations or extensions thereof, all Patent licenses and all proceeds of all of the foregoing, including, without limitation, any claims by Grantor against third parties for infringement thereof for the full term of the Patents, to secure the prompt payment and performance of the Secured Obligations.

 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further confirm, and put on the public record, its grant to the Secured Creditors of a security interest in and mortgage on the Collateral to secure the prompt payment and performance of the Secured Obligations.

 

Section 1.           Grant of Security Interest in Patents Each Grantor hereby grants to the Agent a security interest and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether owned or existing or hereafter acquired or arising and wherever located (collectively, the “Patent Collateral”): all United States and foreign patents and certificates of invention, or similar industrial property rights, including, but not limited to each patent referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time), and with respect to any and all of the foregoing, (i) all applications therefor including the patent applications referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time), (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom, and (vii) all proceeds, payments and rights to payments arising out of the sale, lease, license, assignment, or other disposition thereof.

 

Section 2.           Security Agreement  The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to the Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the Patent Collateral made and granted hereby are supplemental of, and more fully set forth in, the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Patent Security Agreement and the terms of the Guarantee and Collateral Agreement, the terms of the Guarantee and Collateral Agreement shall control.

 

 
 

 

Section 3.           Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in such Grantor’s reasonable business judgment in connection with their Patents subject to a security interest hereunder.

 

Section 4.           GOVERNING LAW  THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

Section 5.           Counterparts.  This Patent Security Agreement may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Patent Security Agreement shall become effective when the Agent has received counterparts bearing the signatures of all parties hereto. Delivery of a signature page of this Patent Security Agreement by facsimile or other electronic means shall be effective as delivery of a manually executed counterpart of such Patent Security Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

2
 

 

IN WITNESS WHEREOF , the undersigned Grantor has duly executed or caused this Patent Security Agreement to be duly executed as of the first date set forth above 

       
  CAREVIEW COMMUNICATIONS, INC.,  
  A Texas corporation  
     
  By: /s/ Steven Johnson  
  Name: Steven Johnson  
  Title: President and CEO  

 

 
 

 

Schedule 1-A to the PATENT SECURITY AGREEMENT

               
  Title     Date Filed
or Granted
    Serial No. or
Patent No.
               
  Non-Intrusive Data Transmission Network for Use in an Enterprise Facility and Method for Implementing     01/13/2009     7,477,285
               
  System and Method for Documenting Patient Procedures     06/25/2013     8,471,899
               
  System and Method for Using a Video Monitoring System to Prevent and Manage Decubitus Ulcers in Patients     03/18/2014     8,675,059
               
  System and Method for Predicting Patient Falls     05/06/2008     12/151,452
               
  System and Method for Using a Video Monitoring System to Prevent and Manage Decubitus Ulcers in Patients     02/24/2014     14/188,396
               
  Electronic Patient Sitter Management System and Method for Implementing     12/14/2012     13/714,587
               
  Noise Correcting Patient Fall Risk State System and Method for Predicting Patient Falls     03/23/2012     13/429,101
               
  System and Method for Monitoring a Fall State of a Patient while Minimizing False Alarms     09/27/2013     14/039,931
               
  Patient Video Monitoring Systems and Methods having Detection Algorithm Recovery from Changes in Illumination     01/17/2014     14/158,016
               
  Systems and Methods for Dynamically Identifying a Patient Support Surface and Patient Monitoring     03/13/2014     14/209,726
               
  System and Method for Documenting Patient Procedures     03/18/2014     8,676,603
               
  System and Method for Predicting Patient Falls     5/26/2015     9,041,810
               
  System and Method for Documenting Patient Procedures     03/14/2014     14/213,163
               
  Electronic Patient Sitter Management System and Method for Implementing     5/12/2015     14/710,009

 

 
 

 

Licensor Licensee Title Date of License
Agreement
Expiration Date of
License
Patents Licensed
Intelliview
Technologies
CareView
Communications, Inc. (Lewisville, TX)

Video Based Monitoring System (Badawy)

 

09/01/2011

 

Upon Expiration of
Patent

 

US 7,612,666*

 

           

 

* (a) License executed 9/1/2011 and recorded 12/20/2011 from Intelliview Technologies Inc. as Assignor to Mann Equity, LLC as Assignee (Reel 027415/Frame 0731).
(b) License executed 9/1/2011 and recorded 12/20/2011 from Mann Equity, LLC as Assignor to CareView Communications, Inc. as Assignee (Reel 27415/Frame 0873).
(c) Amended and Restated Intellectual Property Security Agreement executed 2/17/2015 and recorded 2/18/2015 from CareView Communications, Inc. (NV), CareView Operations, LLC and CareView Communications, Inc. (TX) as Assignors to Healthcor Partners Fund, L.P. as Assignee (Reel 035014/Frame 0408).

 

 

 

 

Careview Communications, Inc. 8-K

 

Exhibit 10.04

 

TRADEMARK SECURITY AGREEMENT

 

WHEREAS , CAREVIEW COMMUNICATIONS, INC., a Texas corporation (herein referred to as “ Grantor ”), having an address at 405 State Highway 121 Bypass, Suite B-240, Lewisville, Texas 75067, (1) has adopted, used and is using, or (2) has intended to use and filed an application indicating that intention, but has not yet filed an allegation of use under Section l(c) or l(d) of the Trademark Act, or (3) has filed an application based on an intention to use and has since used and has filed an allegation of use under Section l(c) or l(d) of the Trademark Act, the trademarks, trade names, trade styles and service marks listed on the annexed Schedule 1-A, which trademarks, trade names, trade styles and service marks are registered, or for which applications for registration have been filed in the United States Patent and Trademark Office (the “ Trademarks ”); and

 

WHEREAS , the Grantor has entered into a Guarantee and Collateral Agreement, dated as of June 26, 2015 (said Guarantee and Collateral Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, the “ Guarantee and Collateral Agreement ”; capitalized terms used but not otherwise defined herein having the meaning assigned to them in the Guarantee and Collateral Agreement) in favor of the Agent, for itself and the Lender party to the Credit Agreement ( the “ Secured Creditors ”); and

 

WHEREAS , pursuant to the Guarantee and Collateral Agreement, the Grantor has granted to the Secured Creditors a security interest in all right, title and interest of the Grantor in and to the Trademarks, together with all prints and labels on which said Trademarks have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, and the goodwill of the business symbolized by the Trademarks and the applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof, or any other country or any political subdivision thereof, all whether now or hereafter owned or licensable by Grantor, and all reissues, extensions or renewals thereof, all Trademark licenses and all proceeds of all of the foregoing, including, without limitation, any claims by Grantor against third parties for infringement thereof, to secure the payment and performance of the Secured Obligations.

 

NOW, THEREFORE , for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further confirm, and put on the public record:

 

Section 1.            Grant of Security Interest in Trademarks . Each Grantor hereby grants to the Agent a security interest and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether owned or existing or hereafter acquired or arising and wherever located (collectively, the “ Trademark Collateral ”):

 

(i)         all United States, State and foreign trademarks, service marks, certification marks, collective marks, trade names, corporate names, d/b/as, business names, fictitious business names, Internet domain names, trade styles, logos, other source or business identifiers, designs and general intangibles of a like nature and, with respect to any and all of the foregoing: (i) all registrations and applications therefor including, but not limited to, the registrations and applications referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time),

 

(ii) the goodwill of the business symbolized thereby,

 

(iii) all rights corresponding thereto throughout the world,

 

 
 

 

(iv) all rights to sue for past, present and future infringement or dilution thereof or for any injury to goodwill,

 

(v) all licenses, claims, damages, and proceeds of suit arising therefrom, and

 

(vi) all payments and rights to payments arising out of the sale, lease, license assignment or other disposition thereof;

 

provided that the security interest granted under Section 2 hereof shall not attach to, and the term “Trademark Collateral” shall not include any applications for trademark filed in the United States Patent and Trademark Office pursuant to 15 U.S.C. § 1051 Section 1(b), only to the extent that the grant of a security interest therein would result in the abandonment, invalidation or unenforceability of the trademarks matured from such application or rights hereunder and only until evidence of the use of such trademarks in commerce, as defined in 15 U.S.C. Section 1127, is submitted to, and accepted by, the United States Patent and Trademark Office pursuant to 15 U.S.C. § 1051 Section 1(c) or 1(d), following which filing all such applications shall automatically become Trademark Collateral.

 

Section 2.           Security Agreement The security interests granted pursuant to this Trademark Security Agreement are granted in conjunction with the security interests granted to the Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the Trademark Collateral made and granted hereby are supplemental of, and more fully set forth in, the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Trademark Security Agreement and the terms of the Guarantee and Collateral Agreement, the terms of the Guarantee and Collateral Agreement shall control.

 

Section 3.           Grantor Remains Liable . Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in such Grantor’s reasonable business judgment in connection with their Trademarks subject to a security interest hereunder.

 

Section 4.            GOVERNING LAW THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

Section 5.            Counterparts . This Trademark Security Agreement may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Trademark Security Agreement shall become effective when the Agent has received counterparts bearing the signatures of all parties hereto. Delivery of a signature page of this Trademark Security Agreement by facsimile or other electronic means shall be effective as delivery of a manually executed counterpart of such Trademark Security Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

 
 

 

IN WITNESS WHEREOF , the undersigned Grantor has duly executed or caused this Trademark Security Agreement to be duly executed as of the date first set forth above.

       
  CAREVIEW COMMUNICATIONS, INC.
  a Texas corporation
     
  By: /s/ Steven Johnson
      Name: Steven Johnson
      Title: President and CEO

 

 
 

 

Schedule 1-A to the TRADEMARK SECURITY AGREEMENT 

 

  Trademark     Application or
Registration Date
    Application Serial No.
or Registration No.
 

 

NetView

    June 16, 2009    

 

77377234

  MovieView     June 16, 2009     77377223
  BabyView     June 16, 2009     77377209
  PatientView     June 16, 2009     77377200
  FacilityView     May 26, 2009     77308398
  SecureView     May 26, 2009     77308365
  NurseView     January 26, 2010     77308303
  PhysicianView     May 26, 2009     77308283
  Virtual Bed Rails     May 15, 2012     85296883
  CareView System     October 2, 2012     85298202
  CareView Communications & Design     November 13, 2012     85298239
  EquipmentView     October 2, 2012     85298243
  SitterView     April 2, 2013     85509600
  View Products     February 26, 2013     85607044
  Virtual Chair Rails     April 2, 2013     85607063
  CareView Networks     Jun. 25, 2013     85298241
  ProcedureView           85298248
  Bedview     May 07, 2013     85607074
  GuestView     Oct. 01, 2013     85689134
  CareView     Sep. 17, 2013     85689162
  See The Possibilities     Nov. 05, 2013     85689183
  See The Possibilities     Oct. 15, 2013     85689193
  See The Possibilities     Oct. 22, 2013     85689206
  See The Possibilities     Oct. 22, 2013     85689217
  NICUView     May 21, 2013     85729701
  SerenityView     Oct. 15, 2013     85826803

 

 

 

  Careview Communications, Inc. 8-K

 

Exhibit 10.05

 

EXECUTION VERSION

 

GUARANTEE AND COLLATERAL AGREEMENT

 

DATED AS OF June 26, 2015

 

BY

 

CAREVIEW COMMUNICATIONS, INC.,

a Nevada corporation,

 

CAREVIEW COMMUNICATIONS, INC.,

a Texas corporation,

 

THE SUBSIDIARY GUARANTORS PARTY HERETO,

 

AS GRANTORS

 

IN FAVOR OF

 

PDL BIOPHARMA, INC.,

as Collateral Agent

 

 
 

 

TABLE OF CONTENTS

             
          Page
             
Section 1.   Definitions   1  
             
  1.01 .   Definition of Terms Used Herein Generally   1  
             
  1.02.   Definition of Certain Terms Used Herein   1  
             
  1.03.   Rules of Interpretation   5  
             
Section 2.   Guarantee   5  
             
  2.01.   Guarantee   5  
             
  2.02.   Subrogration   6  
             
  2.03.   Amendments, etc. with respect to the Borrower Obligations   6  
             
  2.04.   Guarantee Absolute and Unconditional   7  
             
  2.05.   Retirement   8  
             
  2.06.   Payments   8  
             
  2.07.   Election of Remedies   8  
             
  2.08.   Limitation   8  
             
  2.09.   Contribution with Respect to Guaranty Obligations   9  
             
Section 3.   Grant of Security Interest   9  
             
Section 4.   Authorization to File Financing Statements   11  
             
Section 5.   Relation to Intellectual Property Security Agreements   11  
             
Section 6.   Representations and Warranties   11  
             
  6.01.   Grantors’ Legal Status   11  
             
  6.02.   Grantors’ Legal Names   11  
             
  6.03.   Grantors’ Locations   11  
             
  6.04.   Representations in the Credit Agreement   12  
             
  6.05.   Title to Collateral   12  
             
  6.06.   Nature of Collateral   12  
             
  6.07.   Compliance with Laws   12  
             
  6.08.   Validity of Security Interest   12  
             
  6.09.   Perfection Certificate; Intellectual Property Filings   13  
             
  6.10.   Investment Property   13  
             
  6.11.   Accounts   13  
             
  6.12.   Equipment and Inventory   14  
             
Section 7.   Covenants   14  
             
  7.01.   Grantors’ Legal Status   14  

 

 
             
      TABLE OF CONTENTS      
      (continued)      
             
          Page
             
  7.02.   Grantors’ Names   14  
             
  7.03.   Grantors’ Organizational Numbers   14  
             
  7.04.   Locations   14  
             
  7.05.   Covenants in Credit Agreement   14  
             
  7.06.   Promissory Notes and Tangible Chattel Paper   14  
             
  7.07.   Deposit Accounts   15  
             
  7.08.   Investment Property   15  
             
  7.09.   Collateral in the Possession of a Bailee   17  
             
  6.09.   Reserved   17  
             
  7.10.   Electronic Chattel Paper and Transferable Records   17  
             
  7.11.   Letter-of-Credit Rights   18  
             
  7.12.   Commercial Tort Claims   18  
             
  7.13.   Intellectual Property.   18  
             
  7.14.   Maintenance of Collateral; Compliance with Laws   21  
             
  7.15.   Dispositions of Collateral   21  
             
  7.16.   Maintenance of Insurance   21  
             
  7.17.   Periodic Certification.   21  
             
  7.18.   Other Actions as to any and all Collateral   21  
             
  7.19.   Treatment of Accounts   22  
             
  7.20.   Federal, States or Municipal Claims   22  
             
Section 8.   Inspection and Verification   22  
             
Section 9.   Collateral Protection Expenses; Preservation of Collateral   22  
             
  9.01.   Expenses Incurred by the Agent   22  
             
  9.02.   Agent’s Obligations and Duties   22  
             
  9.03.   Duties as to Pledged Securities   23  
             
Section 10. Securities and Deposits   24  
             
Section 11.   Notification to Account Debtors and Other Persons Obligated on Collateral   25  
             
Section 12.   Power of Attorney   25  
             
  12.01.   Appointment and Powers of Agent   25  
             
  12.02.   Failure of Grantor to Perform   26  
             
  12.03.   Expenses of Attorney-in-Fact   27  
             
  12.04.   Ratification by Grantor   27  

 

ii
 
             
      TABLE OF CONTENTS      
      (continued)      
             
          Page
             
  12.05.   No Duty on Agent.   27  
             
Section 13.   Remedies.   27  
             
  13.01.   Default   27  
             
  13.02.   Remedies Upon Default   27  
             
  13.03.   Grant of License to Use Intellectual Property   29  
             
  13.04.   Waivers by Grantors   29  
             
  13.05.   Application of Proceeds   29  
             
  13.06.   Surplus, Deficiency   30  
             
  13.07.   Information Related to the Collateral   30  
             
  13.08.   Sale Exempt from Registration   30  
             
  13.09.   Rights and Remedies Cumulative   31  
             
  13.10.   No Direct Enforcement by Secured Creditors   31  
             
Section 14.   Standards for Exercising Remedies   31  
             
  14.01.   Commercially Reasonable Manner   31  
             
  14.02.   Standard of Care   32  
             
Section 15.   Waivers by Grantor; Obligations Absolute   32  
             
  15.01.   Specific Waivers   32  
             
  15.02.   Obligations Absolute   32  
             
Section 16.   Marshalling   33  
             
Section 17.   Interest.   33  
             
Section 18.   Reinstatement   33  
             
Section 19.   Miscellaneous   33  
             
  19.01.   Notices   33  
             
  19.02.   GOVERNING LAW; CONSENT TO JURISDICTION; SERVICE OF PROCESS   34  
             
  19.03.   WAIVER OF JURY TRIAL, ETC.   34  
             
  19.04.   Counterparts   34  
             
  19.05.   Headings   34  
             
  19.06.   No Strict Construction   34  
             
  19.07.   Severability   34  
             
  19.08.   Survival of Agreement.   35  
             
  19.09.   Fees and Expenses; Indemnification   35  
             
  19.10.   Binding Effect; Several Agreement   35  

 

iii
 
             
      TABLE OF CONTENTS    
      (continued)    
           
          Page
           
  19.11.   Waivers; Amendment   36  
             
  19.12.   Set-Off   36  
             
  19.13.   Integration   36  
             
  19.14.   Acknowledgments   36  
             
  19.15.   Additional Grantors   37  
             
  19.16.   Releases   37  
             
  19.17.   Intercompany Debt   38  

 

     
  EXHIBITS
     
  A Form of Copyright Security Agreement
  B Form of Patent Security Agreement
  C Form of Trademark Security Agreement
     
  ANNEXES
     
  I Form of Joinder Agreement

 

iv
 

 

GUARANTEE AND COLLATERAL AGREEMENT dated as of June 26, 2015 by CareView Communications, Inc., a Texas corporation (“ Holdings ”), CareView Communications, Inc., a Nevada corporation and a wholly-owned subsidiary of Holdings (the “ Borrower ”), and the Subsidiary Guarantors from time to time party hereto, in favor of PDL BioPharma, Inc., a Delaware corporation, as the collateral agent (in such capacity, the “ Agent ”), under the Credit Agreement dated as of June 26, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), among Holdings, the Borrower and PDL BioPharma, Inc., as lender (in such capacity, the “ Lender ”) and agent.

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to the Credit Agreement, the Lender has agreed to make certain extensions of credit to the Borrower upon the terms and conditions set forth therein;

 

WHEREAS, it is a condition precedent to the obligations of the Lender to make its extensions of credit to the Borrower under the Credit Agreement that the Guarantors and the Grantors shall have executed and delivered this Agreement to the Agent; and

 

WHEREAS, the Guarantors are affiliates of the Borrower, will derive substantial benefits from the extension of credit to the Borrower pursuant to the Credit Agreement and are willing to execute and deliver this Agreement in order to induce the Lender to extend such credit.

 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Section 1.                   Definitions .

 

1.01.            Definition of Terms Used Herein Generally . Except as otherwise provided herein, all capitalized terms used herein (including in the preamble hereto) but not defined herein shall have the meanings set forth in the Credit Agreement. Except as specifically provided herein, all terms used herein and defined in the NYUCC shall have the same definitions herein as specified therein as of the date hereof; provided , however , that if a term is defined in Article 9 of the NYUCC differently than in another Article of the NYUCC, the term has the meaning specified in Article 9 of the NYUCC as of the date hereof.

 

1.02.            Definition of Certain Terms Used Herein . As used herein, the following terms shall have the following meanings:

 

Additional Grantor ” has the meaning set forth in Annex I hereto.

 

After-Acquired Intellectual Property ”: as defined in Section 7.13(d) .

 

Agent ”: as defined in the preamble.

 

Agreement ”: this Guarantee and Collateral Agreement, as the same may be amended, restated, supplemented or otherwise modified from time to time.

 

Bankruptcy Code ”: the Internal Revenue Code of 1986, as amended.

 

Borrower ”: as defined in the preamble.

 

1
 

 

Borrower Obligations ”: the Obligations (as defined in the Credit Agreement).

 

Collateral ”: as defined in Section 3 .

 

Copyright Office ”: the United States Copyright Office.

 

Copyright Security Agreement ”: a supplement to this Agreement, executed by one or more Grantors in favor of the Agent, substantially in the form of Exhibit A hereto.

 

Credit Agreement ”: as defined in the preamble.

 

Collateral Documents ”: this Agreement (as may be supplemented from time to time by any Joinder Agreement), the Intellectual Property Security Agreements, all deposit account control agreements and similar agreements, all Collateral Access Agreements and similar agreements, and all other pledge or security agreements, assignments or other similar agreements or instruments executed and delivered by any Grantor pursuant to Section 6.7 of the Credit Agreement or otherwise in connection with the transactions contemplated thereby, in each case as amended, restated, supplemented or otherwise modified from time to time.

 

Event ”: as defined in Section 9.03 .

 

Fully Satisfied ”: with respect to the Secured Obligations, Guarantor Obligations or Borrower Obligations, as the case may be, at any time that (a) all principal constituting Secured Obligations, Guarantor Obligations or Borrower Obligations, as the case may be, and all interest (including interest that shall have accrued after the commencement of a bankruptcy proceeding with respect to the Borrower or any Guarantor at the rate provided in the Loan Documents) accrued to such time on such principal and on all other Secured Obligations, Guarantor Obligations or Borrower Obligations, as the case may be, shall have been paid in full in cash; (b) all fees, expenses and other amounts (including contingent obligations, including those in respect of indemnification provisions contained in the Loan Documents, but excluding obligations in respect of such indemnification provisions for which no claim has been made and for which no notice of claim has been given) unpaid as of such time which constitute Secured Obligations, Guarantor Obligations or Borrower Obligations, as the case may be, shall have been paid in full in cash; and (c) the Commitments shall have expired or been terminated.

 

General Intangibles ”: all “general intangibles” as such term is defined in Section 9-102(42) of the NYUCC as in effect on the date hereof and, in any event, including, without limitation, with respect to any Grantor, all contracts, agreements, instruments and indentures and all licenses and permits issued by Governmental Authorities in any form, and portions thereof, to which such Grantor is a party or under which such Grantor has any right, title or interest or to which such Grantor or any property of such Grantor is subject, as the same may from time to time be amended, restated, supplemented, replaced or otherwise modified, including, without limitation, (i) all rights of such Grantor to receive moneys due and to become due to it thereunder or in connection therewith; (ii) all rights of such Grantor to receive proceeds of any insurance, indemnity, warranty or guaranty with respect thereto; (iii) all rights of such Grantor to damages arising thereunder; (iv) all rights of such Grantor to receive any tax refunds; and (v) all rights of such Grantor to terminate and to perform, to compel performance and to exercise all remedies thereunder.

 

Grantor ”: each of Holdings, the Borrower and each Subsidiary Guarantor.

 

2
 

 

Guarantor ”: each of Holdings and each Subsidiary Guarantor.

 

Guarantor Obligations ”: with respect to any Guarantor, all liabilities, indebtedness and obligations of such Guarantor which may arise under or in connection with this Agreement (including, without limitation, Section 2) or any other Loan Document to which such Guarantor is a party (monetary (including interest accrued at the rate provided in the applicable Loan Document after the commencement of a bankruptcy proceeding whether or not a claim for such interest is allowed) or otherwise), in each case whether on account of guarantee obligations, reimbursement obligations, fees, indemnities, costs, expenses or otherwise (including, without limitation, all fees and disbursements of counsel to any Secured Creditor that are required to be paid by such Guarantor pursuant to the terms of this Agreement or any other Loan Document), and in each case howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, or due or to become due.

 

Intellectual Property Security Agreement ”: each of a Copyright Security Agreement, a Patent Security Agreement and a Trademark Security Agreement.

 

Intercompany Debt ”: as defined in Section 19.17 .

 

Investment Property ”: the collective reference to (i) all “investment property” as such term is defined in Section 9-102(48) of the NYUCC on the date hereof including, without limitation, all certificated securities and uncertificated securities, all security entitlements, all securities accounts, all commodity contracts and all commodity accounts; (ii) security entitlements, in the case of any United States Treasury book-entry securities, as defined in 31 C.F.R. § 357.2, or, in the case of any United States federal agency book-entry securities, as defined in the corresponding United States federal regulations governing such book-entry securities; and (iii) whether or not constituting “investment property” as so defined, all Pledged Notes, all Pledged Stock, all Pledged Security Entitlements and all Pledged Commodity Contracts.

 

Issuers ”: the collective reference to each issuer of a Pledged Security.

 

Joinder Agreement ”: each agreement, in the form of Annex I hereto, executed and delivered by each Person that shall become an Additional Grantor hereunder.

 

Lease ”: any lease of personal property under which any Grantor is the lessee.

 

NYUCC ”: the UCC as in effect in the State of New York from time to time.

 

Patent Security Agreement ”: a supplement to this Agreement, executed by one or more Grantors in favor of Agent, substantially in the form of Exhibit B hereto.

 

Perfection Certificate ”: shall mean that certain Perfection Certificate dated as of the date hereof executed by Holdings and the Borrower in favor of the Agent, as updated by Holdings, the Borrower or any other Grantor from time to time after the Closing Date, and as supplemented from time to time with Annex I-A to each Joinder Agreement executed and delivered to the Agent by each Person that shall become an Additional Grantor hereunder.

 

Perfection Supplement ”: shall have the meaning assigned to such term in Section 7.17 .

 

3
 

 

Person ”: any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.

 

Pledged Commodity Contracts ”: all commodity contracts to which any Grantor is party from time to time.

 

Pledged Debt Securities ”: the debt securities listed in Schedule 8 of the Perfection Certificate, together with any other certificates, options, rights or security entitlements of any nature whatsoever in respect of the debt securities of any Person that may be issued or granted to, or held by, any Grantor while this Agreement is in effect.

 

Pledged Notes ”: all promissory notes listed in Schedule 8 of the Perfection Certificate, all intercompany notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor.

 

Pledged Securities ”: the collective reference to the Pledged Debt Securities, the Pledged Notes and the Pledged Stock.

 

Pledged Stock ”: the shares of capital stock or other equity interests owned at any time or from time to time by any Grantor, including, without limitation, in the case of Holdings or the Borrower, all shares of capital stock, or membership interests, as applicable, in all Grantors that are Subsidiaries of Holdings or the Borrower, together with any other shares, stock certificates, options, rights or security entitlements of any nature whatsoever in respect of the capital stock or other equity interests of any Person that may be issued or granted to, or held by, any Grantor while this Agreement is in effect; provided that “Pledged Stock” shall not include more than 65% of the total outstanding voting stock of any Subsidiary that is a CFC.

 

Proceeds ”: all “proceeds” as such term is defined in Section 9-102(64) of the NYUCC in effect on the date hereof and, in any event, shall include, without limitation, all dividends or other income from the Pledged Securities, collections thereon or distributions or payments with respect thereto.

 

Property ”: any right or interest in or to property of any kind whatsoever, whether real, personal or mixed and whether tangible or intangible, including capital stock or other equity interests.

 

PTO ”: the United States Patent and Trademark Office.

 

Receivable ”: any right to payment on account of any obligation that could create any right to receive money, whether or not such right is evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including, without limitation, any account or payment intangible).

 

Secured Creditors ”: the Agent, in both its capacities as administrative agent under the Credit Agreement and collateral agent under the Collateral Documents, and the Lender under the Credit Agreement, and each of their successors and assigns.

 

Securities Act ”: the Securities Act of 1933, as amended.

 

4
 

 

Stock Rights ”: all dividends, instruments or other distributions and any other right or property which a Grantor shall receive or shall become entitled to receive for any reason whatsoever with respect to, in substitution for, or in exchange for any Pledged Stock constituting Collateral, any right to receive Pledged Stock and any right to receive earnings, in which a Grantor now has or hereafter acquires any right, issued by an issuer of such Pledged Stock.

 

Subsidiary Guarantor ”: each Subsidiary of Holdings party hereto as a Guarantor and each other Subsidiary that is or becomes a party to this Agreement in accordance with the terms hereof.

 

Security Interest ”: the security interest granted pursuant to Section 3 , as well as all other security interests created or assigned as additional security for the Secured Obligations pursuant to the provisions of this Agreement.

 

Secured Obligations ”: collectively, the Borrower Obligations and the Guarantor Obligations.

 

Trademark Security Agreement ”: a supplement to this Agreement, executed by the Grantor in favor of Agent, substantially in the form of Exhibit C hereto.

 

UCC ”: the Uniform Commercial Code as in effect in any jurisdiction (except as otherwise contemplated in Section 7.18 ). References to particular sections of Article 9 of the UCC shall be, unless otherwise indicated, references to revised Article 9 of the UCC adopted and effective in certain jurisdictions on or after July 1, 2001.

 

1.03.          Rules of Interpretation . The rules of interpretation specified in Section 1.2 of Credit Agreement shall be applicable to this Agreement. References to “Sections,” “Exhibits” and “Schedules” shall be to Sections, Exhibits and Schedules, respectively, of this Agreement unless otherwise specifically provided. Any of the terms defined in this Section 1 may, unless the context otherwise requires, be used in the singular or the plural depending on the reference. All references to statutes and related regulations shall include (unless otherwise specifically provided herein) any amendments of same and any successor statutes and regulations.

 

Section 2.                Guarantee .

 

2.01.         Guarantee .

 

  (a)      (a) Each of the Guarantors hereby, jointly and severally, unconditionally and irrevocably, guarantees to the Agent, for the ratable benefit of the Secured Creditors and their respective successors, indorsees, transferees and assigns, the prompt and complete payment and performance by the Borrower when due (whether at the stated maturity, by acceleration or otherwise) of the Borrower Obligations.

 

  (b)      Anything herein or in any other Loan Document to the contrary notwithstanding, the maximum liability of each Guarantor hereunder and under the other Loan Documents shall in no event exceed the amount which can be guaranteed by such Guarantor under applicable federal, state and other laws relating to the insolvency of debtors (after giving effect to the right of contribution established in Section 2.10).

 

5
 

 

  (c)      Each Guarantor agrees that the Borrower Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing the guarantee contained in this Section 2 or affecting the rights and remedies of any Secured Creditor hereunder.

 

  (d)      The guarantee contained in this Section 2 shall remain in full force and effect until all the Borrower Obligations and Guarantor Obligations shall have been Fully Satisfied.

 

  (e)      No payment made by the Borrower, any of the Guarantors, any other guarantor or any other Person or received or collected by any Secured Creditor from the Borrower, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Borrower Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Secured Obligations or any payment received or collected from such Guarantor in respect of the Secured Obligations), remain liable for the Borrower Obligations up to the maximum liability of such Guarantor hereunder until the Borrower Obligations are Fully Satisfied.

 

2.02.         Subrogation . Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by any Secured Creditor, (i) no Guarantor shall be entitled to be subrogated to any of the rights of any Secured Creditor against the Borrower or any other Guarantor or Grantor or any collateral security or guarantee or right of offset held by any Secured Creditor for the payment of the Borrower Obligations, (ii) no Guarantor shall seek or be entitled to seek any contribution or reimbursement from the Borrower or any other Guarantor or Grantor in respect of payments made by such Guarantor hereunder, and (iii) each Guarantor hereby expressly and irrevocably waives any and all rights at law or in equity to subrogation, reimbursement, exoneration, contribution, indemnification or set off and any and all defenses available to a surety, guarantor or accommodation co-obligor, in each case, until all Secured Obligations are Fully Satisfied and the Commitments have been terminated pursuant to the Credit Agreement. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Secured Obligations shall not have been Fully Satisfied, such amount shall be held by such Guarantor in trust for the Secured Creditors, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to the Agent in the exact form received by such Guarantor (duly endorsed by such Guarantor to the Agent, if required), to be applied against the Secured Obligations, whether matured or unmatured, in such order as the Agent may determine. Each Guarantor acknowledges and agrees that this waiver is intended to benefit the Secured Creditors and shall not limit or otherwise affect such Guarantor’s liability hereunder or the enforceability of this Section 2.02, and that the Secured Creditors and their respective successors and assigns are intended third-party beneficiaries of the waivers and agreements set forth in this Section 2.02, and their rights under this Section 2.02, shall survive until all Secured Obligations are Fully Satisfied.

 

2.03.         Amendments, etc. with respect to the Borrower Obligations . Each Guarantor shall remain obligated hereunder notwithstanding that, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, any demand for payment of any of the Borrower Obligations made by any Secured Creditor may be rescinded by such Secured Creditor and any of the Borrower Obligations continued, and the Borrower Obligations, or the liability of any other Person upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by any Secured Creditor, and the Credit Agreement and the other Loan Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as the Agent (or the Lender under the Credit Agreement, as the case may be) may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held by any Secured Creditor for the payment of the Borrower Obligations may be sold, exchanged, waived, surrendered or released. No Secured Creditor shall have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Borrower Obligations or for the guarantee contained in this Section 2 or any property subject thereto.

 

6
 

 

2.04.         Guarantee Absolute and Unconditional . Each Guarantor waives any and all notice of the creation, renewal, extension or accrual of any of the Borrower Obligations and notice of or proof of reliance by any Secured Creditor upon the guarantee contained in this Section 2 or acceptance of the guarantee contained in this Section 2; the Borrower Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guarantee contained in this Section 2; and all dealings between the Borrower and any of the Guarantors, on the one hand, and the Secured Creditors, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guarantee contained in this Section 2. Each Guarantor waives diligence, presentment, protest, demand for payment and notice of default or nonpayment to or upon Borrower or any of the Guarantors with respect to the Borrower Obligations, except as required pursuant to the Credit Agreement. Each Guarantor understands and agrees that the guarantee contained in this Section 2 shall be construed as a continuing, absolute and unconditional guarantee of payment and performance (and not of collection) without regard to (a) the validity or enforceability of the Credit Agreement or any other Loan Document (other than this Agreement), any of the Borrower Obligations or any other collateral security therefor or guarantee or right of offset with respect thereto at any time or from time to time held by any Secured Creditor; (b) any defense, set-off or counterclaim (other than a defense of complete payment and performance hereunder) which may at any time be available to or be asserted by the Borrower or any other Person against any Secured Creditor; or (c) any other circumstance whatsoever (with or without notice to or knowledge of Borrower or such Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of Borrower for the Borrower Obligations, or of such Guarantor under the guarantee contained in this Section 2, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, any Secured Creditor may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have against Borrower, any other Guarantor or any other Person or against any collateral security or guarantee for the Borrower Obligations or any right of offset with respect thereto, and any failure by any Secured Creditor to make any such demand, to pursue such other rights or remedies or to collect any payments from Borrower, any other Guarantor or any other Person or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any release of Borrower, any other Guarantor or any other Person or any such collateral security, guarantee or right of offset, shall not relieve any Guarantor of any obligation or liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of any Secured Creditor against any Guarantor. For the purposes hereof, “demand” shall include the commencement and continuance of any legal proceedings.

 

7
 

 

2.05.         Reinstatement . The guarantee contained in this Section 2 shall continue to be effective, or be reinstated, as the case may be, if at any time payment, or any part thereof, of any of the Borrower Obligations is rescinded or must otherwise be restored or returned by any Secured Creditor upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of the Borrower or any Guarantor, or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee or similar officer for, the Borrower or any Guarantor or any substantial part of its property, or otherwise, all as though such payments had not been made.

 

2.06.         Payments . Each Guarantor hereby guarantees that payments hereunder will be paid to the Agent without set-off or counterclaim in Dollars in immediately available funds to the deposit account of Agent specified by Agent and that all such payments will be subject to the provisions of Section 2.6 of the Credit Agreement.

 

2.07.         Election of Remedies . If any Secured Creditor may, under applicable law, proceed to realize its benefits under any of the Loan Documents giving such Secured Creditor a Lien upon any Collateral, whether owned by any Guarantor or by any other Person, either by judicial foreclosure or by nonjudicial sale or enforcement, such Secured Creditor may, at its sole option, determine which of its remedies or rights it may pursue without affecting any of its rights and remedies under this Section 2. If, in the exercise of any of its rights and remedies, any Secured Creditor shall forfeit any of its rights or remedies, including its right to enter a deficiency judgment against any Guarantor or any other Person, whether because of any applicable laws pertaining to “election of remedies” or the like, each Guarantor hereby consents to such action by such Secured Creditor and waives, to the extent permitted by applicable law, any claim based upon such action, even if such action by such Secured Creditor shall result in a full or partial loss of any rights of subrogation that each Guarantor might otherwise have had but for such action by such Secured Creditor. Any election of remedies that results in the denial or impairment of the right of any Secured Creditor to seek a deficiency judgment against any Guarantor shall not impair any other Guarantor’s obligation to pay the full amount of the Secured Obligations. In the event any Secured Creditor shall bid at any foreclosure or trustee’s sale or at any private sale permitted by law or the Loan Documents, such Secured Creditor may bid all or less than the amount of the Secured Obligations and the amount of such bid need not be paid by such Secured Creditor but shall be credited against the Secured Obligations. The amount of the successful bid at any such public sale, whether such Secured Creditor or any other party is the successful bidder, shall be conclusively deemed to be the fair market value of the Collateral and the difference between such bid amount and the remaining balance of the Secured Obligations shall be conclusively deemed to be the amount of the Secured Obligations guaranteed under this Section 2, notwithstanding that any present or future law or court decision or ruling may have the effect of reducing the amount of any deficiency claim to which any Secured Creditor might otherwise be entitled but for such bidding at any such sale.

 

2.08.         Limitation . Notwithstanding any provision herein contained to the contrary, each Guarantor’s liability under this Section 2 shall be limited to an amount not to exceed as of any date of determination the amount that could be claimed by the Agent and the Lender from such Guarantor under this Section 2.10 without rendering such claim voidable or avoidable under Section 548 of Chapter 11 of the Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law after taking into account, among other things, such Guarantor’s right of contribution and indemnification from each other Guarantor under Section 2.09.

 

8
 

 

2.09.         Contribution with Respect to Guaranty Obligations .

 

  (a)      To the extent that any Guarantor shall make a payment under this Section 2.09 of all or any of the Secured Obligations which it has agreed to guarantee pursuant hereto (a “ Guarantor Payment ”) that, taking into account all other Guarantor Payments then previously or concurrently made by any other Guarantor, exceeds the amount that such Guarantor would otherwise have paid if each Guarantor had paid the aggregate Secured Obligations satisfied by such Guarantor Payment in the same proportion that such Guarantor’s Allocable Amount (as defined below) (as determined immediately prior to such Guarantor Payment) bore to the aggregate Allocable Amounts of each of the Guarantors as determined immediately prior to the making of such Guarantor Payment, then, following the time that all Secured Obligations are Fully Satisfied, such Guarantor shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other Guarantor for the amount of such excess, pro rata based upon their respective Allocable Amounts in effect immediately prior to such Guarantor Payment.

 

  (b)      As of any date of determination, the “ Allocable Amount ” of any Guarantor shall be equal to the maximum amount of the claim that could then be recovered from such Guarantor under this Section 2 without rendering such claim voidable or avoidable under Section 548 of Chapter 11 of the Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law.

 

  (c)      This Section 2.09 is intended only to define the relative rights of Guarantors and nothing set forth in this Section 2.09 is intended to or shall impair the obligations of Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Agreement, including Section 2.01. Nothing contained in this Section 2.09 shall limit the liability of Borrower to pay the Loans and accrued interest, fees and expenses with respect thereto for which Borrower shall be primarily liable.

 

  (d)      The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Guarantor to which such contribution and indemnification is owing.

 

  (e)      The rights of the indemnifying Guarantors against other Loan Parties under this Section 2.09 shall be exercisable at such time as all Secured Obligations are Fully Satisfied.

 

Section 3.               Grant of Security Interest .

 

Each Grantor hereby grants to the Agent, for the ratable benefit of the Secured Creditors, a security interest in all of the following property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has, or at any time in the future may acquire, any right, title or interest (collectively, the “ Collateral ”), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations:

 

a.            all Accounts;

 

b.            all Chattel Paper, including tangible chattel paper and electronic chattel paper;

 

c.            all Goods;

 

9
 

 

d.            all Documents;

 

e.            all Equipment;

 

f.             all Fixtures;

 

g.            all General Intangibles, including all Payment Intangibles;

 

h.            all Instruments;

 

i.             all Intellectual Property;

 

j.             all Inventory;

 

k.            all Investment Property;

 

l.             all Leases;

 

m.           all Letter-of-Credit Rights;

 

n.            all money;

 

o.            all Supporting Obligations;

 

p.            all tort claims, including Commercial Tort Claims;

 

q.            all Deposit Accounts, all claims now or hereafter arising therefrom, all funds now or hereafter held therein, all amounts now or hereafter credited thereto and all certificates and instruments, if any, from time to time representing or evidencing such bank accounts;

 

r.             all other property not otherwise described above; and

 

s.            all accessions to, substitutions for and replacements, Proceeds (including Stock Rights), insurance proceeds and products of the foregoing, together with all books and records, customer lists, credit files, computer files, programs, printouts and other computer materials and records related thereto and any General Intangibles at any time evidencing or relating to any of the foregoing, and all collateral security and guarantees given by any Person with respect to any of the foregoing.

 

Any of the foregoing to the contrary notwithstanding (a) the “Collateral” shall not include, and the security interest granted herein shall not attach to, any asset subject to a rule of law, statute or regulation (including a permit, license or franchise), where the grant of such security interest would invalidate or constitute a breach or violation of any such rule of law, statute or regulation, provided that the limitation set forth in this sentence shall (i) exist only for so long as such rule of law, statute or regulation, continues to be effective (and, upon the cessation, termination, expiration of such rule of law, statute or regulation, or if any such rule of law, statue or regulation is no longer applicable, the security interest granted herein shall be deemed to have automatically attached to such asset), and (ii) not apply with respect to any asset if and to the extent that the security interest in and to such asset granted in this Security Agreement is permitted under Section 9-406, 9-407, 9-408, or 9-409 of the UCC, and (b) in the case of a Subsidiary that is a CFC, in no event shall the “Collateral” include more than sixty-five percent (65%) of the total outstanding voting stock of such Subsidiary that is a CFC.

 

10
 

 

Section 4.               Authorization to File Financing Statements . Each Grantor hereby irrevocably authorizes the Agent at any time and from time to time to file in any applicable jurisdiction in which the UCC has been adopted any initial financing statements and amendments thereto that (a) indicate the Collateral (i) as “all assets” of such Grantor or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls within the scope of Article 9 of the UCC of such jurisdiction, or (ii) as being of an equal or lesser scope or with greater detail, and (b) contain any other information required by part 5 of Article 9 of the UCC for the sufficiency or filing office acceptance of any initial financing statement or amendment, including whether such Grantor is an organization, the type of organization and any organization identification number issued to such Grantor. Each Grantor agrees to furnish any such information to the Agent promptly upon request. Each Grantor also ratifies its authorization for the Agent to have filed in any UCC jurisdiction any like initial financing statements or amendments thereto if filed prior to the date hereof.

 

Section 5.               Relation to Intellectual Property Security Agreements.  Concurrently herewith the Grantor is executing and delivering to the Agent for recording in the PTO the Patent Security Agreement and the Trademark Security Agreement. As of the Closing Date the Grantors hold no Copyrights or applications in respect thereof that are registered with the Copyright Office. The provisions of any current or any future Patent Security Agreement, Trademark Security Agreement or Copyright Security Agreement are supplemental to the provisions of this Agreement. Nothing contained in any current or future Patent Security Agreement, Trademark Security Agreement or Copyright Security Agreement shall derogate from any of the rights or remedies of any Secured Creditor hereunder, nor shall anything contained in any such current or future Patent Security Agreement, Trademark Security Agreement or Copyright Security Agreement be deemed to prevent or extend the time of attachment or perfection of any Security Interest in such Collateral created hereby.

 

Section 6.               Representations and Warranties . To induce the Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make its extensions of credit to the Borrower thereunder, each Grantor hereby represents and warrants to the Secured Creditors that:

 

6.01.         Grantors’ Legal Status . (a) Such Grantor is an organization as set forth in the Perfection Certificate; (b) such organization is of the type, and is organized in the jurisdiction, set forth in the Perfection Certificate; and (c) the Perfection Certificate sets forth such Grantor’s correct organizational identification number or accurately states that such Grantor has none.

 

6.02.         Grantors’ Legal Names . Such Grantor’s exact legal name is that set forth in the Perfection Certificate and on the signature page hereof.

 

6.03.         Grantors’ Locations . The Perfection Certificate sets forth such Grantor’s place of business or (if it has more than one place of business) its chief executive office, as well as its mailing address if different. Such Grantor’s place of business or (if it has more than one place of business) its chief executive office is located in a jurisdiction that has adopted the UCC or whose laws generally require that information concerning the existence of nonpossessory security interests be made generally available in a filing, recording or registration system as a condition or result of the security interest obtaining priority over the rights of a lien creditor with respect to the Collateral.

 

11
 

 

6.04.         Representations in the Credit Agreement . The representations and warranties set forth in Section 5 of the Credit Agreement and as otherwise made by such Grantor in each other Loan Document to which such Grantor is a party, each of which is hereby incorporated herein by reference, are true and correct in all material respects, and the Secured Creditors shall be entitled to rely on each of them as if they were fully set forth herein.

 

6.05.         Title to Collateral . The Collateral of such Grantor is owned by such Grantor free and clear of any Lien, except for Liens expressly permitted pursuant to the Credit Agreement. Such Grantor has not filed or consented to the filing of (a) any financing statement or analogous document under the UCC or any other Applicable Laws covering any of its Collateral, (b) any assignment (other than pursuant to an assignment or disposition permitted by the Credit Agreement) in which such Grantor assigns any Collateral or any security agreement or similar instrument covering any Collateral with the PTO or the Copyright Office or (c) any assignment (other than pursuant to an assignment or disposition permitted by the Credit Agreement) in which such Grantor assigns any Collateral or any security agreement or similar instrument covering any Collateral with any foreign governmental, municipal or other office, which financing statement or analogous document, assignment, security agreement or similar instrument is still in effect, except, in each case, with respect to Liens expressly permitted pursuant to the Credit Agreement.

 

6.06.         Nature of Collateral . None of the Collateral of such Grantor constitutes, or is the proceeds of, farm products and none of the Collateral has been purchased or will be used by such Grantor primarily for personal, family or household purposes, and as of the Closing Date, except as indicated in the Perfection Certificate, and as of any date of any Perfection Supplement, except as indicated in such Perfection Supplement or in the Perfection Certificate:

 

  (a)      none of the account debtors or other persons obligated on any of the Collateral of such Grantor is a Governmental Authority subject to the Federal Assignment of Claims Act or like federal, state or local statute or rule in respect of such Collateral;

 

  (b)      such Grantor holds no commercial tort claims that it has asserted against any other Person;

 

  (c)      such Grantor has no deposit accounts or other bank accounts;

 

  (d)      such Grantor owns no motor vehicles;

 

  (e)      such Grantor has no securities accounts or securities entitlements or commodities accounts or commodities contracts;

 

  (f)      such Grantor holds no interest in, title to or power to transfer, any registered Patents, registered Trademarks, registered Copyrights or material inbound licenses (other than off-the-shelf software and open source technology).

 

6.07.          Compliance with Laws . Such Grantor has at all times operated its business in compliance with all applicable federal, state and local laws and regulations, except as could not reasonably be expected to have a Material Adverse Effect.

 

6.08.         Validity of Security Interest .   (a) The Security Interest granted by each Grantor constitutes, to the extent possible under Applicable Law, a legal and valid security interest in all of the Collateral of such Grantor securing the payment and performance of the Secured Obligations and (b) upon the filing of financing statements describing the Collateral in the offices listed on the Perfection Certificate, the recording in the PTO of the Patent Security Agreement and Trademark Security Agreement, and the taking of all applicable actions in respect of perfection contemplated by Sections 7.06, 7.07, 7.08, 7.10, 7.11 and 7.12 in respect of Collateral, the Security Interest will be valid, enforceable and perfected in all Collateral of such Grantor. The Security Interest is and shall be prior to any other Lien on the Collateral, other than Liens expressly permitted to be prior to the Security Interest under the Credit Agreement.

 

12
 

 

6.09.         Perfection Certificate; Intellectual Property Filings .

 

  (a)      All information set forth on the Perfection Certificate is, and all information set forth on each Perfection Supplement shall be, true, accurate and complete.

 

  (b)      As of the Closing Date, a fully executed Patent Security Agreement and Trademark Security Agreement containing a description of all Collateral of such Grantor consisting of United States Patents and United States registered Trademarks (and Patents and Trademarks for which United States registration applications are pending) have been delivered to the Agent for recording by the PTO.

 

6.10.         Investment Property .

 

  (a)      The shares of Pledged Stock pledged by such Grantor hereunder, if any, constitute all of the issued and outstanding shares of all classes of the capital stock or other equity interests of each Issuer owned by such Grantor, except as otherwise indicated in Schedule 10(b) of the Perfection Certificate.

 

  (b)      All the shares of the Pledged Stock pledged by such Grantor have been duly and validly issued, and are fully paid and non-assessable.

 

  (c)      Other than with respect to the limited liability company interests of CareView Operations, L.L.C., a Texas limited liability company and an Issuer hereunder, the terms of any uncertificated limited liability company interests and partnership interests in any limited liability company or partnership organized under the laws of the United States or any state thereof, included in the Pledged Stock expressly provide that they are securities governed by Article 8 of the UCC in effect from time to time in the “issuer’s jurisdiction” of each Issuer thereof (as such term is defined in the UCC in effect in such jurisdiction).

 

  (d)      Such Grantor is the record and beneficial owner of, and has good and marketable title to, the Pledged Securities pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except the Security Interest created by this Agreement.

 

6.11.         Accounts . (i) Each account of such Grantor is genuine and in all material respects what they purport to be, (ii) each account arises out of (A) a bona fide sale of goods sold and delivered by such Grantor (or is in the process of being delivered) or (B) services theretofore actually rendered or to be rendered by such Grantor to the account debtor named therein, (iii) no material account of such Grantor is evidenced by any instrument or chattel paper other than any such instrument or chattel paper that has been theretofore endorsed over, assigned and delivered to, or submitted to the control of, the Agent (accompanied by such instruments of transfer and assignment duly executed in blank as the Agent may from time to time specify), and (iv) no surety bond was required or given in connection with any account of such Grantor or the contracts or purchase orders out of which they arose and the right to receive payment under each account is assignable.

 

13
 

 

6.12.         Equipment and Inventory . With respect to any   material equipment and/or material inventory of such Grantor, each such Grantor has exclusive possession and control of such equipment and inventory of such Grantor except for (i) equipment leased by such Grantor as a lessor permitted by Section 7.1(b) of the Credit Agreement, (ii) equipment or inventory in transit with common or other carriers or (iii) as disclosed under Section 7(c) of the Perfection Certificate. No material inventory is held by such Grantor pursuant to consignment, sale or return, sale on approval or similar arrangement.

 

Section 7.               Covenants . Until such time as the Collateral is released pursuant to Section 19.16 hereof, each Grantor covenants and agrees with the Agent, in each case at such Grantor’s own cost and expense, as follows.

 

7.01.         Grantors’ Legal Status . Such Grantor shall not change its type of organization, jurisdiction of organization or other legal structure except upon not less than ten (10) days’ prior written notice to the Agent.

 

7.02.         Grantors’ Names . Such Grantor shall not change its name except upon not less than ten (10) days’ prior written notice to the Agent.

 

7.03.         Grantors’ Organizational Numbers . Without providing at least ten (10) days’ prior written notice to the Agent, such Grantor shall not change its organizational identification number if it has one. If such Grantor does not have an organizational identification number and later obtains one, such Grantor shall forthwith notify the Agent of such organizational identification number promptly upon obtaining such identification number.

 

7.04.         Locations . Without providing at least twenty (20) days’ prior written notice to the Agent, such Grantor shall not change its place of business or (if it has more than one place of business) its chief executive office and shall promptly notify the Agent of any new location where books and records of  Holdings, the Borrower or a Subsidiary thereof are maintained that is not set forth on a Perfection Certificate or Perfection Supplement.

 

7.05.         Covenants in Credit Agreement . Each Grantor shall take, or shall refrain from taking, as the case may be, each action that is necessary to be taken or not taken, as the case may be, so that no Default or Event of Default is caused by the failure to take such action or to refrain from taking such action by such Grantor or any of its Subsidiaries under the Credit Agreement.

 

7.06.         Promissory Notes and Tangible Chattel Paper . If such Grantor shall at any time hold or acquire any promissory note with a face value in excess of $100,000, such Grantor shall forthwith endorse, assign and deliver the same to the Agent, accompanied by such instruments of transfer or assignment duly executed in blank as the Agent may from time to time specify to be held by the Agent as Collateral pursuant to this Agreement. Upon the request of the Agent, each Grantor shall promptly endorse, assign and deliver to the Agent any tangible chattel paper (or any other instrument (other than checks received in the ordinary course of business) evidencing any account of such Grantor) held by such Grantor, accompanied by such instruments of transfer or assignment duly executed in blank as the Agent may from time to time specify to be held by the Agent as Collateral pursuant to this Agreement.

 

14
 

 

7.07.         Deposit Accounts . For each deposit account that such Grantor at any time opens or maintains, such Grantor shall comply with the provisions of Section 7.12 of the Credit Agreement.

 

7.08.         Investment Property .

 

  (a)      If any of the Collateral shall be or become evidenced or represented by an uncertificated security, such Grantor shall cause the Issuer thereof either (i) to register the Agent as the registered owner of such uncertificated security, upon original issue or registration of transfer or (ii) to agree in writing with such Grantor and the Agent that such Issuer will comply with instructions with respect to such uncertificated security originated by the Agent without further consent of such Grantor, such agreement to be in such form as the Agent shall approve.

 

  (b)      If any of the Collateral shall be or become evidenced or represented by a security entitlement, such Grantor shall cause the securities intermediary with respect to such security entitlement either (i) to identify in its records the Agent as having such security entitlement against such securities intermediary or (ii) to agree in writing with such Grantor and the Agent, including pursuant to a Control Agreement in accordance with Section 7.12 of the Credit Agreement, that such securities intermediary will comply with entitlement orders originated by the Agent without further consent of such Grantor, such agreement to be in such form as the Agent shall approve.

 

  (c)      If any of the Collateral shall be or become evidenced or represented by a commodity contract, such Grantor shall cause the commodity intermediary with respect to such commodity contract to agree in writing with such Grantor and the Agent that such commodity intermediary will apply any value distributed on account of such commodity contract as directed by the Agent without further consent of such Grantor, such agreement to be in such form as the Agent shall approve.

 

  (d)      If any of the Collateral shall be or become evidenced or represented by or held in a securities account or a commodity account, such Grantor shall, in the case of a securities account, comply with clause (b) of this Section 7.08 with respect to all security entitlements carried in such securities account and, in the case of a commodity account, comply with clause (c) of this Section 7.08 with respect to all commodity contracts carried in such commodity account.

 

  (e)      If such Grantor shall receive any stock or other ownership certificate (including, without limitation, any certificate representing a stock dividend or a distribution in connection with any reclassification, increase or reduction of capital or any certificate issued in connection with any reorganization), option or rights in respect of the capital stock or other equity interests of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any shares of or other ownership interests in the Pledged Stock, or otherwise in respect thereof, such Grantor shall accept the same as the agent of the Secured Creditors, hold the same in trust for the Secured Creditors and deliver the same forthwith to the Agent in the exact form received, duly endorsed by such Grantor to the Agent, if required, together with an undated stock power covering such certificate duly executed in blank by such Grantor and with, if the Agent so requests, signature guaranteed, to be held by the Agent, subject to the terms hereof, as additional collateral security for the Secured Obligations.

 

15
 

 

  (f)      Subject to Section 7.08(h) hereof, such Grantor shall be entitled:

 

(i)           to exercise, as it shall think fit, but in a manner not inconsistent with the terms hereof and of the Credit Agreement, the voting power with respect to the Pledged Stock of such Grantor, and for that purpose the Agent shall (if any Pledged Stock shall be registered in the name of the Agent or its nominee) execute or cause to be executed from time to time, at the expense of such Grantor, such proxies or other instruments in favor of such Grantor or its nominee, in such form and for such purposes as shall be reasonably required by such Grantor and shall be specified in a written request therefor, to enable it to exercise such voting power with respect to the Pledged Stock; and

 

(ii)           except as otherwise provided in paragraphs (g) and (h) of this Section 7.08 , to receive and retain for its own account any and all payments made in respect of the Pledged Securities to the extent such are permitted pursuant to the terms of the Credit Agreement.

 

  (g)      Any sums paid upon or in respect of the Pledged Securities upon the liquidation or dissolution of any Issuer shall be paid over to the Agent to be held by it hereunder as additional collateral security for the Secured Obligations, and in case any distribution of capital shall be made on or in respect of the Pledged Securities or any property shall be distributed upon or with respect to the Pledged Securities pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected security interest in favor of the Agent, be delivered to the Agent to be held by it hereunder as additional collateral security for the Secured Obligations. If any sums of money or property so paid or distributed in respect of the Pledged Securities shall be received by such Grantor, such Grantor shall, until such money or property is paid or delivered to the Agent, hold such money or property in trust for the Secured Creditors, segregated from other funds of such Grantor, as additional collateral security for the Secured Obligations.

 

  (h)      Upon the occurrence and during the continuance of any Event of Default, all rights of such Grantor to exercise or refrain from exercising the voting and other consensual rights that it would otherwise be entitled to exercise pursuant to Section 7.08(f)(i) hereof and to receive the payments pursuant to Section 7.08(f)(ii) hereof shall cease, and thereupon the Agent shall be entitled to exercise all voting power with respect to the Pledged Securities and to receive and retain, as additional collateral hereunder, any and all such payments any time declared or paid upon any of the Pledged Securities during such an Event of Default and otherwise to act with respect to the Pledged Securities as outright owner thereof.

 

  (i)      At any time and from time to time during the continuance of an Event of Default, subject to Applicable Law, the Agent may cause all or any of the Pledged Securities to be transferred to or registered in its name or the name of its nominee or nominees.

 

  (j)      Without the prior written consent of the Agent, such Grantor will not (i) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, any of the Investment Property or Proceeds thereof or any interest therein (except pursuant to a transaction permitted by the Credit Agreement); (ii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Investment Property or Proceeds thereof, or any interest therein, except for the Security Interests created by this Agreement and except for Permitted Liens; or (iii) enter into any agreement or undertaking expressly restricting the foreclosure of the Agent’s Security Interest in any of the Investment Property or Proceeds thereof or any interest therein.

 

16
 

 

  (k)      In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Pledged Securities issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify the Agent promptly in writing of the occurrence of any of the events described in Section 7.08(e) or Section 7.08(g) with respect to the Pledged Securities issued by it, and (iii) the terms of Section 13.04(c) shall apply to it, mutatis   mutandis , with respect to all actions that may be required of it with respect to the Pledged Securities issued by it. Each Grantor which is an Issuer consents to the grant of a Security Interest in capital stock or other equity interests of such Issuer and the exercise of rights by the Agent in respect of such capital stock or other equity interests, including (to the extent permitted hereunder) the foreclosure thereon, and the Agent, its nominee or transferee becoming a partner or member of any such Issuer that is a partnership or limited liability company.

 

  (l)      If the organizational documents of any Issuer of Pledged Securities restrict the transfer of such Pledged Securities, each such Issuer shall deliver to the Agent all consents required to authorize the transfer of such Pledged Securities to the Agent or its nominee, or to a third-party transferee upon the exercise by the Agent of it rights and remedies hereunder.

 

7.09.         Collateral in the Possession of a Bailee . If any goods with a book value in excess of $100,000 with respect to each location in the United States where any Collateral is stored or located (other than hospital or acute care sites on which CareView Systems are installed) are at any time in the possession of a bailee, such Grantor shall promptly notify the Agent thereof and, if requested by the Agent, shall promptly obtain an acknowledgement from such bailee, in form and substance reasonably satisfactory to the Agent, that such bailee holds such Collateral for the benefit of the Secured Creditors.

 

7.10.         Electronic Chattel Paper and Transferable Records . If such Grantor shall at any time hold or acquire interests in any electronic chattel paper or any “transferable record,” as that term is defined in Section 201 of the federal Electronic Signatures in Global and National Commerce Act or in Section 16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, such Grantor shall promptly notify the Agent thereof and, at the request of the Agent, shall take such action as the Agent may reasonably request to vest in the Agent control, under Section 9-105 of the UCC, of such electronic chattel paper or control under Section 201 of the federal Electronic Signatures in Global and National Commerce Act or, as the case may be, Section 16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record. The Agent agrees with such Grantor that the Agent shall arrange, pursuant to procedures reasonably satisfactory to the Agent and so long as such procedures will not result in the Agent’s loss of control, for such Grantor to make alterations to the electronic chattel paper or transferable record permitted under Section 9-105 of the UCC or, as the case may be, Section 201 of the federal Electronic Signatures in Global and National Commerce Act or Section 16 of the Uniform Electronic Transactions Act, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such electronic chattel paper or transferable record.

 

17
 

 

7.11.         Letter-of-Credit Rights . If such Grantor shall at any time be beneficiaries under one or more letters of credit, such Grantor shall promptly notify the Agent thereof and, at the request and option of the Agent, such Grantor shall either (a) arrange, for the issuer and any nominated person with respect to such letter of credit to consent, pursuant to an agreement or other authenticated record with and in such form and in substance satisfactory to the Agent, to an assignment to the Agent of the proceeds of any drawing under the letter of credit or (b) arrange for the Agent to become the transferee beneficiary of the letter of credit.

 

7.12.         Commercial Tort Claims . If such Grantor shall at any time hold or acquire a commercial tort claim that it has asserted against any other Person having a value in excess of $100,000, such Grantor shall notify the Agent, promptly and in any case within five (5) business days, in a writing signed by such Grantor of the brief details thereof and grant to the Agent for the benefit of the Secured Creditors in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to the Agent.

 

7.13.         Intellectual Property .

 

  (a)      Except in any respect that would not materially impair the right, power, authority and ability of any Grantor to use its intellectual property as necessary or convenient for the profitable conduct of their businesses and would not reasonably be expected to have a Material Adverse Effect:

 

(i)           Such Grantor (either itself or through licensees) will (A) continue to use each material Trademark on each and every trademark class of goods in the ordinary course of business in order to maintain such Trademark in full force free from any claim of abandonment for non-use in any class of goods for which registration was obtained, (B) maintain in the ordinary course of business the quality of products and services offered under such Trademark and take all necessary steps to ensure that all licensed users of such Trademark maintain as in the past such quality, (C) use such Trademark with the appropriate notice of registration and all other notices and legends required by applicable requirements of Applicable Law, (D) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless the Agent, for the ratable benefit of the Secured Creditors, shall obtain a perfected security interest in such mark pursuant to this Agreement and the Intellectual Property Security Agreement, and (E) not (and not permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby such Trademark may become invalidated or impaired in any way.

 

(ii)           Without the prior written consent of the Agent, such Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby any material Patent may become forfeited, abandoned or dedicated to the public.

 

(iii)           Such Grantor (either itself or through licensees) (A) will employ each material Copyright and (B) will not (and will not permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby any material portion of the Copyrights may become invalidated or otherwise impaired. Such Grantor will not (either itself or through licensees) do any act whereby any material portion of the Copyrights may fall into the public domain.

 

18
 

 

(iv)           Such Grantor (either itself or through licensees) will not do any act that knowingly uses any material Intellectual Property to infringe the intellectual property rights of any other Person.

 

(v)           Such Grantor (either itself or through licensees) will use proper statutory notice in connection with the use of each material Patent, Trademark and Copyright included in the Intellectual Property.

 

(vi)           Such Grantor will take all reasonable and necessary steps, including, without limitation, in any proceeding before the PTO, the Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the relevant registration) and to maintain each registration of material Intellectual Property, including, without limitation, the payment of required fees and taxes, the filing of responses to office actions issued by the PTO and the Copyright Office, the filing of applications for renewal or extension, the filing of affidavits of use and affidavits of incontestability, the filing of divisional, continuation, continuation-in-part, reissue, and renewal applications or extensions, the payment of maintenance fees, and the participation in interference, reexamination, opposition, cancellation, infringement and misappropriation proceedings.

 

(vii)           Such Grantor (either itself or through licensees) will not, without the prior written consent of the Agent, discontinue use of or otherwise abandon any Intellectual Property or abandon any right to file an application for letters patent, trademark, or copyright, unless such Grantor shall have previously determined that such use or the pursuit or maintenance of such Intellectual Property is no longer desirable in the conduct of such Grantor’s business and that the loss thereof could not reasonably be expected to have a Material Adverse Effect, and, in which case, such Grantor shall give prompt notice of any such abandonment to the Agent in accordance herewith.

 

(viii)           In the event that any material Intellectual Property is infringed, misappropriated or diluted by a third party, such Grantor shall (A) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (B) if such infringement, misappropriation or dilution has or would reasonably be expected to have a material negative effect on revenue, promptly notify the Agent after it learns thereof and sue for infringement, misappropriation or dilution, seek injunctive relief where appropriate and recover any and all damages for such infringement, misappropriation or dilution.

 

(ix)           Such Grantor will do all things that are necessary and proper within such Grantor’s power and control to keep each license of Intellectual Property held by such Grantor as licensee or licensor in full force and effect except to the extent that (A) such Grantor has reasonably determined that the failure to keep any such license in full force and effect could not be reasonably expected to have a Material Adverse Effect or (B) any such license would expire by its terms or is terminable at will by a Person other than Grantor.

 

(x)           Such Grantor shall not sell, transfer, dispose of, convey or license any of its Intellectual Property other than as permitted by Section 7.4(b) of the Credit Agreement.

 

19
 

 

(xi)           Such Grantor shall maintain all of its rights to its domain names in full force and effect, other than any, the loss of which could not reasonably be expected to result in a Material Adverse Effect.

 

  (b)      Such Grantor will notify the Agent promptly and in any case within five (5) business days if it knows (i) that any registration relating to any material Intellectual Property has been or could reasonably be expected to be forfeited, abandoned or dedicated to the public, or of any adverse determination or development (including, without limitation, the institution of, or any such determination or development in, any proceeding in the PTO, the Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any material Intellectual Property or such Grantor’s right to register the same or to own and maintain the same or (ii) of any, or any claim by any Person of any, default or event of default, or of the termination of any rights, in each case under any contract or agreement with respect to Intellectual Property, including any IP License, to which such Grantor is a party.

 

  (c)      Whenever such Grantor, either by itself or through any agent, employee, licensee or designee, shall file an application for the registration of any Intellectual Property with the PTO, the Copyright Office or any similar office or agency in any other country or any political subdivision thereof, such Grantor shall report such filing to the Agent within five Business Days after the last day of the fiscal quarter in which such filing occurs. Upon request of the Agent, such Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents, and papers as the Agent may request to evidence the Secured Creditors’ Security Interest in any Copyright, Patent, Trademark or other Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.

 

  (d)      Such Grantor agrees that, should it obtain an ownership interest in any item of Intellectual Property which is not now a part of the Intellectual Property that constitutes Collateral (the “ After-Acquired Intellectual Property ”), (i) the provisions of Section 3 shall automatically apply thereto; (ii) any such After-Acquired Intellectual Property, and in the case of Trademarks, the goodwill of the business connected therewith or symbolized thereby, shall automatically become part of the Collateral; and (iii) within five (5) Business Days after such acquisition occurs, such Grantor shall provide the Agent with an amended Perfection Certificate and amended schedules to the applicable Intellectual Property Security Agreement reflecting the acquisition of such After-Acquired Intellectual Property. Such Grantor authorizes the Agent to modify this Agreement by amending the Perfection Certificate and to modify the schedules to the applicable Intellectual Property Security Agreement if such Grantor fails to provide the Agent with satisfactory amended schedules hereto or thereto within the time period required hereunder (and will cooperate with the Agent in effecting any such amendment) to include any After-Acquired Intellectual Property which becomes part of the Intellectual Property that constitutes Collateral under this Section 7.13(d) , and to record any such modified agreement with the PTO, the Copyright Office, or any other applicable Governmental Authority.

 

  (e)      Such Grantor assumes all responsibility and liability arising from the use of the Intellectual Property and hereby indemnifies and holds the Secured Creditors harmless from and against any claim, suit, loss, damage or expense (including reasonable attorneys’ fees) arising out of any alleged defect in any product manufactured, promoted or sold by such Grantor (or any affiliate or subsidiary thereof) in connection with such Intellectual Property or out of the manufacture, promotion, labeling, sale or advertisement of any such product by such Grantor (or any affiliate or subsidiary thereof), except for any claim, suit, loss, damage or expense arising solely from the gross negligence or willful misconduct of a Secured Creditor as finally determined in a non-appealable judgment by a court of competent jurisdiction.

 

20
 

 

  (f)      Such Grantor agrees to execute one or more applicable Intellectual Property Security Agreements with respect to its Intellectual Property in order to record the Security Interest granted herein to the Agent for the ratable benefit of the Secured Creditors with the PTO, the Copyright Office, and any other applicable Governmental Authority within the time period set forth in Section 6.7(d) of the Credit Agreement.

 

7.14.         Maintenance of Collateral; Compliance with Laws . Such Grantor shall keep the Collateral provided by it in good order and repair and shall not use the same in violation of any law to the extent that such violation could reasonably be expected to have a Material Adverse Effect.

 

7.15.         Dispositions of Collateral . Such Grantor shall not sell or otherwise dispose, or offer to sell or otherwise dispose, the Collateral or any interest therein except for dispositions expressly permitted by the Credit Agreement.

 

7.16.         Maintenance of Insurance . Such Grantor, at its sole cost and expense, shall maintain or cause to be maintained insurance covering physical loss or damage to the Collateral provided by it in accordance with the Credit Agreement.

 

7.17.         Periodic Certification . Concurrently with the delivery of each Compliance Certificate, such Grantor shall deliver to the Agent a supplemental perfection certificate (each, a “ Perfection   Supplement ”) executed by such Grantor setting forth the information required pursuant to the Perfection Certificate or confirming that there has been no change in such information since the date of such certificate or the date of the most recent certificate delivered pursuant to this  Section 7.17 .

 

7.18.         Other Actions as to any and all Collateral . Such Grantor further agrees to take any other action reasonably requested by the Agent to insure the attachment, perfection and first priority (subject to Permitted Liens) of, and the ability of the Agent to enforce, the Security Interest in any and all of the Collateral provided by such Grantor including, without limitation, (a) executing, delivering and, where appropriate, filing financing statements and amendments relating thereto under the UCC, to the extent, if any, that such Grantor’s signature thereon is required therefor; (b) causing the Agent’s name to be noted as secured party on any certificate of title for a titled good if such notation is a condition to attachment, perfection or priority of, or ability of the Agent to enforce, the Security Interest in such Collateral; (c) complying with any provision of any statute, regulation or treaty of the United States of America as to any Collateral if compliance with such provision is a condition to the attachment, perfection or priority of, or the ability of the Agent to enforce, the Security Interest in such Collateral; (d) obtaining governmental and other third-party consents and approvals, including without limitation any consent of any licensor, lessor or other person obligated on such Collateral; (e) obtaining waivers from mortgagees, bailees, landlords and any other person who has possession of or any interest in any Collateral or any real property on which any such Collateral may be located, in form and substance satisfactory to the Agent; (f) providing to the Agent “control” over such Collateral, to the extent that perfection can only be achieved under the UCC by control or where obtaining perfection by control provides more protection to the Secured Creditors that perfection by filing a financing statement; and (g) taking all actions required by the UCC or by other law, as applicable in any relevant UCC jurisdiction, or by other law as applicable in any foreign jurisdiction; provided , however , that nothing contained in clause (d) or (e) shall require such Grantor to pay any consideration (other than any governmental application, processing, filing or recording fees) in order to obtain any consent or waiver referred to in such clauses.

 

21
 

 

7.19.         Treatment of Accounts . No Grantor shall grant or extend the time for payment of any material account, or compromise or settle any account for less than the full amount thereof, or release any Person or property, in whole or in part, from payment thereof, or allow any credit or discount thereon, other than as normal and customary in the ordinary course of a Grantor’s business.

 

7.20.         Federal, State or Municipal Claims . Such Grantor shall, within five (5) Business Days, notify Agent of any Collateral which constitutes a claim against the United States government or any state or local government or any instrumentality or agency thereof having a value in excess of $100,000, the assignment of which claim is restricted by federal, state or municipal law.

 

Section 8.               Inspection and Verification . The Agent and such Persons as the Agent may designate shall have the right, to inspect the Collateral of such Grantor, all records related thereto (and to make extracts and copies from such records for purposes of conducting an audit) and the premises upon which any of the Collateral of such Grantor is located, and to discuss such Grantor’s affairs with the directors or officers and independent auditor, if any, of such Grantor, (i) in the absence of an Event of Default, upon reasonable prior notice and at reasonable times during business hours of such Grantor and (ii) otherwise, at any time as the Agent shall decide in its sole discretion, in all respects in accordance with Section 6.2(b) of the Credit Agreement.

 

Section 9.               Collateral Protection Expenses; Preservation of Collateral .

 

9.01.         Expenses Incurred by the Agent . In its discretion, the Agent may, if the relevant Grantor fails to do so, discharge taxes and other encumbrances at any time levied or placed on any material portion of the Collateral, make repairs thereto and pay any necessary filing fees or insurance premiums. Each Grantor agrees to reimburse the Agent on demand for any and all expenditures so made, and all sums disbursed by the Agent in connection with this Section 9.01 , including reasonable attorneys’ fees, court costs, expenses and other charges relating thereto, shall be payable, upon demand, by such Grantor to the Agent shall bear interest at the per annum rate specified in Section 17 and shall constitute additional Secured Obligations. The Agent shall have no obligation to any Grantor to make any such expenditures, nor shall the making thereof relieve any Grantor of any default.

 

9.02.         Agent’s Obligations and Duties .

 

  (a)      Anything herein to the contrary notwithstanding, each Grantor shall remain liable under each contract or agreement comprised in the Collateral required to be observed or performed by such Grantor. Neither the Agent nor any other Secured Creditor shall have any obligation or liability under any such contract or agreement by reason of or arising out of this Agreement or the receipt by the Agent or any other Secured Creditor of any payment relating to any of the Collateral, nor shall the Agent or any other Secured Creditor be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any such contract or agreement, to make inquiry as to the nature or sufficiency of any payment received by the Agent or any other Secured Creditor in respect of the Collateral or as to the sufficiency of any performance by any party under any such contract or agreement, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to the Agent or any other Secured Creditor or to which the Agent or any other Secured Creditor may be entitled at any time or times.

 

22
 

 

  (b)      The Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under Section 9-207 of the UCC or otherwise, shall be to deal with such Collateral in the same manner as the Agent deals with similar property for its own account.

 

  (c)      Neither the Agent, nor any other Secured Creditor nor any of their respective officers, directors, partners, employees, agents, attorneys and other advisors, attorneys-in-fact or affiliates shall be liable for failure to demand, collect or realize upon any of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to the Collateral or any part thereof. The powers conferred on the Secured Creditors hereunder are solely to protect the Secured Creditors’ interests in the Collateral and shall not impose any duty upon any Secured Creditor to exercise any such powers. The Secured Creditors shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their officers, directors, partners, employees, agents, attorneys and other advisors, attorneys-in-fact or affiliates shall be responsible to any Grantor for any act or failure to act hereunder, except to the extent that any such act or failure to act is found by a final and non-appealable decision of a court of competent jurisdiction to have resulted from their respective gross negligence or willful misconduct.

 

  (d)      Each Grantor acknowledges that the rights and responsibilities of the Agent under this Agreement with respect to any action taken by the Agent or the exercise or non-exercise by the Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between the Agent and the other Secured Creditors, be governed by the Credit Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between the Agent and the Grantors, the Agent shall be conclusively presumed to be acting as agent for the Secured Creditors with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation, or entitlement, to make any inquiry respecting such authority.

 

9.03.         Duties as to Pledged Securities .

 

  (a)      With respect to any calls, conversions, exchanges, redemptions, offers, tenders or similar matters relating to any such Pledged Securities (herein called “ Events ”), any duty in connection therewith imposed on the Agent by Applicable Law shall be fully satisfied if:

 

(i)           the Agent exercises reasonable care to ascertain the occurrence and to give reasonable notice to the applicable Grantor of any Events applicable to any Pledged Securities that are registered and held in the name of Agent or its nominee;

 

(ii)           the Agent gives the applicable Grantor reasonable notice of the occurrence of any Events of which the Agent has received actual knowledge, which Events are applicable to any securities that are in bearer form or are not registered and held in the name of the Agent or its nominee (each Grantor agreeing to give the Agent reasonable notice of the occurrence of any Events of which such Grantor has knowledge, which Events are applicable to any securities in the possession of the Agent); and

 

23
 

 

(iii)           the Agent endeavors to take such action with respect to any of the Events as the applicable Grantor may reasonably and specifically request in writing in sufficient time for such action to be evaluated and taken or, if the Agent reasonably believes that the action requested would adversely affect the value of the Pledged Securities as collateral or the collection of the Secured Obligations, or would otherwise prejudice the interests of any Secured Creditor, the Agent gives reasonable notice to such Grantor that any such requested action will not be taken and, if the Agent makes such determination or if such Grantor fails to make such timely request, the Agent takes such other action as it reasonably deems advisable in the circumstances.

 

  (b)      Except as hereinabove specifically set forth, neither the Agent nor any other Secured Creditor shall have any further obligation to ascertain the occurrence of, or to notify any Grantor with respect to, any Events and shall not be deemed to assume any such further obligation as a result of the establishment by the Agent or any other Secured Creditor of any internal procedures with respect to any securities in its possession, nor shall the Agent or any other Secured Creditor be deemed to assume any other responsibility for, or obligation or duty with respect to, any Pledged Securities or its use of any nature or kind, or any matter or proceedings arising out of or relating thereto, including, without limitation, any obligation or duty to take any action to collect, preserve or protect its or any Grantor’s rights in the Pledged Securities or against any prior parties thereto, but the same shall be at such Grantor’s sole risk and responsibility at all times.

 

  (c)      Nothing contained in this Section 9.03 shall be deemed to create any obligation in respect of Events on the Agent, the purpose of this Section 9.03 being solely to provide standards, in the event that Applicable Law imposes any obligations on the Agent as to Events.

 

Section 10.             Securities and Deposits . Without limitation of Section 7.08, but subject to Section 7.08(i) , the Agent may at any time at its option, transfer to itself or any nominee any securities constituting Collateral, and, subject to Section 7.08(f)(ii) , receive any income thereon and hold such income as additional Collateral or apply it to the Secured Obligations. The Agent may, after the occurrence and during the continuance of an Event of Default, demand, sue for, collect, or make any settlement or compromise which it deems desirable with respect to the Collateral. Regardless of the adequacy of Collateral or any other security for the Secured Obligations, any deposits or other sums at any time credited by or due from the Agent or any other Secured Creditor to any Grantor may at any time be applied to or set off against any of the Secured Obligations whether or not due and owing after the occurrence and during the continuance of an Event of Default.

 

24
 

 

Section 11.             Notification to Account Debtors and Other Persons Obligated on Collateral . If an Event of Default shall have occurred and be continuing, each Grantor shall, at the request of the Agent, notify account debtors and other persons obligated on any of the Collateral of such Grantor of the Security Interest in any account, chattel paper, General Intangible, instrument or other claims constituting such Collateral and that payment thereof is to be made directly to the Agent or to any financial institution designated by the Agent as the Agent’s agent therefor, and the Agent may itself, if an Event of Default shall have occurred and be continuing, without notice to or demand upon any Grantor, so notify account debtors and other persons obligated on Collateral. After the making of such a request or the giving of any such notification, each Grantor shall hold any proceeds of collection of accounts, chattel paper, General Intangibles, instruments and other claims constituting Collateral received by the Grantor as trustee for the Secured Creditors without commingling the same with other funds of the Grantor and shall turn the same over to the Agent in the identical form received, together with any necessary endorsements or assignments. The Agent shall have no liability or responsibility to any Grantor for acceptance of a check, draft or other order for payment of money bearing the legend “payment in full” or words of similar import or any other restrictive legend or endorsement or be responsible for determining the correctness of any remittance. Without limitation of the foregoing, during the continuation of an Event of Default (1) the Agent shall have the right, but not the obligation, to make test verifications of the accounts in any manner and through any medium that it reasonably considers advisable, and the Grantors shall furnish all such assistance and information as the Agent may require in connection with such test verifications, and (2) the Agent in its own name or in the name of others may communicate with account debtors on the accounts to verify with them to the Agent’s satisfaction the existence, amount and terms of any accounts. The Agent may apply the proceeds of collection of accounts, chattel paper, general intangibles, instruments and other claims constituting Collateral received by the Agent or any other Secured Creditor to the Secured Obligations or hold such proceeds as additional Collateral, at the option of the Agent. The provisions of Section 9-209 of the UCC shall not apply to any account, chattel paper or payment intangible as to which notification of assignment has been sent to the account debtor or other persons obligated on the Collateral, whether under this Section 11 , Section 12 or Section 13 .

 

Section 12.             Power of Attorney .

 

12.01.       Appointment and Powers of Agent . Upon the occurrence and during the continuation of an Event of Default, each Grantor hereby irrevocably constitutes and appoints the Agent and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Agreement, and, without limiting the generality of the foregoing, each Grantor hereby gives the Agent the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any or all of the following:

 

  (a)           in the name of such Grantor or its own name, or otherwise, take possession of and endorse and collect any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Receivable or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by the Agent for the purpose of collecting any and all such moneys due under any Receivable or with respect to any other Collateral whenever payable;

 

  (b)      in the case of any Intellectual Property, execute and deliver, and record or have recorded, any and all agreements, instruments, documents and papers as the Agent may request to evidence the Security Interest in such Intellectual Property, and the goodwill and General Intangibles of such Grantor relating thereto or represented thereby;

 

25
 

 

  (c)      pay or discharge taxes and Liens levied or placed on or threatened against the Collateral, effect any repairs or provide any insurance and pay all or any part of the premiums therefor and the costs thereof;

 

  (d)      execute, in connection with any sale provided for in Section 13 , any endorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral;

 

  (e)      exercise all rights of such Grantor as owner of the Pledged Securities or as party to any partnership, limited liability company or similar agreement, including, without limitation, the right to sign any and all amendments, instruments, certificates, proxies, and other writings and exercise all voting and consent rights with respect to the Pledged Securities;

 

  (f)      (1) direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due thereunder directly to the Agent or as the Agent shall direct; (2) ask or demand for, collect, and receive payment of and receipt for, any and all moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral; (3) sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications, notices and other documents in connection with any of the Collateral; (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion thereof and to enforce any other right in respect of any Collateral; (5) defend any suit, action or proceeding brought against such Grantor with respect to any Collateral; (6) settle, compromise or adjust any such suit, action or proceeding and, in connection therewith, give such discharges or releases as the Agent may deem appropriate; (7) assign any Copyright, Patent or Trademark (along with the goodwill of the business to which any such Copyright, Patent or Trademark pertains) throughout the world for such term or terms, on such conditions, and in such manner, as the Agent shall in its sole discretion determine; and (8) generally, sell, transfer, pledge and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though the Agent were the absolute owner thereof for all purposes, and do, at the Agent’s option and such Grantor’s expense, at any time, or from time to time, all acts and things which the Agent deems necessary to protect, preserve or realize upon the Collateral and the Security Interest therein and to effect the intent of this Agreement, all as fully and effectively as such Grantor might do; and

 

  (g)      to the extent that such Grantor’s authorization given in Section 4 is not sufficient, to file such financing statements or similar documents under the laws of any jurisdiction with respect hereto, with or without such Grantor’s signature, or a photocopy of this Agreement in substitution for a financing statement or such other document, as the Agent may deem appropriate and to execute in such Grantor’s name such financing statements, other such documents and amendments thereto and continuation statements which may require such Grantor’s signature.

 

Anything in this Section 12.01 to the contrary notwithstanding, the Agent agrees that it will not exercise any rights under the power of attorney provided for in this Section 12.01 (other than under paragraph (g) of this Section 12.01 ) unless an Event of Default shall have occurred and be continuing.

 

12.02.       Failure of Grantor to Perform . If any Grantor fails to perform or comply with any of its agreements contained herein, the Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement.

 

26
 

 

12.03.       Expenses of Attorney-in-Fact . The expenses of the Agent incurred in connection with actions undertaken as provided in this Section 12 , together with interest thereon at a rate per annum equal to the Default Rate, from the date of payment by the Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to the Agent on demand.

 

12.04.       Ratification by Grantor . To the extent permitted by law, each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of this Section 12 . This power of attorney is a power coupled with an interest and is irrevocable.

 

12.05.       No Duty on Agent . The powers conferred on the Agent, its directors, officers and agents pursuant to this Section 12 are solely to protect the Secured Creditors’ interests in the Collateral and shall not impose any duty upon any of them to exercise any such powers. Each Secured Creditor shall be accountable only for the amounts that it actually receives as a result of the exercise of such powers, and neither it nor any of its officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act, except for such Secured Creditor’s own gross negligence or willful misconduct as determined in a final and non-appealable judgment by a court of competent jurisdiction.

 

Section 13.              Remedies .

 

13.01.       Default . Grantors shall be in default under this Agreement (a) whenever any Event of Default has occurred and is continuing (and each of the Grantors shall thereupon be in default hereunder without regard to whether or to what degree any Grantor individually may have caused, participated in, or had any knowledge of the occurrence of such Event of Default) and (b) at all times after any Loan has become due and payable and remains unpaid beyond any applicable grace period, whether at maturity, upon acceleration pursuant to the Credit Agreement or otherwise.

 

13.02.       Remedies Upon Default . At any time when any Grantor is in default under this Agreement as set forth in Section 13.01 , the Agent may exercise and enforce, in any order, (i) each and all of the rights and remedies available to a secured party upon default under the NYUCC or any other applicable UCC or other Applicable Law, (ii) each and all of the rights and remedies available to it under the Credit Agreement or any other Loan Document, and (iii) each and all of the following rights and remedies:

 

  (a)       Collection Rights . Without notice to any Grantor or any other Loan Party, the Agent may notify any or all account debtors and obligors on any accounts, instruments, general intangibles or other claims constituting Collateral of the Secured Creditors’ Security Interests therein and may direct, demand and enforce payment thereof directly to the Agent. The provisions of Section 9-209 of the NYUCC shall not apply to any account, chattel paper or payment intangible as to which notification of assignment has been sent to the account debtor.

 

  (b)       Taking Possession . The Agent may (i) enter upon any and all premises owned or leased by any Grantor where Collateral is located (or believed by the Agent to be located), with or (to the fullest extent permitted by law) without judicial process and without any obligation to pay rent; (ii) prior to the disposition of the Collateral, store, process, repair or recondition the Collateral or otherwise prepare the Collateral for disposition in any manner to the extent the Agent deems appropriate; (iii) take possession of any Grantor’s premises or place custodians in exclusive control thereof, remain on such premises and use the same and any Grantor’s equipment for the purpose of completing any work in process or otherwise preparing the Collateral for sale or selling or otherwise transferring the Collateral; (iv) take possession of all items of Collateral that are not then in its possession, either upon such premises or by removal from such premises; and (v) require any Grantor or the Person in possession thereof to deliver such Collateral to the Agent at one or more locations designated by the Agent and reasonably convenient to it and each Grantor owning an interest therein.

 

27
 

 

  (c)       Foreclosure . The Agent may sell, lease, license or otherwise dispose of or transfer any or all of the Collateral or any part thereof in one or more parcels at public sale or in private sale or transaction, on any exchange or market or at the Agent’s offices or on any Grantor’s premises or at any other location, for cash, on credit or for future delivery, and may enter into all contracts necessary or appropriate in connection therewith, without any notice whatsoever unless required by law. Where permitted by law, one or more of the Secured Creditors may be the purchasers at any such sale and in such event, the Secured Creditors bidding at such sale may bid part or all of the Secured Obligations owing to them without necessity of any cash payment on account of the purchase price, even though any other purchaser at such sale is required to bid a purchase price payable in cash. Each Grantor agrees that at least ten (10) calendar days’ written notice to such Grantor of the time and place of any public sale of Collateral owned by it (or, to the extent such Grantor is entitled by law to notice thereof, the public sale of any other Collateral), or the time after which any private sale of Collateral owned by it (or, to the extent such Grantor is entitled by law to notice thereof, the private sale of any other Collateral) is to be made, shall be commercially reasonable. For purposes of such notice, to the fullest extent permitted by law (i) each Grantor waives notice of any sale of Collateral owned by any other Grantor and (ii) each Grantor agrees that notice given to the Borrower shall constitute notice given to such Grantor. The giving of notice of any such sale or other disposition shall not obligate the Agent to proceed with the sale or disposition, and any such sale or disposition may be postponed or adjourned from time to time, without further notice.

 

  (d)       Voting Rights . The Agent may exercise any and all rights of any Grantor as the owner of any Pledged Securities, including, without limitation, voting rights, rights to give or withhold consent under any agreement under which any Pledged Security is issued and all other rights referred to in Section 12.01(e) .

 

  (e)       Use of Intellectual Property . The Agent may, on a royalty-free basis, use and license use of any Trademark, Trade Secret, trade name, trade style, Copyright, Patent, technical knowledge or process or other Intellectual Property owned, held or used by any Grantor in respect of any Collateral as to which any right or remedy of the Agent is exercised or enforced. In addition, the Agent may exercise and enforce such rights and remedies for collection as may be available to it by law or agreement. Each Grantor grants a license pursuant to Section 13.03 in connection therewith.

 

  (f)       Use of Collateral . With respect to any Collateral in the possession of the Agent or any other Secured Creditor, or a bailee or other third party holding on its behalf, the Agent or such other Secured Creditor may use or operate such Collateral in any manner and to the extent determined by the Agent or such Secured Creditor.

 

28
 

 

  (g)       Appointment of Receiver . Without limiting any other right or remedy of the Agent in this Agreement, upon the occurrence and during the continuance of any Event of Default, the Agent may by instrument in writing appoint any person as a receiver of all or any part of the Collateral of each applicable Grantor. The Agent may from time to time remove or replace a receiver, or make application to any court of competent jurisdiction for the appointment of a receiver. Any receiver appointed by the Agent shall (for purposes relating to responsibility for the receiver’s acts or omissions) be considered to be the agent of each applicable Grantor. The Agent may from time to time fix the receiver’s remuneration and the Grantors shall pay the amount of such remuneration to the Agent. The Agent shall not be liable to any Grantor or any other person in connection with appointing or not appointing a receiver or in connection with the receiver’s actions or omissions.

 

13.03.       Grant of License to Use Intellectual Property . Solely for the purpose of enabling the Agent to exercise rights and remedies under this Section 13 at such time as the Agent shall be lawfully and otherwise entitled to exercise such rights and remedies, each Grantor hereby grants to the Agent an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) to use, license or sub-license any of the Collateral consisting of Intellectual Property now owned or hereafter acquired by the Grantor to the extent that such Grantor is not legally or contractually prohibited from doing so (Grantor agreeing to use commercially reasonable efforts not to enter into, after the Closing Date, any such contractual prohibition), and wherever the same may be located, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof. The use of such license by the Agent shall be exercised, at the Agent’s option, only upon the occurrence and during the continuation of an Event of Default; provided that any license, sub-license or other transaction entered into by the Agent in accordance herewith shall be binding upon each Grantor notwithstanding any subsequent cure, waiver or other termination of an Event of Default.

 

13.04.       Waivers by Grantors . Each Grantor hereby irrevocably waives (a) all rights of redemption from any foreclosure sale; (b) the benefit of all valuation, appraisal, exemption and moratorium laws; (c) to the fullest extent permitted by law, all rights to notice or a hearing prior to the exercise by the Agent of its right to take possession of any Collateral, whether by self-help or by legal process and any right to object to the Agent taking possession of any Collateral by self-help; and (d) if the Agent seeks to obtain possession of any Collateral by replevin, claim and delivery, attachment, levy or other legal process, (i) any notice or demand for possession prior to the commencement of legal proceedings, (ii) the posting of any bond or security in any such proceedings, and (iii) any requirement that the Agent retain possession and not dispose of any Collateral until after a trial or final judgment in such proceedings.

 

13.05.       Application of Proceeds . Except as expressly provided elsewhere in this Agreement, all proceeds received by the Agent in respect of any sale of, collection from, or other realization upon all or any part of the Collateral may, in the discretion of the Agent, be held by the Agent as Collateral for, or then, or at any other time thereafter, applied in full or in part by the Agent against, the Secured Obligations in the following order of priority:

 

FIRST: to the payment of all reasonable costs and expenses of such sale, collection or other realization, including reasonable compensation to the Agent and its agents and counsel, and all other reasonable expenses, liabilities and advances made or incurred by the Agent in connection therewith, and all amounts for which the Agent is entitled to indemnification hereunder and all reasonable advances made by the Agent hereunder for the account of any Grantor, and to the payment of all reasonable costs and expenses paid or incurred by the Agent in connection with the exercise of any right or remedy hereunder, all in accordance with Section 19.09 ;

 

29
 

 

SECOND: to the payment of all other Secured Obligations (for the ratable benefit of the holders thereof) then due and payable in the manner and order provided in the Credit Agreement;

 

THIRD: to any payments required by Section 9-608(a)(1)(C) or 9-615(a)(3) of the NYUCC or in accordance with other Applicable Law; and

 

FOURTH, to the payment to or upon the order of the Grantor entitled thereto, or to whomsoever may be lawfully entitled to receive the same or as a court of competent jurisdiction may direct, of any surplus then remaining from such proceeds.

 

13.06.       Surplus; Deficiency . Any surplus proceeds of any sale or other disposition by the Agent of any Collateral remaining after discharge of the Credit Agreement and after all Secured Obligations are Paid in Full and in cash and any payments required by Section 9-608(a)(1)(C) or 9-615(a)(3) of the NYUCC are Paid in Full shall be paid over to the Grantor entitled thereto, or to whomever may be lawfully entitled to receive such surplus or as a court of competent jurisdiction may direct, but prior to termination and discharge of the Credit Agreement, such surplus proceeds may be retained by the Agent and held as Collateral until termination and discharge of the Credit Agreement. The Borrower and each other Grantor shall be and remain liable for any deficiency.

 

13.07.       Information Related to the Collateral . If, during the continuance of an Event of Default, the Agent determines to sell or otherwise transfer any Collateral, each Grantor shall, and shall cause any Person controlled by it to, furnish to the Agent all information the Agent may request that pertains or could pertain to the value or condition of the Collateral or that would or might facilitate such sale or transfer. The Agent shall have the right, notwithstanding any confidentiality obligation or agreement otherwise binding upon it, freely (but not in violation of any law, including federal securities laws) to disclose such information, and any and all other information (including confidential information) pertaining in any manner to the Collateral or the assets, liabilities, results of operations, business or prospects of any Grantor, freely to any Person that the Agent in good faith believes to be a potential or prospective purchaser in such sale or transfer, without liability for any disclosure, dissemination or use that may be made as to such information by any such Person.

 

13.08.       Sale Exempt from Registration . The Agent shall be entitled at any such sale or other transfer, if it deems it advisable to do so, to restrict the prospective bidders or purchasers to Persons who will provide assurances satisfactory to the Agent that the Collateral may be offered and sold to them without registration under the Securities Act, and without registration or qualification under any other applicable state or federal law. Upon the consummation of any such sale, the Agent shall have the right to assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. The Agent may solicit offers to buy the Collateral, or any part of it, from a limited number of investors deemed by the Agent, in its good faith judgment or in good faith reliance upon advice of its counsel, to meet the requirements to purchase securities under Regulation D promulgated under the Securities Act (or any other regulation of similar import). If the Agent solicits such offers from such investors, then the acceptance by the Agent of the highest offer obtained from any of them shall be deemed to be a commercially reasonable method of disposition of the Collateral. Each Grantor recognizes that, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws, Agent may be compelled, with respect to any sale of all or any part of the Pledged Securities conducted without prior registration or qualification of such Pledged Securities under the Securities Act and/or such state securities laws, to limit purchasers to those who will agree, among other things, to acquire the Pledged Securities for their own account, for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges that any such private placement may be at prices and on terms less favorable than those obtainable through a sale without such restrictions (including an offering made pursuant to a registration statement under the Securities Act) and, notwithstanding such circumstances and the registration rights granted to Agent by such Grantor pursuant hereto, each Grantor agrees that any such private placement shall not be deemed, in and of itself, to be commercially unreasonable solely because it is a private placement and that Agent shall have no obligation to delay the sale of any Pledged Securities for the period of time necessary to permit the issuer thereof to register it for a form of sale requiring registration under the Securities Act or under applicable state securities laws, even if such issuer would, or should, agree to so register it. If Agent determines to exercise its right to sell any or all of the Pledged Securities, upon written request, each Grantor shall and shall cause each issuer of any Pledged Securities to be sold hereunder from time to time to furnish to Agent all such information as Agent may request in order to determine the amount of Pledged Securities which may be sold by Agent in exempt transactions under the Securities Act and the rules and regulations of the Securities and Exchange Commission thereunder, as the same are from time to time in effect.

 

30
 

 

13.09.       Rights and Remedies Cumulative . The rights provided for in this Agreement and the other Loan Documents are cumulative and are not exclusive of any other rights, powers or privileges or remedies provided by law or in equity, or under any other instrument, document or agreement. The Agent may exercise and enforce each right and remedy available to it either before or concurrently with or after, and independently of, any exercise or enforcement of any other right or remedy of the Agent or any other Secured Creditor against any Person or property. All such rights and remedies shall be cumulative, and no one of them shall exclude or preclude any other.

 

13.10.       No Direct Enforcement by Secured Creditors . The Agent may freely exercise and enforce any and all of its rights and remedies hereunder, for the benefit of the Secured Creditors. Except to the extent the Agent may consent in writing, no Secured Creditor, other than the Agent, shall have any independent right to collect, take possession of, foreclose against or otherwise enforce the Security Interests granted hereby.

 

Section 14.             Standards for Exercising Remedies .

 

14.01.       Commercially Reasonable Manner . To the extent that Applicable Law imposes duties on the Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for the Agent (a) to fail to incur expenses reasonably deemed significant by the Agent to prepare Collateral for disposition or otherwise to complete raw material or work in process into finished goods or other finished products for disposition or to postpone any such disposition pending any such preparation or processing; (b) to fail to obtain third-party consents for access to Collateral to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third-party consents for the collection or disposition of Collateral to be collected or disposed of; (c) to fail to exercise collection remedies against account debtors or other persons obligated on Collateral or to remove any Lien on or any adverse claims against Collateral; (d) to exercise collection remedies against account debtors and other persons obligated on Collateral directly or through the use of collection agencies and other collection specialists; (e) to advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature; (f) to contact other persons, whether or not in the same business as such Grantor, for expressions of interest in acquiring all or any portion of the Collateral; (g) to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the collateral is of a specialized nature; (h) to dispose of Collateral by utilizing Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match buyers and sellers of assets; (i) to dispose of assets in wholesale rather than retail markets; (j) to disclaim disposition warranties; (k) to purchase insurance or credit enhancements to insure the Agent against risks of loss, collection or disposition of Collateral or to provide to the Agent a guaranteed return from the collection or disposition of Collateral; or (l) to the extent deemed appropriate by the Agent, to obtain the services of other brokers, investment bankers, consultants and other professionals to assist the Agent in the collection or disposition of any of the Collateral. Each Grantor acknowledges that the purpose of this Section 14 is to provide non-exhaustive indications of what actions or omissions by the Agent would not be commercially unreasonable in the Agent’s exercise of remedies against the Collateral and that other actions or omissions by the Agent shall not be deemed commercially unreasonable solely on account of not being indicated in this Section 14 . Without limiting the foregoing, nothing contained in this Section 14 shall be construed to grant any rights to any Grantor or to impose any duties on the Agent that would not have been granted or imposed by this Agreement or by Applicable Law in the absence of this Section 14 .

 

31
 

 

14.02.       Standard of Care . The powers conferred on the Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Agent shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or to protect, preserve, vote or exercise any rights pertaining to any Collateral. The Agent shall be deemed to have exercised reasonable care in the custody and preservation of Collateral in its possession if such Collateral is accorded treatment substantially equal to that which the Agent accords its own property or if it selects, with reasonable care, a custodian to hold such Collateral on its behalf.

 

Section 15.             Waivers by Grantor; Obligations Absolute.

 

15.01.       Specific Waivers . Each Grantor waives demand, notice, protest, notice of acceptance of this Agreement, notice of loans made, credit extended, Collateral received or delivered or other action taken in reliance hereon and all other demands and notices of any description other than those required pursuant to the Credit Agreement or any other Loan Documents to which such Grantor is a party.

 

15.02.       Obligations Absolute . All rights of the Agent hereunder, the Security Interest and all obligations of the Grantors hereunder shall be absolute and unconditional irrespective of (a) any lack of validity or enforceability of the Credit Agreement, any other Loan Document, any agreement with respect to any of the Secured Obligations or any other agreement or instrument relating to any of the foregoing; (b) any change in the time, manner or place of payment of, or in any other term of, all or any of the Secured Obligations, or any other amendment or waiver of or any consent to any departure from the Credit Agreement, any other Loan Document, or any other agreement or instrument; (c) any exchange, release or non-perfection of any Lien on other collateral, or any release or amendment or waiver of or consent under or departure from or any acceptance of partial payment thereon and or settlement, compromise or adjustment of any Secured Obligation or of any guarantee, securing or guaranteeing all or any of the Secured Obligations; or (d) any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Grantor in respect of the Secured Obligations or this Agreement other than the prompt and complete performance and payment in full of the Secured Obligations.

 

32
 

 

Section 16.             Marshalling . The Agent shall not be required to marshal any present or future collateral security (including but not limited to this Agreement and the Collateral) for, or other assurances of payment of, the Secured Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order, and all of its rights hereunder and in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights, however existing or arising. To the extent that it lawfully may, each Grantor hereby agrees that it shall not invoke any law relating to the marshalling of collateral which might cause delay in or impede the enforcement of the Agent’s rights under this Agreement or under any other instrument creating or evidencing any of the Secured Obligations or under which any of the Secured Obligations is outstanding or by which any of the Secured Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws.

 

Section 17.             Interest . Until paid, all amounts due and payable by each Grantor hereunder shall be a debt secured by the Collateral and shall bear, whether before or after judgment, interest at a rate per annum equal to the Default Rate, from the date of payment by the Agent to the date reimbursed by such Grantor, and such interest shall be payable by such Grantor to the Agent on demand.

 

Section 18.             Reinstatement . The obligations of each Grantor pursuant to this Agreement shall continue to be effective or automatically be reinstated, as the case may be, if at any time payment of any of the Secured Obligations is rescinded or otherwise must be restored or returned by the Agent or any other Secured Creditor upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of such Grantor or any other obligor or otherwise, all as though such payment had not been made.

 

Section 19.             Miscellaneous .

 

19.01.       Notices . All notices, requests and demands to or upon the Agent or any Grantor hereunder shall be effected in the manner provided for in Section 10.2 of the Credit Agreement.

 

33
 

 

19.02.       GOVERNING LAW; CONSENT TO JURISDICTION; SERVICE OF PROCESS . THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW). ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH PARTY HERETO HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH PARTY HERETO FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK. EACH PARTY HERETO HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. Each Grantor hereby appoints CT Corporation as such Grantor’s agent where notices and demands to or upon such Grantor in respect of this Agreement or any other Loan Document may be served (without prejudice to the right of Agent or Lender to serve process in any other manner permitted by law). If for any reason such process agent is unable to act as such, such Grantor will within 30 days appoint a substitute process agent located in the State of New York and give notice of such appointment to Agent.

 

19.03.       WAIVER OF JURY TRIAL, ETC. EACH PARTY HERETO HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT, ANY NOTE, ANY OTHER LOAN DOCUMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY LENDING RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

 

19.04.       Counterparts . This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

 

19.05.       Headings . The headings of each section of this Agreement are for convenience only and shall not define or limit the provisions thereof.

 

19.06.       No Strict Construction . The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

19.07.       Severability . The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.

 

34
 

 

19.08.       Survival of Agreement . All representations, warranties and agreements made by or on behalf of any Grantor or any other Loan Party in this Agreement and in the other Loan Documents shall survive the execution and delivery hereof or thereof and the making and repayment of the Loans. In addition, notwithstanding anything herein or under Applicable Law to the contrary, the provisions of this Agreement and the other Loan Documents relating to indemnification or payment of costs and expenses, including, without limitation, the provisions of Sections 3.1, 3.2, 3.3, 3.4, 10.3 and 10.4 of the Credit Agreement, shall survive the Payment in Full of the Loans, the termination of the Commitments and any termination of this Agreement or any of the other Loan Documents.

 

19.09.       Fees and Expenses; Indemnification .

 

  (a)      The Grantors, jointly and severally, agree to pay within five (5) Business Days of receipt of a reasonably detailed invoice (a) all reasonable out-of-pocket and documented costs and expenses of the Secured Creditors (including Legal Costs) in connection with the administration (including perfection and protection of Collateral subsequent to the Closing Date) of this Agreement, the Credit Agreement, the other Loan Documents and all other documents provided for herein or delivered or to be delivered hereunder or in connection herewith (including any proposed or actual amendment, supplement or waiver to any Loan Document), and (b) all out-of-pocket costs and expenses (including Legal Costs) incurred by the Secured Creditors in connection with the collection of the Obligations and enforcement of this Agreement, the Credit Agreement, the other Loan Documents or any such other documents (including any such costs and expenses incurred in connection with the custody or preservation of, or the sale of, collection from or other realization upon, any of the Collateral).

 

  (b)      Each Grantor agrees to pay, and to save the Secured Creditors harmless from, any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements with respect to the execution, delivery, enforcement, performance and administration of this Agreement to the extent the Borrower would be required to do so pursuant to Section 10.4 of the Credit Agreement.

 

  (c)      The agreements in this Section shall survive repayment of the Secured Obligations and all other amounts payable under the Credit Agreement and the other Loan Documents.

 

  (d)      Each Grantor agrees that the provisions of Section 3.1 of the Credit Agreement are hereby incorporated herein by reference, mutatis   mutandis , and each Secured Creditor shall be entitled to rely on each of them as if they were fully set forth herein.

 

19.10.       Binding Effect; Several Agreement . This Agreement is binding upon each Grantor and the Secured Creditors and their respective successors and permitted assigns, and shall inure to the benefit of the Grantors, the Secured Creditors and their respective successors and permitted assigns, except that no Grantor shall have any right to assign or transfer its rights or obligations hereunder or any interest herein, except as specifically permitted by the Credit Agreement, without the prior written consent of the Agent (and any such assignment or transfer shall be void).

 

35
 

 

19.11.       Waivers; Amendment .

 

  (a)      No failure or delay of the Agent in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Secured Creditors hereunder and of the Secured Creditors under the Credit Agreement and other Loan Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provisions of this Agreement or consent to any departure by any Grantor therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) below, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand on any Grantor in any case shall entitle such or any other Grantor to any other or further notice or demand in similar or other circumstances.

 

  (b)      Neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Agent and each affected Grantor; provided that any provision of this Agreement imposing obligations on any Grantor may be waived by the Agent in a written instrument executed by the Agent in accordance with Section 10.1 of the Credit Agreement.

 

19.12.       Set Off . Each Grantor hereby irrevocably authorizes each Secured Creditor at any time and from time to time while an Event of Default shall have occurred and be continuing, without notice to such Grantor or any other Grantor, any such notice being expressly waived by each Grantor, to set off and appropriate and apply any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or owing by such Secured Creditor to or for the credit or the account of such Grantor, or any part thereof in such amounts as such Secured Creditor may elect, against and on account of the obligations and liabilities of such Grantor to such Secured Creditor hereunder and claims of every nature and description of such Secured Creditor against such Grantor, in any currency, whether arising hereunder, under the Credit Agreement, any other Loan Document or otherwise, as such Secured Creditor may elect, whether or not any Secured Creditor has made any demand for payment and although such obligations, liabilities and claims may be contingent or unmatured. Each Secured Creditor shall notify such Grantor promptly of any such set-off and the application made by such Secured Creditor of the proceeds thereof; provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of each Secured Creditor under this Section are in addition to other rights and remedies (including, without limitation, other rights of set-off) which such Secured Creditor may have.

 

19.13.       Integration . This Agreement and the other Loan Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.

 

19.14.       Acknowledgments . Each Grantor hereby acknowledges that:

 

  (a)      it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a party;

 

36
 

 

  (b)      no Secured Creditor has any fiduciary relationship with or duty to any Grantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors, on the one hand, and the Secured Creditors, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and

 

  (c)      no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Secured Creditors or among the Grantors and the Secured Creditors.

 

19.15.       Additional Grantors . Each Subsidiary of the Borrower that is required to become a party to this Agreement pursuant to Section 6.7 of the Credit Agreement shall become a Grantor for all purposes of this Agreement upon execution and delivery by such Subsidiary of an Joinder Agreement in the form of Annex I hereto and shall concurrently therewith deliver to the Agent any other Collateral Documents as required by the Credit Agreement.

 

19.16.       Releases .

 

  (a)      Notwithstanding anything to the contrary contained in the Credit Agreement, herein or in any other Loan Document, upon request of the Borrower in connection with any disposition of Property permitted by the Loan Documents, the Agent shall (without notice to or vote or consent of any other Secured Creditor) take such actions as shall be required to release the Security Interest in any Collateral being disposed of in such disposition, to the extent necessary to permit consummation of such disposition in accordance with the Loan Documents; provided that the Borrower shall have delivered to the Agent, at least three (3) Business Days prior to the date of the proposed release, a written request for release identifying the relevant Collateral being disposed of in such disposition and the terms of such disposition in reasonable detail, including the date thereof, the price thereof and any estimated expenses in connection therewith, together with a certification by the Borrower stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents and that the proceeds of such disposition will be applied in accordance with the Credit Agreement and the other Loan Documents.

 

  (b)      At the request and sole expense of the Borrower, a Grantor (other than the Borrower) shall be released from its obligations hereunder in the event that all the capital stock or other equity interests of such Grantor shall be disposed of in a transaction permitted by the Credit Agreement; provided that such the Borrower shall have delivered to the Agent, at least three (3) Business Days prior to the date of the proposed release, a written request for release identifying the relevant Grantor and the terms of the disposition in reasonable detail, including the price thereof and any expenses in connection therewith, together with a certification by the Borrower stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents and that the Proceeds of such disposition will be applied in accordance therewith.

 

  (c)      At such time as all Secured Obligations are Fully Satisfied, the Collateral shall be released from the Liens created hereby and this Agreement and all obligations (other than those expressly stated to survive such termination) of the Agent and each Grantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall revert to the Grantors. At the request of any Grantor following any such termination, Agent shall deliver to such Grantor any Collateral of such Grantor held by Agent hereunder and execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination, all at the sole expense of such Grantor.

 

37
 

 

19.17.       Intercompany Debt .

 

  (a)      Each Grantor hereby agrees that any intercompany Debt or other intercompany payables or receivables directly or indirectly made by or owed to such Grantor by any other Grantor (collectively, “ Intercompany Debt ”), of whatever nature at any time outstanding shall be subordinate and subject in right of payment to the prior payment in full in cash of the Secured Obligations. Each Grantor hereby agrees that following a single written notice to the Borrower from Agent, such Grantor will not, while any Event of Default is continuing, accept any payment, including by offset, on any Intercompany Debt until all Secured Obligations have been Fully Satisfied and the Commitments have been terminated, in each case, except with the prior written consent of the Agent.

 

  (b)      In the event that any payment on any Intercompany Debt shall be received by a Grantor other than as permitted by this Section 19.17 before all Secured Obligations have been Fully Satisfied and the Commitments have been terminated pursuant to the Credit Agreement, such Grantor shall receive such payments and hold the same in trust for, segregate the same from its own assets and shall immediately pay over to, the Agent for the benefit of the Agent and the other Secured Creditors all such sums to the extent necessary so that the Agent and the other Secured Creditors shall have been Paid in Full, in cash, all Secured Obligations owed or which may become owing.

 

  (c)      Upon any payment or distribution of any assets of any Grantor of any kind or character, whether in cash, property or securities by set-off, recoupment or otherwise, to creditors in any liquidation or other winding-up of such Grantor or in the event of any case, proceeding or other action described in Section 8.1.3 of the Credit Agreement, the Agent and the other Secured Creditors shall first be entitled to receive payment in full in cash, in accordance with the terms of the Secured Obligations and of this Agreement, of all amounts payable under or in respect of such Secured Obligations to which the Agent or any other Secured Creditor would be entitled, before any payment or distribution is made on, or in respect of, any Intercompany Debt in any such case, proceeding or other action or any such distribution or payment, except that the provisions hereof shall be paid by such Grantor, or by any receiver, trustee in bankruptcy, liquidating trustee, agent or other person making such payment or distribution, directly to the Agent (for the benefit of the Agent and the other Secured Creditors) to the extent necessary to pay all such Secured Obligations in full in cash, after giving effect to any concurrent payment or distribution to the Agent and other Secured Creditors (or to the Agent, for the benefit of the Agent and the other Secured Creditors).

 

[ Remainder of Page Intentionally Left Blank ]

 

38
 

 

IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee and Collateral Agreement to be duly executed and delivered as of the date first above written.

 

  GRANTORS:
   
  CAREVIEW COMMUNICATIONS, INC. ,
  a Nevada corporation,
  as Guarantor and Grantor
   
   By:   /s/ Steven G. Johnson
     Name: Steven G. Johnson
 Title: President and CEO
   
  CAREVIEW COMMUNICATIONS, INC. ,
  a Texas corporation,
  as Borrower and Grantor
   
   By:   /s/ Steven G. Johnson
     Name: Steven G. Johnson
 Title: President and CEO
   
  CAREVIEW OPERATIONS, L.L.C. ,
  a Texas limited liability company,
  as a Subsidiary Guarantor and Grantor
   
   By:   /s/ Steven G. Johnson
     Name: Steven G. Johnson
 Title: President and CEO

 

[ Signature Page to Guarantee and Collateral Agreement ]

 

 
 

 

   
  PDL BIOPHARMA, INC. ,
  a Delaware corporation,
  as Agent
   
   By:   /s/ John P. McLaughlin
     Name: John P. McLaughlin
 Title: President and CEO

  

[ Signature Page to Guarantee and Collateral Agreement ]

 

 
 

 

Exhibit A to Guarantee and Collateral Agreement

 

COPYRIGHT SECURITY AGREEMENT

 

WHEREAS, [      ] , a [    ] (herein referred to as “ Grantor ”), having an address at [       ], has adopted, used and is using the copyrights listed on the annexed Schedule 1-A , which copyrights are registered in the United States Copyright Office (the “ Copyrights ”);

 

WHEREAS , the Grantor has entered into a Guarantee and Collateral Agreement, dated as of June 26, 2015 (said Guarantee and Collateral Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, the “ Guarantee and Collateral Agreement ”; capitalized terms used but not otherwise defined herein having the meaning assigned to them in the Guarantee and Collateral Agreement) in favor of the Agent, for itself and the Lender party to the Credit Agreement (the “ Secured Creditors ”); and

 

WHEREAS ,   pursuant to the Guarantee and Collateral Agreement, the Grantor has granted to the Secured Creditors a security interest in all right, title and interest of the Grantor in and to the Copyrights, and the registrations and recordings thereof in the United States Copyright Office or any other country or any political subdivision thereof, all whether now or hereafter owned or licensable by the Grantor and all extensions or renewals thereof and all Copyright licenses, and all proceeds of all of the foregoing, including, without limitation, any claims by the Grantor against third parties for infringement thereof, to secure the payment and performance of the Secured Obligations.

 

NOW, THEREFORE , for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further confirm, and put on the public record:

 

Section 1.                Grant of Security Interest in Copyright Collateral . Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations of such Grantor, hereby mortgages, pledges and hypothecates to the Agent for the benefit of the Secured Creditors, and grants to the Agent for the benefit of the Secured Creditors a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the “ Copyright Collateral ”):

 

(i)             all of its Copyrights, including, without limitation, those referred to on Schedule 1-A hereto;

 

(ii)            all renewals, reversions and extensions of the foregoing; and

 

(iii)           all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

 

 
 

 

Section 2.                Security Agreement . The security interest granted pursuant to this Copyright Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Copyright Collateral made and granted hereby are more fully set forth in the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Copyright Security Agreement and the terms of the Guarantee and Collateral Agreement, the terms of the Guarantee and Collateral Agreement shall control.

 

SECTION 3.           Grantor Remains Liable . Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in such Grantor’s reasonable business judgment in connection with their Copyrights subject to a security interest hereunder.

 

SECTION 4.          GOVERNING LAW THIS COPYRIGHT SECURITY AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

Section 5.               Counterparts. This Copyright Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of a signature page of this Copyright Security Agreement by facsimile or other electronic means shall be effective as delivery of a manually executed counterpart of such Copyright Security Agreement.

 

[SIGNATURE PAGES FOLLOW]

 

 
 

 

IN WITNESS WHEREOF ,   the undersigned Grantor has duly executed or caused this Copyright Security Agreement to be duly executed as of the date first set forth above.

 

  [         ]
   
   By:    
    Name:
Title:

 
 

Schedule 1-A to the COPYRIGHT SECURITY AGREEMENT

 

Copyright   Registration Date   Registration No.
         
         

 
 


Exhibit B to Guarantee and Collateral Agreement

 

PATENT SECURITY AGREEMENT

 

WHEREAS, [      ] , a [    ] (herein referred to as “ Grantor ”), having an address at [       ], owns the letters patent and/or applications for letters patent of the United States of America more particularly described on Schedule 1-A annexed hereto as part hereof (the “ Patents ”);

 

WHEREAS , the Grantor has entered into a Guarantee and Collateral Agreement, dated as of June 26, 2015 (said Guarantee and Collateral Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, the “ Guarantee and Collateral Agreement ”; capitalized terms used but not otherwise defined herein having the meaning assigned to them in the Guarantee and Collateral Agreement) in favor of the Agent, for itself and the Lender party to the Credit Agreement (the “ Secured Creditors ”); and

 

WHEREAS , pursuant to the Guarantee and Collateral Agreement, the Grantor has granted to the Secured Creditors a security interest in all right, title and interest of Grantor in and to the Patents, together with all registrations and recordings thereof, including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, all whether now or hereafter owned or licensable by Grantor, and all reissues, divisions, continuations, continuations-in-part, term restorations or extensions thereof, all Patent licenses and all proceeds of all of the foregoing, including, without limitation, any claims by Grantor against third parties for infringement thereof for the full term of the Patents, to secure the prompt payment and performance of the Secured Obligations.

 

NOW, THEREFORE , for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further confirm, and put on the public record, its grant to the Secured Creditors of a security interest in and mortgage on the Collateral to secure the prompt payment and performance of the Secured Obligations.

 

Section 1.               Grant of Security Interest in Patents Each Grantor hereby grants to the Agent a security interest and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether owned or existing or hereafter acquired or arising and wherever located (collectively, the “Patent Collateral”): all United States and foreign patents and certificates of invention, or similar industrial property rights, including, but not limited to each patent referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time), and with respect to any and all of the foregoing, (i) all applications therefor including the patent applications referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time), (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom, and (vii) all proceeds, payments and rights to payments arising out of the sale, lease, license, assignment, or other disposition thereof.

 

B- 1
 

 

Section 2.               Security Agreement The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to the Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the Patent Collateral made and granted hereby are supplemental of, and more fully set forth in, the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Patent Security Agreement and the terms of the Guarantee and Collateral Agreement, the terms of the Guarantee and Collateral Agreement shall control.

 

Section 3.               Grantor Remains Liable . Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in such Grantor’s reasonable business judgment in connection with their Patents subject to a security interest hereunder.

 

Section 4.                GOVERNING LAW THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

Section 5.               Counterparts. This Patent Security Agreement may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Patent Security Agreement shall become effective when the Agent has received counterparts bearing the signatures of all parties hereto. Delivery of a signature page of this Patent Security Agreement by facsimile or other electronic means shall be effective as delivery of a manually executed counterpart of such Patent Security Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

 
 

 

IN WITNESS WHEREOF ,   the undersigned Grantor has duly executed or caused this Patent Security Agreement to be duly executed as of the date first set forth above.

 

  [         ]
   
   By:    
    Name:
Title:

 

 
 

 

Schedule 1-A to the PATENT SECURITY AGREEMENT

 

Title  

Date Filed 

or Granted

 

Serial No. or 

Patent No. 

         
         

 
 

 

Exhibit C to Guarantee and Collateral Agreement

 

TRADEMARK SECURITY AGREEMENT

 

WHEREAS, [      ] , a [    ] (herein referred to as “ Grantor ”), having an address at [       ], (1) has adopted, used and is using, or (2) has intended to use and filed an application indicating that intention, but has not yet filed an allegation of use under Section l(c) or l(d) of the Trademark Act, or (3) has filed an application based on an intention to use and has since used and has filed an allegation of use under Section l(c) or l(d) of the Trademark Act, the trademarks, trade names, trade styles and service marks listed on the annexed Schedule 1-A , which trademarks, trade names, trade styles and service marks are registered, or for which applications for registration have been filed in the United States Patent and Trademark Office (the “ Trademarks ”); and

 

WHEREAS , the Grantor has entered into a Guarantee and Collateral Agreement, dated as of June 26, 2015 (said Guarantee and Collateral Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, the “ Guarantee and Collateral Agreement ”; capitalized terms used but not otherwise defined herein having the meaning assigned to them in the Guarantee and Collateral Agreement) in favor of the Agent, for itself and the Lender party to the Credit Agreement ( the “ Secured Creditors ”); and

 

WHEREAS , pursuant to the Guarantee and Collateral Agreement, the Grantor has granted to the Secured Creditors a security interest in all right, title and interest of the Grantor in and to the Trademarks, together with all prints and labels on which said Trademarks have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, and the goodwill of the business symbolized by the Trademarks and the applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof, or any other country or any political subdivision thereof, all whether now or hereafter owned or licensable by Grantor, and all reissues, extensions or renewals thereof, all Trademark licenses and all proceeds of all of the foregoing, including, without limitation, any claims by Grantor against third parties for infringement thereof, to secure the payment and performance of the Secured Obligations.

 

NOW, THEREFORE , for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further confirm, and put on the public record:

 

Section 1.               Grant of Security Interest in Trademarks . Each Grantor hereby grants to the Agent a security interest and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether owned or existing or hereafter acquired or arising and wherever located (collectively, the “ Trademark Collateral ”):

 

 (i)           all United States, State and foreign trademarks, service marks, certification marks, collective marks, trade names, corporate names, d/b/as, business names, fictitious business names, Internet domain names, trade styles, logos, other source or business identifiers, designs and general intangibles of a like nature and, with respect to any and all of the foregoing: (i) all registrations and applications therefor including, but not limited to, the registrations and applications referred to in Schedule 1-A hereto (as such schedule may be amended or supplemented from time to time),

 

 
 

 

(ii) the goodwill of the business symbolized thereby,

 

(iii) all rights corresponding thereto throughout the world,

 

(iv) all rights to sue for past, present and future infringement or dilution thereof or for any injury to goodwill,

 

(v) all licenses, claims, damages, and proceeds of suit arising therefrom, and

 

(vi) all payments and rights to payments arising out of the sale, lease, license assignment or other disposition thereof;

 

provided that the security interest granted under Section 2 hereof shall not attach to, and the term “Trademark Collateral” shall not include any applications for trademark filed in the United States Patent and Trademark Office pursuant to 15 U.S.C. § 1051 Section 1(b), only to the extent that the grant of a security interest therein would result in the abandonment, invalidation or unenforceability of the trademarks matured from such application or rights hereunder and only until evidence of the use of such trademarks in commerce, as defined in 15 U.S.C. Section 1127, is submitted to, and accepted by, the United States Patent and Trademark Office pursuant to 15 U.S.C. § 1051 Section 1(c) or 1(d), following which filing all such applications shall automatically become Trademark Collateral.

 

Section 2.               Security Agreement The security interests granted pursuant to this Trademark Security Agreement are granted in conjunction with the security interests granted to the Agent pursuant to the Guarantee and Collateral Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the Trademark Collateral made and granted hereby are supplemental of, and more fully set forth in, the Guarantee and Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Trademark Security Agreement and the terms of the Guarantee and Collateral Agreement, the terms of the Guarantee and Collateral Agreement shall control.

 

Section 3.               Grantor Remains Liable . Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in such Grantor’s reasonable business judgment in connection with their Trademarks subject to a security interest hereunder.

 

Section 4.               GOVERNING LAW THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

 
 

 

Section 5.               Counterparts . This Trademark Security Agreement may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Trademark Security Agreement shall become effective when the Agent has received counterparts bearing the signatures of all parties hereto. Delivery of a signature page of this Trademark Security Agreement by facsimile or other electronic means shall be effective as delivery of a manually executed counterpart of such Trademark Security Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

 
 

   

IN WITNESS WHEREOF ,   the undersigned Grantor has duly executed or caused this Trademark Security Agreement to be duly executed as of the date first set forth above. 

 

  [         ]
   
   By:    
    Name:
Title:

 
 

 

Schedule 1-A to the TRADEMARK SECURITY AGREEMENT

 

Trademark   Application or
Registration Date
  Application Serial
No. or Registration
No.
         

 

 
 

 

Annex I to Guarantee and Collateral Agreement

 

[FORM OF] JOINDER AGREEMENT

 

JOINDER AGREEMENT, dated as of ____________, 20__, made by ______________________, a _______________ (the “ Additional Grantor ”), in favor of PDL BIOPHARMA, INC., a Delaware corporation, as Agent (in such capacity, the “ Agent ”) for (i) the lender (the “ Lender ”) party to the Credit Agreement referred to below and (ii) the other Secured Creditors (as defined in the Guarantee and Collateral Agreement (as hereinafter defined)). All capitalized terms not defined herein shall have the meaning ascribed to them in such Credit Agreement.

 

W I T N E S S E T H:

 

WHEREAS, CareView Communications, Inc., a Nevada corporation ( Holdings ”), CareView Communications, Inc., a Texas corporation (the “ Borrower ”), the Lender and the Agent have entered into the Credit Agreement dated as of June 26, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”);

 

WHEREAS, in connection with the Credit Agreement, Holdings and the Borrower have entered into a Guarantee and Collateral Agreement dated as of June 26, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “ Guarantee and Collateral Agreement ”) in favor of the Agent for the benefit of the Secured Creditors;

 

WHEREAS, the Credit Agreement requires the Additional Grantor to become a party to the Guarantee and Collateral Agreement; and

 

WHEREAS, the Additional Grantor has agreed to execute and deliver this Joinder Agreement in order to become a party to the Guarantee and Collateral Agreement;

 

NOW, THEREFORE, IT IS AGREED:

 

1.            Guarantee and Collateral Agreement . By executing and delivering this Joinder Agreement, the Additional Grantor, as provided in Section 19.15 of the Guarantee and Collateral Agreement, hereby becomes a party to the Guarantee and Collateral Agreement as a Grantor thereunder with the same force and effect as if originally named therein as a Grantor and, without limiting the generality of the foregoing, hereby expressly assumes all obligations and liabilities of a Grantor thereunder. The information set forth in Annex I-A hereto is hereby added to the information set forth in the Perfection Certificate or Perfection Supplement most recently delivered pursuant to the terms of the Guarantee and Collateral Agreement. The Additional Grantor hereby represents and warrants that each of the representations and warranties as to the Additional Grantor contained in Section 6 of the Guarantee and Collateral Agreement is true and correct in all material respects on and as the date hereof (after giving effect to this Joinder Agreement) as if made on and as of such date.

 

2.            GOVERNING LAW . THIS JOINDER AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

 

 
 

 

IN WITNESS WHEREOF, the undersigned has caused this Joinder Agreement to be duly executed and delivered as of the date first above written.

 

  ADDITIONAL GRANTOR:
   
  [NAME OF GRANTOR]
   
   By:    
    Name:
Title:

 

 
 

 

Annex I-A to Joinder Agreement

 

 

 

  Careview Communications, Inc. 8-K

 

Exhibit 10.06 

 

Execution Version

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS AGREEMENT (this “ Agreement ”) is entered into as of June 26, 2015 by and between CareView Communications, Inc., a Nevada corporation (the “ Company ”) and PDL BioPharma, Inc., a Delaware corporation (the “ Original Holder ”).

 

RECITALS

 

A.            The Company, certain subsidiaries and the Original Holder have entered into a Credit Agreement dated as of June 26, 2015 pursuant to which the Original Holder has agreed to lend to the Company up to Forty Million Dollars ($40,000,000.00) on the terms and conditions set forth therein (the “ Credit Agreement ”).

 

B.            Pursuant to the Credit Agreement, the Company has issued to the Original Holder a Warrant dated as of June 26, 2015 (the “ Warrant ”), pursuant to which the Original Holder and its assignees have the right to acquire shares of common stock, par value $0.001 per share, of the Company.

 

C.           In connection with the execution and delivery of the Credit Agreement and the Warrant and the consummation of the transactions contemplated thereby, the Company has agreed to grant the Original Holder certain registration rights as set forth below.

 

AGREEMENT

 

In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the parties agree as follows:

 

Article I
DEFINITIONS

 

Section 1.1          Certain Definitions . As used in this Agreement, capitalized terms not otherwise defined herein shall have the meanings ascribed to them below:

 

Business Day ” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in The City of New York.

 

Common Stock ” means the common stock, par value $0.001 per share, of the Company, and any equity securities issued or issuable in exchange for or with respect to the Common Stock by way of a stock dividend, stock split or combination of shares or in connection with a reclassification, recapitalization, merger, consolidation or other reorganization or otherwise.

 

Common Stock Equivalent ” means all options, warrants and other securities convertible into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting or other conditions to which such securities may be subject), Common Stock.

 

 
 

 

Designated Holder ” means the Original Holder or, if the Original Holder no longer holds more than 10% of the then outstanding Registrable Securities, Participating Holders holding more than 50% of the then outstanding Registrable Securities.

 

Effectiveness Period ” means the period from the date hereof until such date as the Holders no longer hold any Registrable Securities.

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

FINRA ” means the Financial Industry Regulatory Authority, Inc.

 

HealthCor Holder ” means those holders of the Company’s securities party to the HealthCor Registration Rights Agreement.

 

HealthCor Registration Rights Agreement ” means that certain registration rights agreement dated April 21, 2011, by and among the Company, HealthCor Partners Fund, L.P., HealthCor Hybrid Offshore Master Fund, L.P. and the other investors party thereto, as amended, supplemented or modified from time to time.

 

HealthCor Registrable Securities ” shall have the same meaning as “Registrable Securities” as defined in the HealthCor Registration Rights Agreement.

 

Holder ” or “ Holders ” means the Original Holder and any Person who shall acquire and hold Registrable Securities in accordance with the terms of this Agreement.

 

Issuer Free Writing Prospectus ” means an issuer free writing prospectus, as defined in Rule 433 under the Securities Act, relating to an offer of Registrable Securities.

 

Participating Holders ” has the meaning set forth in Section 2.1(a)(ii).

 

Prospectus ” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 424(b) promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

 

Person ” means any individual, corporation, partnership, limited liability company, limited liability partnership, syndicate, person, trust, association, organization or other entity or any governmental or regulatory body or other agency or authority or political subdivision thereof, including any successor, by merger or otherwise, of any of the foregoing.

 

2
 

 

Registrable Securities ” means the Warrant Shares, any other securities issued or issuable upon exercise of the Warrant and any other securities issued or issuable with respect to or in exchange for any such securities, provided such securities shall cease to be Registrable Securities when: (i) sold pursuant to an effective registration statement or sold pursuant to Rule 144 or any successor provision under the Securities Act; or (ii) such security becomes eligible for sale without restriction by the applicable Holder pursuant to and in compliance with Rule 144 or any successor provision under the Securities Act.

 

Registration Expenses ” means all fees and expenses incurred in connection with the Company’s performance of or compliance with the provisions of Article II, including: (i) all registration, listing, qualification and filing fees (including FINRA filing fees); (ii) fees and expenses of compliance with state securities or “blue sky” laws (including counsel fees in connection with the preparation of a blue sky and legal investment survey and FINRA filings); (iii) printing and copying expenses; (iv) messenger and delivery expenses; (v) expenses incurred in connection with any road show; (vi) fees and disbursements of counsel for the Company; (vii) with respect to each registration, the reasonable fees and disbursements of one counsel for the selling Holder(s) selected by the Designated Holder and reasonably satisfactory to the Company, in the case of a registration pursuant to Section 2.1, and selected by the underwriter and reasonably satisfactory to the Designated Holder, in the case of a registration pursuant to Section 2.2; (viii) fees and disbursements of independent public accountants, including the expenses of any audit or “cold comfort” letter, and fees and expenses of other persons, including special experts, retained by the Company; (ix) underwriter fees, excluding discounts and commissions, and any other expenses which are customarily borne by the issuer or seller of securities in a public equity offering; and (x) all internal expenses of the Company (including all salaries and expenses of officers and employees performing legal or accounting duties).

 

Registration Statement ” means any registration statement required to be filed under this Agreement, including the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.

 

SEC ” means the Securities and Exchange Commission.

 

Securities Act ” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

Warrant Shares ” means the shares of Common Stock issuable upon the exercise of the Warrant.

 

3
 

 

Article II
REGISTRATION RIGHTS

 

Section 2.1          Demand Registrations .

 

(a)            (i)        Subject to Section 2.1(c), at any time following the date hereof but prior to the expiration of the Effectiveness Period, the Designated Holder shall have the right to require the Company to file a registration statement under the Securities Act covering Registrable Securities by delivering a written request therefor to the Company specifying the number of Registrable Securities to be included in such registration and the intended method of distribution thereof. All such requests by any Holder pursuant to this Section 2.1(a)(i) are referred to as “ Demand Registration Requests ,” the registrations so requested are referred to as “ Demand Registrations ” and the Holders making such demand for registration are referred to as the “ Initiating Holders .” As promptly as practicable, but no later than 10 days after receipt of a Demand Registration Request, the Company shall give written notice (a “ Demand Exercise Notice ”) of such Demand Registration Request to all Holders of record of Registrable Securities other than the Initiating Holders.

 

 (ii)        The Company, subject to Sections 2.3 and 2.6, shall include in a Demand Registration (A) the Registrable Securities of the Initiating Holders and (B) the Registrable Securities of any other Holder of Registrable Securities that shall have made a written request to the Company within the time limits specified below for inclusion in such registration (together with the Initiating Holders, the “ Participating Holders ”). Any such request from the other Holders must be delivered to the Company within 15 days after the receipt of the Demand Exercise Notice and must specify the maximum number of Registrable Securities intended to be disposed of by such other Holders.

 

(b)           (i)        The Company shall as soon as practicable (and in the case of an offering to be made on a continuous basis under Rule 415, in no event later than thirty (30) days following the Demand Registration Request) cause to be prepared and filed with the SEC a Registration Statement providing for the resale of all Registrable Securities which Holders request to be registered. The Registration Statement shall be on Form S-3 if the Company is then eligible to register for resale the Registrable Securities on such form (a “ Short Form Registration ”). If the Company is not then eligible to register for resale the Registrable Securities on Form S-3, such registration shall be on Form S-1 or another appropriate form in accordance herewith (a “ Long Form Registration ”).

 

 (ii)        The Company shall cause the Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof (and in the case of an offering to be made on a continuous basis under Rule 415, in no event later than either of (A) 180 calendar days following the date of the Demand Registration Request or (B) five Business Days following notification by the staff of the SEC to the Company that there will be no review of the Registration Statement or, if comments have been given, that the staff will have no further comments with respect thereto). The Company shall keep the Registration Statement continuously effective under the Securities Act until the date when all Registrable Securities covered by such Registration Statement have been sold.

 

4
 

 

 

(c)           The Demand Registration rights granted in Section 2.1(a) to the Holders are subject to the following limitations:

 

(i)          the Company shall not be required to cause a registration pursuant to Section 2.1(a) to be filed within 90 days or to be declared effective within a period of 180 days after the effective date of any other registration statement of the Company filed pursuant to the Securities Act;

 

(ii)         if the Company delivers to the Initiating Holders a certificate signed by the Company’s chief executive officer stating that, in the good faith judgment of the Company’s Board of Directors: (x) the registration could reasonably be expected to materially interfere with an acquisition, corporate reorganization or other material transaction then under consideration by the Company or (y) there is some other material development relating to the operations or condition (financial or other) of the Company that has not been disclosed to the general public and as to which it is in the Company’s best interests not to disclose (each of (x) and (y), a “ Valid Business Reason ”), the Company may postpone or withdraw a filing of a registration statement relating to a Demand Registration Request until such Valid Business Reason no longer exists, but in no event shall the Company avail itself of such right for more than 60 days (unless the Holders of at least a majority of the Registrable Securities consent in writing to a longer delay of up to an additional 30 days) in any period of 365 consecutive days (such period of postponement or withdrawal under this clause (ii), the “ Postponement Period ”); and the Company shall give notice of its determination to postpone or withdraw a registration statement and of the fact that the Valid Business Reason for such postponement or withdrawal no longer exists, in each case, promptly after the occurrence thereof;

 

(iii)        The Company shall not be obligated to effect more than three Long Form Registrations. There shall be no limitation on the number of Short Form Registrations under Section 2.1(a); and

 

(iv)        Notwithstanding any provision of this Agreement to the contrary, neither the Designated Holder nor any other Holder shall have any right under this Agreement to require that a distribution of Registrable Securities be effected by means of an underwriting.

 

If the Company shall give any notice of postponement or withdrawal of any registration statement pursuant to clause (ii) above, the Company shall not register any equity security of the Company during the period of postponement or withdrawal. Each Holder of Registrable Securities agrees that, upon receipt of any notice from the Company that the Company has determined to withdraw any registration statement pursuant to clause (ii) above, such Holder will discontinue its disposition of Registrable Securities pursuant to such registration statement. If the Company shall have withdrawn or prematurely terminated a registration statement filed under Section 2.1(a)(i), the Company shall not be considered to have effected an effective registration for the purposes of this Agreement until the Company shall have filed a new registration statement covering the Registrable Securities covered by the withdrawn registration statement and such registration statement shall have been declared effective and shall not have been withdrawn. If the Company shall give any notice of withdrawal or postponement of a registration statement, at such time as the Valid Business Reason that caused such withdrawal or postponement no longer exists (but in no event more than 60 days, or, with the written consent of the Holders of at least a majority of the Registrable Securities, 90 days, after the date of the postponement or withdrawal), the Company shall use its commercially reasonable efforts to effect the registration under the Securities Act of the Registrable Securities covered by the withdrawn or postponed registration statement in accordance with this Section 2.1.

 

5
 

 

(d)           A Holder may withdraw its Registrable Securities from a Demand Registration at any time. If all such Holders do so, the Company shall cease all efforts to secure registration and such registration nonetheless shall be deemed a Demand Registration for purposes of this Section 2.1 unless (i) the withdrawal is made following withdrawal or postponement of such registration by the Company pursuant to a Valid Business Reason as contemplated by Section 2.1(c), (ii) the withdrawal is based on the reasonable determination of the Holders who requested such registration that there has been, since the date of the Demand Registration Request, a material adverse change in the business or prospects of the Company or (iii) the Holders who requested such registration shall have paid or reimbursed the Company for all of the reasonable out-of-pocket fees and expenses incurred by the Company in connection with the withdrawn registration.

 

(e)            A Demand Registration shall not be deemed to have been effected and shall not count as such (i) unless a registration statement with respect thereto has become effective and has remained effective for a period of at least 180 days or such shorter period during which all Registrable Securities covered by such Registration Statement have been sold or withdrawn, (ii) if, after the registration statement with respect thereto has become effective, it becomes subject to any stop order, injunction or other order or requirement of the SEC or other governmental agency or court for any reason, or (iii) if it is withdrawn by the Company pursuant to a Valid Business Reason as contemplated by Section 2.1(c).

 

Section 2.2          Piggyback Registrations .

 

(a)            If at any time during the Effectiveness Period, the Company shall determine to register any of its equity securities under the Securities Act (other than pursuant to (i) registrations on such form or similar form(s) solely for registration of securities in connection with an employee benefit plan or dividend reinvestment plan or (ii) a Demand Registration under Section 2.1) on a registration statement on Form S-1 or Form S-3 or an equivalent general registration form then in effect (but excluding any registration statement on Form S-4 or Form S-8), whether or not for its own account, the Company shall give prompt written notice of its intention to do so to each Holder of record of Registrable Securities. Upon the written request of any such Holder, made within 15 days following the receipt of any such written notice (which request shall specify the maximum number of Registrable Securities intended to be disposed of by such Holder and the intended method of distribution thereof), the Company, subject to Sections 2.2(b), 2.3 and 2.6, shall use commercially reasonable efforts to cause all such Registrable Securities to be included in the registration statement with the securities that the Company at the time proposes to register to permit the sale or other disposition by the Holders in accordance with the intended method of distribution thereof of the Registrable Securities to be so registered. No registration of Registrable Securities effected under this Section 2.2(a) shall relieve the Company of its obligations to effect Demand Registrations under Section 2.1.

 

6
 

 

(b)            If, at any time after giving written notice of its determination to register any equity securities and prior to the effective date of the registration statement filed in connection with such registration, the Company shall determine for any reason not to register or to delay registration of such equity securities, the Company will give written notice of such determination to each Holder of record of Registrable Securities and (i) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in connection with such abandoned registration, without prejudice, however, to the rights of Holders under Section 2.1 and (ii) in the case of a determination to delay such registration of its equity securities, shall be permitted to delay the registration of such Registrable Securities for the same period as the delay in registering such other equity securities.

 

(c)            Any Holder shall have the right to withdraw its request for inclusion of its Registrable Securities in any registration statement pursuant to this Section 2.2 by giving written notice to the Company of its request to withdraw. Such request must be made in writing prior to the earlier of (i) the use by the Company or any underwriters of any preliminary prospectus or preliminary prospectus supplement that is part of such registration statement, (ii) the execution of the underwriting agreement with respect to such registration or (iii) the execution of the custody agreement with respect to such registration. Such withdrawal shall be irrevocable and, after making such withdrawal, a Holder shall no longer have any right to include Registrable Securities in the registration as to which such withdrawal was made.

 

Section 2.3          Priority in Registrations .

 

(a)            If any registration pursuant to Section 2.2 involves an underwritten offering that is proposed by the Company and the lead managing underwriter of such offering (the “ Manager ”) shall advise the Company that, in its view, the aggregate number of securities requested to be included in such registration by the Company, the Holders and the holders of securities of the Company, including the HealthCor Holders, that have the right to require such registration pursuant to an agreement entered into by the Company (“ Additional Registration Rights ”) exceeds the number (the “ Section 2.3(a) Sale Number ”) that can be sold in an orderly manner in such registration within a price range acceptable to the Company (such difference, the “ Aggregate Underwriter Cutback ”), the Company shall include in such registration: (i) all Common Stock that the Company proposes to register for its own account less such number of shares equal to 50% of the Aggregate Underwriter Cutback (such number of shares to be registered, the “ Company Allotment ”), and (ii) the aggregate of all Registrable Securities and all HealthCor Registrable Securities for which the Holders and the HealthCor Holders, respectively, request registration (such number of securities, the “ Aggregate Registration Request ”) less such number of securities equal to 50% of the Aggregate Underwriter Cutback (such number of securities to be registered, the “ Registrable Securities Allotment ”). To the extent that the Aggregate Registration Request exceeds the Registrable Securities Allotment, the securities to be included in the Registrable Securities Allotment shall be allocated on a pro rata basis among (i) all Holders requesting that Registrable Securities be included in such registration pursuant to the exercise of piggyback rights pursuant to Section 2.2 of this Agreement and (ii) all HealthCor Holders requesting that HealthCor Registrable Securities be included in such registration, based on the number of (x) Registrable Securities that each such Holder is then requesting for inclusion and (y) HealthCor Registrable Securities that each such HealthCor Holder is then requesting for inclusion, which, together with the Company Allotment, shall not exceed the Section 2.3(a) Sale Number.

 

7
 

 

(b)            If any registration pursuant to Section 2.2 involves an underwritten offering that was proposed by the HealthCor Holders or other holders of Additional Registration Rights and the Manager shall advise the Company that, in its view, the number of securities requested to be included in such registration exceeds the number (the “ Section 2.3(b) Sale Number ”) that can be sold in an orderly manner in such registration within a price range acceptable to the Company, the securities to be included in such registration shall be allocated by the Company first , on a pro rata basis among (i) all Holders requesting that Registrable Securities be included in such registration pursuant to the exercise of piggyback rights pursuant to Section 2.2 of this Agreement and (ii) all HealthCor Holders requesting the inclusion in such registration of HealthCor Registrable Securities, based on the number of (x) Registrable Securities that each such Holder is then requesting for inclusion and (y) HealthCor Registrable Securities that each such HealthCor Holder is requesting for inclusion, which shall not exceed the Section 2.3(b) Sale Number, and second , to the other holders of Additional Registration Rights (if any).

 

Section 2.4          Registration Procedures . Whenever the Company is required by the provisions of this Agreement to use commercially reasonable efforts to effect or cause the registration of any Registrable Securities under the Securities Act as provided in this Agreement, the Company as expeditiously as possible:

 

(a)            shall prepare and file with the SEC the requisite Registration Statement, which shall comply as to form in all material respects with the requirements of the applicable form and shall include all financial statements required by the SEC to be filed therewith, and use commercially reasonable efforts to cause such Registration Statement to become and remain effective ( provided , however , that before filing a Registration Statement or Prospectus or any amendments or supplements thereto, or comparable statements under securities or blue sky laws of any jurisdiction, or any Issuer Free Writing Prospectus related thereto, the Company will furnish to one counsel for the Holders participating in the planned offering (selected by the Designated Holder and reasonably satisfactory to the Company, in the case of a registration pursuant to Section 2.1, and selected by the lead managing underwriter, if any, and reasonably satisfactory to the Designated Holder, in the case of a registration pursuant to Section 2.2) and the lead managing underwriter, if any, copies of all such documents proposed to be filed (including all exhibits thereto), which documents will be subject to the reasonable review and reasonable comment of such counsel, and the Company shall not file any Registration Statement or amendment thereto, any Prospectus or supplement thereto or any Issuer Free Writing Prospectus related thereto to which the Designated Holder covered by such Registration Statement or the underwriters, if any, shall reasonably object);

 

(b)            shall prepare and file with the SEC such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective for such period as any seller of Registrable Securities pursuant to such Registration Statement shall request and to comply with the provisions of the Securities Act with respect to the sale or other disposition of all Registrable Securities covered by such Registration Statement in accordance with the intended methods of disposition by the seller or sellers thereof set forth in such Registration Statement;

 

8
 

 

(c)            shall furnish, without charge, to each seller of such Registrable Securities and each underwriter, if any, of the securities covered by such Registration Statement such number of copies of such Registration Statement, each amendment thereto, the Prospectus included in such Registration Statement, each preliminary Prospectus and each Issuer Free Writing Prospectus utilized in connection therewith, all in conformity with the requirements of the Securities Act, and such other documents as such seller and underwriter may reasonably request in order to facilitate the public sale or other disposition of the Registrable Securities owned by such seller, and shall consent to the use in accordance with all applicable law of each such Registration Statement, each amendment thereto, each such Prospectus, preliminary Prospectus or Issuer Free Writing Prospectus by each such seller of Registrable Securities and the underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such Registration Statement or Prospectus;

 

(d)            shall use commercially reasonable efforts to register or qualify the Registrable Securities covered by such Registration Statement under such other securities or “blue sky” laws of such jurisdictions as any sellers of Registrable Securities or any managing underwriter, if any, reasonably shall request, and do any and all other acts and things that may be reasonably necessary or advisable to enable such sellers or underwriter, if any, to consummate the disposition of the Registrable Securities in such jurisdictions, except that in no event shall the Company be required to qualify to do business as a foreign corporation in any jurisdiction where, but for the requirements of this Section 2.4(d), it would not be required to be so qualified, to subject itself to taxation in any such jurisdiction or to consent to general service of process in any such jurisdiction;

 

(e)            shall promptly notify each Holder selling Registrable Securities covered by such Registration Statement and each managing underwriter, if any:

 

(i)          when the Registration Statement, any pre-effective amendment, the Prospectus or any Prospectus supplement related thereto, any post-effective amendment to the Registration Statement or any Issuer Free Writing Prospectus has been filed and, with respect to the Registration Statement or any post-effective amendment, when the same has become effective;

 

(ii)         of any request by the SEC or state securities authority for amendments or supplements to the Registration Statement or the Prospectus related thereto or for additional information;

 

(iii)        of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose;

 

(iv)        of the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable Securities for sale under the securities or blue sky laws of any jurisdiction or the initiation of any proceeding for such purpose;

 

(v)         of the existence of any fact of which the Company becomes aware which results in the Registration Statement, the prospectus related thereto, any document incorporated therein by reference, any Issuer Free Writing Prospectus or the information conveyed to any purchaser at the time of sale to such purchaser containing an untrue statement of a material fact or omitting to state a material fact required to be stated therein or necessary to make any statement therein not misleading; and

 

9
 

 

(vi)        if at any time the representations and warranties contemplated by any underwriting agreement, securities sale agreement, or other similar agreement relating to the offering shall cease to be true and correct in all material respects; and, if the notification relates to an event described in clause (v), the Company, subject to the provisions of Section 2.1(c), promptly shall prepare and file with the SEC, and furnish to each seller and each underwriter, if any, a reasonable number of copies of, a Prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in the light of the circumstances under which they were made not misleading;

 

(f)             shall comply with all applicable rules and regulations of the SEC, and make generally available to its security holders, as soon as reasonably practicable after the effective date of the Registration Statement (and in any event within 90 days after the end of such 12 month period described hereafter), an earnings statement, which need not be audited, covering the period of at least 12 consecutive months beginning with the first day of the Company’s first calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;

 

(g)            shall cause all Registrable Securities covered by such Registration Statement to be authorized to be listed on a national securities exchange if shares of the particular class of Registrable Securities are at that time, or will be immediately following the offering, listed on such exchange;

 

(h)            shall provide and cause to be maintained a transfer agent and registrar for all such Registrable Securities covered by such Registration Statement not later than the effective date of such Registration Statement;

 

(i)             shall enter into such customary agreements (including, if applicable, an underwriting agreement) and take such other actions as the Designated Holder shall reasonably request in order to expedite or facilitate the disposition of such Registrable Securities (it being understood that the Holders of the Registrable Securities that are to be distributed by any underwriters shall be parties to any such underwriting agreement and may, at their option, require that the Company make to and for the benefit of such Holders the representations, warranties and covenants of the Company which are being made to and for the benefit of such underwriters);

 

(j)             in connection with an underwritten offering, shall obtain an opinion from the Company’s counsel and a “cold comfort” letter from the Company’s independent public accountants in customary form and covering such matters as are customarily covered by such opinions and “cold comfort” letters delivered to underwriters in underwritten public offerings, which opinion and letter shall be reasonably satisfactory to the underwriter, if any;

 

10
 

 

(k)            shall use commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration Statement;

 

(l)             shall provide a CUSIP number for all Registrable Securities, not later than the effective date of the Registration Statement;

 

(m)           shall make reasonably available its employees and personnel for participation in “road shows” and other marketing efforts and otherwise provide reasonable assistance to the underwriters, taking into account the needs of the Company’s businesses and the requirements of the marketing process, in the marketing of Registrable Securities in any underwritten offering;

 

(n)            shall promptly prior to the filing of any document that is to be incorporated by reference into the Registration Statement or the Prospectus, and prior to the filing of any Issuer Free Writing Prospectus, provide copies of such document to counsel for the selling holders of Registrable Securities and to each managing underwriter, if any, and make the Company’s representatives reasonably available for discussion of such document and make such changes in such document concerning the selling holders prior to the filing thereof as counsel for such selling holders or underwriters may reasonably request;

 

(o)            shall cooperate with the sellers of Registrable Securities and the managing underwriter, if any, to facilitate the timely preparation and delivery of certificates not bearing any restrictive legends representing the Registrable Securities to be sold, and cause such Registrable Securities to be issued in such denominations and registered in such names in accordance with the underwriting agreement prior to any sale of Registrable Securities to the underwriters or, if not an underwritten offering, in accordance with the instructions of the sellers of Registrable Securities at least three Business Days prior to any sale of Registrable Securities and instruct any transfer agent and registrar of Registrable Securities to release any stop transfer orders in respect thereof;

 

(p)            shall take all such other commercially reasonable actions as are necessary or advisable in order to expedite or facilitate the disposition of such Registrable Securities;

 

(q)            shall not take any direct or indirect action prohibited by Regulation M under the Exchange Act; provided , however , that to the extent that any prohibition is applicable to the Company, the Company will take such action as is necessary to make any such prohibition inapplicable;

 

(r)             shall cooperate with each seller of Registrable Securities and each underwriter or agent participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA; and

 

(s)            shall take all reasonable action to ensure that any Issuer Free Writing Prospectus utilized in connection with any registration covered by Section 2.1 or 2.2 complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

11
 

 

If the Company files any shelf Registration Statement for the benefit of the holders of any of its securities other than the Holders, the Company shall include in such Registration Statement such disclosures as may be required by Rule 430B under the Securities Act, referring to the unnamed selling security holders in a generic manner by identifying the initial offering of the securities to the Holders, in order to ensure that the Holders may be added to such shelf Registration Statement at a later time through the filing of a prospectus supplement rather than a post-effective amendment.

 

The Company may require as a condition precedent to the Company’s obligations under this Section 2.4 that each seller of Registrable Securities as to which any registration is being effected furnish the Company such information in writing regarding such seller and the distribution of such Registrable Securities as the Company from time to time reasonably may request; provided , that such information is necessary for the Company to consummate such registration and shall be used only in connection with such registration.

 

Each seller of Registrable Securities agrees that upon receipt of any notice from the Company under Section 2.4(e)(v), such seller will discontinue such seller’s disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such seller’s receipt of the copies of the supplemented or amended Prospectus. In the event the Company shall give any such notice, the applicable period set forth in Section 2.4(b) shall be extended by the number of days during such period from and including the date of the giving of such notice to and including the date when each seller of any Registrable Securities covered by such Registration Statement shall have received the copies of the supplemented or amended Prospectus.

 

If any such Registration Statement or comparable statement under “blue sky” laws refers to any Holder by name or otherwise as the Holder of any securities of the Company, such Holder shall have the right to require (i) the insertion therein of language, in form and substance reasonably satisfactory to such Holder and the Company, to the effect that the holding by such Holder of such securities is not to be construed as a recommendation by such Holder of the investment quality of the Company’s securities covered thereby and that such holding does not imply that such Holder will assist in meeting any future financial requirements of the Company or (ii) in the event that such reference to such Holder by name or otherwise is not in the judgment of the Company, as advised by counsel, required by the Securities Act or any similar federal statute or any state “blue sky” or securities law then in force, the deletion of the reference to such Holder.

 

Section 2.5          Registration Expenses .

 

(a)            The Company shall pay all Registration Expenses (i) with respect to any Demand Registration whether or not it becomes effective or remains effective for the period contemplated by Section 2.4(b) and (ii) with respect to any registration effected under Section 2.2.

 

(b)            Notwithstanding the foregoing, (i) the provisions of this Section 2.5 shall be deemed amended to the extent necessary to cause these expense provisions to comply with “blue sky” laws of each state in which the offering is made, (ii) in connection with any registration hereunder, each Holder of Registrable Securities being registered shall pay all underwriting discounts and commissions and any transfer taxes, if any, attributable to the sale of such Registrable Securities, pro rata with respect to payments of discounts and commissions in accordance with the number of Registrable Securities sold in the offering by such Holder and (iii) the Company shall, in the case of all registrations under this Article II, be responsible for all its internal expenses.

 

12
 

 

Section 2.6          Underwritten Offerings .

 

(a)            In the case of a registration pursuant to Section 2.2, if the Company shall have determined to enter into an underwriting agreement in connection therewith, any Registrable Securities to be included in such registration shall be subject to such underwriting agreement. Any Holder participating in such registration may, at its option, require that any or all of the representations and warranties by, and the other agreements on the part of, the Company to and for the benefit of such underwriters shall also be made to and for the benefit of such Holder and that any or all of the conditions precedent to the obligations of such underwriters under such underwriting agreement be conditions precedent to the obligations of such Holder. No Holder shall be required to make any representations or warranties to or agreements with the Company or the underwriters other than representations, warranties or agreements regarding such Holder, its ownership of and title to the Registrable Securities and its intended method of distribution; and any liability of such Holder to any underwriter or other Person under such underwriting agreement shall be limited to liability arising from breach of its representations and warranties and shall be limited to an amount equal to the proceeds (net of expenses and underwriting discounts and commissions) that it derives from such registration.

 

(b)            In the case of a registration under Section 2.2, if the Company has determined to enter into an underwriting agreement in connection therewith, all securities to be included in such registration shall be subject to an underwriting agreement and no Person may participate in such registration unless such Person agrees to sell such Person’s securities on the basis provided therein and, subject to the provisions of this Section 2.6, completes and executes all reasonable questionnaires, and other documents, including custody agreements and powers of attorney, that must be executed in connection therewith, and provides such other information to the Company or the underwriter as may be necessary to register such Person’s securities.

 

Section 2.7          Holdback Agreements .

 

(a)            Each seller of Registrable Securities agrees, to the extent requested in writing by a managing underwriter, if any, of any registration effected pursuant to Section 2.2, not to (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for any shares of Common Stock (whether such shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, other than as part of such underwritten public offering during the time period reasonably requested by the managing underwriter, not to exceed 90 days plus such additional period of time as may be required to comply with FINRA Rule 2711 or any similar or successor rules thereto, as such underwriter shall specify reasonably and in good faith.

 

13
 

 

(b)            The Company agrees that, if it shall previously have received a request for registration pursuant to Section  2.2, and if such previous registration shall not have been withdrawn or abandoned, it shall not sell, transfer or otherwise dispose of any Common Stock, or any other equity security of the Company or any security convertible into or exchangeable or exercisable for any equity security of the Company (other than as part of such underwritten public offering, a registration on Form S-4 or Form S-8 or any successor or similar form which is then in effect or upon the conversion, exchange or exercise of any then outstanding Common Stock Equivalent), until a period of 180 days shall have elapsed from the effective date of such previous registration; and the Company shall so provide in any registration rights agreements hereafter entered into with respect to any of its securities.

 

Section 2.8          No Required Sale . Nothing in this Agreement shall be deemed to create an independent obligation on the part of any Holder to sell any Registrable Securities pursuant to any effective registration statement.

 

Section 2.9          Indemnification .

 

(a)            In the event of any registration of any securities of the Company under the Securities Act pursuant to this Article II, the Company will, and hereby agrees to, indemnify and hold harmless, to the fullest extent permitted by law, each Holder of Registrable Securities, its directors, officers, fiduciaries, employees, agents, affiliates, consultants, representatives, general and limited partners, stockholders, successors, assigns (and the directors, officers, employees and stockholders thereof), and each other Person, if any, who controls such Holder within the meaning of the Securities Act, from and against any and all losses, claims, damages or liabilities, joint or several, actions or proceedings (whether commenced or threatened) and expenses (including reasonable fees of counsel and any amounts paid in any settlement effected with the Company’s consent, which consent shall not be unreasonably withheld or delayed) to which each such indemnified party may become subject under the Securities Act or otherwise in respect thereof (collectively, “ Losses ”), insofar as such Losses arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement under which such securities were registered under the Securities Act or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary, final or summary Prospectus or any amendment or supplement thereto, together with the documents incorporated by reference therein, or any Issuer Free Writing Prospectus utilized in connection therewith, or the omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and the Company will reimburse any such indemnified party for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such Loss as such expenses are incurred; provided , however , that the Company shall not be liable (i) to any such indemnified party in any such case to the extent such Loss arises out of or is based upon any untrue statement or alleged untrue statement of a material fact or omission or alleged omission of a material fact made in such Registration Statement or amendment thereof or supplement thereto or in any such prospectus or any preliminary, final or summary Prospectus or Issuer Free Writing Prospectus in reliance upon and in conformity with written information furnished to the Company by or on behalf of such indemnified party specifically for use therein, (ii) for any failure of a Holder to deliver a Prospectus, to the extent that such Holder was required to do so under applicable securities laws, or (iii) for the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective. Such indemnity and reimbursement of expenses shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified party and shall survive the transfer of such securities by such Holder.

 

14
 

 

(b)            Each Holder of Registrable Securities that are included in the securities as to which any registration under Section 2.1 or 2.2 is being effected shall, severally and not jointly, indemnify and hold harmless (in the same manner and to the same extent as set forth in paragraph (a) of this Section 2.9) to the extent permitted by law the Company, its officers and directors, each Person controlling the Company within the meaning of the Securities Act and all other prospective sellers and their respective directors, officers, fiduciaries, employees, agents, affiliates, consultants, representatives, general and limited partners, stockholders, successors, assigns and respective controlling Persons with respect to any untrue statement or alleged untrue statement of any material fact in, or omission or alleged omission of any material fact from, such Registration Statement, any preliminary, final or summary Prospectus contained therein, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus utilized in connection therewith, if such statement or alleged statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company or its representatives by or on behalf of such Holder specifically for use therein and reimburse such indemnified party for any legal or other expenses reasonably incurred in connection with investigating or defending any such Loss as such expenses are incurred; provided , however , that the aggregate amount that any such Holder shall be required to pay pursuant to this Section 2.9(b) and Sections 2.9(c), (e) and (f) shall in no case be greater than the amount of the net proceeds received by such Holder upon the sale of the Registrable Securities pursuant to the Registration Statement giving rise to such claim, except in the case of fraud or willful misconduct by such Holder. Such indemnity and reimbursement of expenses shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified party and shall survive the transfer of such securities by such Holder.

 

15
 

 

(c)            Any Person entitled to indemnification under this Agreement promptly shall notify the indemnifying party in writing of the commencement of any action or proceeding with respect to which a claim for indemnification may be made pursuant to this Section 2.9, but the failure of any such Person to provide such notice shall not relieve the indemnifying party of its obligations under the preceding paragraphs of this Section 2.9, except to the extent the indemnifying party is materially prejudiced thereby and shall not relieve the indemnifying party from any liability that it may have to any such Person otherwise than under this Article II. In case any action or proceeding is brought against an indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, unless in the reasonable opinion of outside counsel to the indemnified party a conflict of interest between such indemnified and indemnifying parties may exist in respect of such claim, to assume the defense thereof jointly with any other indemnifying party similarly notified, to the extent that it chooses, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party that it so chooses, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation; provided , however , that (i) if the indemnifying party fails to take reasonable steps necessary to defend diligently the action or proceeding within 20 days after receiving notice from such indemnified party, (ii) if such indemnified party who is a defendant in any action or proceeding that is also brought against the indemnifying party reasonably shall have concluded that there may be one or more legal defenses available to such indemnified party that are not available to the indemnifying party or (iii) if representation of both parties by the same counsel is otherwise inappropriate under applicable standards of professional conduct, then, in any such case, the indemnified party shall have the right to assume or continue its own defense as set forth above (but with no more than one firm of counsel for all indemnified parties in each jurisdiction, except to the extent any indemnified party or parties reasonably shall have concluded that there may be legal defenses available to such party or parties that are not available to the other indemnified parties or to the extent representation of all indemnified parties by the same counsel is otherwise inappropriate under applicable standards of professional conduct) and the indemnifying party shall be liable for any expenses therefor. Without the written consent of the indemnified party, which consent shall not be unreasonably withheld, no indemnifying party shall effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder, whether or not the indemnified party is an actual or potential party to such action or claim, unless such settlement, compromise or judgment (A) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (B) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.

 

(d)            If for any reason the foregoing indemnity is unavailable or is insufficient to hold harmless an indemnified party under Section 2.9(a), (b) or (c), then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying party, on the one hand, and the indemnified party, on the other hand, with respect to such offering of securities. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. If, however, the allocation provided in the second preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative faults but also the relative benefits of the indemnifying party and the indemnified party as well as any other relevant equitable considerations. The parties hereto agree that it would not be just and equitable if contributions pursuant to this Section 2.9(d) were to be determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the preceding sentences of this Section 2.9(d). The amount paid or payable in respect of any Loss shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such Loss. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. Notwithstanding anything in this Section 2.9(d) to the contrary, no indemnifying party other than the Company shall be required pursuant to this Section 2.9(d) to contribute any amount in excess of the net proceeds received by such indemnifying party from the sale of Registrable Securities in the offering to which the losses, claims, damages or liabilities of the indemnified parties relate, less the amount of any indemnification payment made by such indemnifying party pursuant to Sections 2.9(b) and (c).

 

16
 

 

(e)            The indemnity and contribution agreements contained herein shall be in addition to any other rights to indemnification or contribution which any indemnified party may have pursuant to law or contract and shall remain operative and in full force and effect regardless of any investigation made or omitted by or on behalf of any indemnified party and shall survive the transfer of the Registrable Securities by any such party.

 

(f)             The indemnification and contribution required by this Section 2.9 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or expense, loss, damage or liability is incurred.

 

Article III
GENERAL

 

Section 3.1          Rule 144 . The Company covenants that (a) it will timely file the reports required to be filed by it under the Securities Act or the Exchange Act or, if it is not required to file such reports, upon the request of any Holder it shall make publicly available other information so long as necessary to permit sales of such Registrable Securities in compliance with Rule 144 under the Securities Act and (b) it will take such further action as any Holder of Registrable Securities reasonably may request, all to the extent required from time to time to enable such Holder to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or (ii) any similar rule or regulation hereafter adopted by the SEC. Upon the request of any Holder of Registrable Securities, the Company will deliver to such Holder a written statement as to whether it has complied with such requirements.

 

Section 3.2          Nominees for Beneficial Owners . If Registrable Securities are held by a nominee for the beneficial owner thereof, the beneficial owner thereof may, at its option, be treated as the Holder of such Registrable Securities for purposes of any request or other action by any Holder or Holders of Registrable Securities pursuant to this Agreement or any determination of any number or percentage of shares constituting Registrable Securities held by any Holder or Holders of Registrable Securities contemplated by this Agreement; provided , that the Company shall have received assurances reasonably satisfactory to it of such beneficial ownership.

 

Section 3.3          No Inconsistent Agreements . The rights granted to the Holders of Registrable Securities hereunder do not in any way conflict with and are not inconsistent with any other agreements to which the Company is a party or by which it is bound.

 

17
 

 

Article IV
MISCELLANEOUS

 

Section 4.1          Amendment; Waiver and Termination .

 

(a)            Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by the Company and Holders of a majority of the then outstanding Registrable Securities or, in the case of a waiver, by the party or parties against whom the waiver is to be effective, in an instrument specifically designated as an amendment or waiver hereto; provided , however , that waiver by the Holders shall require the consent of Holders of a majority of the then outstanding Registrable Securities.

 

(b)            No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.

 

(c)            The rights to request registration or inclusion of Registrable Securities in any registration pursuant to the terms of this Agreement shall terminate upon the expiration of the Effectiveness Period.

 

Section 4.2          Notices . All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, or if by facsimile or e-mail, upon written confirmation of receipt sent by the recipient via facsimile, e-mail or otherwise, (b) on the first Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (c) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:

 

(i)          if to any Holder other than the Original Holder, to its last known address appearing on the books of the Company maintained for such purpose, and if to the Original Holder, to:

 

              932 Southwood Boulevard

             Incline Village, NV 89451

             Attention: General Counsel

             Telephone: (775) 832-8500

             Facsimile: (775) 832-8501

 

18
 

 

             with a copy (which shall not constitute notice) to:

 

              Karen E. Bertero

             Gibson Dunn & Crutcher LLP

              333 South Grand Avenue, Los Angeles, CA 90071-3197

              Telephone: (213) 229-7360

             Facsimile: (213) 229-7888

              Email: KBertero@gibsondunn.com

 

(ii)         if to the Company, to:

 

             405 State Highway 121

             Suite B-240

              Lewisville, Texas 75067

              Attention: General Counsel

              Telephone: (972) 943-6050

 

             with a copy (which shall not constitute notice) to:

          

             Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

             One Financial Center, Boston, MA 02111

              Attention: Meryl Epstein

              Telephone: (617) 348-1635

              Facsimile: (617) 542-2241

              E-mail: MJEpstein@mintz.com

 

or such other address as the Company or the Original Holder shall have specified to the other party in writing in accordance with this Section 4.2.

 

Section 4.3          Interpretation . When a reference is made in this Agreement to a Section or Article, such reference shall be to a Section or Article of this Agreement unless otherwise indicated. The headings contained in this Agreement are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. The word “including” and words of similar import when used in this Agreement will mean “including, without limitation,” unless otherwise specified. The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term “or” is not exclusive. The word “will” shall be construed to have the same meaning and effect as the word “shall.” References to days mean calendar days unless otherwise specified.

 

Section 4.4         Entire Agreement . This Agreement, the Warrant and the Credit Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings between the parties with respect to the subject matter hereof and thereof.

 

19
 

 

Section 4.5         No Third-Party Beneficiaries . Except as provided in Section 2.9, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement.

 

Section 4.6          Governing Law . This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of New York.

 

Section 4.7          Submission to Jurisdiction . Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by the other party or its successors or assigns shall be brought and determined in any New York State or federal court sitting in the Borough of Manhattan in The City of New York (or, if such court lacks subject matter jurisdiction, in any appropriate New York State or federal court), and each of the parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in New York, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in New York as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in New York as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

 

Section 4.8         Assignment; Successors . This Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns. If any Person shall acquire Registrable Securities from any Holder in any manner, whether by operation of law or otherwise, such Person shall promptly notify the Company and such Registrable Securities acquired from such Holder shall be held subject to all of the terms of this Agreement, and by taking and holding such Registrable Securities such Person shall be entitled to receive the benefits of and be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement. Any such successor or assign shall agree in writing to acquire and hold the Registrable Securities acquired from such Holder subject to all of the terms hereof. If any Holder shall acquire additional Registrable Securities, such Registrable Securities shall be subject to all of the terms, and entitled to all of the benefits, of this Agreement.

 

20
 

 

Section 4.9         Enforcement . The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any New York State or federal court sitting in the Borough of Manhattan in The City of New York (or, if such court lacks subject matter jurisdiction, in any appropriate New York State or federal court), this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief.

 

Section 4.10        Severability . Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.

 

Section 4.11        Waiver of Jury Trial . EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

Section 4.12        Counterparts . This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties.

 

Section 4.13        Facsimile or .pdf Signature . This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes

 

Section 4.14       Time of Essence . Time is of the essence with regard to all dates and time periods set forth or referred to in this Agreement.

 

Section 4.15       No Presumption Against Drafting Party . Each of the parties hereto acknowledges that it has been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived.

 

[The remainder of this page is intentionally left blank.]

 

21
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.  

       
  CAREVIEW COMMUNICATIONS, INC., a Nevada corporation,
     
  By: /s/ Steven Johnson  
  Name: Steven Johnson
  Title: President and CEO

 

Signature Page to Registration Rights Agreement

 

 
 

 

       
  PDL BIOPHARMA, INC., a Delaware corporation
     
  By: /s/ John P, McLaughlin  
  Name: John P. McLaughlin
  Title:   President and Chief Executive Officer

 

Signature Page to Registration Rights Agreement

 

 

 

 

 

Careview Communications. Inc. 8-K  

  Exhibit 10.07

 

Execution Version

 

THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, DISTRIBUTED, TRANSFERRED OR OTHERWISE DISPOSED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS.

   
Date of Issuance: June 26, 2015 Number of Shares: 4,444,445
  (subject to adjustment)

 

WARRANT TO PURCHASE COMMON STOCK OF  

 

CAREVIEW COMMUNICATIONS, INC.

 

CareView Communications, Inc., a Nevada corporation (the “ Company ”), for value received, hereby certifies that PDL BioPharma, Inc., a Delaware corporation, or its registered assigns (the “ Registered Holder ”), is entitled, subject to the terms set forth herein, to purchase from the Company, at any time after the date hereof and on or before June 26, 2025 (the “ Expiration Date ”), up to Four Million Four Hundred and Forty Four Thousand Four Hundred and Forty Five (4,444,445) shares, as adjusted from time to time pursuant to the provisions of this Warrant, of common stock of the Company, par value $0.001 (“ Common Stock ”), at an exercise price of $0.45 per share. The securities issuable upon exercise of this Warrant and the exercise price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are sometimes hereinafter referred to as the “ Warrant Stock ” and the “ Exercise Price ,” respectively.

 

This Warrant is issued pursuant to that certain Credit Agreement dated as of June 26, 2015 (the “ Credit Agreement ”), by and among the Company, CareView Communications, Inc., a Texas corporation and a wholly-owned subsidiary of the Company, and PDL BioPharma, Inc.

 

1.             EXERCISE OF WARRANT 

 

Section 1.1           Payment . Subject to compliance with the terms and conditions of this Warrant and applicable securities laws, this Warrant may be exercised by the Registered Holder, in whole or in part, at any time or from time to time, on or before the Expiration Date by (a) surrender of this Warrant at the principal office of the Company, or such other office or agency as the Company may designate, together with the form of Notice of Exercise attached hereto as Exhibit A (the “ Notice of Exercise ”) duly executed by the Registered Holder or by such Registered Holder’s duly authorized attorney, and (b) payment in full of the aggregate Exercise Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise (the “ Purchase Price ”), unless the Registered Holder elects a net issue exercise in accordance with Section 1.2. The Purchase Price may be paid by (i) cash, check or wire transfer of immediately available funds to the Company, (ii) cancellation and surrender by the Registered Holder of promissory notes or other instruments representing indebtedness of the Company to the Registered Holder or (iii) a combination of (i) and (ii).

 

 
 

 

Section 1.2           Net Issue Exercise .

 

(a)             In lieu of exercising this Warrant in the manner provided in Section 1.1, the Registered Holder may elect to receive shares of Warrant Stock equal to the value of this Warrant (or the portion thereof being exercised and canceled) by surrender of this Warrant at the principal office of the Company, or such other office or agency as the Company may designate, together with the Notice of Exercise duly executed by the Registered Holder or such Registered Holder’s duly authorized attorney, in which event the Company shall issue to the Registered Holder a number of shares of Warrant Stock computed using the following formula:

   
X = Y (A - B)
  A

 

Where X = The number of shares of Warrant Stock to be issued to the Registered Holder.

 

Y = The number of shares of Warrant Stock being purchased under this Warrant pursuant to the Notice of Exercise (as adjusted to the date of such calculation).

 

A = The Fair Market Value of one share of Warrant Stock (as adjusted to the date of such calculation).

 

B = The Exercise Price (as adjusted to the date of such calculation).

 

All references herein to an “exercise” of the Warrant in this Warrant shall include an exchange pursuant to this Section 1.2.

 

(b)             For purposes of this Warrant, the term “Fair Market Value” of a share of Warrant Stock as of a particular date shall mean:

 

  (i)        If the Common Stock is traded on a securities exchange or Nasdaq, the Fair Market Value shall be deemed to be the average of the closing prices thereof on such exchange or market over the 30 trading days ending immediately prior to (but not including) the applicable date of valuation;

 

   (ii)       If the Common Stock is actively traded over-the-counter, the Fair Market Value shall be deemed to be the average of the closing bid prices over the 30-day period ending immediately prior to (but not including) the applicable date of valuation;

 

2
 

 

  (iii)      If there is no active public market for the Common Stock but there is an active public market for a class or series of capital stock of the Company into which the Common Stock is convertible, then if such class or series of capital stock is:

 

(A)           traded on a securities exchange or Nasdaq, the Fair Market Value shall be deemed to be the average of the closing prices of a share of such class or series of capital stock of the Company on such exchange or market over the five trading days ending immediately prior to (but not including) the applicable date of valuation multiplied by the number of shares of such class or series of capital stock into which one share of the Common Stock is convertible, or

 

(B)           actively traded over-the-counter, the Fair Market Value shall be deemed to be the average of the closing bid prices for a share of such class or series of capital stock of the Company over the 30-day period ending immediately prior to (but not including) the applicable date of valuation multiplied by the number of shares of such class or series of capital stock into which one share of the Common Stock is convertible; or

 

  (iv)          If there is no active public market for the Common Stock or any other class or series of capital stock of the Company into which the Common Stock is convertible, the Fair Market Value shall be the highest price which the Company could obtain on the date of calculation from a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company, from authorized but unissued shares, as reasonably determined in good faith by the Board of Directors.

 

Section 1.3         Effective Time of Exercise . The exercise of this Warrant in whole or in part shall be deemed to have been effected immediately prior to the close of business on the day on which a Notice of Exercise with respect to this Warrant shall have been surrendered to the Company as provided in Section 1.1 or Section 1.2 above, as applicable. The person entitled to receive shares of Warrant Stock issuable upon exercise of this Warrant in whole or in part shall be treated for all purposes as the holder of record of such shares as of the close of business on the date the Registered Holder is deemed to have exercised this Warrant.

 

Section 1.4         Stock Certificates; Fractional Shares; Partial Exercise .

 

(a)          As soon as practicable on or after the date of exercise determined in accordance with Section 1.3, the Company shall issue the number of shares of Warrant Stock to which the Registered Holder is entitled upon the exercise. On or before the first business day following the date of any exercise of this Warrant, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Notice of Exercise to the Registered Holder and the Company’s transfer agent (the “ Transfer Agent ”). On or before the third business day following the date of any exercise of this Warrant, the Company shall (A) provided that the Transfer Agent is participating in The Depository Trust Company (“ DTC ”) Fast Automated Securities Transfer Program, upon the request of the Registered Holder, credit the aggregate number of Warrant Stock to which the Registered Holder is entitled pursuant to such exercise to the Registered Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal At Custodian system, or (B) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver by overnight courier to the address as specified in the Notice of Exercise, a certificate, registered in the Company’s share register in the name of the Registered Holder or its designee, for the number of shares of Warrant Stock to which the Registered Holder is entitled pursuant to such exercise. The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Stock via DTC, if any. Any certificates so delivered shall be in such denominations as may be requested by the Registered Holder and shall be registered in the name of the Registered Holder or such other name as shall be designated by the Registered Holder, as specified in the Notice of Exercise.

 

3
 

 

(b)         No fractional shares or scrip representing fractional shares shall be issued upon an exercise of this Warrant. In lieu of any fraction shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the Fair Market Value of one share of Warrant Stock on the date of exercise determined in accordance with Section 1.3.

 

(c)          In case of any partial exercise of this Warrant, the Company shall cancel this Warrant and shall execute and deliver a new warrant or warrants (dated the date hereof) of like terms and with the same date, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment thereof) to the number of such shares called for on the face of this Warrant minus the number of such shares purchased by the Registered Holder upon such exercise as provided in this Section 1 (without giving effect to any adjustment thereof).

 

2.             ADJUSTMENT OF NUMBER OF SHARES AND EXERCISE PRICE

 

 The number of shares of Warrant Stock issuable upon exercise of this Warrant and the Exercise Price are subject to adjustment as follows:

 

Section 2.1         Adjustment for Stock Splits, Stock Subdivisions or Combinations of Shares . If all or any portion of the outstanding shares of the Common Stock shall be subdivided into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall, simultaneously with the effectiveness of such subdivision, be proportionately reduced. If all or any portion of the outstanding shares of the Common Stock shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Exercise Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (a) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Exercise Price in effect immediately prior to such adjustment, by (b) the Exercise Price in effect immediately after such adjustment.

 

4
 

 

Section 2.2         Adjustment for Dividends or Distributions of Stock or Other Securities or Property . In case the Company shall make or issue, or shall fix a record date for the determination of eligible holders entitled to receive, a dividend or other distribution with respect to all or any portion of the outstanding shares of the Common Stock payable in (a) securities of the Company or (b) assets (excluding cash dividends paid or payable solely out of retained earnings), then, in each such case, the Registered Holder on exercise hereof at any time after the consummation, effective date or record date of such dividend or other distribution, shall receive, in addition to the shares of Warrant Stock issuable on such exercise prior to such date, and without the payment of additional consideration therefor, the securities or such other assets of the Company to which the Registered Holder would have been entitled upon such date if the Registered Holder had exercised this Warrant on the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained such shares and/or all other additional stock available by it as aforesaid during such period giving effect to all adjustments called for by this Section 2.

 

Section 2.3         Reclassification . If the Company, by reclassification of securities or otherwise, shall change the Common Stock into the same or a different number of securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the Common Stock immediately prior to such reclassification or other change and the Exercise Price therefore shall be appropriately adjusted, all subject to further adjustment as provided in this Section 2. No adjustment shall be made pursuant to this Section 2.3 upon any conversion or redemption of Common Stock which is the subject of Section 2.5.

 

Section 2.4         Adjustment for Capital Reorganization, Merger or Consolidation . In case of any capital reorganization of the capital stock of the Company (other than a combination, reclassification, exchange or subdivision of shares otherwise provided for herein), any Acquisition or any other merger or consolidation of the Company with or into another organization, or the sale of all or substantially all the assets of the Company then, and in each such case, as a part of such transaction, lawful provision shall be made so that the Registered Holder shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the applicable Purchase Price, the number of shares of stock or other securities or property of the successor organization resulting from such transaction that a holder of the securities deliverable upon exercise of this Warrant would have been entitled to receive in such transaction if this Warrant had been exercised immediately before such transaction, all subject to further adjustment as provided in this Section 2. The foregoing provisions of this Section 2.4 shall similarly apply to successive acquisitions, reorganizations, consolidations, mergers, sales, transfers and similar transactions and to the stock or securities of any other organizations that are at the time receivable upon the exercise of this Warrant. If the per-share consideration payable to the Registered Holder for shares in connection with any such transaction is in a form other than cash, then the provisions of Section 1.2(b) shall be applied except that each reference to Warrant Stock shall be replaced by the consideration payable in connection with such transaction. If the provisions of Section 1.2(b) cannot be applied to value such consideration, then the value of such consideration shall be determined in good faith by the Company’s Board of Directors. In all events, appropriate adjustment, as determined in good faith by the Company’s Board of Directors, shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Registered Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant.

 

5
 

 

Section 2.5         Conversion of Warrant Stock . In case all or any portion of the outstanding shares of the Common Stock are redeemed or converted into other securities or property pursuant to the Company’s Articles of Incorporation or otherwise, or the Common Stock otherwise ceases to exist, then, in such case, the Registered Holder of this Warrant, upon exercise hereof at any time after the date on which the Common Stock is so redeemed or converted, or ceases to exist (the “ Termination Date ”), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Termination Date, the securities or property that would have been received if this Warrant had been exercised in full and the Warrant Stock received thereupon had been simultaneously converted immediately prior to the Termination Date, all subject to further adjustment as provided in this Warrant. Additionally, the Exercise Price shall be immediately adjusted to equal the quotient obtained by dividing (a) the aggregate Purchase Price of the maximum number of shares of Warrant Stock for which this Warrant was exercisable immediately prior to the Termination Date by (b) the number of shares of Warrant Stock for which this Warrant is exercisable immediately after the Termination Date, all subject to further adjustment as provided herein.

 

Section 2.6         Certificate as to Adjustments . When any adjustment in the Exercise Price or the number or type of shares issuable upon exercise of this Warrant is required to be made pursuant to this Section 2, the Chief Financial Officer or Controller of the Company shall compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth (a) a brief statement of the facts upon which such adjustment is based, (b) the Exercise Price after such adjustment and (c) the kind and amount of stock into which this Warrant shall be exercisable after such adjustment. The Company shall promptly send (by electronic transmission and/or facsimile and by either first class mail, postage prepaid or overnight delivery) a copy of each such certificate to the Registered Holder.

 

6
 

 

3.             TRANSFERS

 

Section 3.1         Unregistered Securities . Each holder of this Warrant acknowledges that this Warrant and the Warrant Stock have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), and agrees not to sell, offer for sale, pledge, hypothecate, distribute, transfer or otherwise dispose of this Warrant or any Warrant Stock issued upon its exercise in the absence of (a) an effective registration statement under the Securities Act as to this Warrant or such Warrant Stock and registration or qualification of this Warrant or such Warrant Stock under any applicable state securities law then in effect, (b) an applicable exemption from such registration requirements of the Securities Act and registration or qualification requirements under any applicable state securities law then in effect or (c) the availability of Rule 144 promulgated under the Securities Act for the sale of such securities. Each certificate or other instrument for Warrant Stock issued upon the exercise of this Warrant pursuant to Section 1.4(a) shall bear a legend as follows, unless issued or sold pursuant to an effective registration statement or if, in the reasonable opinion of securities counsel for the Company, such legend is not necessary:

 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, DISTRIBUTED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.”

 

Section 3.2         Transferability .

 

(a)         This Warrant and all rights and obligations hereunder may be transferred to any person, in whole or in part, on the books of the Company maintained pursuant to Section 3.3 upon surrender of the Warrant with a properly executed form of Assignment attached hereto as Exhibit B (the “ Form of Assignment ”) at the principal office of the Company. Upon the proper surrender by the Registered Holder of the Warrant, the Company will issue and deliver to or upon the order of the Registered Holder a new Warrant or Warrants of like tenor as such Registered Holder may direct, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock called for on the face of the Warrant so surrendered.

 

(b)         Each holder of this Warrant, by holding the same, consents and agrees that when this Warrant shall have been so endorsed, the person in possession of this Warrant may be treated by the Company, and all other persons dealing with this Warrant, as the absolute owner hereof and as the Registered Holder for any purpose and as the person entitled to exercise the rights represented hereby, any notice to the contrary notwithstanding; provided , however that until a transfer of this Warrant is properly made pursuant to the terms of this Warrant and duly registered on the books of the Company maintained pursuant to Section 3.3, the Company may treat the Registered Holder hereof as the owner for all purposes.

 

7
 

 

Section 3.3         Warrant Register . The Company or its agent will maintain a register containing the names and addresses of the Registered Holder of this Warrant, and will promptly update such register to reflect any transfers in compliance with the terms hereof. Until any transfer of this Warrant is reflected in the warrant register maintained pursuant to this Section 3.3, the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes. Any Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change.

 

4 .             REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

 The Company hereby represents and warrants to the Registered Holder as follows:

 

Section 4.1         Authorization; Enforceability . The Company has full corporate power and authority to execute and deliver this Warrant, to perform its obligations hereunder and to consummate the transactions contemplated hereby, including the authorization, issuance and delivery of the Warrant Stock. The execution, delivery and performance by the Company of this Warrant and the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by the Board of Directors of the Company. This Warrant has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law).

 

Section 4.2         Valid Issuance of Securities . The Warrant Stock to be issued hereunder, when issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under this Warrant and applicable state and federal securities laws and liens or encumbrances created by or imposed by the Registered Holder.

 

Section 4.3         Government Consents . No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the issuance of the Warrant or the Warrant Stock by the Company.

 

Section 4.4         No Conflict . The execution and delivery of this Warrant and the performance of the Company’s obligations hereunder, including the issuance of the Warrant Stock, (a) will not result in any violation of the Company’s Articles of Incorporation or Bylaws or (b) be in conflict with or constitute, with or without the passage of time or giving of notice, either or both a material violation or default under any material agreement, instrument, judgment, order, writ, decree or contract or an event which results in the creation of any material lien, charge or encumbrance upon any assets of the Company or cause an acceleration of any obligation under any such material agreement, instrument, judgment, order, writ, decree or contract.

 

8
 

 

5 .             REPRESENTATIONS AND WARRANTIES OF THE REGISTERED HOLDER

 

 The Registered Holder hereby represents and warrants to the Company as follows:

 

Section 5.1         Certain Securities Laws Matters . By acceptance of this Warrant, the Registered Holder hereby confirms that this Warrant is acquired for investment only and not with a view to, or for sale in connection with, any distribution; that the Registered Holder has had such opportunity as such Registered Holder has deemed adequate to obtain from representatives of the Company such information as is necessary to permit the Registered Holder to evaluate the merits and risks of its investment in the Company; that the Registered Holder is able to bear the economic risk of holding the Warrant and/or the Warrant Stock (or any shares of stock or other securities at the time issuable upon exercise of the Warrant) for an indefinite period; that the Registered Holder understands that this Warrant and the Warrant Stock (or any shares of stock or other securities at the time issuable upon exercise of the Warrant) are not and will not be registered under the Securities Act except as set forth in in the Registration Rights Agreement (as defined in Section 6.4 hereof) and will be “restricted securities” within the meaning of Rule 144 under the Securities Act; and that the Registered Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act.

 

6 .             COVENANTS OF THE COMPANY

 

Section 6.1         Reservation and Listing of Securities . The Company hereby covenants that (a) at all times there shall be reserved for issuance and delivery upon exercise of this Warrant such number of shares of Common Stock as may be issuable from time to time upon exercise hereof in full and, from time to time, will take all steps necessary to amend its Articles of Incorporation to provide sufficient reserves of shares of Common Stock, and (b) it will cause the Warrant Stock to be authorized to be listed on a securities exchange or Nasdaq if the Common Stock is listed on such exchange or Nasdaq.

 

Section 6.2         No Impairment . The Company will not, by amendment of its Articles of Incorporation or Bylaws, or through reorganization, consolidation, merger, dissolution, issue or sale of securities, sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Registered Holder against impairment.

 

Section 6.3         Replacement Warrants . Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor.

 

Section 6.4         Registration Rights . All shares of Warrant Stock are subject to that certain Registration Rights Agreement dated as of June 26, 2015 by and between the Company and the Registered Holder (the “ Registration Rights Agreement ”), and the Registered Holder shall be deemed to be a “Holder” pursuant to the Registration Rights Agreement and is entitled, subject to the terms and conditions of the Registration Rights Agreement, to all registration rights granted to Holders thereunder.

 

9
 

 

7 .             NOTICES

 

Section 7.1         Record Dates . In case:

 

(a)          the Company shall set a record date for the holders of the Common Stock for the purpose of entitling or enabling them to receive any dividend or other distribution (excluding cash dividends paid or payable solely out of retained earnings), or to receive any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right;

 

(b)         of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger of the Company with or into another organization (other than a consolidation or merger in which the Company is the surviving entity), or any transfer of all or substantially all of the assets of the Company; or

 

(c)         of the voluntary or involuntary dissolution, liquidation or winding-up of the Company,

 

then, and in each such case, the Company will mail or cause to be mailed to the Registered Holder of this Warrant a notice specifying, as the case may be, (i) the record date for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is to take place, the time, if any is to be fixed, as of which the holders of record of capital stock of the Company (or such other securities at the time deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up) are to be determined, and the material terms and conditions of the impending transaction. In each such case, the notice shall be provided at least 20 business days prior to the record date or effective date for the event specified in such notice, in each case in accordance with the provisions of Section 7.2.

 

Section 7.2         Generally . Unless otherwise provided herein, any notice required or permitted by this Warrant shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or if sent by facsimile, upon written confirmation of receipt of facsimile, or five business days following deposit in the U.S. mail, as certified or registered mail, with postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page, or as subsequently modified by written notice.

 

8 .             MISCELLANEOUS

 

Section 8.1         No Rights or Liabilities as a Stockholder . This Warrant shall not entitle the Registered Holder to any voting rights or other rights as a stockholder of the Company. In the absence of affirmative action by the Registered Holder to purchase Warrant Stock by exercise of this Warrant, no provisions of this Warrant, and no enumeration herein of the rights or privileges of the Registered Holder hereof, shall cause the Registered Holder to be or have any rights of a stockholder of the Company for any purpose.

 

10
 

 

Section 8.2         Survival of Representations and Warranties . Unless otherwise set forth in this Warrant, the warranties, representations and covenants of the Company and the Registered Holder contained in or made pursuant to this Warrant shall survive the execution and delivery of this Warrant.

 

Section 8.3         Amendment and Modification . This Warrant may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.

 

Section 8.4         Waiver . No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. Any agreement on the part of a party hereto to waive any right or power hereunder shall be valid only if set forth in a written instrument executed and delivered by or on behalf of such party. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.

 

Section 8.5         Assignment; Successors and Assigns . This Warrant and any of the rights, interests or obligations under this Warrant may be assigned, in whole or in part, by operation of law or otherwise, by the Registered Holder. This Warrant will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.

 

Section 8.6         Interpretation . When a reference is made in this Warrant to a Section or Exhibit such reference shall be to a Section or Exhibit of this Warrant unless otherwise indicated. The headings contained in this Warrant or in any Exhibit are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Warrant. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Exhibit but not otherwise defined therein shall have the meaning as defined in this Warrant. All Exhibits annexed hereto or referred to herein are hereby incorporated in and made a part of this Warrant as if set forth herein. The word “including” and words of similar import when used in this Agreement will mean “including, without limitation,” unless otherwise specified.

 

Section 8.7         Governing Law . This Warrant and all disputes or controversies arising out of or relating to this Warrant or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of New York.

 

11
 

 

Section 8.8         Severability . Whenever possible, each provision or portion of any provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision or portion of any provision of this Warrant is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Warrant shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.

 

Section 8.9         Counterparts . This Warrant may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties.

 

[The remainder of this page is intentionally left blank.]

 

12
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Warrant as of June 26, 2015. 

     
  CAREVIEW COMMUNICATIONS, INC.
   
  /s/ Steven Johnson
  Name: Steven Johnson
  Title:   CEO

 

Signature Page to Warrant to Purchase Commomn Stock of CareView Communications, Inc.

 

 
 

 

Acknowledged and Agreed:

   
REGISTERED HOLDER :
 
PDL BIOPHARMA, INC.
 
By: /s/ John P. McLaughlin
Name: John P. McLaughlin
Title:   President and Chief Executive Officer

 

Signature Page to Warrant to Purchase Commomn Stock of CareView Communications, Inc.

 

 
 

  

EXHIBIT A

 

NOTICE OF EXERCISE

 

WARRANT TO PURCHASE COMMON STOCK OF CAREVIEW COMMUNICATIONS, INC.

 

The undersigned hereby irrevocably elects to exercise the right of purchase represented by the Warrant of CareView Communications, Inc. dated June 26, 2015 for, and to purchase thereunder, such number of shares of Warrant Stock (or such other securities or property for which this Warrant may then be exercised) indicated below of CareView Communications, Inc. as provided for therein, and (check the applicable box(es)):

 

Tenders herewith payment of the Purchase Price in the form of cash or a certified or official bank check in same-day funds (or has initiated a wire) in the amount of $____________ for _________ shares of Warrant Stock.

 

Tenders herewith payment of the Purchase Price in the form of the surrender and cancellation of indebtedness of the Company held by the Registered Holder in the amount of $____________ (the “ Indebtedness ”) for _________ shares of Warrant Stock. The Indebtedness represents a portion of the indebtedness outstanding under the Credit Agreement (as such term is defined in the Warrant).

 

Elects a Net Issue Exercise pursuant to Section 1.2, and accordingly requests delivery of a net of _________ shares of Warrant Stock, calculated as follows:
         
X =   Y (A-B)   (        ) =  (        ) [(        ) – (         )]
  A                 (_____)

 

X = the number of shares of Warrant Stock to be issued to the Registered Holder.
Y = the number of shares of Warrant Stock purchasable under the portion of the Warrant being exchanged (as adjusted to the date of such calculation).
A = the Fair Market Value of one share of Warrant Stock
B = Purchase Price (as adjusted to the date of such calculation)

 

Please issue such shares of Warrant Stock in the name of and pay any cash for any fractional share to (please print name, address and taxpayer i.d. number): 

   
Name:  
   
Address:  
   
Tax. I.D.:  
   
Signature:  

 

Notice of Exercise

 

 
 

 

Note: The above signature must correspond to the name as written upon the face of the Warrant in every particular, without alteration or any change whatsoever. If said number of Warrant Shares shall not be all of the Warrant Shares purchasable under the Warrant, a new Warrant is to be issued in the name of said undersigned for the balance remaining of the Warrant Shares purchasable thereunder.

 

Notice of Exercise

 

 
 

 

EXHIBIT B

 

ASSIGNMENT

 

WARRANT TO PURCHASE COMMON STOCK OF CAREVIEW COMMUNICATIONS, INC.

 

For value received, the undersigned hereby sells, assigns and transfers unto ________________________ the within Warrant, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint _________________________ attorney, to transfer said Warrant on the books of CareView Communications, Inc. with respect to the number of shares of Warrant Stock set forth below, with full power of substitution in the premises:

 

Name(s) of Assignee(s) Address # of Shares of Warrant Stock
     
     
     
     
     

 

And if said number of shares of Warrant Stock shall not be all the number of shares of Warrant Stock represented by the Warrant, a new Warrant is to be issued in the name of said undersigned for the balance remaining of the Warrants registered by said Warrant.

   
Dated:  
   
Signature:  

 

Note: The signature to the foregoing Assignment must correspond to the name as written upon the face of the Warrant in every particular, without alteration or any change whatsoever.

 

Form of Assignment

 

 

 

 

Careview Communications, Inc. 8-K

 

 

Exhibit 10.08

 

Execution Copy

 

SEVENTH AMENDMENT TO
NOTE AND WARRANT PURCHASE AGREEMENT

 

This SEVENTH AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT , dated as of June 26, 2015 (this “ Amendment ”), is made by and among CAREVIEW COMMUNICATIONS, INC. , a Nevada corporation (the “ Company ”), and the undersigned Majority Investors (as defined below).

 

WITNESSETH:

 

WHEREAS , the Company, HealthCor Partners Fund, L.P. (“ HealthCor Partners ”), HealthCor Hybrid Offshore Master Fund, L.P. (“ HealthCor Hybrid ” and, together with HealthCor Partners, the “ HealthCor Parties ”), and certain additional investors (collectively with the HealthCor Parties, the “ Investors ”) are party to that certain Note and Warrant Purchase Agreement, dated as of April 21, 2011 (as amended from time to time, including without limitation pursuant to that certain Note and Warrant Amendment Agreement dated December 30, 2011, that certain Second Amendment to Note and Warrant Purchase Agreement dated January 31, 2012, that certain Third Amendment to Note and Warrant Purchase Agreement dated August 20, 2013, that certain Fourth Amendment to Note and Warrant Purchase Agreement dated January 16, 2014, that certain Fifth Amendment to Note and Warrant Purchase Agreement dated December 15, 2014, and that certain Sixth Amendment to Note and Warrant Purchase Agreement dated March 31, 2015, the “ Purchase Agreement ”); and

 

WHEREAS , the HealthCor Parties are the record and beneficial owners of Notes and Warrants representing a majority of the shares of Common Stock issued or issuable (on an as converted basis) upon conversion of all Notes and Warrants held by any Investor (in such capacity, the “ Majority Investors ”), and Section 7.9 of the Purchase Agreement provides that amendments to the Purchase Agreement may be made pursuant to a written instrument executed by the Company and the Majority Investors;

 

WHEREAS , the Company intends to enter into (i) that certain Credit Agreement, dated on or about the date hereof, among the Company, CareView Communications, Inc., a Texas corporation and a wholly-owned subsidiary of the Company, as the borrower (“ CareView TX ”), PDL BioPharma, Inc., a Delaware corporation, as the lender (“ PDL ”), and PDL, not individually, but as the agent (the “ PDL Credit Agreement ”) and (ii) that certain Guarantee and Collateral Agreement dated on or about the date hereof by and among the Company, CareView TX and certain subsidiary guarantors party thereto, as grantors, in favor of PDL, as collateral agent (the “ PDL Collateral Agreement ”);

 

WHEREAS , in connection with the PDL Credit Agreement, the Company intends to issue to PDL a warrant to purchase up to 4,444,445 shares of Common Stock, as adjusted from time to time pursuant to the terms of such warrant, at an exercise price of $0.45 per share (as may be amended, restated, supplemented or otherwise modified from time to time, the “ PDL Warrant ”);

 

 
 

 

WHEREAS , pursuant to Section 7.9 of the Purchase Agreement and subject to the terms and conditions contained herein, the parties hereto desire to amend the Purchase Agreement as set forth herein for the purposes of, among other things, permitting the Company and its subsidiaries to enter into the PDL Credit Agreement, the PDL Collateral Agreement and the transactions contemplated thereby.

 

NOW, THEREFORE , in consideration of the mutual promises, representations, warranties and covenants contained herein and in the Purchase Agreement, which represent integral components of the transactions contemplated hereby and thereby and shall be fully enforceable by the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors mutually agree as follows:

 

1.             Definitions . Capitalized terms used in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Purchase Agreement.

 

2.             Amendments to Purchase Agreement .

 

a.               Section 6.4 ( Investments ) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.4             Investments and Acquisitions . Other than Permitted Investments, the Company shall not invest in, acquire any interest in (including the acquisition of assets out of the ordinary course of business), or otherwise divert any of the funds of the Company to, any Person, provided that the Company may make investments permitted by Sections 7.10(e) , (f) , (g) , (h) , (i) or (j) of the PDL Credit Agreement.

 

b.              Section 6.8 ( Guarantees and Loans ) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.8           Guarantees and Loans . The Company shall not guarantee or endorse any obligation of, or make any advance or loan to, any Person, or assume any contingent liability of any Person; provided that the Company may guarantee the obligations of any of its Subsidiaries arising under the PDL Credit Agreement as contemplated by the PDL Collateral Agreement.

 

c.               Section 6.9 ( Related Party Transactions ) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.9             Related Party Transactions . The Company shall not enter into, or commit directly or indirectly to, any transaction, agreement or arrangement with any Affiliate of the Company or with any manager, member, shareholder, officer, director or employee of the Company or any Affiliate of the Company unless such transaction, agreement or arrangement is consummated on arms-length terms and is approved by the Company’s Board of Directors; provided that the Company may enter into, without the foregoing limitations, any transactions, agreements or arrangements with any Affiliate of the Company or with any manager, member, shareholder, officer, director or employee of the Company or any Affiliate of the Company that are otherwise permitted by (i) Section 6.4 or Section 6.10 of this Agreement or (ii) Section 7.7(c) of the PDL Credit Agreement.

 

- 2 -
 

 

d.               Section 6.10 ( Distributions; Redemptions ) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.10           Distributions; Redemptions . The Company shall not directly or indirectly (a) declare or pay any dividend or distribution to any equityholder of the Company, provided that the Company may declare or pay any dividend or distribution permitted under Sections 7.3(c) or (d) of the PDL Credit Agreement; or (b) redeem, purchase, retire or otherwise extinguish any shares of the Company’s capital stock or securities convertible into shares of the Company’s capital stock (except as required by any of the Transaction Documents), provided that the Company may repurchase outstanding shares of its capital stock pursuant to a stock repurchase program approved by the Board of Directors, including the Investor Designee, and provided , further , each such repurchase is in compliance with the Company’s covenants under the PDL Credit Agreement and any other Indebtedness.

 

e.              The first paragraph of Section 6.12 ( Equity Issuance ) of the Purchase Agreement is hereby amended by inserting, immediately prior to the period (.) therein, a semi-colon (;) followed by the following proviso:

 

and provided , further that the Company shall be permitted to issue, without requiring any such consent, (i) the PDL Warrant and (ii) the shares of Common Stock issuable upon exercise of the PDL Warrant

 

f.                Section 6.13 ( Sale of Assets ) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

6.13           Sale of Assets . The Company shall not sell, lease or otherwise transfer any assets used or held for use in the Company’s business outside of the ordinary course of business, provided that the Company may effect any sale, lease or other transfer of assets permitted under Section 7.4 of the PDL Credit Agreement.

 

g.               Clause (b) of the definition of “Permitted Encumbrances” in Section 7.1(j) of the Purchase Agreement is hereby replaced in its entirety with the following:

 

(j)             “ Permitted Encumbrances ” means (a) Liens in favor of and for the benefit of the Investors; (b) Liens in favor of and for the benefit of PDL BioPharma, Inc., as agent under the PDL Collateral Agreement; (c) Liens permitted under Sections 7.2(d) , (g) , (i) , (k) , (l) , (m) or (n) of the PDL Credit Agreement; (d) non-exclusive licenses of the Company’s or its Subsidiaries’ intellectual property granted to hospitals in the ordinary course of the Company’s or its Subsidiaries’ business pursuant to the Company’s or its Subsidiaries’ hospital contracts; (e) non-exclusive licenses of the Company’s or its Subsidiaries’ intellectual property granted to Subsidiaries of the Company in connection with existing joint venture transactions and future joint venture transactions entered into by the Company or its Subsidiaries to the extent involving new hospitals, new businesses or international markets; (f) Liens in favor and for the benefit of joint venture partners arising from joint venture transactions entered into by the Company or its Subsidiaries to the extent involving new hospitals, new businesses or international markets; (g) Liens for Charges not delinquent or being contested in good faith and by appropriate proceedings and with respect to which proper reserves have been established by the Company on its financial statements in accordance with GAAP; (h) deposits or pledges to secure obligations under workers’ compensation, social security or similar laws, or with respect to unemployment insurance; (i) bonded and statutory Liens of landlords, mechanics, workers, materialmens or other like Liens arising in the ordinary course of the business with respect to obligations which are not delinquent; (j) Liens placed upon tangible assets hereafter acquired to secure payment of the purchase price thereof, provided that any such Lien shall not encumber any other property of the Company or its Subsidiaries; and (k) zoning restrictions and easements, licenses, covenants and other restrictions that do not individually, or in the aggregate, materially and adversely affect the use of the Company’s or its Subsidiaries’ owned, leased or licensed real property for its intended purpose in connection with the business.

 

- 3 -
 

 

h.              The definition of “Permitted Indebtedness” in Section 7.1(k) of the Purchase Agreement is hereby replaced in its entirety with the following:

 

(k)            “ Permitted Indebtedness ” shall mean (i) the indebtedness arising under the PDL Credit Agreement, in an amount not to exceed the “First Lien Cap Amount” as such term is defined in the PDL Subordination Agreement, (ii) any indebtedness permitted under Sections 7.1(d) , (e) , (g) , (h) , (j) or (k) of the PDL Credit Agreement and (iii) purchase money indebtedness (including, but not limited to, mortgages, credit card indebtedness and automobile loans) of the Company or its Subsidiaries or Capital Lease Obligations not to exceed the amount of $2,000,000.00 in the aggregate.

 

i.                Section 7.1 ( Definitions ) is hereby amended to add the following paragraphs thereto:

 

(o)            “ PDL ” means PDL BioPharma, Inc., a Delaware corporation, together with its permitted successors and assignees.

 

(p)            “ PDL Collateral Agreement ” means that certain Guarantee and Collateral Agreement dated on or about June 26, 2015 by and among the Company, CareView Communications, Inc., a Texas corporation and a wholly owned subsidiary of the Company (“ CareView Texas ”) and certain subsidiary guarantors party thereto, as grantors, in favor of PDL, as collateral agent, and its permitted successors and assignees, as amended, modified, supplemented or restated from time to time.

 

(q)            “ PDL Credit Agreement ” means that certain Credit Agreement, dated on or about June 26, 2015, by and among the Company, CareView Texas, as the borrower, PDL, as the lender, and PDL, not individually, but as the agent, as amended, modified, supplemented or restated from time to time.

 

- 4 -
 

 

  (r)             “ PDL Subordination Agreement ” means that certain Subordination and Intercreditor Agreement, dated on or about June 26, 2015, by and among PDL, as agent for the first lien claimholders described therein, and each of the Investors, as initial second lien claimholders therein, as amended, modified, supplemented or restated from time to time.

 

3.               Section 7.1 ( Definitions ) is hereby amended by deleting in its entirety the defined term “ Revolving Debt Facility ”.

 

4.               No Further Amendments . Except as amended by this Amendment, the Purchase Agreement shall remain in full force and effect in accordance with its terms.

 

5.               Miscellaneous .

 

a.               Ratification and Confirmation . The Company acknowledges, agrees and confirms that: (x) the Purchase Agreement and each of the other Transaction Documents, as amended and otherwise modified by the amendments and other modifications specifically provided herein or contemplated hereby, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed; and (y) without limiting the generality of the foregoing clause (x), all obligations, liabilities and Indebtedness of the Company under the Transaction Documents, as amended hereby, constitute “Obligations” (as defined in the Security Agreement) secured by and entitled to the benefits of the security set forth in the Security Agreement and the IP Security Agreement, and the liens and security interests granted in favor of the Investors under the terms of the Security Agreement and the IP Security Agreement are and remain perfected, effective, enforceable and valid and such liens and security interests are hereby in all respects ratified and confirmed, it being understood that such liens and security interests granted in favor of the Investors are subject to the PDL Subordination Agreement to the extent described therein.

 

b.               Expenses . The Company will pay and bear full responsibility for the reasonable legal fees and other out-of-pocket costs and expenses of the Investors attributable to the negotiation and consummation of the transactions contemplated hereby.

 

c.              Further Assurances . The Company shall duly execute and deliver, or cause to be duly executed and delivered, at its own cost and expense, such further instruments and documents and to take all such action, in each case as may be necessary or proper in the reasonable judgment of the Investors to carry out the provisions and purposes of this Amendment.

 

d.               Survival . The representations, warranties, covenants and agreements made herein shall survive any investigation made by any party hereto, the execution and delivery of this Amendment and the closing of the transactions contemplated hereby.

 

e.               Governing Law . All questions concerning the construction, interpretation and validity of this Amendment shall be governed by and construed and enforced in accordance with the domestic laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether in the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. In furtherance of the foregoing, the internal law of the State of Delaware will control the interpretation and construction of this Amendment, even if under such jurisdiction’s choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply.

 

- 5 -
 

 

f.               Construction . The Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent counsel have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect that drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

g.              Counterparts; Facsimile and Electronic Signatures . This Amendment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Counterpart signatures to this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

h.              Headings . The section and paragraph headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Amendment.

 

[ Signature Pages Follow ]

 

- 6 -
 

 

IN WITNESS WHEREOF , each of the undersigned has duly executed this Seventh Amendment to Note and Warrant Purchase Agreement as of the date first written above. 

       
  COMPANY:  
       
  CareView Communications, Inc., A Nevada corporation
       
  By:     /s/ Steven G. Johnson  
    Name: Steven G. Johnson  
    Title:   President  
     
  MAJORITY INVESTORS:  
     
  HealthCor Partners Fund, L.P.  
  By: HealthCor Partners Management L.P., as Manager  
  By: HealthCor Partners Management, G.P., LLC, as General Partner  

         
  By:     /s/ Jeffrey C. Lightcap  
  Name: Jeffrey C. Lightcap  
  Title: Senior Managing Director  
       
  Address: HealthCor Partners  
    Carnegie Hall Towers  
    152 West 57th Street  
    New York, NY 10019  

         
  HealthCor Hybrid Offshore Master Fund, L.P.
  By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
       
  By:     /s/ Joseph P. Healey  
  Name: Joseph P. Healey  
  Title: Co-CEO  
       
  Address: HealthCor Partners  
    Carnegie Hall Towers  
    152 West 57th Street  
    New York, NY 10019  

 

 
 

 

ACKNOWLEDGED AND AGREED :

 

CareView Communications, Inc., a Texas corporation 

       
By:   /s/ Steven G. Johnson  
    Name: Steven G. Johnson  
    Title:   President  

       
By:   /s/ Steven G. Johnson  
    Name: Steven G. Johnson  
    Title:   President  

 

 

C

 

Careview Communication, Inc. 8-K

Exhibit 10.09

 

AMENDMENT TO  

REGISTRATION RIGHTS AGREEMENT

 

This AMENDMENT TO REGISTRATION RIGHTS AGREEMENT , dated as of June 26, 2015 (this “ Amendment ”), is made by and among CAREVIEW COMMUNICATIONS, INC. , a Nevada corporation (the “ Company ”), and the undersigned investors (together with their respective successors and permitted assigns, the “ Investors ”).

 

WITNESSETH:

 

WHEREAS , the Company, HealthCor Partners Fund, L.P. (“ HealthCor Partners ”), HealthCor Hybrid Offshore Master Fund, L.P. (“ HealthCor Hybrid ” and, together with HealthCor Partners, the “ HealthCor Parties ”), and certain additional investors are party to that certain Registration Rights Agreement, dated as of April 21, 2011 (as amended from time to time, the “ Registration Rights Agreement ”); and

 

WHEREAS , the Company and PDL BioPharma, Inc., a Delaware corporation, are entering into on the date hereof that certain Registration Rights Agreement, dated as of the date hereof (as amended from time to time, the “ PDL Registration Rights Agreement ”); and

 

WHEREAS , pursuant to Section 11(c) of the Registration Rights Agreement and subject to the terms and conditions contained herein, the Investors constitute the Holders of not less than a majority of the then outstanding Registrable Securities and the Investors and the Company desire to amend the Registration Rights Agreement as set forth herein for the purposes of, among other things, ensuring that the underwriter cut back provisions in the Registration Rights Agreement are consistent with the underwriter cut back provisions in the PDL Registration Rights Agreement.

 

NOW, THEREFORE , in consideration of the mutual promises, representations, warranties and covenants contained herein and in the Registration Rights Agreement, which represent integral components of the transactions contemplated hereby and thereby and shall be fully enforceable by the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors mutually agree as follows:

 

1.            Definitions .  Capitalized terms used in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Registration Rights Agreement.

 

 
 

 

2.            Amendments to Registration Rights Agreement .

 

a.           Section 4(b) of the Registration Rights Agreement is hereby amended and restated in its entirety to read as follows:

 

(b)  In the event of an Underwriting Request, the Company, together with all Holders proposing to distribute their securities through such underwriting (the “Participating Stockholders”), shall enter into an underwriting agreement in customary form with the managing underwriter(s) selected for such underwriting by the Requesting Stockholders, which underwriter(s) shall be reasonably acceptable to the Company; provided, however, that no Holder shall be required to make any representations or warranties concerning the Company or its business, properties, prospects, financial condition or related matters.  Notwithstanding any other provision of this Section 4, if the managing underwriter(s) advises the Company and the Participating Stockholders in writing that because the number of shares requested by the Participating Stockholders to be included in the registration exceeds the number which can be sold in an orderly manner in such offering within a price range acceptable to the Requesting Stockholders or that marketing factors require a limitation of the number of shares to be underwritten on behalf of the Participating Stockholders (the “Underwritten Registration Cutback”), and such Underwritten Registration Cutback results in less than all of the Registrable Securities of the Participating Stockholders that are requested to be included in such registration to actually be included in such registration, then the Company will include in such registration, to the extent of the number which the Company is so advised can be sold in (or during the time of) such offering without such interference or affect on the price or sale: (i) if the PDL Holders have not exercised their right to request inclusion in such registration statement pursuant to the PDL Registration Rights Agreement, such number of Registrable Securities shared pro rata among all of the Participating Stockholders based on the total number of Registrable Securities held by each such Participating Stockholder, or (ii) if the PDL Holders have exercised their right to request inclusion in such registration statement pursuant to the PDL Registration Rights Agreement, the aggregate of such number of (x) Registrable Securities and (y) PDL Registrable Securities proposed to be included in such registration by the PDL Holders shared pro rata among all of the Participating Stockholders and such PDL Holders based on the number of Registrable Securities and PDL Registrable Securities being requested for inclusion, respectively, by each such Participating Holder and PDL Holder.  For the avoidance of doubt, the Company shall not sell shares in any underwritten offering in connection with a Registration Statement filed pursuant to Section 2 in the event of an Underwritten Registration Cutback.  “PDL Holders” shall mean those holders of the Company’s securities party to that certain registration rights agreement dated June 26, 2015 by and between the Company and PDL BioPharma, Inc., a Delaware corporation, as amended, supplemented or modified from time to time (the “PDL Registration Rights Agreement”).  “PDL Registrable Securities” shall have the same meaning as “Registrable Securities” as defined in the PDL Registration Rights Agreement.

 

- 2 -
 

 

b.           Section 8 of the Registration Rights Agreement is hereby amended and restated in its entirety to read as follows:

 

8.   Piggy-Back Registrations .  If at any time during the Effectiveness Period, the Company shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the each Holder written notice of such determination and if, within fifteen (15) days after receipt of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered.  Notwithstanding the foregoing, if the Company’s proposed registration of equity securities hereunder is, in whole or in part, an underwritten public offering, and the managing underwriter of such proposed registration determines and advises in writing that the inclusion of all Registrable Securities proposed to be included in the underwritten public offering, together with any other issued and outstanding shares of the Company’s common stock proposed to be included therein (such other shares hereinafter collectively referred to as the “Other Shares”), would interfere with the successful marketing of the Company’s securities, then the total number of such securities proposed to be included in such underwritten public offering shall be reduced, (i) first by the shares requested to be included in such registration by the holders of Other Shares (excluding the shares requested for inclusion by the PDL Holders), and (ii) second, if necessary, (A) one-half (½) by the securities proposed to be issued by the Company, and (B) one-half (½) by the aggregate of (x) the Registrable Securities proposed to be included in such registration by the Holders and (y) the PDL Registrable Securities proposed to be included in such registration by the PDL Holders, on a pro rata basis, based upon the number of Registrable Securities and PDL Registrable Securities being requested for inclusion, respectively by each such Holder and PDL Holder. The shares of the Company’s common stock held by the Holders that are excluded from the underwritten public offering pursuant to the preceding sentence shall be withheld from the market by the holders thereof for a period, not to exceed 90 days from the closing of such underwritten public offering plus such additional period of time as may be required to comply with Rule 2711 of the Financial Industry Regulatory Authority, Inc. or any similar or successor rules thereto, that the managing underwriter reasonably determines as necessary in order to effect such underwritten public offering.  Notwithstanding anything to the contrary contained herein, the amount of Registrable Securities required to be included in the initial Registration Statement as described in this Section 8 shall not exceed the lesser of (a) the amount of Registrable Securities that Holders request to have so registered pursuant to this Section 8 and (b) the maximum amount of Registrable Securities which may be included in a Registration Statement without exceeding the Rule 415 Amount.

 

3.            No Further Amendments .  Except as amended by this Amendment, the Registration Rights Agreement shall remain in full force and effect in accordance with its terms.

 

- 3 -
 

 

4.            Miscellaneous .

 

a.            Governing Law .  This Amendment shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, without giving effect to principles of conflicts of law or choice of law that would cause the laws of any other jurisdiction to apply.

 

b.            Construction .  The Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent counsel have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect that drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

c.            Counterparts; Facsimile and Electronic Signatures .  This Amendment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.  Counterpart signatures to this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

d.            Headings .  The section and paragraph headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Amendment.

 

[ Signature Pages Follow ]

 

- 4 -
 

 

IN WITNESS WHEREOF , the parties hereto have executed this Amendment to Registration Rights Agreement as of the date and year first set forth above.

 

  CAREVIEW COMMUNICATIONS, INC.
   
   By: /s/ Steven Johnson
    Name: Steven G. Johnson
Title:   President

 

[SIGNATURE PAGE TO AMENDMENT TO REGISTRATION RIGHTS AGREEMENT]

 

 
 

 

  INVESTORS:
   
  HEALTHCOR PARTNERS FUND, L.P.
   
  By: HealthCor Partners Management L.P., as Manager
   
  By: HealthCor Partners Management, G.P., LLC, as General Partner
   
  By: /s/ J. C. Lightcap
  Name: Jeffrey C. Lightcap
Title: Senior Managing Director

 

  HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.
   
  By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
   
   By: /s/ Joseph P. Healey
Name: Joseph P. Healey
Title:   Co-CEO

 

[SIGNATURE PAGE TO AMENDMENT TO REGISTRATION RIGHTS AGREEMENT]

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.10

 

HEALTHCOR PARTNERS FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued April 21, 2011)

 

June 26, 2015

 

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated April 21, 2011 (the “ Note ”), issued in the original principal amount of $9,316,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Partners Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.                Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.                Amendment to Maturity Date . The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

 

The “ Maturity Date ” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “ Maturity Date ” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

 

3.                Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 
 

 

 

4.                Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

5.                Defined Terms . Section 23 of the Note shall be amended to add the following at the end thereof:

 

(u) “ PDL Credit Agreement ” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

 

(v) “ Tranche Two Funding Date, ” “ Tranche Two Loan ” and “ Tranche Two Maturity Date ” shall each have the meanings given to such term under the PDL Credit Agreement.

 

6.                No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

 [ Signature Pages Follow ]

 
 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR PARTNERS FUND, L.P.

By:   HealthCor Partners Management L.P., as Manager  
By:   HealthCor Partners Management, G.P., LLC, as General Partner  
       
       
By:   /s/ Jeffrey Lightcap  
Name:   Jeffrey Lightcap  
Title:   Senior Managing Director  

 

 

   

 

Careview Communications, Inc, 8-K

 

Exhibit 10.11

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued April 21, 2011)

 

June 26, 2015

 

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated April 21, 2011 (the “ Note ”), issued in the original principal amount of $10,684,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.                 Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.                 Amendment to Maturity Date . The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

 

The “ Maturity Date ” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “ Maturity Date ” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

 

3.                 Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 
 

 

 

4.                 Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

5.                 Defined Terms . Section 23 of the Note shall be amended to add the following at the end thereof:

 

(u) “ PDL Credit Agreement ” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

 

(v) “ Tranche Two Funding Date, ” “ Tranche Two Loan ” and “ Tranche Two Maturity Date ” shall each have the meanings given to such term under the PDL Credit Agreement.

 

6.                 No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

 

 

[ Signature Pages Follow ]

 
 

  IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:   HealthCor Hybrid Offshore G.P., LLC, as General Partner  
       
       
By:   /s/ Joseph P. Healey  
Name:   Joseph P. Healey  
Title:   Co-CEO  

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.12

 

HEALTHCOR PARTNERS FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 31, 2012)

 

June 26, 2015

 

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated January 31, 2012 (the “ Note ”), issued in the original principal amount of $2,329,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Partners Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.               Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.               Amendment to Maturity Date . The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

 

The “ Maturity Date ” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “ Maturity Date ” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

 

3.               Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 

 
 

 

 

4.               Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

5.               Defined Terms . Section 23 of the Note shall be amended to add the following at the end thereof:

 

(u) “ PDL Credit Agreement ” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

 

(v) “ Tranche Two Funding Date, ” “ Tranche Two Loan ” and “ Tranche Two Maturity Date ” shall each have the meanings given to such term under the PDL Credit Agreement.

 

6.               No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

 

[ Signature Pages Follow ]

 

 
 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

   

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR PARTNERS FUND, L.P.

By:   HealthCor Partners Management L.P., as Manager  
By:   HealthCor Partners Management, G.P., LLC, as General Partner  
       
       
By:   /s/ Jeffrey Lightcap  
Name:   Jeffrey Lightcap  
Title:   Senior Managing Director  

 

 

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.13

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 31, 2012)

 

June 26, 2015

 

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated January 31, 2012 (the “ Note ”), issued in the original principal amount of $2,671,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.               Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.               Amendment to Maturity Date . The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

 

The “ Maturity Date ” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “ Maturity Date ” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

 

3.               Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 

 
 

 

 

4.               Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

5.               Defined Terms . Section 23 of the Note shall be amended to add the following at the end thereof:

 

(u) “ PDL Credit Agreement ” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

 

(v) “ Tranche Two Funding Date, ” “ Tranche Two Loan ” and “ Tranche Two Maturity Date ” shall each have the meanings given to such term under the PDL Credit Agreement.

 

6.               No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

[ Signature Pages Follow ]

 
 

 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:   HealthCor Hybrid Offshore G.P., LLC, as General Partner  
       
       
By:   /s/ Joseph P. Healey  
Name:   Joseph P. Healey  
Title:   Co-CEO  

 

 

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.14

 

HEALTHCOR PARTNERS FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 16, 2014)

 

June 26, 2015

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated January 16, 2014 (the “ Note ”), issued in the original principal amount of $2,329,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Partners Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.                Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.                Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 

3.                Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

 

 
 

 

4.                   No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

 

 

 

 

[ Signature Pages Follow ]

 
 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR PARTNERS FUND, L.P.

By:   HealthCor Partners Management L.P., as Manager  
By:   HealthCor Partners Management, G.P., LLC, as General Partner  
       
       
By:   /s/ Jeffrey Lightcap  
Name:   Jeffrey Lightcap  
Title:   Senior Managing Director  

 

 

 

 

 

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.15

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 16, 2014)

 

June 26, 2015

 

This Allonge No. 1 to Senior Secured Convertible Note (this “ Allonge ”) shall be affixed to that certain Senior Secured Convertible Note dated January 16, 2014 (the “ Note ”), issued in the original principal amount of $2,671,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “ Holder ”), and shall become a permanent part thereof and shall amend the Note as provided therein.

 

1.                Amendment to Legend . The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.                Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 

3.                Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

 
 

 

4.                No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 

 

 

[ Signature Page Follows ]

 

 
 

 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

HOLDER :

 

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:   HealthCor Hybrid Offshore G.P., LLC, as General Partner  
       
       
By:   /s/ Joseph P. Healey  
Name:   Joseph P. Healey  
Title:   Co-CEO  

 

 

 

 

Careview Communications, Inc, 8-K

 

Exhibit 10.16

 

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTES

(issued February 17, 2015)

 

June 26, 2015

 

 

This Allonge No. 1 to Senior Secured Convertible Notes (this “ Allonge ”) shall be affixed to each of those certain Senior Secured Convertible Notes dated February 17, 2015 (the “ Notes ” and each, a “ Note ”), issued in the original aggregate principal amount of $6,000,000, made by CareView Communications, Inc., a Nevada corporation (the “ Company ”), and payable to the order of the Holders specified therein (each, a “ Holder ”), and shall become a permanent part thereof and shall amend each such Note as provided by Section 11 of each such Note.

 

1.               Amendment to Legend . The Note is hereby amended to insert the following paragraph at the end of the legend on the cover page thereof:

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “ INTERCREDITOR AGREEMENT ”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

 

2.               Amendment to Event of Default Acceleration Threshold . Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

 

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

 

3.               Amendment to Event of Default Payment Threshold . Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

 

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“ Material Indebtedness ”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

 

 
 

 

 

4.               No Further Amendments; Authorization to Affix to Note . Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes each Holder to affix this Allonge to its Note and it shall for all purposes henceforth be part of the Note.

 

 

 

 

[Signature page follows]

 
 

 

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

 

  COMPANY
   
  CAREVIEW COMMUNICATIONS, INC.,
  a Nevada corporation
   
  By:  /s/ Steven Johnson
  Name: Steven Johnson
  Title: Chief Executive Officer

 

 

AGREED AND ACCEPTED:

 

By the MAJORITY FEBRUARY 2015 INVESTORS (as defined in the Notes)

on behalf of all Holders of the Notes: 

  

HEALTHCOR PARTNERS FUND, L.P.

By:   HealthCor Partners Management L.P., as Manager  
By:   HealthCor Partners Management, G.P., LLC, as General Partner  
       
       
By:   /s/ Jeffrey Lightcap  
Name:   Jeffrey Lightcap  
Title:   Senior Managing Director  
       
       
       
/s/ Arthur B. Cohen  
Arthur B. Cohen  
   
   
/s/ Joseph B. Healey  
Joseph B. Healey  
   
   
   
/s/ Steven Johnson  
Steven Johnson  

 

 

 

  

 

Careview Communications Inc. 8-K

Exhibit 99-1

 

 

FOR IMMEDIATE RELEASE  SYMBOL:   CRVW
June 29, 2015 TRADED:   OTCQB

 

 

CareView Communications Announces $40 Million Financing Transaction

with PDL BioPharma

 

LEWISVILLE, Texas -- CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry focused on patient care monitoring, announced today that it has entered into a credit agreement with PDL BioPharma, Inc. (“PDL”) (NASDAQ: PDLI) whereby PDL will provide CareView with up to $40 million of secured debt financing. PDL manages a portfolio of patents and royalty assets and seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies.

 

Under the credit agreement, PDL will provide CareView with up to $40 million of debt financing in two tranches of $20 million, based upon the achievement of specified milestones. Each tranche has a five year maturity. PDL will receive interest on the principal amount outstanding and a security interest in substantially all of CareView’s assets. As part of the transaction, PDL received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share.

 

“We are pleased to collaborate with PDL and look forward to sharing the success related to the growth we are experiencing. Further, this transaction potentially provides us with a significant source of non-dilutive financing as we seek to continue our growth,” stated Steve Johnson, chief executive officer of CareView. “We have installed or are installing CareView Systems ® in eight of the top 10 largest for-profit hospital companies in the U.S. and are making similar progress in the non-profit hospital arena.”

 

“CareView’s subscription business model with hospitals is a cost-effective approach to reducing accidental falls, and the fact that many of the top hospitals in the U.S. have become customers of CareView speaks volumes. We look forward to CareView’s continued growth,” stated John McLaughlin, president and chief executive officer of PDL.

 

About CareView Communications, Inc.

 

CareView’s mission is to be the leading provider of products and on-demand application services for the healthcare industry by specializing in bedside video monitoring, archiving and patient care documentation systems and patient entertainment services. Through the use of telecommunications technology and the Internet, our products and on-demand services will greatly increase the access to quality medical care and education for both consumers and healthcare professionals. We offer the next generation of patient care through our unique data and patient monitoring system that connects patients, families and healthcare professionals (the “CareView System ® ”). Our proprietary, high-speed data network system may be deployed throughout a healthcare facility to provide the facility with recurring revenue and infrastructure for future applications. Real-time bedside and point-of-care video monitoring and recording improve efficiency while limiting liability, and entertainment packages and patient education enhance the patient’s quality of stay. Through continued investment in patient care technology, we are helping hospitals and assisted living facilities build a safe, high quality healthcare delivery system that best serves the patient, while striving for the highest level of patient satisfaction and comfort. CareView is dedicated to working with all types of hospitals, nursing homes, adult living centers and selected outpatient care facilities domestically and internationally. More information about the Company and its products and services is available on the Company’s website at www.care-view.com .

 

 

 

 

 

 
 

 

Forward-looking Statements

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of CareView Communications, Inc. Certain statements in this release are “forward looking statements” within the meaning of the federal securities laws, including statements regarding future events and developments, our future financial and operational performance, and management’s expectations, beliefs, plans, estimates or projections relating to the future. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “may,” “should,” “potentially,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are subject to a number of risks and uncertainties including market acceptance of the Company’s services and projects, the Company’s continued access to capital and other risks and uncertainties set forth in filings made by the Company with the Securities and Exchange Commission. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.

 

 

Contact

 

CareView Communications, Inc.

Steven Johnson, 972-943-6050

President and Chief Executive Officer